Conformational,O
studies,O
on,O
30g,O
indicated,O
that,O
the,O
two,O
stable,O
conformers,O
of,O
30g,O
are,O
quite,O
similar,O
to,O
those,O
of,O
CP,O
-,O
"99,994",O
.,O
The,O
in,O
vitro,O
antitumor,O
potency,O
was,O
studied,O
in,O
two,O
human,O
cancer,O
cell,O
lines,O
(,O
41M,O
and,O
SK,O
-,O
BR,O
-,O
3,O
),O
.,O
This,O
compound,O
is,O
1',B-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
fluorophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
indol,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
butyl,I-IUPAC
],I-IUPAC
spiro,I-IUPAC
[,I-IUPAC
isobenzofuran,I-IUPAC
-,I-IUPAC
1,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
",",I-IUPAC
4',I-IUPAC
-,I-IUPAC
piperidine,I-IUPAC
],I-IUPAC
",",O
14f,O
(,O
code,O
no,O
.,O
avium,O
DHFR,O
",",O
and,O
its,O
SI,O
was,O
no,O
better,O
than,O
that,O
of,O
TMP,O
.,O
The,O
(,B-IUPAC
propargyloxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
acyclonucleoside,I-IUPAC
analogues,B-MODIFIER
of,O
6,B-IUPAC
-,I-IUPAC
chloropurine,I-IUPAC
",",O
adenine,B-IUPAC
",",O
6,B-IUPAC
-,I-IUPAC
methoxypurine,I-IUPAC
",",O
hypoxanthine,B-IUPAC
",",O
6,B-IUPAC
-,I-IUPAC
mercaptopurine,I-IUPAC
",",O
and,O
azathioprine,B-IUPAC
have,O
been,O
prepared,O
.,O
A,O
series,O
of,O
aza,B-IUPAC
-,I-IUPAC
5,I-IUPAC
[,I-IUPAC
H,I-IUPAC
],I-IUPAC
-,I-IUPAC
phenanthridin,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
were,O
synthesized,O
and,O
evaluated,O
as,O
inhibitors,O
of,O
poly,O
ADP,O
-,O
ribose,O
polymerase,O
-,O
1,O
(,O
PARP,O
-,O
1,O
),O
.,O
Hydrolysis,O
of,O
"2,4",B-IUPAC
-,I-IUPAC
dichloroquinazoline,I-IUPAC
to,O
2,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
quinazolinol,I-IUPAC
was,O
followed,O
by,O
condensation,O
with,O
the,O
appropriate,O
N,B-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
dialkylalkylenediamine,I-IUPAC
to,O
give,O
an,O
array,O
of,O
2,B-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
(,I-IUPAC
dialkylamino,I-IUPAC
),I-IUPAC
alkyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
quinazolinols,I-IUPAC
(,O
IXa,O
),O
.,O
1-1,O
microM,O
range,O
against,O
13,O
cell,O
lines,O
(,O
52%,O
),O
.,O
The,O
four,O
corresponding,O
isomers,O
were,O
prepared,O
in,O
which,O
the,O
beta,B-IUPAC
-,I-IUPAC
methylphenylalanine,I-IUPAC
residue,B-MODIFIER
was,O
p,O
-,O
nitro,O
substituted,O
",",O
that,O
is,O
with,O
a,O
beta,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
nitrophenylalanine,I-IUPAC
(,O
beta,O
-,O
Me,O
-,O
p,O
-,O
NO2Phe,O
),O
residue,O
",",O
to,O
give,O
[,O
(,O
2S,O
",",O
3S,O
),O
-,O
beta,O
-,O
Me,O
-,O
p,O
-,O
NO2Phe4,O
],O
DPDPE,O
(,O
6,O
),O
",",O
[,O
(,O
2R,O
",",O
3R,O
),O
-,O
beta,O
-,O
Me,O
-,O
p,O
-,O
NO2Phe4,O
],O
DPDPE,O
(,O
7,O
),O
",",O
[,O
(,O
2S,O
",",O
3R,O
),O
-,O
beta,O
-,O
Me,O
-,O
p,O
-,O
NO2Phe4,O
],O
DPDPE,O
(,O
8,O
),O
",",O
and,O
[,O
(,O
2R,O
",",O
3S,O
),O
-,O
beta,O
-,O
Me,O
-,O
p,O
-,O
NO2Phe4,O
],O
DPDPE,O
(,O
9,O
),O
",",O
respectively,O
.,O
Specific,O
binding,O
ratios,O
[,O
region,O
of,O
interest,O
(,O
ROI,O
),O
/,O
cerebellum,O
-,O
1,O
],O
in,O
control,O
studies,O
for,O
cortex,O
(,O
Ctx,O
),O
and,O
hippocampus,O
(,O
H,O
),O
were,O
higher,O
for,O
[,O
carbonyl,O
-,O
11C,O
],O
4a,O
and,O
[,O
18F,O
],O
4d,O
compared,O
to,O
[,O
18F,O
],O
4b,O
and,O
[,O
18F,O
],O
4c,O
.,O
A,O
variety,O
of,O
1,O
-,O
O,O
-,O
acetylated,O
pentose,O
sugar,O
derivatives,O
were,O
condensed,O
with,O
silylated,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
oxopyrido,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
",",O
followed,O
by,O
protection,O
",",O
to,O
afford,O
a,O
series,O
of,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
oxopyrido,I-IUPAC
[,I-IUPAC
2,I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
nucleosides,B-MODIFIER
.,O
On,O
the,O
basis,O
of,O
the,O
selective,O
incorporation,O
of,O
deuterium,O
into,O
these,O
products,O
",",O
we,O
provide,O
rational,O
mechanistic,O
interpretations,O
of,O
the,O
disproportionation,O
reaction,O
and,O
the,O
rearrangement,O
of,O
the,O
cyano,O
adducts,O
.,O
Conformational,O
analysis,O
of,O
the,O
stereoisomers,O
",",O
assuming,O
rotation,O
of,O
the,O
aryl,O
substituent,O
and,O
ester,O
groups,O
",",O
shows,O
small,O
energy,O
differences,O
(,O
about,O
4,O
kcal,O
.,O
The,O
aldehydes,O
were,O
converted,O
to,O
the,O
cyanohydrin,B-IUPAC
trimethylsilyl,I-IUPAC
ethers,I-IUPAC
",",O
which,O
",",O
in,O
turn,O
",",O
were,O
reduced,O
to,O
the,O
dimethoxyphenethanolamines,B-IUPAC
.,O
The,O
strongest,O
inhibitor,O
",",O
the,O
[,B-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
4a,I-IUPAC
",",I-IUPAC
10a,I-IUPAC
-,I-IUPAC
dihydrophenothiazin,I-IUPAC
-,I-IUPAC
10,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
],I-IUPAC
(,I-IUPAC
3,I-IUPAC
",",I-IUPAC
4,I-IUPAC
-,I-IUPAC
dichlorobenzyl,I-IUPAC
),I-IUPAC
dimethylammonium,I-IUPAC
derivative,B-MODIFIER
(,O
K,O
(,O
i,O
),O
0.12,O
microM,O
),O
",",O
was,O
approximately,O
2,O
orders,O
of,O
magnitude,O
more,O
inhibitory,O
than,O
the,O
parent,O
chlorpromazine,O
.,O
A,O
series,O
of,O
"2,3",B-IUPAC
-,I-IUPAC
diaryl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
analogues,B-MODIFIER
substituted,B-MODIFIER
at,O
position,O
4,O
of,O
2,B-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
with,O
a,O
hydroxy,B-IUPAC
or,O
pyrrolidinoethoxy,B-IUPAC
residue,B-MODIFIER
were,O
synthesized,O
as,O
models,O
for,O
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
triarylpropenones,I-IUPAC
constrained,O
in,O
the,O
s,O
-,O
trans,O
conformation,O
.,O
Condensation,O
of,O
5,B-IUPAC
-,I-IUPAC
fluoro,I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
bis,I-IUPAC
[,I-IUPAC
(,I-IUPAC
trimethylsilyl,I-IUPAC
),I-IUPAC
oxy,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
with,O
2,B-IUPAC
-,I-IUPAC
acetoxyethyl,I-IUPAC
acetoxymethyl,I-IUPAC
ether,I-IUPAC
(,O
6,O
),O
in,O
the,O
presence,O
of,O
SnCl4,O
afforded,O
the,O
acetate,O
ester,O
7,O
",",O
which,O
on,O
deprotection,O
with,O
NaOMe,O
gave,O
3,O
in,O
50-60%,O
overall,O
yield,O
.,O
The,O
biological,O
activity,O
of,O
these,O
heteroarotinoids,O
was,O
assayed,O
by,O
either,O
the,O
suppression,O
of,O
the,O
12,B-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
tetradecanoylphorbol,I-IUPAC
13,I-IUPAC
-,I-IUPAC
acetate,I-IUPAC
(,O
TPA,O
),O
induced,O
synthesis,O
of,O
ornithine,O
decarboxylase,O
(,O
ODC,O
),O
in,O
mouse,O
skin,O
or,O
the,O
induction,O
of,O
differentiation,O
of,O
human,O
(,O
HL,O
-,O
60,O
),O
promyelocytic,O
cells,O
.,O
N,B-IUPAC
-,I-IUPAC
Methoxy,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
[,I-IUPAC
5,I-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methoxyamidino,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
furan,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
-,I-IUPAC
nicotinamidine,I-IUPAC
(,O
6a,O
),O
was,O
prepared,O
via,O
methylation,O
of,O
the,O
respective,O
diamidoxime,O
5a,O
with,O
dimethylsulfate,O
.,O
The,O
synthesis,O
of,O
ethyl,B-IUPAC
or,O
methyl,B-IUPAC
4,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
or,O
unsubstituted,B-MODIFIER
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
pyrimidinecarboxylates,I-IUPAC
10-20,O
",",O
which,O
is,O
mainly,O
carried,O
out,O
by,O
reaction,O
of,O
ethyl,B-IUPAC
or,O
methyl,B-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
methylene,I-IUPAC
],I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
oxoalkanoates,I-IUPAC
with,O
"1,1",B-IUPAC
-,I-IUPAC
dimethylguanidine,I-IUPAC
",",O
is,O
described,O
.,O
IC50,O
ratios,O
for,O
[,O
3H,O
],O
cocaine,O
binding,O
/,O
[,O
3H,O
],O
DA,O
uptake,O
ranged,O
from,O
0.47,O
for,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
benzo,I-IUPAC
[,I-IUPAC
b,I-IUPAC
],I-IUPAC
thienyl,I-IUPAC
),I-IUPAC
cyclopentyl,I-IUPAC
],I-IUPAC
homopiperidine,I-IUPAC
(,O
11,O
),O
to,O
8.8,O
for,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
benzo,I-IUPAC
[,I-IUPAC
b,I-IUPAC
],I-IUPAC
thienyl,I-IUPAC
),I-IUPAC
cyclohexylamine,I-IUPAC
(,O
4,O
),O
.,O
For,O
comparison,O
reasons,O
",",O
the,O
cytotoxicity,O
of,O
the,O
complexes,O
alpha,O
-,O
[,O
Ru,O
(,O
azpy,O
),O
(,O
2,O
),O
Cl,O
(,O
2,O
),O
],O
",",O
alpha,O
-,O
[,O
Ru,O
(,O
azpy,O
),O
(,O
2,O
),O
(,O
NO,O
(,O
3,O
),O
),O
(,O
2,O
),O
],O
",",O
beta,O
-,O
[,O
Ru,O
(,O
azpy,O
),O
(,O
2,O
),O
Cl,O
(,O
2,O
),O
],O
(,O
beta,O
indicating,O
the,O
coordinating,O
pairs,O
Cl,O
",",O
N,O
(,O
py,O
),O
",",O
and,O
N,O
(,O
azo,O
),O
as,O
cis,O
",",O
cis,O
",",O
cis,O
",",O
respectively,O
),O
",",O
and,O
beta,O
-,O
[,O
Ru,O
(,O
azpy,O
),O
(,O
2,O
),O
(,O
NO,O
(,O
3,O
),O
),O
(,O
2,O
),O
],O
have,O
been,O
determined,O
in,O
this,O
cell,O
line,O
.,O
Selective,O
N,O
-,O
acetylation,O
and,O
subsequent,O
Friedel,O
-,O
Crafts,O
acylation,O
with,O
phthalic,O
anhydride,O
produced,O
2,B-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
"5,12",I-IUPAC
-,I-IUPAC
dihydroxy,I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
azanaphthacene,I-IUPAC
-,I-IUPAC
"6,11",I-IUPAC
-,I-IUPAC
dione,I-IUPAC
",",O
which,O
was,O
protected,O
as,O
its,O
dimethyl,O
ether,O
and,O
epoxidized,O
to,O
an,O
acylated,O
aza,O
Brigl,O
's,O
anhydride,O
.,O
The,O
beta,O
-,O
keto,O
derivative,O
was,O
converted,O
by,O
reaction,O
with,O
MeMgBr,O
",",O
and,O
after,O
reaction,O
with,O
thymine,O
and,O
subsequent,O
deprotection,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3',I-IUPAC
-,I-IUPAC
C,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
threo,I-IUPAC
-,I-IUPAC
pentofuranosyl,I-IUPAC
),I-IUPAC
thymine,I-IUPAC
and,O
its,O
beta,O
-,O
anomer,O
were,O
obtained,O
.,O
As,O
part,O
of,O
a,O
search,O
for,O
dihydrofolate,O
reductase,O
(,O
DHFR,O
),O
inhibitors,O
combining,O
the,O
high,O
potency,O
of,O
piritrexim,O
(,O
PTX,O
),O
with,O
the,O
high,O
antiparasitic,O
vs,O
mammalian,O
selectivity,O
of,O
trimethoprim,O
(,O
TMP,O
),O
",",O
the,O
heretofore,O
undescribed,O
"2,4",B-PARTIUPAC
-,I-PARTIUPAC
diamino,I-PARTIUPAC
-,I-PARTIUPAC
6,I-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
2',B-MODIFIER
",",I-MODIFIER
5',I-MODIFIER
-,I-MODIFIER
disubstituted,I-MODIFIER
benzyl,B-PARTIUPAC
),I-PARTIUPAC
pyrido,I-PARTIUPAC
[,I-PARTIUPAC
"2,3",I-PARTIUPAC
-,I-PARTIUPAC
d,I-PARTIUPAC
],I-PARTIUPAC
pyrimidines,I-PARTIUPAC
6-14,O
with,O
O,B-IUPAC
-,I-IUPAC
(,I-IUPAC
omega,I-IUPAC
-,I-IUPAC
carboxyalkyl,I-IUPAC
),I-IUPAC
or,O
omega,B-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
alkynyl,I-IUPAC
groups,B-MODIFIER
on,O
the,O
benzyl,B-IUPAC
moiety,B-MODIFIER
were,O
synthesized,O
and,O
tested,O
against,O
Pneumocystis,O
carinii,O
",",O
Toxoplasma,O
gondii,O
",",O
and,O
Mycobacterium,O
avium,O
DHFR,O
vs,O
rat,O
DHFR,O
.,O
The,O
key,O
step,O
in,O
the,O
synthetic,O
route,O
to,O
12a,O
was,O
Wittig,O
condensation,O
of,O
the,O
tributylphosphorane,O
derived,O
from,O
6,B-IUPAC
-,I-IUPAC
(,I-IUPAC
bromomethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
diamino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methylpyrido,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
(,O
7a,O
),O
with,O
methyl,B-IUPAC
4,I-IUPAC
-,I-IUPAC
propionylbenzoate,I-IUPAC
.,O
In,O
mediated,O
influx,O
into,O
L1210,O
cells,O
",",O
5,O
and,O
6,O
were,O
transported,O
2.7,O
-,O
and,O
8.5,O
-,O
fold,O
",",O
respectively,O
",",O
more,O
readily,O
than,O
MTX,O
.,O
Most,O
of,O
the,O
BTCP,O
homologues,O
displayed,O
greater,O
ability,O
to,O
inhibit,O
[,O
3H,O
],O
DA,O
uptake,O
in,O
rat,O
forebrain,O
synaptosomes,O
than,O
cocaine,O
.,O
No,O
affinity,O
for,O
NMDA,O
receptors,O
(,O
NMDA,O
-,O
sensitive,O
[,O
3H,O
],O
glutamic,O
acid,O
binding,O
),O
was,O
found,O
",",O
and,O
only,O
weak,O
affinity,O
in,O
[,O
3H,O
],O
kainic,O
acid,O
binding,O
(,O
IC50,O
=,O
6.3,O
microM,O
),O
was,O
detected,O
.,O
A,O
composite,O
hydrogen,O
-,O
bonding,O
environment,O
has,O
been,O
constructed,O
for,O
the,O
TRH,O
analogue,O
system,O
and,O
examined,O
for,O
its,O
inference,O
with,O
respect,O
to,O
receptor,O
binding,O
.,O
In,O
earlier,O
reports,O
we,O
identified,O
specific,O
point,O
substitutions,O
(,O
DPhe12,O
",",O
Nle21,O
",",O
38,O
),O
",",O
cyclization,O
strategies,O
[,O
in,O
particular,O
",",O
introduction,O
of,O
lactam,O
rings,O
such,O
as,O
that,O
of,O
cyclo,O
(,O
Glu30,O
",",O
Lys33,O
),O
],O
",",O
and,O
deletions,O
(,O
residues,O
1-7,O
),O
in,O
the,O
CRF,O
molecule,O
that,O
led,O
to,O
agonists,O
.,O
Application,O
of,O
lactam,O
constraints,O
in,O
the,O
C,O
-,O
terminus,O
of,O
GHRH,O
(,O
1-29,O
),O
-,O
NH2,O
identified,O
cyclo,O
(,O
25-29,O
),O
[,O
MeTyr1,O
",",O
Ala15,O
",",O
DAsp25,O
",",O
Nle27,O
",",O
Orn29+,O
+,O
+,O
],O
-,O
hGHRH,O
(,O
1-29,O
),O
-,O
NH2,O
(,O
46,O
),O
as,O
containing,O
the,O
optimum,O
bridging,O
element,O
(,O
19,O
-,O
membered,O
ring,O
),O
in,O
this,O
region,O
of,O
the,O
molecule,O
.,O
ATP,O
2,O
-,O
thioethers,O
displayed,O
pD2,O
values,O
in,O
the,O
range,O
of,O
6-8,O
in,O
smooth,O
muscle,O
assay,O
systems,O
for,O
activity,O
at,O
P2Y,O
-,O
receptors,O
.,O
This,O
would,O
give,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
aminomethyl,I-IUPAC
),I-IUPAC
tetrazole,I-IUPAC
(,O
13,O
),O
",",O
the,O
tetrazole,O
acid,O
analog,O
of,O
glycine,O
;,O
and,O
glycine,O
is,O
involved,O
in,O
NMDA,O
receptor,O
activation,O
.,O
Serial,O
measurements,O
of,O
tumor,O
size,O
",",O
and,O
evaluation,O
of,O
increased,O
life,O
span,O
",",O
in,O
response,O
to,O
drug,O
treatment,O
also,O
revealed,O
potentially,O
"1,4",B-PARTIUPAC
-,I-PARTIUPAC
bis,I-PARTIUPAC
(,O
alkylating,O
),O
(,B-PARTIUPAC
bromomethyl,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
"1,4",I-PARTIUPAC
-,I-PARTIUPAC
quinone,I-PARTIUPAC
7,O
and,O
"1,3",B-PARTIUPAC
-,I-PARTIUPAC
bis,I-PARTIUPAC
(,O
alkylating,O
),O
(,B-PARTIUPAC
hydroxymethyl,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
"1,4",I-PARTIUPAC
-,I-PARTIUPAC
quinone,I-PARTIUPAC
10,O
to,O
have,O
variable,O
activity,O
",",O
but,O
none,O
of,O
the,O
potentially,O
bis,O
(,O
alkylating,O
),O
bis,O
(,O
quinones,O
),O
showed,O
antitumor,O
properties,O
in,O
this,O
model,O
.,O
In,O
biodistribution,O
studies,O
using,O
[,O
131I,O
],O
-,O
MIH,O
-,O
OST7,O
and,O
[,O
131I,O
],O
ATE,O
-,O
OST7,O
",",O
while,O
both,O
131I,O
-,O
labeled,O
OST7s,O
registered,O
almost,O
identical,O
radioactivity,O
levels,O
in,O
the,O
blood,O
up,O
to,O
6,O
h,O
postinjection,O
",",O
the,O
former,O
demonstrated,O
a,O
lower,O
radioactivity,O
level,O
than,O
[,O
131I,O
],O
ATE,O
-,O
OST7,O
in,O
nontarget,O
tissues,O
throughout,O
the,O
experiment,O
.,O
Our,O
aim,O
was,O
to,O
develop,O
an,O
(,O
18,O
),O
F,O
-,O
labeled,O
acetylcholine,O
analogue,O
useful,O
for,O
brain,O
AChE,O
mapping,O
with,O
PET,O
",",O
since,O
(,O
18,O
),O
F,O
",",O
with,O
a,O
longer,O
half,O
-,O
life,O
",",O
has,O
advantages,O
over,O
(,O
11,O
),O
C,O
.,O
Condensation,O
of,O
appropriately,O
substituted,O
(,O
arylmethyl,O
),O
triphenylphosphoranes,O
with,O
4,B-IUPAC
",",I-IUPAC
4,I-IUPAC
-,I-IUPAC
ethylenedioxycyclohexanone,I-IUPAC
",",O
followed,O
by,O
hydrogenation,O
(,O
H2,O
/,O
Pd,O
-,O
C,O
),O
and,O
acidolysis,O
",",O
yielded,O
the,O
corresponding,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
arylmethyl,I-IUPAC
),I-IUPAC
cyclohexanones,I-IUPAC
",",O
which,O
were,O
then,O
condensed,O
with,O
cyanoguanidine,O
to,O
form,O
the,O
tetrahydroquinazolines,O
.,O
6,B-IUPAC
-,I-IUPAC
Deoxy,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
fluoro,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
galactose,I-IUPAC
and,O
its,O
enantiomer,O
4a,O
were,O
found,O
to,O
be,O
effective,O
inhibitors,O
of,O
D,B-IUPAC
-,I-IUPAC
[,I-IUPAC
3H,I-IUPAC
],I-IUPAC
galactose,I-IUPAC
and,O
L,B-IUPAC
-,I-IUPAC
[,I-IUPAC
3H,I-IUPAC
],I-IUPAC
fucose,I-IUPAC
incorporation,O
",",O
respectively,O
",",O
into,O
macromolecular,O
components,O
of,O
human,O
mammary,O
tumor,O
cells,O
.,O
Treatment,O
of,O
"4,5,6",B-IUPAC
-,I-IUPAC
triamino,I-IUPAC
-,I-IUPAC
2H,I-IUPAC
-,I-IUPAC
"1,2,6",I-IUPAC
-,I-IUPAC
thiadiazine,I-IUPAC
"1,1",I-IUPAC
-,I-IUPAC
dioxide,I-IUPAC
with,O
N,B-IUPAC
-,I-IUPAC
thionylaniline,I-IUPAC
gave,O
a,O
derivative,O
of,O
another,O
new,O
ring,O
system,O
",",O
7,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
4H,I-IUPAC
-,I-IUPAC
[,I-IUPAC
"1,2,5",I-IUPAC
],I-IUPAC
thiadiazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
c,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,2,6",I-IUPAC
],I-IUPAC
thiadiazine,I-IUPAC
"5,5",I-IUPAC
-,I-IUPAC
dioxide,I-IUPAC
.,O
A,O
few,O
indoles,O
belonging,O
to,O
the,O
previously,O
investigated,O
benzylamides,O
1,O
and,O
phenylhydrazides,O
2,O
were,O
synthesized,O
and,O
tested,O
to,O
enrich,O
the,O
SARs,O
in,O
these,O
two,O
series,O
.,O
The,O
activity,O
of,O
ring,O
-,O
substituted,O
(,O
F,O
",",O
Cl,O
",",O
CH3,O
",",O
and,O
OCH3,O
),O
2,B-IUPAC
-,I-IUPAC
phenethoxyadenosines,I-IUPAC
increases,O
ortho,O
less,O
than,O
meta,O
less,O
than,O
para,O
.,O
Compound,O
7,O
also,O
was,O
the,O
only,O
compound,O
which,O
demonstrated,O
significant,O
in,O
vivo,O
antifilarial,O
activity,O
against,O
the,O
adult,O
worms,O
of,O
Acanthocheilonema,O
viteae,O
in,O
experimentally,O
infected,O
jirds,O
.,O
Med.,O
Chem.,O
1993,O
",",O
36,O
",",O
801-810,O
),O
.,O
This,O
study,O
shows,O
that,O
the,O
pyrrolo,B-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
scaffold,B-MODIFIER
is,O
conducive,O
to,O
dual,O
DHFR,O
-,O
TS,O
and,O
tumor,O
inhibitory,O
activity,O
",",O
and,O
the,O
potency,O
is,O
determined,O
by,O
the,O
4,O
-,O
position,O
substituent,O
.,O
A,O
convenient,O
synthesis,O
of,O
8,O
-,O
azapurine,O
ribonucleosides,O
substituted,O
at,O
the,O
6,O
position,O
with,O
thio,B-IUPAC
",",O
alkylthio,B-IUPAC
",",O
alkoxy,B-IUPAC
",",O
amino,B-IUPAC
",",O
and,O
alkylamino,B-IUPAC
groups,B-MODIFIER
is,O
described,O
.,O
It,O
is,O
concluded,O
that,O
homo,O
-,O
AMPA,O
(,O
8,O
),O
is,O
likely,O
to,O
be,O
a,O
useful,O
tool,O
for,O
studies,O
of,O
the,O
pharmacology,O
and,O
physiological,O
role,O
of,O
mGlu6,O
.,O
Preliminary,O
screening,O
indicated,O
methyl,B-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"1,2,2",I-IUPAC
-,I-IUPAC
trichloroethenyl,I-IUPAC
),I-IUPAC
imidazo,I-IUPAC
[,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
alpha,I-IUPAC
],I-IUPAC
pyridine,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
carbamate,I-IUPAC
to,O
be,O
the,O
most,O
potent,O
derivative,O
in,O
the,O
series,O
.,O
Following,O
alpha,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
and,O
alpha,B-IUPAC
-,I-IUPAC
carboxyl,I-IUPAC
deprotections,B-MODIFIER
of,O
11,O
and,O
12,O
",",O
EEDQ,O
[,O
2,B-IUPAC
-,I-IUPAC
ethoxy,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
ethoxycarbonyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
dihydroquinoline,I-IUPAC
],O
mediated,O
peptide,O
coupling,O
and,O
final,O
deprotection,O
provided,O
amino,O
acid,O
1,O
and,O
six,O
albomycin,O
-,O
like,O
peptides,O
(,O
20,O
",",O
23,O
",",O
25,O
",",O
28,O
",",O
35,O
",",O
and,O
36,O
),O
.,O
Thus,O
",",O
4b,O
",",O
d,O
",",O
e,O
were,O
evaluated,O
for,O
their,O
affinity,O
at,O
muscarinic,O
M1,O
-,O
M5,O
receptors,O
and,O
also,O
assessed,O
for,O
their,O
functional,O
characteristics,O
at,O
the,O
M1,O
and,O
M2,O
isoforms,O
.,O
A,O
number,O
of,O
1,B-IUPAC
-,I-IUPAC
hydroxyazole,I-IUPAC
derivatives,B-MODIFIER
were,O
synthesized,O
as,O
bioisosteres,O
of,O
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
glutamic,I-IUPAC
acid,I-IUPAC
(,O
Glu,O
),O
and,O
as,O
analogues,O
of,O
the,O
AMPA,O
receptor,O
agonist,O
(,B-IUPAC
R,I-IUPAC
",",I-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
isoxazolyl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
AMPA,O
",",O
3b,O
),O
.,O
Rotationally,O
restricted,O
analogues,O
of,O
5,B-IUPAC
-,I-IUPAC
deazapteroyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
glutamate,I-IUPAC
and,O
(,B-IUPAC
6R,I-IUPAC
",",I-IUPAC
6S,I-IUPAC
),I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
deaza,I-IUPAC
-,I-IUPAC
"5,6,7,8",I-IUPAC
-,I-IUPAC
tetrahydropteroyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
glutamate,I-IUPAC
with,O
a,O
one,O
-,O
carbon,O
bridge,O
between,O
the,O
amide,O
nitrogen,O
and,O
the,O
6',O
-,O
position,O
of,O
the,O
p,B-IUPAC
-,I-IUPAC
aminobenzoyl,I-IUPAC
moiety,B-MODIFIER
were,O
synthesized,O
and,O
tested,O
as,O
substrates,O
for,O
folylpolyglutamate,O
synthetase,O
(,O
FPGS,O
),O
",",O
a,O
key,O
enzyme,O
in,O
folate,O
metabolism,O
and,O
an,O
important,O
determinant,O
of,O
the,O
therapeutic,O
potency,O
and,O
selectivity,O
of,O
classical,O
antifolates,O
.,O
A,O
first,O
set,O
of,O
compounds,O
bearing,O
a,O
4,B-MODIFIER
-,I-MODIFIER
(,I-MODIFIER
1,I-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
),I-MODIFIER
piperazine,O
moiety,B-MODIFIER
as,O
terminal,O
fragment,O
on,O
the,O
alkyl,B-IUPAC
chain,B-MODIFIER
showed,O
moderate,O
to,O
high,O
sigma,O
affinity,O
(,O
Ki,O
=,O
5.3-139,O
nM,O
),O
",",O
the,O
most,O
active,O
and,O
selective,O
being,O
1,B-IUPAC
-,I-IUPAC
cyclohexyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
tetrahydronaphthalen,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
propyl,I-IUPAC
],I-IUPAC
piperazine,I-IUPAC
(,O
14,O
),O
",",O
with,O
probable,O
pronounced,O
sigma,O
2,O
affinity,O
(,O
Ki,O
=,O
5.3,O
nM,O
on,O
[,O
3H,O
],O
DTG,O
and,O
Ki,O
=,O
71,O
nM,O
on,O
[,O
3H,O
],O
-,O
(,O
+,O
),O
-,O
pentazocine,O
),O
.,O
However,O
",",O
upon,O
iv,O
administration,O
",",O
35,O
(,O
3-100,O
mg,O
/,O
kg,O
),O
and,O
39,O
(,O
3-300,O
mg,O
/,O
kg,O
),O
failed,O
to,O
inhibit,O
the,O
binding,O
of,O
[,O
3H,O
],O
mepyramine,O
to,O
mouse,O
cerebral,O
cortex,O
in,O
vivo,O
",",O
thereby,O
indicating,O
that,O
these,O
histamine,O
derivatives,O
are,O
not,O
able,O
to,O
penetrate,O
the,O
blood,O
-,O
brain,O
barrier,O
.,O
Synadenol,O
(,O
14,O
),O
and,O
the,O
E,O
-,O
isomer,O
(,O
16,O
),O
were,O
substrates,O
of,O
moderate,O
efficiency,O
for,O
adenosine,O
deaminase,O
from,O
calf,O
intestine,O
.,O
We,O
have,O
previously,O
shown,O
that,O
the,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
isoxazolyl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
AMPA,O
),O
receptor,O
agonist,O
",",O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
isoxazolyl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
ACPA,O
",",O
2,O
),O
",",O
binds,O
to,O
AMPA,O
receptors,O
in,O
a,O
manner,O
different,O
from,O
that,O
of,O
AMPA,O
(,O
1,O
),O
itself,O
and,O
that,O
2,O
",",O
in,O
contrast,O
to,O
1,O
",",O
also,O
binds,O
to,O
kainic,O
acid,O
receptor,O
sites,O
.,O
These,O
glucagon,O
analogues,O
have,O
been,O
made,O
by,O
either,O
deleting,O
or,O
substituting,O
hydrophobic,O
groups,O
",",O
hydrophilic,O
groups,O
",",O
aromatic,O
amino,O
acids,O
",",O
or,O
a,O
D,O
-,O
phenylalanine,O
residue,O
at,O
this,O
position,O
.,O
Compound,O
3,O
inhibited,O
the,O
growth,O
of,O
tumor,O
cells,O
in,O
culture,O
(,O
IC50,O
10,O
(,O
-,O
7,O
),O
M,O
),O
while,O
4,O
showed,O
a,O
low,O
level,O
of,O
growth,O
inhibitory,O
activity,O
.,O
Incubation,O
of,O
AdoHcy,O
hydrolase,O
with,O
7,O
or,O
15,O
resulted,O
in,O
irreversible,O
inactivation,O
and,O
release,O
of,O
bromide,O
ion,O
.,O
Most,O
of,O
the,O
new,O
compounds,O
were,O
active,O
in,O
a,O
PAF,O
-,O
binding,O
assay,O
employing,O
whole,O
",",O
washed,O
dog,O
platelets,O
as,O
the,O
receptor,O
source,O
and,O
inhibited,O
PAF,O
-,O
induced,O
bronchoconstriction,O
in,O
guinea,O
pigs,O
after,O
intravenous,O
administration,O
.,O
Hydrazinolysis,O
of,O
compound,O
4,O
gave,O
1,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
p,I-IUPAC
-,I-IUPAC
(,I-IUPAC
carbomethoxy,I-IUPAC
),I-IUPAC
thiophenoxy,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
butanone,I-IUPAC
oxime,I-IUPAC
(,O
5,O
),O
",",O
which,O
was,O
used,O
for,O
the,O
construction,O
of,O
the,O
title,O
compound,O
2,O
by,O
modification,O
of,O
the,O
Boon,O
and,O
Leigh,O
procedure,O
.,O
(,O
3S,O
",",O
4R,O
),O
-,O
4,O
-,O
(,O
4,O
-,O
Fluorophenyl,O
),O
-,O
3,O
-,O
[,O
[,O
"3,4",O
-,O
(,O
methylenedioxy,O
),O
phenoxy,O
],O
methyl,O
],O
piperidine,O
[,O
(,O
3S,O
",",O
9R,O
),O
-,O
3,O
",",O
paroxetine,O
],O
is,O
a,O
selective,O
serotonin,O
reuptake,O
inhibitor,O
(,O
SSRI,O
),O
used,O
as,O
an,O
antidepressant,O
in,O
humans,O
.,O
The,O
influence,O
of,O
this,O
group,O
on,O
the,O
biological,O
activity,O
was,O
evaluated,O
by,O
testing,O
the,O
corresponding,O
derivatives,O
20-22,O
in,O
which,O
the,O
4,B-PARTIUPAC
-,I-PARTIUPAC
alkylsemicarbazono,I-PARTIUPAC
moiety,B-MODIFIER
was,O
removed,O
(,O
compound,O
20,O
),O
or,O
its,O
alkylureido,O
portion,O
shifted,O
at,O
position,O
1,O
(,O
compounds,O
21-22,O
),O
.,O
DFO,O
-,O
HOPO,O
and,O
"3,4,3",O
-,O
LIHOPO,O
and,O
its,O
Zn,O
(,O
II,O
),O
and,O
Fe,O
(,O
III,O
),O
complexes,O
promoted,O
significantly,O
more,O
Pu,O
excretion,O
than,O
CaNa3,O
-,O
DTPA,O
(,O
61%,O
of,O
injected,O
Pu,O
),O
.,O
Compound,O
37,O
",",O
3,B-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
pyrimidinyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
piperazinyl,I-IUPAC
],I-IUPAC
butyl,I-IUPAC
],I-IUPAC
hexahydro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
",",I-IUPAC
7,I-IUPAC
-,I-IUPAC
etheno,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
cyclobut,I-IUPAC
[,I-IUPAC
f,I-IUPAC
],I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
benzisothiazol,I-IUPAC
-,I-IUPAC
3,I-IUPAC
(,I-IUPAC
2H,I-IUPAC
),I-IUPAC
-,I-IUPAC
one,I-IUPAC
"1,1",I-IUPAC
-,I-IUPAC
dioxide,I-IUPAC
",",O
buspirone,O
",",O
and,O
ipsapirone,O
showed,O
similarities,O
in,O
their,O
neurochemical,O
and,O
behavioral,O
profiles,O
.,O
For,O
example,O
",",O
the,O
difference,O
between,O
N,B-IUPAC
-,I-IUPAC
[,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
pyrrolidinyl,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
N',I-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichlorobenzyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
dimethylethylenediamine,I-IUPAC
(,O
8,O
),O
[,O
K,O
(,O
i,O
),O
=,O
29.9,O
nM,O
at,O
sigma,O
-,O
1,O
receptor,O
and,O
18.3,O
nM,O
at,O
sigma,O
-,O
2,O
receptor,O
],O
to,O
N,B-IUPAC
-,I-IUPAC
[,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
pyrrolidinyl,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
N',I-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichlorobenzyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
dimethylethylenediamine,I-IUPAC
(,O
10,O
),O
[,O
K,O
(,O
i,O
),O
=,O
1.49,O
nM,O
at,O
sigma,O
-,O
1,O
receptor,O
and,O
12.1,O
nM,O
at,O
sigma,O
-,O
2,O
receptor,O
],O
illustrates,O
the,O
importance,O
of,O
internitrogen,O
spacing,O
.,O
Selected,O
ion,O
-,O
monitoring,O
GC,O
-,O
MS,O
analysis,O
",",O
based,O
on,O
use,O
of,O
the,O
synthesized,O
mixture,O
of,O
diastereoisomers,O
of,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
propylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
naphthoxy,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
propanol,I-IUPAC
(,O
2,O
),O
as,O
a,O
standard,O
",",O
established,O
formation,O
of,O
both,O
diastereoisomers,O
of,O
2,O
as,O
metabolites,O
of,O
1,O
.,O
Selectivity,O
at,O
the,O
receptor,O
subclasses,O
was,O
examined,O
by,O
performing,O
an,O
A2,O
adenosine,O
receptor,O
affinity,O
assay,O
with,O
[,O
3H,O
],O
CGS,O
21680,O
.,O
Both,O
di,O
-,O
and,O
triacetylated,O
derivatives,O
of,O
6,B-IUPAC
",",I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
acetoxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methylbutyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxoethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
acetylamino,I-IUPAC
),I-IUPAC
butan,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
olide,I-IUPAC
(,O
8,O
),O
and,O
4,B-IUPAC
-,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
acetoxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
acetoxy,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methylbutyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxoethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
acetylamino,I-IUPAC
),I-IUPAC
butan,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
olide,I-IUPAC
(,O
9,O
),O
",",O
were,O
inactive,O
.,O
It,O
has,O
been,O
observed,O
that,O
the,O
presence,O
of,O
a,O
carbomethoxy,O
at,O
position,O
3,O
and,O
an,O
aryl,O
substituent,O
at,O
position,O
1,O
in,O
beta,O
-,O
carbolines,O
effectively,O
enhances,O
antifilarial,O
activity,O
particularly,O
against,O
A,O
.,O
Spontaneous,O
elimination,O
of,O
acrolein,O
from,O
3a,O
would,O
then,O
generate,O
the,O
free,O
nucleotide,O
",",O
FdUMP,O
.,O
Series,O
of,O
3,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
-,O
"9,10",B-IUPAC
-,I-IUPAC
dimethoxy,I-IUPAC
-,I-IUPAC
"3,4,6,7",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
2H,I-IUPAC
-,I-IUPAC
pyrimido,I-IUPAC
[,I-IUPAC
"6,1",I-IUPAC
-,I-IUPAC
a,I-IUPAC
],I-IUPAC
isoquinoline,I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
diones,I-IUPAC
and,O
2,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
-,O
"9,10",B-IUPAC
-,I-IUPAC
dimethoxy,I-IUPAC
-,I-IUPAC
"6,7",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
4H,I-IUPAC
-,I-IUPAC
pyrimido,I-IUPAC
[,I-IUPAC
"6,1",I-IUPAC
-,I-IUPAC
a,I-IUPAC
],I-IUPAC
isoquinolin,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
were,O
synthesized,O
and,O
tested,O
for,O
blood,O
pressure,O
lowering,O
properties,O
in,O
anesthetized,O
normotensive,O
cats,O
and,O
conscious,O
spontaneously,O
hypertensive,O
rats,O
.,O
The,O
nature,O
of,O
the,O
substituent,O
introduced,O
in,O
the,O
7,O
-,O
position,O
as,O
well,O
as,O
the,O
nature,O
of,O
the,O
alkylamino,O
side,O
chain,O
in,O
the,O
3,O
-,O
position,O
strongly,O
affected,O
both,O
potency,O
and,O
tissue,O
selectivity,O
of,O
4H,B-IUPAC
-,I-IUPAC
"1,2,4",I-IUPAC
-,I-IUPAC
benzothiadiazine,I-IUPAC
"1,1",I-IUPAC
-,I-IUPAC
dioxides,I-IUPAC
.,O
These,O
compounds,O
exhibit,O
different,O
affinities,O
for,O
the,O
muscarinic,O
receptor,O
tissue,O
subtypes,O
in,O
vitro,O
.,O
In,O
series,O
I,O
",",O
the,O
presence,O
of,O
a,O
phenol,B-PARTIUPAC
group,B-MODIFIER
",",O
irrespective,O
of,O
the,O
nature,O
of,O
tertioalkyl,B-PARTIUPAC
group,B-MODIFIER
",",O
imparted,O
at,O
least,O
partial,O
RAR,O
gamma,O
selectivity,O
",",O
whereas,O
in,O
series,O
II,O
",",O
the,O
presence,O
of,O
both,O
adamantyl,B-PARTIUPAC
and,O
phenol,B-PARTIUPAC
groups,B-MODIFIER
is,O
needed,O
to,O
confer,O
RAR,O
gamma,O
selectivity,O
.,O
The,O
biological,O
data,O
indicate,O
strongly,O
that,O
the,O
aqueous,O
solubility,O
and,O
relatively,O
high,O
acidity,O
of,O
the,O
octadentate,O
HOPO,O
ligands,O
",",O
"3,4,3",O
-,O
LIHOPO,O
and,O
DFO,O
-,O
HOPO,O
allow,O
them,O
to,O
form,O
complete,O
eight,O
-,O
coordinate,O
complexes,O
with,O
Pu,O
(,O
IV,O
),O
ion,O
.,O
When,O
the,O
5,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
group,B-MODIFIER
of,O
27,O
and,O
31,O
was,O
replaced,O
by,O
an,O
ethyl,B-IUPAC
or,O
an,O
isopropyl,B-IUPAC
group,B-MODIFIER
",",O
the,O
anti,O
-,O
HIV,O
-,O
1,O
activity,O
was,O
improved,O
remarkably,O
[,O
EC50,O
:,O
5,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
ethoxymethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylthio,I-IUPAC
),I-IUPAC
-,I-IUPAC
uracil,I-IUPAC
(,O
46,O
),O
",",O
0.019,O
microM,O
;,O
5,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
benzyloxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylthio,I-IUPAC
),I-IUPAC
uracil,I-IUPAC
(,O
52,O
),O
",",O
0.0059,O
microM,O
;,O
5,B-IUPAC
-,I-IUPAC
isopropyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
ethoxymethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylthio,I-IUPAC
),I-IUPAC
uracil,I-IUPAC
(,O
55,O
),O
",",O
0.012,O
microM,O
;,O
5,B-IUPAC
-,I-IUPAC
isopropyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
benzyloxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylthio,I-IUPAC
),I-IUPAC
uracil,I-IUPAC
(,O
56,O
),O
",",O
0.0027,O
microM,O
],O
.,O
The,O
strongly,O
increased,O
stereoselectivity,O
of,O
2,O
",",O
4,O
",",O
and,O
5,O
as,O
compared,O
to,O
that,O
of,O
8,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
di,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
propylamino,I-IUPAC
),I-IUPAC
tetralin,I-IUPAC
(,O
8,O
-,O
OH,O
-,O
DPAT,O
;,O
1,O
),O
is,O
rationalized,O
on,O
the,O
basis,O
of,O
steric,O
factors,O
.,O
Syntheses,O
of,O
the,O
enantiomers,O
of,O
myo,B-IUPAC
-,I-IUPAC
inositol,I-IUPAC
"1,3,4",I-IUPAC
-,I-IUPAC
trisphosphate,I-IUPAC
are,O
described,O
.,O
Single,O
-,O
crystal,O
X,O
-,O
ray,O
analysis,O
of,O
(,B-IUPAC
+,I-IUPAC
/,I-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
picrate,I-IUPAC
confirmed,O
its,O
trans,O
configuration,O
and,O
provided,O
conformational,O
data,O
.,O
The,O
compounds,O
were,O
evaluated,O
as,O
inhibitors,O
against,O
DHFR,O
from,O
P,O
.,O
Further,O
",",O
both,O
17c,O
and,O
26,O
displayed,O
high,O
intrinsic,O
activity,O
in,O
stimulating,O
the,O
release,O
of,O
[,O
(,O
3,O
),O
H,O
],O
dopamine,O
from,O
striatal,O
synaptosomes,O
;,O
however,O
",",O
only,O
17c,O
was,O
effective,O
at,O
stimulating,O
the,O
release,O
of,O
[,O
(,O
3,O
),O
H,O
],O
acetylcholine,O
from,O
cortical,O
synaptosomes,O
",",O
suggesting,O
differential,O
selectivity,O
.,O
These,O
chlorins,O
on,O
reacting,O
with,O
osmium,O
tetraoxide,O
produced,O
the,O
corresponding,O
vic,O
-,O
dihydroxybacteriochlorins,O
.,O
Removal,O
of,O
the,O
p,B-IUPAC
-,I-IUPAC
methoxybenzyl,I-IUPAC
and,O
allyl,B-IUPAC
groups,B-MODIFIER
gave,O
"2,4,5",B-IUPAC
-,I-IUPAC
tri,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
-,I-IUPAC
myo,I-IUPAC
-,I-IUPAC
inositol,I-IUPAC
which,O
was,O
phosphitylated,O
with,O
bis,B-IUPAC
(,I-IUPAC
benzyloxy,I-IUPAC
),I-IUPAC
(,I-IUPAC
diisopropylamino,I-IUPAC
),I-IUPAC
phosphine,I-IUPAC
to,O
give,O
the,O
fully,O
protected,O
trisphosphite,O
triester,O
.,O
The,O
non,O
-,O
nucleoside,O
nitrile,O
analogs,O
4a,O
-,O
m,O
and,O
carboxamide,B-IUPAC
derivatives,B-MODIFIER
5a,O
-,O
l,O
were,O
",",O
with,O
a,O
few,O
exceptions,O
",",O
essentially,O
inactive,O
against,O
HCMV,O
and,O
HSV,O
-,O
1,O
and,O
relatively,O
nontoxic,O
.,O
Several,O
4,B-MODIFIER
-,I-MODIFIER
N,I-MODIFIER
-,I-MODIFIER
unsubstituted,I-MODIFIER
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
alkylamino,I-IUPAC
),I-IUPAC
pyridothiadiazines,I-IUPAC
and,O
some,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
alkylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
chlorobenzothiadiazines,I-IUPAC
were,O
found,O
to,O
be,O
more,O
potent,O
than,O
diazoxide,O
for,O
the,O
inhibition,O
of,O
the,O
insulin,O
-,O
releasing,O
process,O
.,O
To,O
confirm,O
the,O
presence,O
of,O
DiHPhe,O
in,O
the,O
analogue,O
",",O
an,O
enzymatic,O
procedure,O
employing,O
Aspergillus,O
oryzae,O
was,O
developed,O
that,O
liberates,O
in,O
high,O
yield,O
the,O
amino,O
acid,O
residue,O
in,O
position,O
3,O
of,O
the,O
posterior,O
pituitary,O
hormone,O
structure,O
.,O
The,O
linear,O
octadentate,O
ligand,O
"3,4,3",O
-,O
LIHOPO,O
",",O
which,O
contains,O
four,O
1,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
),I-IUPAC
-,I-IUPAC
pyridinone,I-IUPAC
(,O
"1,2",O
-,O
HOPO,O
),O
groups,O
",",O
is,O
the,O
most,O
effective,O
agent,O
for,O
in,O
vivo,O
chelation,O
of,O
Pu,O
(,O
IV,O
),O
yet,O
prepared,O
.,O
Water,O
-,O
soluble,O
prodrugs,O
of,O
potent,O
",",O
A,O
(,O
2A,O
),O
-,O
selective,O
adenosine,O
receptor,O
(,O
AR,O
),O
antagonists,O
were,O
prepared,O
.,O
The,O
most,O
potent,O
compound,O
of,O
the,O
series,O
was,O
(,B-IUPAC
1S,I-IUPAC
",",I-IUPAC
2R,I-IUPAC
),I-IUPAC
-,I-IUPAC
cis,I-IUPAC
-,I-IUPAC
2,I-IUPAC
[,I-IUPAC
[,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxyamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxoethyl,I-IUPAC
],I-IUPAC
methylamino,I-IUPAC
],I-IUPAC
carbonyl,I-IUPAC
],I-IUPAC
cyclohexanecarboxylic,I-IUPAC
acid,I-IUPAC
(,O
21a,O
),O
with,O
an,O
IC50,O
value,O
of,O
7.0,O
nM,O
compared,O
with,O
the,O
value,O
of,O
3.0,O
nM,O
for,O
captopril,O
.,O
The,O
replacement,O
of,O
the,O
phenyl,O
ring,O
in,O
etoxadrol,O
by,O
either,O
a,O
2,O
-,O
or,O
3,O
-,O
thienyl,O
ring,O
led,O
to,O
compounds,O
with,O
affinity,O
comparable,O
to,O
etoxadrol,O
",",O
and,O
the,O
replacement,O
of,O
the,O
ethyl,O
moiety,O
on,O
etoxadrol,O
's,O
dioxolane,O
ring,O
with,O
propyl,O
(,O
7,O
),O
or,O
isopropyl,O
(,O
8,O
),O
led,O
to,O
compounds,O
which,O
were,O
more,O
potent,O
than,O
etoxadrol,O
or,O
PCP,O
.,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
Hydroxyethoxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methylimidazole,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
was,O
prepared,O
by,O
alkylation,O
of,O
the,O
imidazole,O
13,O
with,O
(,B-IUPAC
2,I-IUPAC
-,I-IUPAC
acetoxyethoxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
bromide,I-IUPAC
followed,O
by,O
treatment,O
with,O
methanolic,O
ammonia,O
.,O
An,O
I2,O
-,O
catalyzed,O
isomerization,O
of,O
the,O
intermediate,O
9Z,B-IUPAC
-,I-IUPAC
aldehyde,I-IUPAC
yielded,O
the,O
all,B-IUPAC
-,I-IUPAC
E,I-IUPAC
-,I-IUPAC
aldehyde,I-IUPAC
",",O
which,O
was,O
olefinated,O
as,O
above,O
to,O
yield,O
the,O
(,B-PARTIUPAC
all,I-PARTIUPAC
-,I-PARTIUPAC
E,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
and,O
(,B-IUPAC
13Z,I-IUPAC
),I-IUPAC
-,I-IUPAC
retinoic,I-IUPAC
acid,I-IUPAC
analogs,B-MODIFIER
of,O
1,O
.,O
The,O
rank,O
order,O
of,O
potency,O
was,O
(,O
R,O
",",O
S,O
),O
-,O
trans,O
-,O
8,O
-,O
OH,O
-,O
PIPAT,O
&,O
gt,O
;,O
(,O
R,O
",",O
S,O
),O
-,O
8,O
-,O
OH,O
-,O
DPAT,O
&,O
gt,O
;,O
WB4101,O
&,O
gt,O
;,O
5,O
-,O
HT,O
&,O
gt,O
;,O
(,O
R,O
",",O
S,O
),O
-,O
trans,O
-,O
7,O
-,O
OH,O
-,O
PIPAT,O
&,O
gt,O
;,O
(,O
R,O
",",O
S,O
),O
-,O
7,O
-,O
OH,O
-,O
DPAT,O
&,O
gt,O
;,O
(,B-IUPAC
R,I-IUPAC
",",I-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
propranolol,I-IUPAC
&,O
gt,O
;,O
spiperone,O
&,O
gt,O
;,O
&,O
gt,O
;,O
ketanserin,O
&,O
gt,O
;,O
&,O
gt,O
;,O
dopamine,O
&,O
gt,O
;,O
atropine,O
.,O
Antiviral,O
evaluation,O
of,O
these,O
compounds,O
revealed,O
a,O
very,O
potent,O
antiherpetic,O
activity,O
associated,O
with,O
the,O
Northern,O
thymidine,O
analogue,O
2,O
",",O
which,O
was,O
more,O
powerful,O
than,O
the,O
reference,O
standard,O
acyclovir,O
against,O
both,O
HSV,O
-,O
1,O
and,O
HSV,O
-,O
2,O
.,O
The,O
isomeric,B-MODIFIER
pivaloyloxymethyl,B-IUPAC
derivatives,B-MODIFIER
of,O
9,O
",",O
compounds,O
43,O
and,O
44,O
",",O
were,O
synthesized,O
and,O
tested,O
as,O
potential,O
prodrugs,O
in,O
the,O
isoniazide,O
animal,O
model,O
.,O
The,O
thioanilide,O
side,O
chain,O
featured,O
in,O
3,B-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
trifluoromethyl,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
thioxoethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
phthalazineacetic,I-IUPAC
acid,I-IUPAC
(,O
195,O
),O
proved,O
to,O
be,O
an,O
effective,O
surrogate,O
for,O
benzothiazole,O
.,O
Condensation,O
of,O
4,B-IUPAC
-,I-IUPAC
bromo,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methylisoquinoline,I-IUPAC
(,O
4,O
),O
with,O
ammonium,O
hydroxide,O
",",O
methylamine,O
",",O
ethylamine,O
",",O
and,O
N,B-IUPAC
-,I-IUPAC
acetylethylenediamine,I-IUPAC
gave,O
the,O
corresponding,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
",",O
4,B-IUPAC
-,I-IUPAC
methylamino,I-IUPAC
",",O
4,B-IUPAC
-,I-IUPAC
ethylamino,I-IUPAC
",",O
and,O
4,B-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
acetylethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
derivatives,B-MODIFIER
",",O
which,O
were,O
then,O
converted,O
to,O
amides,O
and,O
subsequently,O
oxidized,O
to,O
aldehydes,O
followed,O
by,O
condensation,O
with,O
thiosemicarbazide,O
to,O
yield,O
thiosemicarbazones,O
8a,O
-,O
c,O
",",O
9a,O
-,O
c,O
",",O
and,O
16,O
.,O
Strips,O
of,O
rabbit,O
bladder,O
neck,O
were,O
employed,O
as,O
a,O
predictive,O
assay,O
for,O
antagonism,O
in,O
the,O
human,O
lower,O
tract,O
.,O
These,O
compounds,O
will,O
serve,O
as,O
templates,O
in,O
the,O
design,O
of,O
still,O
further,O
sigma,O
-,O
2,O
subtype,O
selective,O
ligands,O
.,O
Negative,O
results,O
obtained,O
with,O
other,O
17,O
alpha,O
-,O
electrophilic,O
estradiol,O
derivatives,O
suggested,O
that,O
affinity,O
labeling,O
of,O
the,O
receptor,O
by,O
such,O
derivatives,O
required,O
a,O
minimal,O
distance,O
",",O
including,O
at,O
least,O
four,O
C,O
-,O
C,O
or,O
C,O
-,O
N,O
bonds,O
",",O
between,O
the,O
steroid,O
and,O
the,O
electrophilic,O
carbon,O
.,O
The,O
development,O
of,O
a,O
prostaglandin,O
PGF2,O
alpha,O
photoaffinity,O
probe,O
led,O
to,O
the,O
synthesis,O
and,O
biological,O
evaluation,O
of,O
azide,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
17,B-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
"18,19,20",I-IUPAC
-,I-IUPAC
trinorprostaglandin,I-IUPAC
F2,I-IUPAC
alpha,I-IUPAC
and,O
16,B-IUPAC
-,I-IUPAC
phenoxy,I-IUPAC
-,I-IUPAC
"17,18,19,20",I-IUPAC
-,I-IUPAC
tetranorprostaglandin,I-IUPAC
F2,I-IUPAC
alpha,I-IUPAC
derivatives,O
.,O
The,O
novel,O
agonists,O
described,O
inhibit,O
6,B-IUPAC
",",I-IUPAC
7,I-IUPAC
-,I-IUPAC
dimethoxy,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
carboline,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
carboxylate,I-IUPAC
-,O
induced,B-MODIFIER
seizures,I-MODIFIER
",",O
and,O
in,O
mouse,O
locomotor,O
activity,O
higher,O
doses,O
are,O
required,O
to,O
reach,O
ED,O
(,O
50,O
),O
values,O
than,O
for,O
reference,O
A,O
(,O
1,O
),O
agonists,O
.,O
This,O
compound,O
shows,O
low,O
cytotoxicity,O
in,O
human,O
peripheral,O
blood,O
mononuclear,O
cells,O
and,O
also,O
has,O
favorable,O
properties,O
in,O
vivo,O
.,O
These,O
results,O
",",O
together,O
with,O
previous,O
autoradiographic,O
brain,O
receptor,O
-,O
mapping,O
studies,O
that,O
indicate,O
similar,O
distribution,O
of,O
[,O
(,O
3,O
),O
H,O
],O
-,O
(,O
-,O
),O
-,O
trans,O
-,O
H,O
(,O
2,O
),O
-,O
PAT,O
sites,O
and,O
[,O
(,O
3,O
),O
H,O
],O
mepyramine,O
-,O
labeled,O
H,O
(,O
1,O
),O
receptors,O
",",O
suggest,O
that,O
both,O
radioligands,O
label,O
the,O
same,O
histamine,O
H,O
(,O
1,O
),O
receptors,O
in,O
rodent,O
brain,O
.,O
This,O
uncommon,O
ring,O
system,O
was,O
obtained,O
in,O
a,O
highly,O
substituted,O
form,O
and,O
in,O
high,O
yield,O
by,O
ozonolysis,O
of,O
the,O
enamine,O
bond,O
of,O
"1,2,3,4",B-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
9H,I-IUPAC
-,I-IUPAC
pyrido,I-IUPAC
[,I-IUPAC
3,I-IUPAC
",",I-IUPAC
4,I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
indole,I-IUPAC
derivatives,B-MODIFIER
(,O
4,O
),O
",",O
in,O
which,O
the,O
configuration,O
of,O
the,O
substituents,O
was,O
established,O
stereoselectively,O
via,O
the,O
Pictet,O
-,O
Spengler,O
reaction,O
.,O
Synthesis,O
methodology,O
was,O
developed,O
for,O
compounds,O
combining,O
three,O
moieties,O
:,O
pyridin,B-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ylmethyl,I-IUPAC
or,O
6,B-IUPAC
-,I-IUPAC
chloropyridin,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ylmethyl,I-IUPAC
and,O
their,O
4,B-PARTIUPAC
-,I-PARTIUPAC
and,O
5,B-IUPAC
-,I-IUPAC
azido,I-IUPAC
analogues,B-MODIFIER
;,O
imidazolidine,B-IUPAC
",",O
4,B-IUPAC
-,I-IUPAC
imidazoline,I-IUPAC
or,O
4,B-IUPAC
-,I-IUPAC
thiazoline,I-IUPAC
;,O
and,O
N,B-MODIFIER
-,I-MODIFIER
unsubstituted,I-MODIFIER
imine,B-IUPAC
",",O
nitroimine,O
",",O
cyanoimine,O
",",O
or,O
nitromethylene,O
.,O
Both,O
the,O
interaction,O
with,O
the,O
receptor,O
and,O
inhibition,O
of,O
cell,O
growth,O
by,O
these,O
two,O
glucocorticoids,O
are,O
reversible,O
.,O
carinii,O
or,O
T,O
.,O
The,O
Ki,O
for,O
inhibition,O
of,O
human,O
DHFR,O
by,O
the,O
5,B-IUPAC
-,I-IUPAC
deaza,I-IUPAC
and,O
5,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
deaza,I-IUPAC
analogues,B-MODIFIER
was,O
about,O
the,O
same,O
as,O
that,O
of,O
3,O
(,O
0.35,O
pM,O
),O
",",O
11,O
-,O
fold,O
lower,O
than,O
that,O
of,O
aminopterin,O
(,O
AMT,O
",",O
1,O
),O
",",O
and,O
15,O
-,O
fold,O
lower,O
than,O
that,O
of,O
methotrexate,O
(,O
MTX,O
",",O
2,O
),O
.,O
Analogue,O
4a,O
and,O
its,O
enantiomer,O
have,O
been,O
tritiated,O
at,O
C,O
-,O
1,O
and,O
both,O
were,O
found,O
to,O
be,O
activated,O
to,O
a,O
nucleotide,O
sugar,O
",",O
which,O
was,O
followed,O
by,O
incorporation,O
into,O
the,O
macromolecular,O
fraction,O
of,O
SW613,O
human,O
mammary,O
tumor,O
cells,O
in,O
vitro,O
.,O
Acylation,O
of,O
THF,O
with,O
chloroacetyl,O
chloride,O
gave,O
a,O
N5,O
",",O
N10,O
-,O
diacylated,O
product,O
(,O
18,O
or,O
19,O
),O
",",O
which,O
could,O
not,O
be,O
converted,O
to,O
"5,10",O
-,O
COCH2,O
),O
-,O
THF,O
(,O
17,O
),O
.,O
The,O
delta,O
Tm,O
values,O
for,O
the,O
5H,O
series,O
were,O
found,O
to,O
be,O
about,O
10,O
times,O
as,O
high,O
as,O
those,O
for,O
the,O
6H,O
compounds,O
.,O
To,O
provide,O
a,O
firm,O
basis,O
for,O
comparison,O
purposes,O
of,O
future,O
analogues,O
",",O
an,O
X,O
-,O
ray,O
analysis,O
was,O
performed,O
on,O
a,O
single,O
crystal,O
of,O
ethyl,B-IUPAC
(,I-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
dimethylthiochroman,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propenyl,I-IUPAC
],I-IUPAC
benzoate,I-IUPAC
(,O
1b,O
),O
and,O
a,O
precursor,O
"4,4",B-IUPAC
-,I-IUPAC
dimethylthiochroman,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
methyl,I-IUPAC
ketone,I-IUPAC
"1,1",I-IUPAC
-,I-IUPAC
dioxide,I-IUPAC
(,O
18,O
),O
.,O
The,O
3,B-IUPAC
-,I-IUPAC
deazaguanosine,I-IUPAC
3',I-IUPAC
",",I-IUPAC
5',I-IUPAC
-,I-IUPAC
cyclic,I-IUPAC
phosphate,I-IUPAC
(,O
13,O
),O
was,O
prepared,O
from,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
cyanomethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
ribofuranosyl,I-IUPAC
-,I-IUPAC
imidazole,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
5',I-IUPAC
-,I-IUPAC
phosphate,I-IUPAC
.,O
It,O
was,O
more,O
potent,O
than,O
",",O
and,O
equally,O
efficacious,O
to,O
",",O
L,O
-,O
glutamate,O
in,O
[,O
3H,O
],O
MK801,O
binding,O
.,O
5,O
-,O
Bromo,O
-,O
dUMP,O
and,O
5,O
-,O
iodo,O
-,O
dUMP,O
showed,O
substrate,O
activity,O
independent,O
of,O
N,B-IUPAC
(,I-IUPAC
5,I-IUPAC
),I-IUPAC
",",I-IUPAC
N,I-IUPAC
(,I-IUPAC
10,I-IUPAC
),I-IUPAC
-,I-IUPAC
methylenetetrahydrofolate,I-IUPAC
in,O
the,O
thymidylate,O
synthase,O
-,O
catalyzed,O
dehalogenation,O
reaction,O
.,O
Conversely,O
",",O
(,B-IUPAC
1R,I-IUPAC
",",I-IUPAC
2R,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
chlorobenzylamino,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
imidazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
cyclopropane,I-IUPAC
(,O
10a,O
),O
with,O
the,O
(,O
1R,O
),O
-,O
trans,O
structure,O
was,O
selective,O
for,O
the,O
H4,O
receptor,O
(,O
Ki,O
=,O
118,O
nM,O
),O
compared,O
to,O
the,O
H3,O
receptor,O
(,O
Ki,O
&,O
gt,O
;,O
10,O
(,O
3,O
),O
nM,O
),O
.,O
The,O
conformation,O
of,O
sulfonyl,B-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
hydroxyguanidine,I-IUPAC
derivatives,B-MODIFIER
",",O
such,O
as,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
chlorophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N',I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
benzo,I-IUPAC
[,I-IUPAC
"2,1,3",I-IUPAC
],I-IUPAC
thiadiazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
sulfonyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
N,I-IUPAC
"""",I-IUPAC
-,I-IUPAC
hydroxyguanidine,I-IUPAC
(,O
4g,O
),O
",",O
investigated,O
utilizing,O
HMBC,O
NMR,O
",",O
theoretical,O
calculations,O
",",O
and,O
X,O
-,O
ray,O
crystallography,O
",",O
indicated,O
stacking,O
of,O
the,O
two,O
aromatic,O
rings,O
.,O
The,O
protected,O
intermediate,O
above,O
was,O
synthesized,O
from,O
Z,O
-,O
Cys,O
(,O
Bzl,O
),O
-,O
Pro,O
-,O
Leu,O
-,O
Gly,O
-,O
NH2,O
by,O
the,O
stepwose,O
p,O
-,O
nitrophenyl,O
ester,O
method,O
using,O
Nalpha,O
-,O
Boc,O
protection,O
at,O
the,O
penta,O
-,O
",",O
hexa,O
-,O
",",O
and,O
octapeptide,O
stages,O
.,O
The,O
two,O
classes,O
of,O
inactivators,O
(,O
O',B-IUPAC
-,I-IUPAC
epoxyalkyl,I-IUPAC
and,O
carboxy,B-IUPAC
-,I-IUPAC
epoxyalkyl,I-IUPAC
),O
appear,O
to,O
operate,O
by,O
different,O
mechanisms,O
.,O
Phosphates,O
of,O
the,O
aliphatic,O
alcohol,O
5e,O
could,O
be,O
obtained,O
by,O
both,O
methods,O
in,O
similar,O
yields,O
.,O
Treatment,O
of,O
the,O
iodohydrins,O
11a,O
-,O
c,O
with,O
methanolic,O
sulfuric,O
acid,O
afforded,O
the,O
corresponding,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
iodoethyl,I-IUPAC
),I-IUPAC
derivatives,B-MODIFIER
(,O
12a,O
-,O
c,O
),O
.,O
The,O
"4,5",B-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
3H,I-IUPAC
-,I-IUPAC
naphtho,I-IUPAC
[,I-IUPAC
"1,8",I-IUPAC
-,I-IUPAC
bc,I-IUPAC
],I-IUPAC
thiophene,I-IUPAC
derivative,B-MODIFIER
(,B-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
7,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
pyrrolidinyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
oxaspiro,I-IUPAC
[,I-IUPAC
4.5,I-IUPAC
],I-IUPAC
dec,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
-,I-IUPAC
3H,I-IUPAC
-,I-IUPAC
naphthol,I-IUPAC
[,I-IUPAC
"1,8",I-IUPAC
-,I-IUPAC
bc,I-IUPAC
],I-IUPAC
thiophene,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
p,I-IUPAC
-,I-IUPAC
toluenesulfonate,I-IUPAC
(,O
17,O
),O
also,O
has,O
high,O
kappa,O
opioid,O
receptor,O
affinity,O
and,O
selectivity,O
(,O
kappa,O
Ki,O
=,O
4.65,O
nM,O
",",O
mu,O
/,O
kappa,O
=,O
109,O
),O
.,O
The,O
prototypes,O
",",O
belonging,O
to,O
five,O
chemical,O
series,O
",",O
were,O
evaluated,O
for,O
their,O
estrogen,O
receptor,O
affinity,O
and,O
for,O
estrogen,O
agonist,O
-,O
antagonist,O
activities,O
.,O
The,O
key,O
step,O
in,O
each,O
preparation,O
was,O
the,O
condensation,O
of,O
the,O
appropriate,O
chroman,B-IUPAC
-,O
",",O
thiochroman,B-IUPAC
-,I-IUPAC
",",O
or,O
benzothienyl,B-IUPAC
-,I-IUPAC
substituted,B-MODIFIER
phosphorus,B-IUPAC
ylide,I-IUPAC
",",O
obtained,O
from,O
the,O
independent,O
synthesis,O
of,O
the,O
corresponding,O
phosphonium,O
salts,O
",",O
with,O
selected,O
polyene,B-IUPAC
-,O
substituted,B-MODIFIER
aldehyde,B-IUPAC
esters,I-IUPAC
.,O
An,O
enzymatically,O
activated,O
liposome,O
-,O
based,O
drug,O
-,O
delivery,O
concept,O
involving,O
masked,O
antitumor,O
ether,O
lipids,O
(,O
AELs,O
),O
has,O
been,O
investigated,O
.,O
The,O
three,O
synthesized,O
proAELs,O
were,O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
hexadecyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
palmitoyl,I-IUPAC
-,I-IUPAC
sn,I-IUPAC
-,I-IUPAC
glycero,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
phosphocholine,I-IUPAC
(,O
1,O
-,O
O,O
-,O
DPPC,O
),O
",",O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
hexadecyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
palmitoyl,I-IUPAC
-,I-IUPAC
sn,I-IUPAC
-,I-IUPAC
glycero,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
phosphoethanolamine,I-IUPAC
poly,I-IUPAC
(,I-IUPAC
ethylene,I-IUPAC
glycol,I-IUPAC
),I-IUPAC
(,O
350,O
),O
(,O
1,O
-,O
O,O
-,O
DPPE,O
-,O
PEG,O
(,O
350,O
),O
),O
",",O
and,O
1,O
-,O
O,O
-,O
DPPE,O
-,O
PEG,O
(,O
2000,O
),O
of,O
which,O
1,O
-,O
O,O
-,O
DPPC,O
was,O
the,O
main,O
liposome,O
component,O
.,O
Although,O
beta,B-IUPAC
",",I-IUPAC
gamma,I-IUPAC
-,I-IUPAC
methylene,I-IUPAC
-,I-IUPAC
ATP,I-IUPAC
was,O
inactive,O
at,O
P2Y,O
receptors,O
",",O
beta,B-IUPAC
",",I-IUPAC
gamma,I-IUPAC
-,I-IUPAC
methylene,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
),I-IUPAC
-,I-IUPAC
methanocarba,I-IUPAC
-,I-IUPAC
ATP,I-IUPAC
was,O
a,O
potent,O
hP2Y,O
(,O
1,O
),O
receptor,O
agonist,O
with,O
an,O
EC,O
(,O
50,O
),O
of,O
160,O
nM,O
and,O
was,O
selective,O
versus,O
hP2Y,O
(,O
2,O
),O
and,O
hP2Y,O
(,O
4,O
),O
receptors,O
.,O
The,O
cytotoxic,O
activities,O
of,O
the,O
derived,O
compounds,O
against,O
the,O
human,O
tumor,O
cell,O
lines,O
were,O
equal,O
to,O
or,O
greater,O
than,O
that,O
of,O
the,O
lead,O
compound,O
.,O
;,O
Wins,O
",",O
P,O
.,O
The,O
compound,O
3h,O
",",O
which,O
has,O
a,O
3,B-IUPAC
-,I-IUPAC
dimethylaminopropyl,I-IUPAC
substituent,B-MODIFIER
on,O
the,O
quinolone,O
nitrogen,O
and,O
a,O
methoxycarbonyl,B-IUPAC
substituent,B-MODIFIER
at,O
position,O
9,O
",",O
had,O
marked,O
antitumor,O
activity,O
.,O
Orotyl,B-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
leucyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
leucine,I-IUPAC
",",O
5,B-IUPAC
-,I-IUPAC
fluoro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
succinamoyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
alanyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
leucine,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
),I-IUPAC
-,I-IUPAC
pyrimidinone,I-IUPAC
[,O
a,O
5,B-IUPAC
-,I-IUPAC
fluorocytosine,I-IUPAC
derivative,B-MODIFIER
],O
",",O
and,O
5,B-IUPAC
-,I-IUPAC
fluoroorotyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
leucyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
leucine,I-IUPAC
all,O
inhibited,O
the,O
uptake,O
of,O
trimethionine,O
into,O
C,O
.,O
Ten,O
heretofore,O
undescribed,O
"2,4",B-IUPAC
-,I-IUPAC
diamino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
chloroquinazoline,I-IUPAC
analogues,B-MODIFIER
of,O
trimetrexate,O
(,O
TMQ,O
),O
and,O
piritrexim,O
(,O
PTX,O
),O
were,O
synthesized,O
and,O
tested,O
as,O
inhibitors,O
of,O
dihydrofolate,O
reductase,O
(,O
DHFR,O
),O
from,O
rat,O
liver,O
",",O
Pneumocystis,O
carinii,O
",",O
and,O
Toxoplasma,O
gondii,O
.,O
"4,5",O
-,O
Diphenyl,O
-,O
2,O
-,O
oxazolenonanoic,O
acid,O
(,O
2,O
),O
and,O
2,B-IUPAC
-,I-IUPAC
[,I-IUPAC
3,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
diphenyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxazolyl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
phenoxy,I-IUPAC
],I-IUPAC
acetic,I-IUPAC
acid,I-IUPAC
(,O
3,O
),O
were,O
previously,O
identified,O
as,O
nonprostanoid,O
prostacyclin,O
(,O
PGI2,O
),O
mimetics,O
that,O
inhibit,O
ADP,O
-,O
induced,O
aggregation,O
of,O
human,O
platelets,O
in,O
vitro,O
.,O
All,O
of,O
these,O
compounds,O
were,O
cytotoxic,O
to,O
H,O
.,O
2,B-IUPAC
-,I-IUPAC
Amino,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phosphonomethoxy,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
was,O
obtained,O
from,O
the,O
appropriate,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
chloropyrimidine,I-IUPAC
derivative,B-MODIFIER
by,O
alkaline,O
hydrolysis,O
and,O
ester,O
cleavage,O
.,O
The,O
broad,O
spectrum,O
excitatory,O
amino,O
acid,O
antagonist,O
activity,O
of,O
the,O
4,O
-,O
unsubstituted,O
analogue,O
21,O
(,O
KbNMDA,O
=,O
6.7,O
microM,O
",",O
KbAMPA,O
=,O
9.2,O
microM,O
),O
and,O
the,O
glycine,O
/,O
NMDA,O
selectivity,O
of,O
the,O
other,O
3,B-IUPAC
-,I-IUPAC
nitro,I-IUPAC
derivatives,B-MODIFIER
allows,O
the,O
proposal,O
of,O
a,O
model,O
for,O
AMPA,O
receptor,O
binding,O
which,O
differs,O
from,O
the,O
glycine,O
binding,O
pharmacophore,O
in,O
that,O
there,O
is,O
bulk,O
intolerance,O
adjacent,O
to,O
the,O
4,O
-,O
position,O
.,O
The,O
excitatory,O
activity,O
in,O
rat,O
cortical,O
wedge,O
also,O
showed,O
that,O
ACPA,O
was,O
more,O
potent,O
than,O
AMPA,O
(,O
EC50,O
=,O
1.0,O
microM,O
compared,O
to,O
EC50,O
=,O
3.5,O
microM,O
for,O
AMPA,O
),O
.,O
-,O
2,O
cells,O
",",O
but,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
bromoacetamido,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
hypoxanthine,I-IUPAC
displayed,O
in,O
vivo,O
activity,O
against,O
Trypanosoma,O
rhodesiense,O
.,O
A,O
competitive,O
intracellular,O
localization,O
study,O
of,O
these,O
novel,O
structures,O
with,O
Rhodamine,O
-,O
123,O
(,O
a,O
mitochondrial,O
probe,O
),O
indicated,O
their,O
preferential,O
localization,O
in,O
mitochondria,O
",",O
without,O
producing,O
any,O
specific,O
displacement,O
of,O
(,O
3,O
),O
H,O
-,O
PK11195,O
(,O
PBR,O
probe,O
",",O
(,B-MODIFIER
3,I-MODIFIER
),I-MODIFIER
H,I-MODIFIER
-,I-MODIFIER
labeled,I-MODIFIER
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
chlorophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methylpropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
isoquinoline,I-IUPAC
carboxamide,I-IUPAC
),O
.,O
Analogues,O
1,O
",",O
2,O
",",O
3,O
",",O
and,O
5,O
have,O
also,O
been,O
shown,O
to,O
antagonize,O
the,O
in,O
vivo,O
oxytocic,O
responses,O
to,O
oxytocin,O
.,O
While,O
these,O
solubilized,O
pyrimido,B-IUPAC
[,I-IUPAC
"5,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
analogues,B-MODIFIER
were,O
less,O
potent,O
than,O
the,O
NHMe,O
derivative,O
5c,O
in,O
the,O
isolated,O
enzyme,O
assay,O
",",O
some,O
were,O
considerably,O
superior,O
to,O
5c,O
(,O
and,O
among,O
the,O
most,O
potent,O
ever,O
reported,O
),O
as,O
inhibitors,O
of,O
EGFR,O
autophosphorylation,O
in,O
cellular,O
assays,O
.,O
Potent,O
anxiolytic,O
activity,O
in,O
the,O
black,O
/,O
white,O
box,O
exploration,O
test,O
in,O
rats,O
was,O
found,O
with,O
the,O
two,O
most,O
prominent,O
sigma,O
2,O
ligands,O
Lu,O
29-253,O
and,O
Lu,O
28-179,O
.,O
Compound,O
10,O
was,O
also,O
effective,O
in,O
suppressing,O
seizures,O
induced,O
in,O
Swiss,O
mice,O
by,O
maximal,O
electroshock,O
(,O
MES,O
),O
or,O
pentylenetetrazole,O
(,O
PTZ,O
),O
.,O
Two,O
of,O
the,O
designed,O
ligands,O
(,O
10e,O
and,O
10f,O
),O
showed,O
the,O
highest,O
affinities,O
(,O
34,O
and,O
24,O
nM,O
",",O
respectively,O
),O
reported,O
so,O
far,O
for,O
a,O
DAG,O
analogue,O
.,O
The,O
ability,O
of,O
conjugates,O
of,O
peptides,O
and,O
5,B-IUPAC
-,I-IUPAC
fluorocytosine,I-IUPAC
or,O
5,B-IUPAC
-,I-IUPAC
fluoroorotic,I-IUPAC
acid,I-IUPAC
to,O
enter,O
Candida,O
albicans,O
was,O
investigated,O
.,O
While,O
vasorelaxant,O
activity,O
was,O
critically,O
dependent,O
on,O
the,O
size,O
of,O
the,O
C5,O
ester,B-IUPAC
group,B-MODIFIER
",",O
isopropyl,O
ester,O
being,O
the,O
best,O
",",O
a,O
variety,O
of,O
substituents,B-MODIFIER
(,O
carbamate,B-IUPAC
",",O
acyl,B-IUPAC
",",O
sulfonyl,B-IUPAC
",",O
alkyl,B-IUPAC
),O
were,O
tolerated,O
at,O
N3,O
.,O
Condensation,O
of,O
19,O
with,O
morpholine,O
followed,O
by,O
catalytic,O
reduction,O
of,O
the,O
nitro,O
group,O
and,O
treatment,O
with,O
thiosemicarbazide,O
afforded,O
5,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
morpholinoisoquinoline,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
carboxaldehyde,I-IUPAC
thiosemicarbazone,I-IUPAC
(,O
22,O
),O
.,O
A,O
series,O
of,O
unsaturated,O
analogues,O
of,O
nucleosides,O
were,O
prepared,O
and,O
their,O
cytotoxic,O
",",O
antitumor,O
",",O
and,O
antiviral,O
activities,O
were,O
investigated,O
.,O
These,O
same,O
five,O
compounds,O
",",O
as,O
well,O
as,O
the,O
lead,O
compound,O
Analog,O
II,O
",",O
were,O
active,O
in,O
vitro,O
against,O
the,O
estrogen,O
-,O
dependent,O
MCF,O
-,O
7,O
human,O
breast,O
tumor,O
cell,O
line,O
in,O
a,O
dose,O
-,O
dependent,O
fashion,O
.,O
The,O
expected,O
thermodynamic,O
stability,O
resulting,O
from,O
the,O
preorganization,O
of,O
the,O
pseudosugar,O
rings,O
into,O
a,O
Northern,O
conformation,O
",",O
typical,O
of,O
A,O
-,O
DNA,O
",",O
was,O
evident,O
by,O
the,O
increase,O
in,O
Tm,O
of,O
the,O
corresponding,O
DNA,O
/,O
RNA,O
heteroduplex,O
.,O
The,O
aryl,O
group,O
in,O
the,O
"5,6",O
-,O
disubstituted,O
analogues,O
was,O
either,O
attached,O
directly,O
to,O
the,O
hetero,O
ring,O
or,O
was,O
separated,O
from,O
it,O
by,O
one,O
or,O
two,O
carbons,O
",",O
whereas,O
the,O
aryl,O
group,O
in,O
the,O
5,O
-,O
monosubstituted,O
analogues,O
was,O
separated,O
from,O
the,O
hetero,O
ring,O
by,O
two,O
or,O
three,O
carbons,O
.,O
Esterification,O
of,O
2a,O
with,O
isobutylene,O
afforded,O
tert,B-IUPAC
-,I-IUPAC
butyl,I-IUPAC
3,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
carbobenzoxy,I-IUPAC
-,I-IUPAC
(,I-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
diaminopropionate,I-IUPAC
(,O
3a,O
),O
",",O
which,O
was,O
then,O
blocked,O
at,O
the,O
2,O
position,O
with,O
the,O
tert,B-IUPAC
-,I-IUPAC
butoxycarbonyl,I-IUPAC
(,O
Boc,O
),O
group,B-MODIFIER
to,O
give,O
tert,B-IUPAC
-,I-IUPAC
butyl,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
butoxycarbonyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
carbobenzoxy,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
propionate,I-IUPAC
(,O
4,O
),O
.,O
The,O
first,O
one,O
is,O
the,O
presence,O
of,O
a,O
monosubstituted,B-MODIFIER
N,B-IUPAC
-,I-IUPAC
hydroxyguanidine,I-IUPAC
function,O
",",O
since,O
disubstituted,B-MODIFIER
N,B-IUPAC
-,I-IUPAC
hydroxyguanidines,I-IUPAC
",",O
amidoximes,O
",",O
ketoximes,O
",",O
and,O
aldoximes,O
failed,O
to,O
produce,O
NO,O
.,O
),O
indicated,O
that,O
the,O
epoxyalkyl,O
group,O
on,O
the,O
phenolic,O
oxygen,O
had,O
an,O
optimal,O
length,O
of,O
four,O
carbons,O
with,O
respect,O
to,O
the,O
turnover,O
ratio,O
(,O
the,O
ratio,O
of,O
molecules,O
undergoing,O
turnover,O
compared,O
to,O
those,O
that,O
inactivate,O
the,O
enzyme,O
),O
for,O
chymotrypsin,O
.,O
2,B-IUPAC
-,I-IUPAC
Cl,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
),I-IUPAC
-,I-IUPAC
methanocarba,I-IUPAC
-,I-IUPAC
ATP,I-IUPAC
and,O
its,O
N,O
(,O
6,O
),O
-,O
Me,O
analogue,O
were,O
also,O
highly,O
selective,O
",",O
full,O
agonists,O
at,O
P2Y,O
(,O
1,O
),O
receptors,O
.,O
44,O
also,O
inhibited,O
platelet,O
aggregation,O
ex,O
vivo,O
in,O
guinea,O
pigs,O
.,O
Reaction,O
of,O
2,O
with,O
sodium,O
azide,O
",",O
ceric,O
ammonium,O
nitrate,O
",",O
and,O
acetonitrile,O
-,O
methanol,O
or,O
water,O
afforded,O
the,O
5,B-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
1,I-PARTIUPAC
-,I-PARTIUPAC
hydroxy,I-PARTIUPAC
-,I-PARTIUPAC
2,I-PARTIUPAC
-,I-PARTIUPAC
azidoethyl,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
(,O
10,O
),O
and,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
azidoethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridines,I-IUPAC
(,O
11,O
),O
.,O
A,O
number,O
of,O
agents,O
",",O
most,O
notably,O
14,B-IUPAC
-,I-IUPAC
(,I-IUPAC
carbethoxymethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
14,I-IUPAC
-,I-IUPAC
thiaadriamycin,I-IUPAC
and,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
trifluoroacetyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
14,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
14,I-IUPAC
-,I-IUPAC
selenaadriamycin,I-IUPAC
",",O
were,O
active,O
against,O
murine,O
L1210,O
leukemia,O
in,O
vivo,O
.,O
The,O
trans,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
indenes,I-IUPAC
(,O
+,O
),O
-,O
14b,O
and,O
(,O
+,O
),O
-,O
15b,O
represent,O
selective,O
D1,O
agonists,O
lacking,O
a,O
catechol,O
group,O
",",O
which,O
should,O
meet,O
the,O
prerequisites,O
for,O
a,O
central,O
nervous,O
system,O
penetration,O
.,O
By,O
this,O
approach,O
compounds,O
such,O
as,O
(,B-IUPAC
3R,I-IUPAC
",",I-IUPAC
5S,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
adamantyl,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
chlorobenzyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxymet,I-IUPAC
hyl,I-IUPAC
aminocarbonyl,I-IUPAC
-,I-IUPAC
"2,7",I-IUPAC
-,I-IUPAC
dioxo,I-IUPAC
-,I-IUPAC
"2,3,4,5,6,7",I-IUPAC
-,I-IUPAC
hexahydro,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
benzo,I-IUPAC
[,I-IUPAC
h,I-IUPAC
],I-IUPAC
[,I-IUPAC
1,I-IUPAC
",",I-IUPAC
4,I-IUPAC
],I-IUPAC
diazonine,I-IUPAC
(,O
32,O
),O
were,O
prepared,O
.,O
A,O
series,O
of,O
gallium,O
(,O
III,O
),O
and,O
iron,O
(,O
III,O
),O
complexes,O
with,O
five,O
different,O
4N,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
alpha,B-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
heterocyclic,I-IUPAC
thiosemicarbazones,I-IUPAC
",",O
viz,O
.,O
Degarelix,O
(,O
FE200486,O
",",O
Ac,O
-,O
d,O
-,O
2Nal,O
(,O
1,O
),O
-,O
d,O
-,O
4Cpa,O
(,O
2,O
),O
-,O
d,O
-,O
3Pal,O
(,O
3,O
),O
-,O
Ser,O
(,O
4,O
),O
-,O
4Aph,O
(,O
l,O
-,O
Hor,O
),O
(,O
5,O
),O
-,O
d,O
-,O
4Aph,O
(,O
Cbm,O
),O
(,O
6,O
),O
-,O
Leu,O
(,O
7,O
),O
-,O
ILys,O
(,O
8,O
),O
-,O
Pro,O
(,O
9,O
),O
-,O
d,O
-,O
Ala,O
(,O
10,O
),O
-,O
NH,O
(,O
2,O
),O
),O
is,O
a,O
potent,O
and,O
very,O
long,O
acting,O
antagonist,O
of,O
gonadotropin,O
-,O
releasing,O
hormone,O
(,O
GnRH,O
),O
after,O
subcutaneous,O
administration,O
in,O
mammals,O
including,O
humans,O
.,O
Using,O
cultured,O
cerebral,O
cortical,O
neurons,O
and,O
whole,O
-,O
cell,O
patch,O
-,O
clamp,O
techniques,O
",",O
the,O
efficacies,O
of,O
these,O
compounds,O
relative,O
to,O
that,O
of,O
the,O
full,O
GABAA,O
agonist,O
",",O
isoguvacine,O
(,O
8,O
),O
(,O
20,O
microM,O
),O
",",O
were,O
determined,O
.,O
Analogs,O
with,O
dihydroxy,B-IUPAC
substituents,B-MODIFIER
(,O
catechols,O
),O
",",O
as,O
well,O
as,O
nitrogen,O
substituents,O
larger,O
than,O
methyl,O
",",O
had,O
little,O
affinity,O
for,O
[,O
3H,O
],O
4,O
binding,O
sites,O
and,O
did,O
not,O
significantly,O
affect,O
TH,O
activity,O
.,O
Most,O
potent,O
among,O
the,O
bicyclic,O
derivatives,O
was,O
2,B-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
butyl,I-IUPAC
-,I-IUPAC
"5,6",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
2',I-IUPAC
-,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
tetrazol,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
biphenyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
meth,I-IUPAC
yl,I-IUPAC
],I-IUPAC
-,I-IUPAC
3H,I-IUPAC
-,I-IUPAC
imidazo,I-IUPAC
[,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,2,4",I-IUPAC
],I-IUPAC
triazole,I-IUPAC
(,O
93,O
",",O
IC50,O
7.8,O
nM,O
),O
.,O
The,O
42,O
platinum,O
(,O
II,O
),O
complexes,O
having,O
a,O
seven,O
-,O
membered,O
ring,O
structure,O
in,O
this,O
series,O
have,O
been,O
prepared,O
and,O
characterized,O
by,O
1H,O
NMR,O
",",O
13C,O
NMR,O
",",O
IR,O
",",O
FAB,O
-,O
MS,O
",",O
and,O
elemental,O
analysis,O
.,O
Synthesis,O
was,O
accomplished,O
via,O
a,O
Schmidt,O
reaction,O
with,O
"5,6,7,8",B-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
methoxynaphthalene,I-IUPAC
-,I-IUPAC
"1,4",I-IUPAC
-,I-IUPAC
diones,I-IUPAC
(,O
THMNDs,O
),O
followed,O
by,O
demethylation,O
.,O
Several,O
of,O
the,O
compounds,O
showed,O
much,O
lower,O
levels,O
of,O
cross,O
-,O
resistance,O
to,O
the,O
P388,O
/,O
AMSA,O
line,O
than,O
classical,O
DNA,O
-,O
intercalating,O
agents,O
",",O
which,O
suggests,O
that,O
their,O
primary,O
mechanism,O
of,O
action,O
may,O
not,O
be,O
via,O
interference,O
with,O
topoisomerase,O
II,O
alpha,O
.,O
Hydrolysis,O
with,O
sodium,O
hydroxide,O
solution,O
gave,O
the,O
corresponding,O
N,B-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
(,I-IUPAC
m,I-IUPAC
-,I-IUPAC
phenylene,I-IUPAC
),I-IUPAC
dioxamic,I-IUPAC
acids,I-IUPAC
.,O
Desulfurization,O
of,O
these,O
thioureas,O
by,O
Raney,O
nickel,O
furnished,O
the,O
desired,O
formamidines,O
(,O
3b,O
-,O
d,O
),O
.,O
On,O
the,O
basis,O
of,O
X,O
-,O
ray,O
crystallographic,O
analyses,O
",",O
the,O
configuration,O
of,O
oxime,O
22a,O
was,O
shown,O
to,O
be,O
E,O
and,O
the,O
absolute,O
configurations,O
of,O
(,O
-,O
),O
-,O
8,O
x,O
HCl,O
and,O
(,O
+,O
),O
-,O
9,O
x,O
HBr,O
were,O
established,O
to,O
be,O
R,O
.,O
Binding,O
studies,O
demonstrated,O
that,O
the,O
activities,O
of,O
2,O
-,O
alkynylAdos,O
were,O
slightly,O
increased,O
for,O
the,O
adenosine,O
A,O
(,O
1,O
),O
receptor,O
and,O
slightly,O
decreased,O
for,O
both,O
A,O
(,O
3,O
),O
and,O
A,O
(,O
2B,O
),O
subtypes,O
compared,O
to,O
those,O
of,O
their,O
corresponding,O
NECA,O
derivatives,O
",",O
whereas,O
the,O
A,O
(,O
2A,O
),O
receptor,O
affinities,O
of,O
the,O
two,O
series,O
of,O
nucleosides,O
were,O
similar,O
.,O
We,O
have,O
developed,O
a,O
new,O
class,O
of,O
sigma,O
subtype,O
selective,O
receptor,O
ligands,O
that,O
are,O
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
benzylidene,I-IUPAC
derivatives,B-MODIFIER
of,O
the,O
synthetic,O
opioid,O
(,B-PARTIUPAC
+,I-PARTIUPAC
/,I-PARTIUPAC
-,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
",",O
(,B-PARTIUPAC
+,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
",",O
and,O
(,B-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxyphenyl,I-IUPAC
),I-IUPAC
morphan,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
1,O
),O
.,O
Structure,O
-,O
activity,O
studies,O
showed,O
that,O
the,O
C,O
-,O
5,O
substituent,O
(,O
I,O
",",O
Br,O
",",O
Cl,O
),O
was,O
a,O
determinant,O
of,O
anti,O
-,O
HIV,O
-,O
1,O
activity,O
where,O
the,O
potency,O
order,O
was,O
I,O
&,O
gt,O
;,O
or,O
=,O
Br,O
&,O
gt,O
;,O
Cl,O
.,O
None,O
of,O
the,O
compounds,O
showed,O
significant,O
activity,O
.,O
Biophys,O
.,O
Several,O
of,O
the,O
amino,O
glycoside,O
unsubstituted,O
14,B-IUPAC
-,I-IUPAC
thiaadriamycin,I-IUPAC
analogues,B-MODIFIER
exhibited,O
DNA,O
-,O
binding,O
properties,O
equivalent,O
to,O
those,O
of,O
adriamycin,O
.,O
These,O
data,O
indicate,O
that,O
such,O
compounds,O
penetrate,O
the,O
blood,O
-,O
brain,O
barrier,O
but,O
their,O
MES,O
activity,O
may,O
not,O
be,O
related,O
to,O
NMDA,O
receptor,O
antagonism,O
.,O
Although,O
2,B-IUPAC
-,I-IUPAC
oxoadenosine,I-IUPAC
is,O
3,O
times,O
more,O
vasoactive,O
than,O
2,B-IUPAC
-,I-IUPAC
aminoadenosine,I-IUPAC
",",O
the,O
activities,O
of,O
the,O
phenyl,B-IUPAC
derivatives,B-MODIFIER
are,O
markedly,O
different,O
;,O
2,B-IUPAC
-,I-IUPAC
phenoxyadenosine,I-IUPAC
is,O
23,O
times,O
weaker,O
than,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylamino,I-IUPAC
),I-IUPAC
adenosine,I-IUPAC
(,O
CV,O
-,O
1808,O
),O
.,O
[,O
3,O
-,O
(,O
"1,4",O
-,O
Cyclohexadienyl,O
),O
-,O
L,O
-,O
alanine,O
",",O
8,O
-,O
lysine,O
],O
vasopressin,O
",",O
otherwise,O
known,O
as,O
[,B-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,5",I-IUPAC
-,I-IUPAC
dihydrophenylalanine,I-IUPAC
),I-IUPAC
",",I-IUPAC
8,I-IUPAC
-,I-IUPAC
lysine,I-IUPAC
],I-IUPAC
vasopressin,I-IUPAC
or,O
[,O
DiHPhe3,O
],O
lysine,O
-,O
vasopressin,O
",",O
has,O
been,O
synthesized,O
in,O
an,O
attempt,O
to,O
utilize,O
"2,5",B-IUPAC
-,I-IUPAC
dihydrophenylalanine,I-IUPAC
(,O
DiHPhe,O
),O
to,O
evaluate,O
the,O
contribution,O
of,O
aromaticity,O
in,O
position,O
3,O
to,O
biological,O
activity,O
.,O
),O
afforded,O
symmetrical,O
dialkylpyrazolo,B-IUPAC
[,I-IUPAC
"1,5",I-IUPAC
-,I-IUPAC
a,I-IUPAC
],I-IUPAC
pyrimidines,I-IUPAC
(,O
5,O
),O
.,O
Addition,O
of,O
2,O
to,O
an,O
equimolar,O
amount,O
of,O
the,O
reaction,O
product,O
of,O
HOPO,O
-,O
C,O
and,O
CDI,O
in,O
N,B-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
dimethylacetamide,I-IUPAC
(,O
DMAA,O
),O
",",O
purification,O
of,O
the,O
hexadentate,O
intermediate,O
",",O
subsequent,O
treatment,O
with,O
an,O
equimolar,O
amount,O
of,O
"2,3",B-IUPAC
-,I-IUPAC
dimethoxybenzoyl,I-IUPAC
chloride,I-IUPAC
(,O
DMB,O
),O
",",O
and,O
deprotection,O
with,O
BBr3,O
gave,O
"1,5,14",B-IUPAC
-,I-IUPAC
tris,I-IUPAC
(,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dihydroxybenzoyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
10,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
pyridon,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
oyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
",",I-IUPAC
"5,10,14",I-IUPAC
-,I-IUPAC
tetraazatetradecane,I-IUPAC
[,O
4,O
",",O
"3,4,3",O
-,O
LI,O
(,O
triCAM,O
-,O
HOPO,O
),O
],O
in,O
5%,O
yield,O
.,O
8,B-IUPAC
-,I-IUPAC
(,I-IUPAC
m,I-IUPAC
-,I-IUPAC
Hydroxystyryl,I-IUPAC
),I-IUPAC
-,I-IUPAC
DMPX,I-IUPAC
(,O
7,O
),O
and,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxypropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
(,I-IUPAC
m,I-IUPAC
-,I-IUPAC
methoxystyryl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
propargylxanthine,I-IUPAC
(,O
5e,O
",",O
MSX,O
-,O
2,O
),O
were,O
the,O
most,O
potent,O
and,O
A,O
(,O
2A,O
),O
-,O
selective,O
compounds,O
and,O
were,O
selected,O
for,O
prodrug,O
formation,O
.,O
An,O
increase,O
in,O
the,O
size,O
of,O
the,O
4,O
substitutent,O
of,O
the,O
3,O
-,O
(,O
aryloxy,O
),O
moiety,O
to,O
caproamido,O
leads,O
to,O
a,O
substantially,O
higher,O
affinity,O
for,O
the,O
beta,O
1,O
-,O
-,O
adrenoceptor,O
of,O
rat,O
ventricular,O
muscle,O
in,O
the,O
presence,O
of,O
the,O
"3,4",B-IUPAC
-,I-IUPAC
dimethoxyphenethyl,I-IUPAC
than,O
in,O
the,O
presence,O
of,O
the,O
4,B-IUPAC
-,I-IUPAC
hydroxyphenethyl,I-IUPAC
or,O
isopropyl,O
group,O
;,O
this,O
combination,O
also,O
gave,O
the,O
highest,O
cardioselectivity,O
.,O
X,O
-,O
ray,O
crystal,O
structures,O
were,O
determined,O
for,O
the,O
three,O
NHMe,O
derivatives,O
2,O
",",O
3,O
",",O
and,O
5c,O
in,O
the,O
pyrido,B-PARTIUPAC
[,I-PARTIUPAC
"9,2",I-PARTIUPAC
-,I-PARTIUPAC
d,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
",",I-PARTIUPAC
pyrido,I-PARTIUPAC
[,I-PARTIUPAC
"3,4",I-PARTIUPAC
-,I-PARTIUPAC
d,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
",",O
and,O
pyrimido,B-IUPAC
[,I-IUPAC
"5,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
-,I-IUPAC
pyrimidine,I-IUPAC
series,B-MODIFIER
",",O
respectively,O
.,O
Although,O
their,O
affinities,O
for,O
the,O
estrogen,O
receptor,O
were,O
very,O
low,O
(,O
from,O
0.008%,O
to,O
0.02%,O
that,O
of,O
estradiol,O
),O
",",O
they,O
appeared,O
to,O
be,O
efficient,O
affinity,O
labels,O
of,O
the,O
receptor,O
due,O
to,O
their,O
irreversible,O
inhibition,O
of,O
[,B-IUPAC
3H,I-IUPAC
],I-IUPAC
estradiol,I-IUPAC
specific,O
binding,O
in,O
lamb,O
uterine,O
cytosol,O
.,O
Inhibition,O
of,O
[,O
3H,O
],O
AMPA,O
binding,O
by,O
ATPA,O
was,O
1,O
order,O
of,O
magnitude,O
weaker,O
than,O
that,O
of,O
AMPA,O
",",O
in,O
agreement,O
with,O
the,O
relative,O
potency,O
of,O
these,O
compounds,O
in,O
vivo,O
.,O
The,O
relative,O
amounts,O
of,O
these,O
materials,O
excreted,O
during,O
the,O
24,O
-,O
h,O
period,O
following,O
administration,O
of,O
tolazamide,O
were,O
10,O
",",O
5,O
",",O
5,O
",",O
and,O
80%,O
for,O
1-4,O
",",O
respectively,O
.,O
gondii,O
tachyzoites,O
in,O
culture,O
and,O
were,O
found,O
to,O
have,O
a,O
potency,O
(,O
IC50,O
=,O
0.1-0.5,O
microM,O
),O
similar,O
to,O
that,O
of,O
pyrimethamine,O
(,O
IC50,O
=,O
0.69,O
microM,O
),O
",",O
a,O
standard,O
clinical,O
agent,O
for,O
the,O
treatment,O
of,O
cerebral,O
toxoplasmosis,O
in,O
AIDS,O
patients,O
.,O
The,O
high,O
specific,O
activity,O
one,O
-,O
step,O
radiolabeling,O
preparation,O
and,O
high,O
selectivity,O
of,O
[,O
(,O
123,O
),O
I,O
],O
ZIENT,O
for,O
SERT,O
support,O
its,O
candidacy,O
as,O
a,O
radioligand,O
for,O
mapping,O
brain,O
SERT,O
sites,O
.,O
All,O
the,O
new,O
synthesized,O
pyrimidines,O
were,O
evaluated,O
in,O
spontaneously,O
beating,O
and,O
electrically,O
driven,O
atria,O
from,O
reserpine,O
-,O
treated,O
guinea,O
pigs,O
.,O
The,O
original,O
synthetic,O
procedure,O
for,O
the,O
preparation,O
of,O
21,O
of,O
these,O
compounds,O
is,O
also,O
reported,O
.,O
Three,O
of,O
these,O
compounds,O
-,O
8azaadenosine,B-IUPAC
(,O
4,O
),O
",",O
8,B-IUPAC
-,I-IUPAC
aza,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
methylthio,I-IUPAC
),I-IUPAC
purine,I-IUPAC
ribonucleoside,I-IUPAC
(,O
5,O
),O
",",O
and,O
8,B-IUPAC
-,I-IUPAC
aza,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
methoxy,I-IUPAC
),I-IUPAC
purine,I-IUPAC
ribonucleoside,I-IUPAC
(,O
7,O
),O
-,O
showed,O
borderline,O
activity,O
in,O
the,O
leukemia,O
L1210,O
system,O
.,O
The,O
importance,O
of,O
this,O
ratio,O
remains,O
unclear,O
in,O
terms,O
of,O
identification,O
of,O
potential,O
cocaine,O
antagonists,O
.,O
When,O
tested,O
against,O
herpes,O
simplex,O
virus,O
type,O
1,O
",",O
only,O
9,O
was,O
active,O
with,O
an,O
IC50,O
=,O
8,O
microM,O
.,O
Reduction,O
with,O
trimethyl,O
phosphite,O
of,O
the,O
furoxan,O
derivatives,O
afforded,O
the,O
corresponding,O
furazans,O
",",O
while,O
oxidation,O
with,O
an,O
equimolar,O
amount,O
of,O
30%,O
hydrogen,O
peroxide,O
in,O
acetic,O
acid,O
or,O
with,O
an,O
excess,O
of,O
81%,O
hydrogen,O
peroxide,O
in,O
trifluoroacetic,O
acid,O
afforded,O
the,O
corresponding,O
arylsulfinyl,B-IUPAC
and,O
arylsulfonyl,B-IUPAC
analogues,B-MODIFIER
",",O
respectively,O
.,O
The,O
comparable,O
whole,O
brain,O
and,O
blood,O
half,O
-,O
lives,O
for,O
Me,O
[,O
18F,O
],O
FBWAY,O
(,O
[,O
18F,O
],O
4c,O
),O
were,O
16,O
and,O
18,O
min,O
",",O
respectively,O
.,O
The,O
site,O
of,O
glycosylation,O
and,O
the,O
anomeric,O
configuration,O
of,O
these,O
nucleosides,O
have,O
been,O
assigned,O
on,O
the,O
basis,O
of,O
1',O
NMR,O
and,O
UV,O
spectral,O
characteristics,O
and,O
by,O
single,O
-,O
crystal,O
X,O
-,O
ray,O
analysis,O
for,O
27-29,O
.,O
New,O
water,O
-,O
soluble,O
bis,B-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenylazopyridine,I-IUPAC
),I-IUPAC
ruthenium,I-IUPAC
(,I-IUPAC
II,I-IUPAC
),I-IUPAC
complexes,B-MODIFIER
",",O
all,O
derivatives,O
of,O
the,O
highly,O
cytotoxic,O
alpha,O
-,O
[,O
Ru,O
(,O
azpy,O
),O
(,O
2,O
),O
Cl,O
(,O
2,O
),O
],O
(,O
alpha,O
denoting,O
the,O
coordinating,O
pairs,O
Cl,O
",",O
N,O
(,O
py,O
),O
",",O
and,O
N,O
(,O
azo,O
),O
as,O
cis,O
",",O
trans,O
",",O
cis,O
",",O
respectively,O
),O
have,O
been,O
developed,O
.,O
This,O
trend,O
was,O
consistent,O
with,O
the,O
published,O
literature,O
on,O
the,O
corresponding,O
DHFR,O
inhibitors,O
with,O
a,O
glutamate,O
side,O
chain,O
.,O
The,O
5,B-IUPAC
-,I-IUPAC
H,I-IUPAC
(,I-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
indanylamide,I-IUPAC
7a,O
displayed,O
a,O
lower,O
affinity,O
(,O
K,O
(,O
i,O
),O
675,O
nM,O
),O
.,O
Thus,O
",",O
nine,O
new,O
bis,O
-,O
carbamates,O
:,O
methoxycarbonyl,B-IUPAC
(,O
2,O
),O
",",O
"2,2,2",B-IUPAC
-,I-IUPAC
trichloroethoxycarbonyl,I-IUPAC
(,O
3,O
),O
",",O
ethylthiocarbonyl,B-IUPAC
(,O
4,O
),O
",",O
benzyloxycarbonyl,B-IUPAC
(,O
5,O
),O
",",O
(,B-IUPAC
4,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
1,I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
dioxol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
en,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
methoxycarbonyl,I-IUPAC
(,O
6,O
),O
",",O
phenoxycarbonyl,B-IUPAC
(,O
7,O
),O
",",O
4,B-IUPAC
-,I-IUPAC
fluorophenoxycarbonyl,I-IUPAC
(,O
8,O
),O
",",O
4,B-IUPAC
-,I-IUPAC
methoxyphenoxycarbonyl,I-IUPAC
(,O
9,O
),O
",",O
and,O
(,B-IUPAC
1,I-IUPAC
-,I-IUPAC
acetoxy,I-IUPAC
),I-IUPAC
ethoxycarbonyl,I-IUPAC
(,O
10,O
),O
and,O
a,O
bis,B-IUPAC
-,I-IUPAC
carbonate,I-IUPAC
ethoxycarbonyloxy,I-IUPAC
(,O
11,O
),O
of,O
the,O
bis,O
-,O
amidine,O
1,O
have,O
been,O
synthesized,O
and,O
evaluated,O
.,O
These,O
compounds,O
are,O
useful,O
models,O
for,O
research,O
to,O
determine,O
the,O
molecular,O
basis,O
of,O
the,O
strong,O
enhancement,O
of,O
carcinogenicity,O
consequent,O
upon,O
methyl,B-IUPAC
substitution,B-MODIFIER
in,O
nonbenzo,O
bay,O
molecular,O
sites,O
and,O
meso,O
regions,O
of,O
polycyclic,O
hydrocarbons,O
.,O
Molecular,O
mechanics,O
calculations,O
with,O
AMBER,O
show,O
that,O
the,O
two,O
species,O
with,O
the,O
thermodynamically,O
most,O
favorable,O
binding,O
energies,O
are,O
the,O
11R,O
",",O
11aS,O
and,O
11S,O
",",O
11aS,O
isomers,O
with,O
their,O
aromatic,O
rings,O
to,O
the,O
5',O
and,O
3',O
sides,O
of,O
the,O
covalently,O
bound,O
guanine,O
",",O
respectively,O
.,O
The,O
prodrugs,O
were,O
found,O
to,O
be,O
quite,O
stable,O
at,O
physiological,O
pH,O
and,O
were,O
more,O
than,O
200,O
-,O
fold,O
less,O
active,O
as,O
inactivators,O
of,O
O,B-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
-,I-IUPAC
alkylguanine,I-IUPAC
-,O
DNA,O
alkyltransferase,O
(,O
alkyltransferase,O
),O
than,O
either,O
O,B-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
-,I-IUPAC
benzylguanine,I-IUPAC
or,O
O,B-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyguanosine,I-IUPAC
.,O
Within,O
this,O
series,O
of,O
derivatives,O
",",O
2,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
aminophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methylsemicarbazono,I-IUPAC
),I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
methylenedioxyphenylacetic,I-IUPAC
acid,I-IUPAC
methyl,I-IUPAC
ester,I-IUPAC
(,O
10,O
),O
proved,O
to,O
be,O
the,O
most,O
active,O
compound,O
.,O
Two,O
-,O
dimensional,O
correlation,O
spectroscopy,O
(,O
2D,O
-,O
COSY,O
),O
studies,O
also,O
show,O
connectivities,O
for,O
four,O
cytosine,O
H5,O
-,O
H6,O
and,O
eight,O
thymine,O
methyl,O
-,O
H6,O
protons,O
and,O
thus,O
clearly,O
establish,O
the,O
presence,O
of,O
two,O
distinct,O
species,O
of,O
tomaymycin,O
-,O
d,O
(,O
ATGCAT,O
),O
2,O
adducts,O
in,O
solution,O
.,O
Dextromethorphan,O
(,O
1,O
",",O
(,B-IUPAC
+,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
17,I-IUPAC
-,I-IUPAC
methylmorphinan,I-IUPAC
),O
demonstrates,O
anticonvulsant,O
activity,O
in,O
a,O
variety,O
of,O
in,O
vitro,O
and,O
in,O
vivo,O
models,O
of,O
convulsive,O
action,O
.,O
The,O
relative,O
efficacy,O
of,O
11,O
",",O
which,O
has,O
a,O
higher,O
receptor,O
affinity,O
(,O
IC50,O
=,O
1.3,O
+,O
/,O
-,O
0.3,O
microM,O
),O
than,O
10,O
(,O
IC50,O
=,O
9.3,O
+,O
/,O
-,O
2.6,O
microM,O
),O
",",O
was,O
comparable,O
with,O
that,O
of,O
10,O
(,O
30-35%,O
),O
.,O
Regeneration,O
of,O
the,O
"5,6",O
-,O
olefinic,O
bond,O
to,O
give,O
AZT,O
",",O
upon,O
incubation,O
of,O
the,O
5,B-IUPAC
-,I-IUPAC
halo,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
"5,6",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
compounds,B-MODIFIER
with,O
glutathione,O
",",O
mouse,O
blood,O
",",O
or,O
mouse,O
liver,O
homogenate,O
",",O
was,O
dependent,O
upon,O
the,O
nature,O
of,O
the,O
5,B-IUPAC
-,I-IUPAC
halo,I-IUPAC
substituent,B-MODIFIER
(,O
I,O
&,O
gt,O
;,O
Br,O
),O
.,O
Compound,O
3,O
is,O
the,O
first,O
example,O
",",O
to,O
our,O
knowledge,O
",",O
of,O
a,O
"2,4",O
-,O
diamino,O
classical,O
antifolate,O
that,O
has,O
potent,O
inhibitory,O
activity,O
against,O
both,O
human,O
dihydrofolate,O
reductase,O
(,O
DHFR,O
),O
and,O
human,O
thymidylate,O
synthase,O
(,O
TS,O
),O
.,O
The,O
diester,O
of,O
5,B-IUPAC
-,I-IUPAC
chloromethyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
(,O
27,O
),O
treated,O
with,O
methanol,B-IUPAC
or,O
sodium,O
azide,O
gave,O
5,B-PARTIUPAC
-,I-PARTIUPAC
methoxymethyl,I-PARTIUPAC
-,I-PARTIUPAC
(,O
29,O
),O
and,O
5,B-PARTIUPAC
-,I-PARTIUPAC
azidomethyl,I-PARTIUPAC
-,I-PARTIUPAC
(,O
31,O
),O
2',B-IUPAC
-,I-IUPAC
deoxyuridines,I-IUPAC
.,O
These,O
discrepancies,O
may,O
reflect,O
different,O
selectivities,O
among,O
delta,O
receptor,O
subtypes,O
for,O
the,O
analogues,O
or,O
may,O
represent,O
differing,O
efficacies,O
among,O
these,O
conformationally,O
restricted,O
peptides,O
.,O
The,O
depolarizing,O
effect,O
of,O
ACPA,O
could,O
be,O
fully,O
antagonized,O
by,O
the,O
selective,O
non,O
-,O
NMDA,O
antagonist,O
6,B-IUPAC
-,I-IUPAC
cyano,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
nitro,I-IUPAC
-,I-IUPAC
quinoxazoline,I-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dione,I-IUPAC
(,O
CNQX,O
),O
",",O
but,O
was,O
unaffected,O
by,O
the,O
selective,O
NMDA,O
antagonist,O
D,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
phosphonovaleric,I-IUPAC
acid,I-IUPAC
(,O
AP5,O
),O
.,O
Hydrogen,O
bonding,O
is,O
hereby,O
gradually,O
replaced,O
by,O
van,O
der,O
Waals,O
interactions,O
involving,O
a,O
relatively,O
large,O
lipophilic,O
pocket,O
.,O
The,O
results,O
obtained,O
through,O
site,O
-,O
directed,O
mutagenic,O
analysis,O
support,O
our,O
predicted,O
binding,O
models,O
for,O
these,O
ligands,O
and,O
provide,O
new,O
insights,O
into,O
PKC,O
-,O
ligand,O
binding,O
.,O
In,O
an,O
attempt,O
to,O
increase,O
the,O
combined,O
toxicity,O
of,O
the,O
metabolic,O
end,O
-,O
products,O
[,O
acrolein,O
(,O
4,O
),O
and,O
phosphoramide,O
mustard,O
(,O
3,O
),O
],O
from,O
cyclophosphamide,O
(,O
1,O
),O
",",O
the,O
analog,B-MODIFIER
2,B-IUPAC
-,I-IUPAC
[,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
chloroethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
trifluoromethyl,I-IUPAC
-,I-IUPAC
2H,I-IUPAC
-,I-IUPAC
"1,3,2",I-IUPAC
-,I-IUPAC
oxazaphosphorine,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxide,I-IUPAC
(,O
2,O
",",O
6,B-IUPAC
-,I-IUPAC
trifluoromethylcyclophosphamide,I-IUPAC
),O
was,O
synthesized,O
and,O
its,O
metabolism,O
and,O
antitumor,O
activity,O
studied,O
.,O
Pyrimido,B-IUPAC
[,I-IUPAC
"5,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
analogues,B-MODIFIER
bearing,O
bulky,O
",",O
weakly,O
basic,O
solubilizing,O
side,O
chains,O
linked,O
to,O
the,O
6,O
-,O
position,O
through,O
a,O
secondary,O
amine,O
generally,O
retained,O
potency,O
both,O
against,O
the,O
isolated,O
enzyme,O
and,O
for,O
inhibition,O
of,O
autophosphorylation,O
of,O
EGFR,O
in,O
intact,O
A431,O
cells,O
.,O
It,O
gave,O
100%,O
protection,O
against,O
PAF,O
-,O
induced,O
mortality,O
in,O
mice,O
7,O
h,O
after,O
i,O
.,O
The,O
new,O
analogues,O
were,O
all,O
obtained,O
from,O
"2,4",B-IUPAC
-,I-IUPAC
diamino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
5',I-IUPAC
-,I-IUPAC
iodo,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
methoxybenzyl,I-IUPAC
),I-IUPAC
pyrimidine,I-IUPAC
via,O
a,O
Sonogashira,O
reaction,O
",",O
followed,O
",",O
where,O
appropriate,O
",",O
by,O
catalytic,O
hydrogenation,O
.,O
A,O
significant,O
finding,O
was,O
that,O
monocyclic,O
5,B-IUPAC
-,I-IUPAC
alkyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
oxazolidinediones,I-IUPAC
provided,O
relatively,O
potent,O
",",O
nontoxic,O
",",O
broad,O
-,O
spectrum,O
anticonvulsants,O
.,O
Induction,O
of,O
cell,O
death,O
in,O
a,O
variety,O
of,O
tumor,O
cell,O
lines,O
was,O
determined,O
in,O
a,O
monolayer,O
assay,O
using,O
propidium,O
iodide,O
.,O
The,O
ring,O
closure,O
of,O
3,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
5,B-PARTIUPAC
-,I-PARTIUPAC
cyclopentanecarboxamido,I-PARTIUPAC
-,I-PARTIUPAC
and,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
benzoylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
aminouracils,I-IUPAC
requires,O
drastic,O
reaction,O
conditions,O
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
400,O
WORDS,O
),O
The,O
synthesis,O
of,O
certain,O
heteroarotinoids,O
has,O
been,O
achieved,O
",",O
namely,O
the,O
systems,O
(,B-IUPAC
2E,I-IUPAC
",",I-IUPAC
4E,I-IUPAC
",",I-IUPAC
6E,I-IUPAC
),I-IUPAC
-,I-IUPAC
"3,7",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
thiochromanyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,4,6",I-IUPAC
-,I-IUPAC
heptatrienoic,I-IUPAC
acid,I-IUPAC
(,O
1a,O
),O
",",O
ethyl,B-IUPAC
(,I-IUPAC
2E,I-IUPAC
",",I-IUPAC
4E,I-IUPAC
",",I-IUPAC
6E,I-IUPAC
),I-IUPAC
-,I-IUPAC
"3,7",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
teterahydro,I-IUPAC
-,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
thiochromanyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,4,6",I-IUPAC
-,I-IUPAC
heptatrienoate,I-IUPAC
(,O
1b,O
),O
",",O
(,B-IUPAC
2E,I-IUPAC
",",I-IUPAC
4E,I-IUPAC
",",I-IUPAC
6E,I-IUPAC
),I-IUPAC
-,I-IUPAC
"3,7",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
chromanyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,4,6",I-IUPAC
-,I-IUPAC
heptatrienoic,I-IUPAC
acid,I-IUPAC
(,O
1c,O
),O
",",O
2,B-IUPAC
-,I-IUPAC
phthalimidoethyl,I-IUPAC
"3,7",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
4,I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
thiochromanyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,4,6",I-IUPAC
-,I-IUPAC
heptatrienoate,I-IUPAC
(,O
1d,O
),O
",",O
methyl,B-IUPAC
(,I-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
chromanyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
propenyl,I-IUPAC
],I-IUPAC
benzoate,I-IUPAC
(,O
2a,O
),O
",",O
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
chromanyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
propenyl,I-IUPAC
],I-IUPAC
benzyl,I-IUPAC
alcohol,I-IUPAC
(,O
2b,O
),O
",",O
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
chromanyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
propenyl,I-IUPAC
],I-IUPAC
benzonitrile,I-IUPAC
(,O
2c,O
),O
",",O
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
chromanyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
propenyl,I-IUPAC
],I-IUPAC
benzaldehyde,I-IUPAC
(,O
2d,O
),O
",",O
methyl,B-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
"3,3",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
benzofuranyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
propenyl,I-IUPAC
],I-IUPAC
benzoate,I-IUPAC
(,O
3a,O
),O
",",O
and,O
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
"3,3",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
benzofuranyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
propenyl,I-IUPAC
],I-IUPAC
benzoic,I-IUPAC
acid,I-IUPAC
(,O
3b,O
),O
.,O
One,O
of,O
the,O
most,O
potent,O
DNA,O
-,O
PK,O
inhibitors,O
identified,O
",",O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methoxyphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
morpholin,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
pyran,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
16,O
;,O
DNA,O
-,O
PK,O
;,O
IC50,O
=,O
220,O
nM,O
),O
effectively,O
sensitized,O
HeLa,O
cells,O
to,O
the,O
topoisomerase,O
II,O
inhibitor,O
etoposide,O
in,O
vitro,O
.,O
In,O
functional,O
in,O
vitro,O
studies,O
on,O
histamine,O
H2,O
",",O
H3,O
",",O
and,O
other,O
neurotransmitter,O
receptors,O
the,O
selectivity,O
of,O
39,O
was,O
found,O
to,O
be,O
2138,O
(,O
H1,O
:,O
H2,O
),O
",",O
&,O
gt,O
;,O
64,O
(,O
H1,O
:,O
H3,O
),O
",",O
1000,O
(,O
H1,O
:,O
M3,O
),O
",",O
105,O
(,O
H1,O
:,O
alpha,O
1,O
),O
",",O
708,O
(,O
H1,O
:,O
beta,O
1,O
),O
",",O
and,O
71,O
(,O
H1,O
:,O
5HT2A,O
),O
.,O
The,O
biological,O
data,O
support,O
the,O
hypothesis,O
that,O
the,O
increase,O
in,O
binding,O
affinity,O
for,O
PK,O
-,O
C,O
shown,O
by,O
some,O
of,O
these,O
constrained,O
DAG,O
mimetics,O
appears,O
to,O
be,O
entropic,O
in,O
nature,O
.,O
Preparation,O
of,O
the,O
target,O
5,B-IUPAC
-,I-IUPAC
alkyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
alkoxymethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
benzyluracil,I-IUPAC
derivatives,B-MODIFIER
27-34,O
was,O
carried,O
out,O
by,O
acetylation,O
of,O
9-14,O
followed,O
by,O
Pd,O
-,O
catalyzed,O
hydrogenolysis,O
.,O
With,O
the,O
goal,O
of,O
developing,O
high,O
affinity,O
P2,O
-,O
purinoceptor,O
-,O
selective,O
agonist,O
",",O
we,O
have,O
synthesized,O
a,O
series,O
of,O
analogues,O
of,O
adenine,O
nucleotides,O
modified,O
on,O
the,O
purine,O
ring,O
as,O
chain,O
-,O
extended,O
2,O
-,O
thioethers,O
or,O
as,O
N6,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,O
substituted,B-MODIFIER
compounds,O
.,O
Three,O
N,B-IUPAC
-,I-IUPAC
fluoroethyl,I-IUPAC
-,I-IUPAC
substituted,B-MODIFIER
(,B-IUPAC
imidazolylphenyl,I-IUPAC
),I-IUPAC
formamidine,I-IUPAC
derivatives,B-MODIFIER
",",O
namely,O
",",O
2,B-IUPAC
-,I-IUPAC
fluoroethyl,I-IUPAC
(,O
3b,O
),O
",",O
"2,2",B-IUPAC
-,I-IUPAC
difluoroethyl,I-IUPAC
(,O
3c,O
),O
",",O
and,O
"2,2,2",B-IUPAC
-,I-IUPAC
trifluoroethyl,I-IUPAC
(,O
3d,O
),O
",",O
were,O
prepared,O
to,O
test,O
the,O
effect,O
of,O
fluorine,O
substitution,O
on,O
basicity,O
and,O
",",O
then,O
",",O
on,O
H2,O
-,O
antagonist,O
affinity,O
in,O
comparison,O
with,O
the,O
unsubstituted,B-MODIFIER
N,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
derivative,B-MODIFIER
(,O
3a,O
),O
",",O
taken,O
as,O
a,O
model,O
of,O
mifentidine,O
.,O
The,O
structure,O
of,O
compound,O
69,O
is,O
of,O
interest,O
because,O
it,O
provides,O
only,O
a,O
single,O
aromatic,O
unit,O
linked,O
through,O
a,O
chain,O
to,O
a,O
basic,O
nitrogen,O
",",O
while,O
most,O
H1,O
-,O
antihistaminic,O
agents,O
have,O
structures,O
that,O
comprise,O
a,O
double,O
-,O
aromatic,O
unit,O
linked,O
through,O
a,O
chain,O
to,O
a,O
basic,O
tertiary,O
amino,O
group,O
.,O
An,O
antagonism,O
toward,O
the,O
negative,O
influence,O
exerted,O
by,O
endogenous,O
adenosine,O
on,O
the,O
heart,O
seems,O
to,O
be,O
involved,O
in,O
the,O
contractile,O
activity,O
of,O
compound,O
28,O
.,O
Finally,O
",",O
the,O
iron,O
-,O
clearing,O
efficiency,O
of,O
the,O
(,O
S,O
),O
-,O
4',O
-,O
(,O
HO,O
),O
-,O
DADFT,O
conjugates,O
was,O
determined,O
in,O
a,O
bile,O
-,O
duct,O
-,O
cannulated,O
rodent,O
model,O
.,O
Methyl,B-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
isothiocyanatomethyl,I-IUPAC
),I-IUPAC
thiazole,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
carbamate,I-IUPAC
(,O
7,O
),O
was,O
the,O
most,O
active,O
compound,O
in,O
this,O
screen,O
",",O
inhibiting,O
the,O
growth,O
of,O
L1210,O
leukemic,O
cells,O
with,O
an,O
IC50,O
=,O
3.2,O
microM,O
.,O
Routes,O
were,O
developed,O
for,O
the,O
synthesis,O
of,O
congeners,O
of,O
3,O
by,O
cyclization,O
of,O
4,B-PARTIUPAC
-,I-PARTIUPAC
(,O
substituted,B-MODIFIER
amino,B-IUPAC
),O
-,B-PARTIUPAC
"5,6",I-PARTIUPAC
-,I-PARTIUPAC
diaminopyridines,I-PARTIUPAC
with,O
ethyl,O
orthoformate,O
.,O
The,O
relative,O
influx,O
of,O
12a,O
was,O
enhanced,O
about,O
3.2,O
-,O
fold,O
over,O
MTX,O
",",O
but,O
as,O
an,O
inhibitor,O
of,O
dihydrofolate,O
reductase,O
(,O
DHFR,O
),O
from,O
L1210,O
cells,O
and,O
in,O
the,O
inhibition,O
of,O
L1210,O
cell,O
growth,O
in,O
vitro,O
",",O
this,O
compound,O
was,O
approximately,O
20,O
-,O
fold,O
less,O
effective,O
than,O
MTX,O
(,O
DHFR,O
inhibition,O
",",O
Ki,O
=,O
4.82,O
+,O
/,O
-,O
0.60,O
pM,O
for,O
MTX,O
",",O
100,O
pM,O
for,O
12a,O
;,O
cell,O
growth,O
",",O
IC50,O
=,O
3.4,O
+,O
/,O
-,O
1.0,O
nM,O
for,O
MTX,O
",",O
65,O
+,O
/,O
-,O
18,O
nM,O
for,O
12a,O
),O
.,O
H,O
-,O
Dmt,O
-,O
Tic,O
-,O
NH,O
-,O
CH,O
(,O
2,O
),O
-,O
1H,O
-,O
benzimidazole,O
-,O
2,O
-,O
yl,O
(,O
Bid,O
),O
(,O
2,O
),O
became,O
a,O
highly,O
potent,O
delta,O
-,O
agonist,O
(,O
pEC,O
(,O
50,O
),O
",",O
9.90,O
),O
",",O
slightly,O
greater,O
than,O
deltorphin,O
C,O
(,O
pEC,O
(,O
50,O
),O
",",O
9.56,O
),O
",",O
with,O
mu,O
-,O
agonism,O
(,O
pE,O
(,O
50,O
),O
",",O
7.57,O
),O
",",O
while,O
H,O
-,O
Dmt,O
-,O
Tic,O
-,O
Gly,O
-,O
NH,O
-,O
CH,O
(,O
2,O
),O
-,O
Bid,O
(,O
4,O
),O
retained,O
potent,O
delta,O
-,O
antagonism,O
(,O
pA,O
(,O
2,O
),O
",",O
9.0,O
),O
but,O
with,O
an,O
order,O
of,O
magnitude,O
less,O
mu,O
-,O
agonism,O
.,O
Reductive,O
deamination,O
of,O
compounds,O
1a,O
-,O
k,O
provides,O
the,O
2,B-IUPAC
-,I-IUPAC
quinoxalinecarbonitriles,I-IUPAC
5a,O
-,O
k,O
",",O
which,O
are,O
more,O
potent,O
",",O
while,O
selectivity,O
is,O
maintained,O
or,O
increased,O
in,O
some,O
derivatives,O
.,O
malayiat,O
50,O
mg,O
/,O
kg,O
x,O
5,O
days,O
(,O
ip,O
),O
or,O
at,O
200,O
mg,O
/,O
kg,O
x,O
5,O
days,O
(,O
po,O
),O
.,O
[,O
1,O
-,O
Beta,O
-,O
mercapto,O
-,O
beta,O
",",O
beta,O
-,O
pentamethylenepropionic,O
acid,O
],O
oxytocin,O
was,O
prepared,O
from,O
beta,O
-,O
Mpa,O
(,O
beta,O
-,O
(,O
CH2,O
),O
5,O
),O
(,O
Bzl,O
),O
-,O
Tyr,O
(,O
Bzl,O
),O
-,O
Ile,O
-,O
Gln,O
-,O
Asn,O
-,O
Cys,O
(,O
Bzl,O
),O
-,O
Pro,O
-,O
Leu,O
-,O
Gly,O
-,O
NH2,O
by,O
removal,O
of,O
the,O
Bzl,O
-,O
protecting,O
groups,O
with,O
Na,O
-,O
NH3,O
followed,O
by,O
cyclization,O
of,O
the,O
resulting,O
disulfhydryl,O
compound,O
with,O
K3Fe,O
(,O
CN,O
),O
6,O
.,O
Cytallene,O
(,O
5b,O
),O
and,O
6',B-IUPAC
beta,I-IUPAC
-,I-IUPAC
hydroxyaristeromycin,I-IUPAC
(,O
10,O
),O
exhibited,O
significant,O
activity,O
against,O
Friend,O
and,O
Rauscher,O
murine,O
leukemia,O
viruses,O
.,O
It,O
was,O
anticipated,O
that,O
1c,O
would,O
be,O
hydrolyzed,O
in,O
vivo,O
by,O
carboxylate,O
esterase,O
(,O
E,O
.,O
In,O
this,O
paper,O
",",O
we,O
describe,O
the,O
synthesis,O
of,O
a,O
series,O
of,O
novel,O
substituted,B-MODIFIER
4,B-IUPAC
-,I-IUPAC
aryl,I-IUPAC
-,I-IUPAC
"6,7",I-IUPAC
-,I-IUPAC
methylenedioxyphthalazin,I-IUPAC
-,I-IUPAC
1,I-IUPAC
(,I-IUPAC
2H,I-IUPAC
),I-IUPAC
-,I-IUPAC
ones,I-IUPAC
.,O
Affinity,O
for,O
brain,O
A1,O
and,O
A2,O
adenosine,O
receptors,O
was,O
determined,O
in,O
binding,O
assays,O
for,O
these,O
and,O
other,O
xanthines,O
with,O
substituents,O
in,O
1,O
-,O
",",O
3,O
-,O
",",O
7,O
-,O
",",O
8,O
-,O
",",O
and,O
9,O
-,O
positions,O
.,O
Western,O
blotting,O
analysis,O
demonstrated,O
that,O
9h,O
caused,O
a,O
shift,O
in,O
tubulin,O
concentration,O
from,O
the,O
polymerized,O
state,O
found,O
in,O
the,O
cell,O
pellet,O
to,O
the,O
unpolymerized,O
state,O
found,O
in,O
the,O
cell,O
supernatant,O
.,O
With,O
the,O
plasma,O
enzyme,O
",",O
the,O
ID50,O
values,O
were,O
II,O
",",O
1.6,O
X,O
10,O
(,O
-,O
4,O
),O
M,O
;,O
III,O
",",O
5,O
X,O
10,O
(,O
-,O
5,O
),O
M,O
;,O
V,O
",",O
1.2,O
X,O
10,O
(,O
-,O
4,O
),O
M,O
;,O
VI,O
5,O
X,O
10,O
(,O
-,O
4,O
),O
M,O
;,O
VII,O
5,O
X,O
10,O
(,O
-,O
5,O
),O
M,O
;,O
VIII,O
",",O
5,O
X,O
10,O
(,O
-,O
4,O
),O
M,O
.,O
Using,O
the,O
patch,O
-,O
clamp,O
technique,O
in,O
primary,O
cultures,O
of,O
granule,O
neurons,O
we,O
tested,O
compounds,O
10,O
and,O
21,O
for,O
their,O
ability,O
to,O
modulate,O
currents,O
evoked,O
by,O
KA,O
and,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
butylisoxazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
ATPA,O
),O
.,O
Most,O
of,O
these,O
analogues,O
demonstrated,O
high,O
affinity,O
binding,O
to,O
the,O
dopamine,O
transporter,O
(,O
DAT,O
;,O
K,O
(,O
i,O
),O
=,O
1.8-40,O
nM,O
),O
",",O
and,O
selectivity,O
over,O
the,O
other,O
monoamine,O
transporters,O
and,O
muscarinic,O
M,O
(,O
1,O
),O
receptors,O
.,O
The,O
space,O
group,O
for,O
both,O
molecules,O
was,O
P1,O
in,O
triclinic,O
systems,O
.,O
Analogues,O
with,O
ring,O
sizes,O
of,O
18,O
\C2,O
\BF,O
cyclo,O
(,O
1,O
",",O
1',O
-,O
3,O
),O
[,O
Ac,O
-,O
DGlu,O
(,O
1,O
),O
(,O
Gly,O
),O
",",O
DCpa,O
(,O
2,O
),O
",",O
DLys,O
(,O
3,O
),O
",",O
DNal,O
(,O
6,O
),O
",",O
DA,O
la,O
(,O
10,O
),O
],O
GnRH,O
(,O
24,O
),O
\C2,O
\BF,O
and,O
19,O
\C2,O
\BF,O
cyclo,O
(,O
"1,1",O
',O
-,O
3,O
),O
[,O
Ac,O
-,O
DGlu,O
(,O
1,O
),O
(,O
betaAla,O
),O
",",O
DCpa,O
(,O
2,O
),O
",",O
DLys,O
(,O
3,O
),O
",",O
DNal,O
(,O
6,O
),O
",",O
DAla,O
(,O
10,O
),O
],O
GnRH,O
(,O
25,O
),O
\C2,O
\BF,O
atoms,O
were,O
also,O
less,O
potent,O
than,O
21,O
with,O
slightly,O
higher,O
K,O
(,O
i,O
),O
values,O
(,O
1.5,O
and,O
2.2,O
nM,O
",",O
respectively,O
),O
.,O
In,O
contrast,O
",",O
2,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2',I-IUPAC
-,I-IUPAC
hydroxyethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxypyridin,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
",",O
which,O
is,O
not,O
metabolized,O
to,O
the,O
corresponding,O
(,O
carboxyalkyl,O
),O
hydroxypyridinone,O
",",O
was,O
found,O
to,O
be,O
superior,O
to,O
Deferiprone,O
and,O
therefore,O
deserves,O
further,O
consideration,O
as,O
an,O
orally,O
active,O
iron,O
chelator,O
with,O
potential,O
for,O
the,O
treatment,O
of,O
iron,O
overload,O
associated,O
with,O
transfusion,O
-,O
dependent,O
thalassemia,O
.,O
Now,O
we,O
report,O
the,O
details,O
required,O
for,O
its,O
synthesis,O
",",O
together,O
with,O
its,O
potency,O
and,O
efficacy,O
in,O
two,O
assays,O
of,O
functional,O
activation,O
of,O
the,O
NMDA,O
receptor,O
",",O
namely,O
agonist,O
-,O
influenced,O
[,O
3H,O
],O
MK801,O
binding,O
and,O
agonist,O
-,O
induced,O
release,O
of,O
the,O
neurotransmitter,O
[,O
3H,O
],O
-,O
norepinephrine,O
from,O
brain,O
slices,O
.,O
A,O
series,O
of,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
diethylamino,I-IUPAC
),I-IUPAC
thieno1,I-IUPAC
",",I-IUPAC
3,I-IUPAC
\C5,I-IUPAC
\8F,I-IUPAC
xazin,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
was,O
synthesized,O
and,O
evaluated,O
in,O
vitro,O
for,O
inhibitory,O
activity,O
toward,O
human,O
leukocyte,O
elastase,O
(,O
HLE,O
),O
.,O
3D,O
contour,O
maps,O
generated,O
from,O
these,O
models,O
were,O
analyzed,O
individually,O
",",O
which,O
provides,O
the,O
regions,O
in,O
space,O
where,O
interactive,O
fields,O
may,O
influence,O
the,O
activity,O
.,O
Synthetic,O
routes,O
to,O
the,O
heretofore,O
unknown,O
ylidenemalononitriles,O
",",O
and,O
the,O
ketone,O
precursors,O
thereof,O
",",O
were,O
developed,O
.,O
Synthesis,O
and,O
antitetrabenazine,O
activity,O
of,O
4,B-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
arylmethyl,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
],I-IUPAC
piperidines,I-IUPAC
and,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
benzyloxy,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
phenylpiperidines,I-IUPAC
",",O
prepared,O
as,O
simplified,O
and,O
possibly,O
more,O
readily,O
synthesized,O
analogues,O
of,O
3,B-IUPAC
-,I-IUPAC
phenylspiro,I-IUPAC
[,I-IUPAC
isobenzofuran,I-IUPAC
-,I-IUPAC
1,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
",",I-IUPAC
4',I-IUPAC
-,I-IUPAC
piperidine,I-IUPAC
],I-IUPAC
",",O
are,O
reported,O
.,O
The,O
potency,O
pattern,O
due,O
to,O
substituents,O
of,O
the,O
phenyl,B-IUPAC
ring,B-MODIFIER
was,O
found,O
to,O
parallel,O
that,O
found,O
in,O
a,O
previously,O
reported,O
"1,3",B-IUPAC
-,I-IUPAC
dialkyl,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
phenylxanthine,I-IUPAC
series,B-MODIFIER
.,O
This,O
hypothesis,O
can,O
be,O
tested,O
by,O
using,O
two,O
photoaffinity,O
probes,O
that,O
differ,O
only,O
in,O
the,O
N,O
-,O
unsubstituted,O
imine,O
vs,O
negatively,O
charged,O
(,O
delta,O
(,O
-,O
),O
),O
tip,O
.,O
[,O
dPen1,O
",",O
cyclo,O
(,O
Glu4,O
",",O
Lys8,O
),O
],O
oxytocin,O
also,O
was,O
a,O
weak,O
antagonist,O
in,O
the,O
pressor,O
assay,O
with,O
a,O
pA2,O
of,O
6.3,O
.,O
In,O
this,O
study,O
",",O
13,O
heteroarotinoids,O
were,O
synthesized,O
.,O
The,O
synthesis,O
and,O
in,O
vitro,O
sigma,O
receptor,O
activity,O
of,O
the,O
two,O
diastereomers,O
of,O
U50,O
",",O
488,O
[,O
(,O
+,O
/,O
-,O
),O
-,O
2,O
],O
",",O
namely,O
",",O
(,B-IUPAC
1R,I-IUPAC
",",I-IUPAC
2S,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
+,I-IUPAC
),I-IUPAC
-,I-IUPAC
cis,I-IUPAC
-,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichloro,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
pyrrolidinyl,I-IUPAC
),I-IUPAC
cyclohexyl,I-IUPAC
],I-IUPAC
benzeneacet,I-IUPAC
ami,I-IUPAC
de,I-IUPAC
[,B-PARTIUPAC
(,I-PARTIUPAC
+,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
1,I-PARTIUPAC
],I-PARTIUPAC
and,O
(,B-IUPAC
1S,I-IUPAC
",",I-IUPAC
2R,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
cis,I-IUPAC
-,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichloro,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
pyrrolidinyl,I-IUPAC
),I-IUPAC
cyclohexyl,I-IUPAC
],I-IUPAC
benzeneacetamide,I-IUPAC
[,O
(,O
-,O
),O
-,O
1,O
],O
",",O
are,O
described,O
.,O
The,O
general,O
trend,O
is,O
that,O
",",O
up,O
to,O
a,O
certain,O
size,O
",",O
the,O
more,O
lipophilic,O
the,O
N,O
-,O
substituent,O
",",O
the,O
higher,O
the,O
affinity,O
for,O
sigma,O
receptor,O
sites,O
.,O
We,O
have,O
previously,O
described,O
(,B-IUPAC
RS,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
"7,8",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
6H,I-IUPAC
-,I-IUPAC
cyclohepta,I-IUPAC
[,I-IUPAC
d,I-IUPAC
],I-IUPAC
isoxazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
4,O
-,O
AHCP,O
),O
as,O
a,O
highly,O
effective,O
agonist,O
at,O
non,B-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
d,I-IUPAC
-,I-IUPAC
aspartate,I-IUPAC
(,O
non,O
-,O
NMDA,O
),O
glutamate,O
(,O
Glu,O
),O
receptors,O
in,O
vivo,O
",",O
which,O
is,O
more,O
potent,O
than,O
(,B-IUPAC
RS,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methylisoxazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
AMPA,O
),O
but,O
inactive,O
at,O
NMDA,O
receptors,O
.,O
A,O
series,O
of,O
O',B-IUPAC
-,I-IUPAC
(,I-IUPAC
epoxyalkyl,I-IUPAC
),I-IUPAC
tyrosines,I-IUPAC
and,O
a,O
carboxy,O
terminal,O
(,B-IUPAC
epoxyalkyl,I-IUPAC
),I-IUPAC
tyrosine,I-IUPAC
and,O
-,B-PARTIUPAC
phenylalanine,I-PARTIUPAC
were,O
synthesized,O
as,O
potential,O
serine,O
protease,O
inhibitors,O
.,O
Sulfenylation,O
of,O
3,O
with,O
NPS,O
-,O
Cl,O
gave,O
Z,O
-,O
Lys,O
(,O
Z,O
),O
-,O
Trp,O
(,O
NPS,O
),O
-,O
OMe,O
",",O
which,O
",",O
on,O
catalytic,O
hydrogenation,O
of,O
the,O
nitro,O
group,O
using,O
10%,O
Pd,O
/,O
C,O
followed,O
by,O
acetylation,O
of,O
the,O
resulting,O
amino,O
function,O
and,O
removal,O
of,O
the,O
protecting,O
Z,O
groups,O
",",O
gave,O
17,O
.,O
In,O
particular,O
",",O
compounds,O
37,O
and,O
47,O
proved,O
lethal,O
at,O
100,O
micrograms,O
/,O
mL,O
after,O
an,O
exposure,O
of,O
only,O
1,O
h,O
.,O
This,O
suggests,O
that,O
both,O
the,O
action,O
on,O
A1,O
receptors,O
or,O
interaction,O
with,O
adenosine,O
and,O
the,O
cyclic,O
AMP,O
-,O
PDE,O
inhibitory,O
activity,O
contribute,O
to,O
the,O
bronchodilator,O
action,O
of,O
1,O
-,O
and,O
7,O
-,O
substituted,O
xanthines,O
.,O
Two,O
of,O
the,O
compounds,O
possessed,O
Ki,O
values,O
of,O
about,O
2x,O
10,O
(,O
-,O
4,O
),O
M,O
with,O
guanine,O
aminohydrolase,O
",",O
but,O
no,O
inhibition,O
of,O
xanthine,O
oxidase,O
was,O
observed,O
by,O
any,O
at,O
5,O
x,O
10,O
(,O
-,O
4,O
),O
M,O
.,O
Optimal,O
activity,O
was,O
attained,O
when,O
the,O
two,O
nipecotoyl,O
ring,O
N,O
atoms,O
were,O
connected,O
by,O
an,O
aralkyl,B-IUPAC
group,B-MODIFIER
",",O
and,O
separated,O
by,O
approximately,O
7,O
A,O
.,O
Compounds,O
in,O
series,O
3,O
tended,O
to,O
be,O
more,O
potent,O
",",O
10a,O
and,O
10c,O
having,O
scores,O
of,O
91,O
and,O
80%,O
",",O
respectively,O
.,O
Optimization,O
of,O
the,O
structural,O
parameters,O
for,O
this,O
activity,O
yiedled,O
5,B-IUPAC
-,I-IUPAC
[,I-IUPAC
m,I-IUPAC
-,I-IUPAC
trifluorobenzyl,I-IUPAC
),I-IUPAC
thio,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
pyridinecarboxylic,I-IUPAC
acid,I-IUPAC
(,O
41,O
),O
and,O
its,O
sulfoxide,O
",",O
42,O
.,O
The,O
(,O
N,O
),O
isomer,O
was,O
hardly,O
hydrolyzed,O
by,O
NTPDase,O
2,O
",",O
while,O
the,O
(,O
S,O
),O
isomer,O
was,O
hydrolyzed,O
at,O
one,O
-,O
third,O
of,O
the,O
rate,O
of,O
ATP,O
hydrolysis,O
.,O
A,O
novel,O
conversion,O
of,O
(,B-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
nicotine,I-IUPAC
to,O
its,O
6,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
analogue,B-MODIFIER
increased,O
the,O
potency,O
2,O
-,O
fold,O
.,O
The,O
rates,O
of,O
hydrolysis,O
of,O
Northern,O
(,O
N,O
),O
and,O
Southern,O
(,O
S,O
),O
methanocarba,O
analogues,O
of,O
AMP,O
by,O
rat,O
5',O
-,O
ectonucleotidase,O
were,O
negligible,O
.,O
These,O
four,O
compounds,O
together,O
with,O
the,O
2,B-IUPAC
-,I-IUPAC
desamino,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
analogue,B-MODIFIER
were,O
tested,O
for,O
their,O
activity,O
against,O
L1210,O
thymidylate,O
synthase,O
(,O
TS,O
),O
.,O
IR,O
",",O
1H,O
NMR,O
and,O
13C,O
NMR,O
data,O
have,O
been,O
recorded,O
for,O
each,O
compound,O
and,O
support,O
the,O
structural,O
assignments,O
.,O
Binding,O
sites,O
with,O
the,O
lowest,O
affinity,O
for,O
II,O
were,O
found,O
in,O
cortical,O
",",O
striatal,O
",",O
and,O
hippocampal,O
regions,O
(,O
IC50,O
values,O
greater,O
than,O
2.0,O
microM,O
),O
.,O
4,B-IUPAC
-,I-IUPAC
Aminopyrazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
was,O
converted,O
into,O
the,O
desired,O
intermediate,O
",",O
ethyl,B-IUPAC
pyrazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carbamate,I-IUPAC
(,O
2,O
),O
.,O
The,O
ID50,O
of,O
3,O
against,O
L1210,O
mouse,O
leukemia,O
cells,O
in,O
culture,O
was,O
1.7,O
x,O
10,O
(,O
-,O
5,O
),O
M,O
",",O
as,O
compared,O
with,O
1,O
x,O
10,O
(,O
-,O
6,O
),O
M,O
for,O
FU,O
.,O
Five,O
compounds,O
exhibited,O
inhibitory,O
activity,O
in,O
the,O
same,O
range,O
as,O
the,O
standards,O
",",O
4,B-IUPAC
-,I-IUPAC
hydroxypyrazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
and,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
pyridyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
trifluoromethylimidazole,I-IUPAC
(,O
22,O
),O
.,O
Hydrogenolytic,O
removal,O
of,O
the,O
carbobenzyloxy,O
groups,O
",",O
followed,O
by,O
iodoacetylation,O
of,O
the,O
omega,O
-,O
amino,O
groups,O
with,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
iodoacetoxy,I-IUPAC
),I-IUPAC
succinimide,I-IUPAC
",",O
gave,O
N6,O
-,O
R,O
-,O
ATP,O
",",O
where,O
R,O
=,O
(,O
CH2,O
),O
nNHCOCH2I,O
(,O
n,O
=,O
2,O
-,O
-,O
8,O
),O
or,O
(,O
CH2,O
),O
nCON,O
),O
CH3,O
),O
(,O
CH2,O
),O
mN,O
(,O
CH3,O
),O
CO,O
(,O
CH2,O
),O
nNHCOCH2I,O
(,O
n,O
=,O
m,O
=,O
3,O
;,O
n,O
=,O
3,O
",",O
m,O
=,O
4,O
;,O
n,O
=,O
4,O
",",O
m,O
=,O
3,O
;,O
n,O
=,O
m,O
=,O
4,O
),O
.,O
Structure,O
-,O
activity,O
relationships,O
are,O
discussed,O
.,O
Another,O
route,O
using,O
Grewe,O
cyclization,O
was,O
also,O
examined,O
for,O
the,O
synthesis,O
of,O
3,O
.,O
"3,5",O
-,O
Disubstitution,O
and,O
2,O
-,O
substitution,O
led,O
to,O
a,O
decline,O
in,O
activity,O
.,O
Syntheses,O
of,O
several,O
carbamate,O
analogues,O
of,O
2,B-IUPAC
",",I-IUPAC
5,I-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
amidinophenyl,I-IUPAC
),I-IUPAC
furan,I-IUPAC
(,O
1,O
),O
under,O
mild,O
conditions,O
and,O
their,O
evaluation,O
as,O
prodrugs,O
against,O
Pneumocystis,O
carinii,O
pneumonia,O
(,O
PCP,O
),O
in,O
an,O
immunosuppressed,O
rat,O
model,O
are,O
described,O
.,O
The,O
lead,O
compound,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
toluoylethynyl,I-IUPAC
),I-IUPAC
uracil,I-IUPAC
effectively,O
inhibited,O
thymidylate,O
synthetase,O
.,O
This,O
derivative,O
inhibited,O
FT,O
with,O
an,O
IC50,O
of,O
0.6,O
nM,O
and,O
inhibited,O
anchorage,O
-,O
independent,O
growth,O
of,O
stably,O
transformed,O
NIH,O
-,O
3T3,O
fibroblast,O
cells,O
by,O
50%,O
at,O
5,O
microM,O
.,O
Three,O
electrophilic,O
amide,O
analogues,O
of,O
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
diaminopropionic,I-IUPAC
acid,I-IUPAC
(,O
1,O
",",O
DAP,O
),O
have,O
been,O
prepared,O
as,O
potential,O
inhibitors,O
of,O
L,O
-,O
asparagine,O
synthetase,O
(,O
ASase,O
",",O
from,O
Novikoff,O
hepatoma,O
",",O
EC,O
6.3.5.4,O
),O
.,O
beta,O
-,O
(,O
1,O
-,O
Chloro,O
-,O
2,O
-,O
naphthyl,O
),O
alanine,O
and,O
beta,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
bromo,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
naphthyl,I-IUPAC
),I-IUPAC
alanine,I-IUPAC
were,O
synthesized,O
by,O
ammonolysis,O
of,O
the,O
corresponding,O
alpha,B-IUPAC
",",I-IUPAC
1,I-IUPAC
-,I-IUPAC
dihalo,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
naphthalenepropanoic,I-IUPAC
acids,I-IUPAC
derived,O
from,O
1,B-IUPAC
-,I-IUPAC
nitro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
naphthylamine,I-IUPAC
by,O
diazotization,O
and,O
condensation,O
with,O
acrylic,O
acid,O
in,O
the,O
presence,O
of,O
cuprous,O
halides,O
.,O
In,O
each,O
case,O
",",O
the,O
activity,O
or,O
minimal,O
activity,O
of,O
each,O
compound,O
can,O
be,O
explained,O
on,O
the,O
basis,O
of,O
the,O
ability,O
of,O
one,O
or,O
more,O
accessible,O
conformer,O
of,O
each,O
molecule,O
to,O
clear,O
the,O
REV,O
calculated,O
here,O
.,O
Compounds,O
3-6,O
were,O
deblocked,O
with,O
chlorotrimethylsilane,B-IUPAC
and,O
sodium,O
iodide,O
in,O
acetonitrile,O
to,O
the,O
corresponding,O
5,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
acyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
iodo,I-IUPAC
),I-IUPAC
vinyl,I-IUPAC
],I-IUPAC
uracils,I-IUPAC
(,O
7-10,O
),O
",",O
which,O
on,O
treatment,O
with,O
potassium,O
hydroxide,O
in,O
dioxane,O
yielded,O
the,O
corresponding,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
acylethynyl,I-IUPAC
),I-IUPAC
uracils,I-IUPAC
(,O
11-14,O
),O
.,O
The,O
receptor,O
binding,O
potencies,O
IC50,O
values,O
are,O
48,O
(,O
1,O
),O
",",O
126,O
(,O
2,O
),O
",",O
40,O
(,O
3,O
),O
",",O
19,O
(,O
4,O
),O
",",O
100,O
(,O
5,O
),O
",",O
48,O
(,O
6,O
),O
",",O
2000,O
(,O
7,O
),O
",",O
52,O
(,O
8,O
),O
",",O
113,O
(,O
9,O
),O
",",O
512,O
(,O
10,O
),O
",",O
128,O
(,O
11,O
),O
",",O
1000,O
(,O
12,O
),O
",",O
2000,O
(,O
13,O
),O
",",O
500,O
(,O
14,O
),O
",",O
and,O
200,O
nM,O
(,O
15,O
),O
.,O
A,O
series,O
of,O
substituted,B-MODIFIER
dibenzo,B-IUPAC
[,I-IUPAC
"1,4",I-IUPAC
],I-IUPAC
dioxin,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
carboxamides,I-IUPAC
has,O
been,O
synthesized,O
and,O
evaluated,O
for,O
in,O
vitro,O
and,O
in,O
vivo,O
antitumor,O
activity,O
.,O
"8,9",O
-,O
Dioxo,O
-,O
6,O
-,O
phenyl,O
-,O
1,O
-,O
aza,O
-,O
7,O
-,O
oxabicyclo,O
[,O
4.2.1,O
],O
nonane,O
(,O
1,O
),O
and,O
"9,10",B-IUPAC
-,I-IUPAC
dioxo,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
aza,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
oxabicyclo,I-IUPAC
[,I-IUPAC
5.2.1,I-IUPAC
],I-IUPAC
decane,I-IUPAC
(,O
2,O
),O
",",O
examples,O
of,O
anti,O
-,O
Bredt,O
bicyclic,O
"2,4",B-IUPAC
-,I-IUPAC
oxazolidinediones,I-IUPAC
",",O
were,O
investigated,O
as,O
anticonvulsants,O
in,O
mice,O
.,O
In,O
a,O
NOESY,O
experiment,O
",",O
cross,O
-,O
peaks,O
were,O
identified,O
between,O
both,O
the,O
aromatic,O
H9,O
proton,O
and,O
the,O
ethylidine,O
methyl,O
protons,O
of,O
tomaymycin,O
and,O
two,O
different,O
adenine,O
H2,O
protons,O
of,O
d,O
(,O
ATGCAT,O
),O
2,O
.,O
Moreover,O
",",O
compound,O
55,O
exhibited,O
a,O
fairly,O
high,O
ratio,O
of,O
antistereotypic,O
activity,O
to,O
cataleptogenicity,O
compared,O
with,O
haloperidol,O
and,O
metoclopramide,O
.,O
The,O
pharmacological,O
results,O
indicate,O
that,O
this,O
isosteric,O
replacement,O
results,O
in,O
higher,O
selectivity,O
for,O
5,O
-,O
HT2,O
receptors,O
compared,O
to,O
the,O
former,O
series,O
.,O
The,O
incorporation,O
of,O
these,O
residues,O
in,O
the,O
mAZ,O
-,O
pTyr,O
-,O
Xaa,O
-,O
Asn,O
-,O
NH2,O
series,O
provided,O
compounds,O
with,O
very,O
high,O
affinity,O
for,O
the,O
Grb2,O
SH2,O
domain,O
",",O
in,O
the,O
10,O
(,O
-,O
8,O
),O
-,O
10,O
(,O
-,O
9,O
),O
range,O
of,O
Kd,O
values,O
.,O
In,O
conclusion,O
",",O
TRODAT,O
-,O
1,O
formed,O
at,O
least,O
two,O
diastereomers,O
after,O
complexing,O
with,O
a,O
metal,O
(,O
V,O
),O
-,O
oxo,O
(,O
M,O
=,O
99mTc,O
",",O
Re,O
),O
center,O
core,O
.,O
Of,O
the,O
other,O
agents,O
",",O
4,O
exhibited,O
the,O
most,O
favorable,O
pharmaceutical,O
profile,O
:,O
the,O
agent,O
has,O
appropriate,O
stability,O
in,O
the,O
presence,O
of,O
tumor,O
cells,O
and,O
rat,O
liver,O
microsomes,O
and,O
achieves,O
rapid,O
ingress,O
into,O
cell,O
nuclei,O
where,O
the,O
putative,O
molecular,O
target,O
is,O
located,O
.,O
carinii,O
DHFR,O
was,O
20,O
-,O
fold,O
greater,O
than,O
that,O
of,O
PTX,O
(,O
IC,O
(,O
50,O
),O
=,O
13,O
nM,O
),O
",",O
and,O
its,O
selectivity,O
index,O
(,O
SI,O
),O
relative,O
to,O
rat,O
DHFR,O
was,O
85,O
",",O
whereas,O
PTX,O
was,O
nonselective,O
.,O
Two,O
adenosine,O
diphosphate,O
analogues,O
were,O
equipotent,O
to,O
the,O
corresponding,O
ATP,O
analogues,O
.,O
Moreover,O
",",O
affinity,O
and,O
relative,O
efficacy,O
were,O
calculated,O
in,O
vitro,O
for,O
this,O
compound,O
at,O
M2,O
(,O
heart,O
force,O
and,O
rate,O
),O
and,O
M3,O
(,O
ileum,O
and,O
bladder,O
),O
receptors,O
in,O
order,O
to,O
investigate,O
muscarinic,O
receptor,O
heterogeneity,O
.,O
A,O
selective,O
reduction,O
of,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
bromo,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
allylpyrrolo,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
-,I-IUPAC
pyrimidine,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carbon,I-IUPAC
ril,I-IUPAC
e,I-IUPAC
(,O
3k,O
),O
in,O
zinc,O
and,O
acetic,O
acid,O
furnished,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
allylpyrrolo,I-IUPAC
-,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carbonitrile,I-IUPAC
(,O
4k,O
),O
.,O
However,O
",",O
analysis,O
of,O
the,O
high,O
-,O
affinity,O
(,O
2R,O
",",O
3R,O
),O
-,O
MePhe3,O
analog,O
revealed,O
a,O
strong,O
preference,O
for,O
a,O
single,O
side,O
chain,O
conformer,O
(,O
chi,O
1,O
approximately,O
60,O
degrees,O
),O
.,O
The,O
oral,O
activity,O
of,O
the,O
prodrugs,O
was,O
modest,O
with,O
only,O
one,O
showing,O
2/4,O
cures,O
in,O
the,O
same,O
mouse,O
model,O
.,O
Elaboration,O
of,O
the,O
required,O
oligo,B-IUPAC
(,I-IUPAC
gamma,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
glutamate,I-IUPAC
),I-IUPAC
chain,O
was,O
achieved,O
one,O
unit,O
at,O
a,O
time,O
",",O
beginning,O
with,O
the,O
coupling,O
of,O
L,B-IUPAC
-,I-IUPAC
glutamic,I-IUPAC
acid,I-IUPAC
dibenzyl,I-IUPAC
ester,I-IUPAC
with,O
[,B-IUPAC
(,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
butyloxy,I-IUPAC
),I-IUPAC
carbonyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
glutamic,I-IUPAC
acid,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
ester,I-IUPAC
(,O
7,O
),O
",",O
followed,O
by,O
selective,O
removal,O
of,O
the,O
tert,O
-,O
butyloxycarbonyl,O
grouping,O
and,O
another,O
coupling,O
step,O
with,O
5,O
or,O
7,O
as,O
required,O
.,O
(,O
ABSTRACT,O
TRUNCATED,O
AT,O
400,O
WORDS,O
),O
A,O
series,O
of,O
"2,6",B-PARTIUPAC
-,I-PARTIUPAC
and,O
"2,4",B-IUPAC
-,I-IUPAC
dihydroxyphenyl,I-IUPAC
alkyl,I-IUPAC
ketones,I-IUPAC
has,O
been,O
investigated,O
as,O
inhibitors,O
of,O
hepatic,O
microsomal,O
aniline,O
hydroxylase,O
and,O
aminopyrine,O
demethylase,O
activities,O
.,O
None,O
of,O
the,O
amino,O
acids,O
4c,O
-,O
e,O
showed,O
detectable,O
affinity,O
for,O
[,O
3H,O
],O
kainic,O
acid,O
binding,O
sites,O
.,O
The,O
longer,O
analogues,O
PIP,O
(,O
"5,4,5",O
),O
and,O
PYR,O
(,O
"5,4,5",O
),O
are,O
very,O
similar,O
in,O
the,O
spacing,O
of,O
their,O
amino,O
groups,O
.,O
These,O
effects,O
of,O
8,O
and,O
9,O
proved,O
to,O
be,O
enantioselective,O
",",O
(,O
R,O
),O
-,O
(,O
-,O
),O
-,O
8,O
and,O
(,O
R,O
),O
-,O
(,O
+,O
),O
-,O
9,O
being,O
the,O
active,O
inhibitors,O
of,O
both,O
uptake,O
systems,O
.,O
In,O
this,O
experimental,O
system,O
",",O
recovery,O
from,O
hypoglycemia,O
proceeded,O
with,O
a,O
t,O
(,O
1/2,O
),O
value,O
of,O
14,O
+,O
/,O
-,O
1,O
h,O
",",O
as,O
compared,O
with,O
t,O
(,O
1/2,O
),O
=,O
8.0,O
+,O
/,O
-,O
1,O
h,O
for,O
native,O
insulin,O
and,O
t,O
(,O
1/2,O
),O
=,O
10.0,O
+,O
/,O
-,O
1,O
h,O
for,O
NPH,O
-,O
insulin,O
.,O
These,O
results,O
establish,O
that,O
the,O
MAO,O
-,O
catalyzed,O
bioactivation,O
of,O
MPTP,O
leads,O
to,O
the,O
formation,O
of,O
a,O
variety,O
of,O
reactive,O
molecules,O
that,O
are,O
potentially,O
cytotoxic,O
to,O
nigrostriatal,O
cells,O
.,O
In,O
receptor,O
binding,O
(,O
IC50,O
values,O
),O
and,O
rat,O
cortical,O
wedge,O
electrophysiological,O
(,O
EC50,O
values,O
),O
studies,O
",",O
7c,O
(,O
IC50,O
=,O
5.5,O
+,O
/,O
-,O
0.6,O
microM,O
;,O
EC50,O
=,O
96,O
+,O
/,O
-,O
5,O
microM,O
),O
was,O
shown,O
to,O
be,O
markedly,O
weaker,O
than,O
7a,O
(,O
IC50,O
=,O
0.57,O
+,O
/,O
-,O
0.16,O
microM,O
;,O
EC50,O
=,O
7.4,O
+,O
/,O
-,O
0.2,O
microM,O
),O
as,O
an,O
AMPA,O
agonist,O
",",O
whereas,O
7b,O
",",O
d,O
",",O
e,O
were,O
inactive,O
.,O
AlDH,O
activity,O
was,O
only,O
partially,O
restored,O
on,O
incubation,O
with,O
mercaptoethanol,O
(,O
20,O
mM,O
),O
for,O
1,O
h,O
.,O
Modeling,O
of,O
ligand,O
-,O
receptor,O
binding,O
site,O
interactions,O
yielded,O
an,O
interaction,O
site,O
model,O
for,O
the,O
5,O
-,O
HT1A,O
receptor,O
that,O
describes,O
a,O
gradual,O
change,O
in,O
binding,O
mode,O
for,O
C11,B-PARTIUPAC
-,I-PARTIUPAC
hydroxy,I-PARTIUPAC
",",O
-,B-PARTIUPAC
methoxy,I-PARTIUPAC
-,I-PARTIUPAC
",",O
and,O
-,B-PARTIUPAC
phenyl,I-PARTIUPAC
-,O
substituted,B-MODIFIER
derivatives,I-MODIFIER
.,O
Replacement,O
of,O
pyroglutamic,O
acid,O
by,O
pyro,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
aminoadipic,I-IUPAC
acid,I-IUPAC
",",O
2,B-IUPAC
-,I-IUPAC
oxoimidazolidine,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acid,I-IUPAC
or,O
gamma,B-IUPAC
-,I-IUPAC
butyrolactone,I-IUPAC
-,I-IUPAC
gamma,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acid,I-IUPAC
and,O
that,O
of,O
proline,O
by,O
pipecolic,O
acid,O
",",O
thiazolidine,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acid,I-IUPAC
",",O
or,O
homoproline,O
in,O
[,O
Leu2,O
],O
-,O
and,O
[,O
Nva2,O
],O
TRH,O
led,O
to,O
tripeptides,O
structurally,O
widely,O
different,O
from,O
TRH,O
.,O
08,O
mg,O
/,O
kg,O
),O
.,O
Racemic,O
6,O
",",O
but,O
not,O
11,O
",",O
partially,O
substituted,O
for,O
LSD,O
.,O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Lys4AVP,O
and,O
other,O
position,O
-,O
4,O
analogues,O
with,O
side,O
-,O
chain,O
functional,O
groups,O
may,O
be,O
useful,O
covalent,O
ligands,O
with,O
which,O
to,O
probe,O
the,O
structural,O
characteristics,O
of,O
AVP,O
renal,O
and,O
vascular,O
receptors,O
.,O
Collectively,O
",",O
these,O
data,O
suggest,O
that,O
1c,O
acts,O
as,O
a,O
membrane,O
-,O
permeable,O
prodrug,O
of,O
FdUMP,O
.,O
viteae,O
at,O
50,O
mg,O
/,O
kg,O
x,O
5,O
days,O
(,O
ip,O
),O
.,O
For,O
a,O
better,O
understanding,O
of,O
structure,O
-,O
activity,O
relationships,O
",",O
the,O
interaction,O
of,O
1,O
and,O
10,O
",",O
13,O
and,O
14,O
within,O
the,O
transmembrane,O
(,O
TM,O
),O
domains,O
of,O
the,O
human,O
histamine,O
H,O
(,O
1,O
),O
receptor,O
were,O
studied,O
using,O
molecular,O
dynamics,O
simulations,O
.,O
A,O
series,O
of,O
C11,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
aporphines,I-IUPAC
and,O
C11,B-MODIFIER
-,I-MODIFIER
oxygenated,I-MODIFIER
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
noraporphines,I-IUPAC
has,O
been,O
synthesized,O
and,O
evaluated,O
for,O
central,O
serotonergic,O
and,O
dopaminergic,O
effects,O
in,O
vitro,O
and,O
in,O
vivo,O
.,O
Ki,O
values,O
for,O
the,O
in,O
vitro,O
adenosine,O
deaminase,O
(,O
EC,O
3.5.4.4,O
;,O
type,O
I,O
;,O
calf,O
intestinal,O
mucosa,O
),O
inhibitory,O
activities,O
of,O
1b,O
",",O
1c,O
",",O
and,O
2,O
were,O
determined,O
to,O
be,O
1.6,O
X,O
10,O
(,O
-,O
8,O
),O
",",O
1.5,O
X,O
10,O
(,O
-,O
6,O
),O
",",O
and,O
9.8,O
X,O
10,O
(,O
-,O
8,O
),O
M,O
",",O
respectively,O
.,O
In,O
the,O
cyclic,O
series,O
",",O
particularly,O
among,O
the,O
benzamides,O
of,O
1,B-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
aminopyrrolidine,I-IUPAC
",",O
most,O
of,O
the,O
compounds,O
tested,O
were,O
more,O
active,O
than,O
the,O
corresponding,O
linear,O
benzamides,O
.,O
Med.,O
Chem.,O
1998,O
",",O
41,O
),O
.,O
casei,O
.,O
Escherichia,O
coli,O
TK,O
was,O
inactivated,O
by,O
6,O
of,O
25,O
ATP,O
derivatives,O
tested,O
at,O
10,O
mM,O
",",O
6,O
h,O
",",O
0,O
degrees,O
C,O
;,O
inactivation,O
was,O
slowed,O
by,O
MgATP,O
in,O
the,O
case,O
of,O
N6,O
-,O
CH3,O
-,O
N6,O
-,O
R,O
-,O
ATP,O
[,O
R,O
=,O
(,O
CH2,O
),O
4N,O
(,O
CH3,O
),O
CO,O
(,O
CH2,O
),O
5NHCOCH2I,O
],O
.,O
Seven,O
"1,2",B-IUPAC
-,I-IUPAC
dihydroxy,I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
dihydroacronycine,I-IUPAC
and,O
"1,2",B-IUPAC
-,I-IUPAC
dihydroxy,I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
demethoxyacronycine,I-IUPAC
esters,I-IUPAC
and,O
diesters,O
were,O
synthesized,O
via,O
osmic,O
oxidation,O
of,O
acronycine,O
or,O
6,B-IUPAC
-,I-IUPAC
demethoxyacronycine,I-IUPAC
followed,O
by,O
acylation,O
.,O
Here,O
",",O
we,O
investigated,O
structure,O
-,O
activity,O
relationships,O
of,O
the,O
"6,7",B-IUPAC
-,I-IUPAC
dimethoxyquinazolinyl,I-IUPAC
moiety,B-MODIFIER
.,O
Structure,O
-,O
-,O
activity,O
relationships,O
suggest,O
that,O
a,O
proton,O
at,O
the,O
C,O
-,O
1,O
position,O
appears,O
necessary,O
for,O
agonist,O
activity,O
and,O
the,O
acidity,O
of,O
this,O
proton,O
has,O
a,O
relatively,O
greater,O
influence,O
on,O
activity,O
than,O
pendant,O
steric,O
bulk,O
.,O
Bicyclization,O
of,O
this,O
analogue,O
yielded,O
[,O
dPen1,O
",",O
cyclo,O
(,O
Glu4,O
",",O
Lys8,O
),O
],O
oxytocin,O
",",O
a,O
potent,O
antagonist,O
of,O
oxytocin,O
in,O
the,O
uterotonic,O
assay,O
(,O
pA2,O
8.74,O
),O
with,O
a,O
potency,O
3,O
times,O
greater,O
than,O
that,O
of,O
[,O
Mpa1,O
",",O
cyclo,O
(,O
Glu4,O
",",O
Lys8,O
),O
],O
oxytocin,O
.,O
In,O
monkeys,O
",",O
23,O
showed,O
no,O
morphine,O
-,O
like,O
physical,O
dependence,O
liability,O
",",O
cis,B-PARTIUPAC
-,I-PARTIUPAC
and,O
trans,B-IUPAC
-,I-IUPAC
"1,3",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
piperidinol,I-IUPAC
esters,I-IUPAC
24,O
and,O
25,O
showed,O
no,O
binding,O
to,O
the,O
opiate,O
receptor,O
in,O
rat,O
brain,O
homogenates,O
.,O
In,O
this,O
paper,O
",",O
it,O
is,O
hypothesized,O
that,O
the,O
distinction,O
between,O
certain,O
active,O
and,O
inactive,O
cannabinoids,O
is,O
that,O
the,O
inactive,O
analogs,O
possess,O
extra,O
volume,O
associated,O
with,O
their,O
carbocyclic,O
rings,O
that,O
may,O
be,O
responsible,O
for,O
an,O
unfavorable,O
interaction,O
at,O
the,O
cannabinoid,O
receptor,O
.,O
(,B-IUPAC
R,I-IUPAC
",",I-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
Fluoromethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
QNB,I-IUPAC
",",O
and,O
(,O
R,O
",",O
R,O
),O
-,O
IQNB,O
",",O
and,O
(,B-IUPAC
R,I-IUPAC
",",I-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
fluoroethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
QNB,I-IUPAC
exhibit,O
selectivity,O
for,O
the,O
M1,O
subtype,O
",",O
and,O
(,B-IUPAC
R,I-IUPAC
",",I-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
fluoromethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
QNB,I-IUPAC
exhibits,O
selectivity,O
for,O
the,O
M2,O
subtype,O
.,O
carinii,O
DHFR,O
",",O
"2,4",B-IUPAC
-,I-IUPAC
diamino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
3',I-IUPAC
",",I-IUPAC
4',I-IUPAC
",",I-IUPAC
5',I-IUPAC
-,I-IUPAC
trimethoxyanilino,I-IUPAC
),I-IUPAC
methy,I-IUPAC
l,I-IUPAC
],I-IUPAC
quinazoline,I-IUPAC
(,O
10,O
),O
had,O
an,O
IC50,O
of,O
0.012,O
microM,O
and,O
was,O
slightly,O
more,O
potent,O
than,O
TMQ,O
and,O
PTX,O
.,O
The,O
bis,B-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
chloroethyl,I-IUPAC
),I-IUPAC
carbamate,I-IUPAC
moiety,B-MODIFIER
is,O
capable,O
of,O
reacting,O
with,O
nucleophilic,O
groups,O
as,O
evidenced,O
by,O
the,O
colorimetric,O
reaction,O
with,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
p,I-IUPAC
-,I-IUPAC
nitrobenzyl,I-IUPAC
),I-IUPAC
pyridine,I-IUPAC
.,O
However,O
",",O
a,O
selective,O
inhibition,O
to,O
the,O
cancer,O
cells,O
was,O
observed,O
for,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
(,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
xylofuranosyl,I-IUPAC
),I-IUPAC
pyrido,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
(,O
2b,O
),O
",",O
which,O
is,O
a,O
potent,O
inhibitor,O
of,O
HTB,O
-,O
81,O
(,O
EC,O
(,O
50,O
),O
:,O
0.73,O
microM,O
),O
and,O
has,O
a,O
favorable,O
in,O
vitro,O
selectivity,O
index,O
(,O
28,O
),O
.,O
),O
and,O
P,O
.,O
Net,O
Pu,O
removal,O
[,O
Pu,O
excretion,O
(,O
treated,O
),O
-,O
PU,O
excretion,O
(,O
control,O
),O
],O
",",O
expressed,O
as,O
percent,O
of,O
injected,O
Pu,O
",",O
was,O
as,O
follows,O
:,O
Na,O
salts,O
and,O
Zn,O
(,O
II,O
),O
complexes,O
",",O
respectively,O
",",O
of,O
3,O
-,O
LIHOPO,O
(,O
54,O
",",O
56,O
),O
",",O
"3,4",O
-,O
LIHOPO,O
(,O
58,O
",",O
60,O
),O
",",O
"3,4,3",O
-,O
LIHOPO,O
(,O
73,O
",",O
76,O
),O
;,O
Na,O
salts,O
of,O
MEHOPO,O
(,O
46,O
),O
",",O
DFO,O
-,O
HOPO,O
(,O
78,O
),O
;,O
Fe,O
(,O
III,O
),O
complex,O
of,O
"3,4,3",O
-,O
LIHOPO,O
(,O
79,O
),O
.,O
The,O
dedifferentiation,O
agent,O
"""",O
reversine,O
"""",O
[,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
morpholinoanilino,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
-,I-IUPAC
cyclohexyladenine,I-IUPAC
2,I-IUPAC
],O
was,O
found,O
to,O
be,O
a,O
moderately,O
potent,O
antagonist,O
for,O
the,O
human,O
A,O
(,O
3,O
),O
adenosine,O
receptor,O
(,O
AR,O
),O
with,O
a,O
K,O
(,O
i,O
),O
value,O
of,O
0.66,O
microM,O
.,O
Chain,O
extension,O
of,O
14,O
followed,O
by,O
cyclization,O
led,O
to,O
3,B-IUPAC
-,I-IUPAC
ethoxy,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
"5,6",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
7H,I-IUPAC
-,I-IUPAC
cyclopenta,I-IUPAC
[,I-IUPAC
f,I-IUPAC
],I-IUPAC
isoquinolin,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
19,O
),O
which,O
on,O
reduction,O
and,O
subsequent,O
dehydration,O
yielded,O
3,B-IUPAC
-,I-IUPAC
ethoxy,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
7,I-IUPAC
(,I-IUPAC
5,I-IUPAC
),I-IUPAC
H,I-IUPAC
-,I-IUPAC
cyclopenta,I-IUPAC
[,I-IUPAC
f,I-IUPAC
],I-IUPAC
isoquinoline,I-IUPAC
(,O
4,O
),O
.,O
Of,O
the,O
investigated,O
compounds,O
",",O
the,O
most,O
active,O
was,O
"2,5,9,11",B-IUPAC
-,I-IUPAC
tetramethyl,I-IUPAC
-,I-IUPAC
5H,I-IUPAC
-,I-IUPAC
indolo,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
quinoline,I-IUPAC
",",O
a,O
compound,O
bearing,O
the,O
highest,O
number,O
of,O
symmetrically,O
distributed,O
methyl,B-IUPAC
groups,B-MODIFIER
.,O
In,O
general,O
",",O
3alpha,B-IUPAC
-,I-IUPAC
(,I-IUPAC
diphenylmethoxy,I-IUPAC
),I-IUPAC
tropane,I-IUPAC
(,O
benztropine,O
),O
-,O
based,O
dopamine,O
uptake,O
inhibitors,O
do,O
not,O
demonstrate,O
cocaine,O
-,O
like,O
pharmacological,O
activity,O
in,O
models,O
of,O
psychostimulant,O
abuse,O
and,O
have,O
been,O
proposed,O
as,O
potential,O
medications,O
for,O
the,O
treatment,O
of,O
cocaine,O
addiction,O
.,O
The,O
metabolic,O
fate,O
of,O
tolazamide,O
",",O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
hexahydroazepin,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
tolylsulfonylurea,I-IUPAC
(,O
1,O
),O
",",O
was,O
studied,O
in,O
man,O
and,O
in,O
the,O
rat,O
using,O
tritium,O
-,O
labeled,O
1,O
.,O
3,B-IUPAC
-,I-IUPAC
Methoxy,I-IUPAC
-,I-IUPAC
"4,5,6,7",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
benzisoxazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
20a,O
),O
",",O
or,O
the,O
corresponding,O
3,B-IUPAC
-,I-IUPAC
ethoxy,I-IUPAC
analogue,B-MODIFIER
(,O
20b,O
),O
",",O
and,O
3,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
"4,5,6",I-IUPAC
",",I-IUPAC
7,I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
benzisothiazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
51,O
),O
were,O
synthesized,O
by,O
regioselective,O
chromic,O
acid,O
oxidation,O
of,O
the,O
respective,O
bicyclic,O
tetrahydrobenzenes,O
19a,O
",",O
b,O
and,O
50,O
",",O
and,O
they,O
were,O
used,O
as,O
key,O
intermediates,O
for,O
the,O
syntheses,O
of,O
the,O
target,O
zwitterionic,O
3,B-IUPAC
-,I-IUPAC
isoxazolols,I-IUPAC
8-15,O
and,O
3,B-IUPAC
-,I-IUPAC
isothiazolols,I-IUPAC
16,O
and,O
17,O
",",O
respectively,O
.,O
The,O
utility,O
of,O
polyamines,O
as,O
vectors,O
for,O
the,O
intracellular,O
transport,O
of,O
iron,O
chelators,O
is,O
further,O
described,O
.,O
The,O
lead,O
structure,O
19,O
has,O
been,O
selected,O
for,O
in,O
-,O
depth,O
pharmacological,O
evaluation,O
.,O
For,O
the,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,O
substituted,B-MODIFIER
benzo,B-IUPAC
[,I-IUPAC
h,I-IUPAC
],I-IUPAC
chromen,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
",",O
a,O
morpholine,O
substituent,O
at,O
this,O
position,O
was,O
essential,O
for,O
activity,O
.,O
Replacement,O
of,O
the,O
3,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
group,B-MODIFIER
by,O
chlorine,O
affords,O
the,O
potent,O
but,O
nonselective,O
3,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
derivatives,B-MODIFIER
6a,O
-,O
k,O
showing,O
similar,O
toxicities,O
under,O
both,O
aerobic,O
and,O
hypoxic,O
conditions,O
.,O
Excellent,O
in,O
vivo,O
activity,O
in,O
the,O
trypanosomal,O
STIB900,O
mouse,O
model,O
was,O
found,O
for,O
five,O
of,O
the,O
diamidines,O
on,O
ip,O
dosage,O
;,O
these,O
compounds,O
gave,O
4/4,O
cures,O
in,O
this,O
model,O
.,O
The,O
target,O
compounds,O
9-12,O
were,O
obtained,O
by,O
an,O
N1,O
regioselective,O
intramolecular,O
cyclization,O
reaction,O
of,O
silylated,O
5-8,O
using,O
trimethylsilyl,O
trifluoromethanesulfonate,O
(,O
TMS,O
triflate,O
),O
as,O
the,O
catalyst,O
.,O
Tests,O
for,O
time,O
-,O
dependent,O
loss,O
of,O
enzyme,O
activity,O
(,O
inactivation,O
),O
were,O
performed,O
under,O
conditions,O
in,O
which,O
a,O
large,O
proportion,O
of,O
each,O
phosphokinase,O
was,O
present,O
as,O
an,O
enzyme,O
-,O
inhibitor,O
complex,O
.,O
Biodistribution,O
results,O
of,O
[,O
125I,O
],O
-,O
10,O
in,O
mice,O
indicate,O
that,O
compound,O
10,O
is,O
readily,O
metabolized,O
via,O
deiodination,O
in,O
vivo,O
",",O
possibly,O
by,O
serving,O
as,O
a,O
substrate,O
for,O
the,O
enzyme,O
S,B-IUPAC
-,I-IUPAC
adenosyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
homocysteine,I-IUPAC
hydrolase,O
.,O
Similar,O
glycosylations,O
of,O
3,B-IUPAC
-,I-IUPAC
cyanoallopurinol,I-IUPAC
and,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
methylthio,I-IUPAC
),I-IUPAC
allopurinol,I-IUPAC
furnished,O
the,O
corresponding,O
protected,O
N,B-IUPAC
-,I-IUPAC
1,I-IUPAC
glycosyl,I-IUPAC
derivatives,B-MODIFIER
(,O
5b,O
and,O
5c,O
),O
.,O
The,O
complete,O
abolishment,O
or,O
the,O
significant,O
reduction,O
in,O
PKC,O
-,O
ligand,O
binding,O
observed,O
for,O
these,O
mutants,O
thus,O
reflects,O
the,O
loss,O
of,O
certain,O
direct,O
contacts,O
between,O
the,O
side,O
chain,O
of,O
the,O
mutated,O
residue,O
in,O
PKC,O
and,O
ligands,O
as,O
well,O
as,O
the,O
large,O
conformational,O
alteration,O
to,O
the,O
binding,O
site,O
caused,O
by,O
the,O
mutation,O
.,O
The,O
four,O
optically,O
pure,O
compounds,O
were,O
tested,O
in,O
vitro,O
on,O
guinea,O
pig,O
and,O
their,O
muscarinic,O
potency,O
was,O
evaluated,O
at,O
M3,O
(,O
ileum,O
and,O
bladder,O
),O
and,O
M2,O
(,O
heart,O
),O
muscarinic,O
receptor,O
subtypes,O
.,O
Substrate,O
and,O
inhibitor,O
properties,O
indicated,O
that,O
the,O
compounds,O
possessed,O
affinity,O
for,O
the,O
ATP,O
sites,O
of,O
the,O
muscle,O
(,O
M,O
),O
",",O
kidney,O
(,O
K,O
),O
",",O
and,O
liver,O
(,O
L,O
),O
isozymes,O
of,O
rat,O
pyruvate,O
kinase,O
(,O
PK,O
),O
",",O
of,O
E,O
.,O
As,O
part,O
of,O
our,O
investigation,O
into,O
the,O
structure,O
-,O
activity,O
relationship,O
of,O
a,O
novel,O
class,O
of,O
aromatase,O
inhibitors,O
",",O
C,O
(,O
19,O
),O
steroids,O
having,O
no,O
oxygen,O
function,O
at,O
C,O
-,O
3,O
",",O
we,O
tested,O
aromatase,O
inhibition,O
activity,O
of,O
polar,O
diol,O
compounds,O
"4,19",B-IUPAC
-,I-IUPAC
dihydroxyandrost,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
en,I-IUPAC
-,I-IUPAC
17,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
(,O
25,O
and,O
27,O
),O
and,O
"6,19",B-IUPAC
-,I-IUPAC
dihydroxyandrost,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
en,I-IUPAC
-,I-IUPAC
17,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
(,O
36,O
and,O
37,O
),O
.,O
Further,O
evaluation,O
of,O
the,O
growth,O
inhibitory,O
activity,O
of,O
3,O
against,O
the,O
MTX,O
-,O
resistant,O
subline,O
of,O
CCRF,O
-,O
CEM,O
cells,O
(,O
R30dm,O
),O
with,O
decreased,O
FPGS,O
indicated,O
that,O
poly,O
-,O
gamma,O
-,O
glutamylation,O
was,O
important,O
for,O
its,O
action,O
.,O
A,O
novel,O
series,O
of,O
10,B-IUPAC
-,I-IUPAC
benzylidene,I-IUPAC
-,I-IUPAC
9,I-IUPAC
(,I-IUPAC
10H,I-IUPAC
),I-IUPAC
-,I-IUPAC
anthracenones,I-IUPAC
and,O
10,B-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylmethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
9,I-IUPAC
(,I-IUPAC
10H,I-IUPAC
),I-IUPAC
-,I-IUPAC
anthracenones,I-IUPAC
were,O
synthesized,O
and,O
evaluated,O
for,O
antiproliferative,O
activity,O
in,O
an,O
assay,O
based,O
on,O
K562,O
leukemia,O
cells,O
.,O
Attempts,O
to,O
convert,O
20,O
or,O
23,O
to,O
bromocyclopropanes,O
21,O
and,O
22,O
by,O
reaction,O
with,O
ethyl,O
diazoacetate,O
catalyzed,O
by,O
Rh2,O
(,O
OAc,O
),O
4,O
were,O
futile,O
.,O
A,O
series,O
of,O
synthetic,O
estrogens,O
containing,O
hydroxyalkyl,O
side,O
chains,O
at,O
the,O
C,O
-,O
4,O
position,O
of,O
the,O
A,O
ring,O
were,O
designed,O
as,O
metabolically,O
stable,O
analogs,O
of,O
4,B-IUPAC
-,I-IUPAC
hydroxyestradiol,I-IUPAC
",",O
a,O
catechol,O
estrogen,O
.,O
On,O
the,O
basis,O
of,O
in,O
vivo,O
functional,O
tests,O
",",O
8,B-IUPAC
-,I-IUPAC
phenylpiperazinoethylamino,I-IUPAC
(,O
11,O
),O
",",O
8,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2',I-IUPAC
-,I-IUPAC
methoxyphenylpiperazino,I-IUPAC
),I-IUPAC
ethylamino,I-IUPAC
(,O
13,O
),O
",",O
and,O
8,B-IUPAC
-,I-IUPAC
phenylpiperazinopropylamino,I-IUPAC
(,O
14,O
),O
derivatives,B-MODIFIER
of,O
"1,3",B-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
",",I-IUPAC
3H,I-IUPAC
-,I-IUPAC
pyrimido,I-IUPAC
[,I-IUPAC
"2,1",I-IUPAC
-,I-IUPAC
f,I-IUPAC
],I-IUPAC
purine,I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
dione,I-IUPAC
were,O
identified,O
as,O
potent,O
pre,O
-,O
and,O
postsynaptic,O
5,O
-,O
HT,O
(,O
1A,O
),O
receptor,O
antagonists,O
.,O
When,O
3,O
was,O
given,O
ip,O
in,O
water,O
to,O
P388,O
leukemic,O
mice,O
at,O
400,O
mg,O
/,O
kg,O
(,O
b,O
.,O
Several,O
3beta,B-PARTIUPAC
-,I-PARTIUPAC
(,O
substituted,B-MODIFIER
phenyl,B-PARTIUPAC
),O
-,B-PARTIUPAC
2beta,I-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
3,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
isoxazol,B-PARTIUPAC
-,I-PARTIUPAC
5,I-PARTIUPAC
-,I-PARTIUPAC
yl,I-PARTIUPAC
),I-PARTIUPAC
tropanes,I-PARTIUPAC
(,O
3a,O
-,O
t,O
),O
were,O
evaluated,O
for,O
their,O
ability,O
to,O
inhibit,O
radioligand,O
binding,O
at,O
the,O
DAT,O
",",O
5,O
-,O
HTT,O
",",O
and,O
NET,O
as,O
well,O
as,O
in,O
gross,O
observation,O
and,O
locomotor,O
activity,O
in,O
mice,O
and,O
in,O
rats,O
trained,O
to,O
discriminate,O
cocaine,O
.,O
Within,O
this,O
series,O
",",O
naphthalene,O
was,O
found,O
to,O
be,O
superior,O
to,O
other,O
groups,O
for,O
eliciting,O
antihyperglycemic,O
activity,O
",",O
including,O
the,O
p,B-IUPAC
-,I-IUPAC
alkoxyphenyl,I-IUPAC
group,B-MODIFIER
found,O
in,O
ciglitazone,O
",",O
a,O
prototypical,O
agent,O
for,O
this,O
activity,O
.,O
The,O
cytotoxicity,O
of,O
this,O
series,O
of,O
water,O
-,O
soluble,O
bis,B-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenylazopyridine,I-IUPAC
),I-IUPAC
complexes,B-MODIFIER
has,O
been,O
determined,O
in,O
A2780,O
human,O
ovarian,O
carcinoma,O
and,O
A2780cisR,O
",",O
the,O
corresponding,O
cisplatin,O
-,O
resistant,O
cell,O
line,O
.,O
Accordingly,O
",",O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
trifluoroacetyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
14,I-IUPAC
-,I-IUPAC
bromodaunorubicin,I-IUPAC
was,O
used,O
for,O
reaction,O
with,O
thiols,O
to,O
yield,O
thia,O
analogues,O
of,O
the,O
clinically,O
active,O
but,O
non,O
-,O
DNA,O
-,O
binding,O
adriamycin,O
analogue,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
trifluoroacetyl,I-IUPAC
),I-IUPAC
adriamycin,I-IUPAC
14,I-IUPAC
-,I-IUPAC
valerate,I-IUPAC
(,O
AD,O
32,O
),O
.,O
The,O
inactivation,O
was,O
shown,O
to,O
be,O
stereospecific,O
since,O
a,O
D,O
derivative,O
led,O
to,O
no,O
irreversible,O
inactivation,O
.,O
Increasing,O
the,O
chain,O
length,O
and,O
the,O
lipophilicity,O
of,O
the,O
N,O
-,O
substituent,O
result,O
in,O
compounds,O
in,O
which,O
high,O
affinity,O
for,O
sigma,O
2,O
binding,O
sites,O
is,O
retained,O
and,O
with,O
selectivity,O
for,O
sigma,O
2,O
vs,O
sigma,O
1,O
binding,O
sites,O
(,O
e.g.,O
",",O
4,B-IUPAC
-,I-IUPAC
cyclohexyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
butyl,I-IUPAC
:,O
IC50,O
-,O
(,O
sigma,O
1,O
),O
=,O
1.5,O
nM,O
",",O
IC50,O
(,O
sigma,O
2,O
),O
=,O
0.07,O
nM,O
),O
.,O
Under,O
similar,O
treatment,O
conditions,O
(,O
drug,O
dose,O
:,O
5.0,O
micromol,O
/,O
kg,O
;,O
light,O
dose,O
:,O
135,O
J,O
/,O
cm,O
(,O
2,O
),O
",",O
tumors,O
were,O
exposed,O
to,O
light,O
for,O
30,O
min,O
at,O
24,O
h,O
postinjection,O
),O
",",O
the,O
benzobacteriochlorins,O
containing,O
N,O
-,O
substituted,O
-,O
imide,O
ring,O
system,O
produced,O
enhanced,O
photosensitizing,O
efficacy,O
with,O
limited,O
skin,O
phototoxicity,O
.,O
However,O
",",O
contrary,O
to,O
expectations,O
based,O
on,O
the,O
aforementioned,O
F2Pmp,O
work,O
",",O
incorporation,O
of,O
this,O
putative,O
pTyr,O
mimetic,O
into,O
the,O
pseudo,O
-,O
dipeptide,O
",",O
N,B-IUPAC
-,I-IUPAC
[,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
carboxymethyloxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
naphthoyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
glutamic,I-IUPAC
acid,I-IUPAC
",",O
resulted,O
in,O
a,O
substantial,O
loss,O
of,O
binding,O
affinity,O
.,O
Those,O
compounds,O
",",O
structurally,O
related,O
to,O
previously,O
described,O
potassium,O
channel,O
openers,O
such,O
as,O
the,O
benzothiadiazine,O
dioxide,O
BPDZ,O
73,O
",",O
were,O
tested,O
as,O
putative,O
K,O
(,O
ATP,O
),O
channel,O
activators,O
on,O
the,O
pancreatic,O
endocrine,O
tissue,O
and,O
on,O
the,O
vascular,O
smooth,O
muscle,O
tissue,O
.,O
These,O
findings,O
encouraged,O
us,O
to,O
determine,O
the,O
structural,O
differences,O
between,O
"1,2",B-IUPAC
-,I-IUPAC
cyclohexanediamine,I-IUPAC
and,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
aminomethyl,I-IUPAC
),I-IUPAC
cyclohexylamine,I-IUPAC
complexes,B-MODIFIER
.,O
(,O
2R,O
),O
-,O
1,O
",",O
which,O
was,O
metabolized,O
to,O
2,O
to,O
a,O
lesser,O
extent,O
",",O
afforded,O
considerably,O
more,O
(,O
2R,O
",",O
2,O
"""",O
R,O
),O
-,O
2,O
than,O
(,O
2R,O
",",O
2,O
"""",O
S,O
),O
-,O
2,O
.,O
In,O
addition,O
",",O
aralkyl,B-IUPAC
",",O
alkyl,B-IUPAC
",",O
and,O
cycloalkyl,B-IUPAC
carboxylates,B-IUPAC
of,O
the,O
4,B-IUPAC
-,I-IUPAC
piperidinol,I-IUPAC
system,B-MODIFIER
and,O
"3,4",B-IUPAC
-,I-IUPAC
dimethoxybenzoates,I-IUPAC
of,O
isomeric,O
piperidinols,O
(,O
24-26,O
),O
were,O
synthesized,O
.,O
The,O
highest,O
selectivity,O
achieved,O
in,O
this,O
limited,O
series,O
was,O
with,O
"2,4",B-IUPAC
-,I-IUPAC
diamino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
[,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3',I-IUPAC
",",I-IUPAC
4',I-IUPAC
",",I-IUPAC
5',I-IUPAC
-,I-IUPAC
trimethoxybenzyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methylamino,I-IUPAC
],I-IUPAC
quinazoline,I-IUPAC
(,O
17,O
),O
against,O
T,O
.,O
Of,O
particular,O
interest,O
are,O
"1,3",B-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
methoxymethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"5,5",I-IUPAC
-,I-IUPAC
diphenylhydantoin,I-IUPAC
and,O
3,B-IUPAC
-,I-IUPAC
acetoxymethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
phenylhydantoin,I-IUPAC
",",O
which,O
show,O
good,O
activity,O
against,O
maximal,O
electroshock,O
seizures,O
",",O
and,O
3,B-IUPAC
-,I-IUPAC
methoxymethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
phenylhydantoin,I-IUPAC
",",O
which,O
is,O
effective,O
against,O
both,O
maximal,O
electroshock,O
and,O
pentylenetetrazole,B-IUPAC
.,O
For,O
the,O
preparation,O
of,O
5e,O
a,O
new,O
ring,O
-,O
closure,O
method,O
was,O
applied,O
.,O
We,O
prepared,O
six,O
pairs,O
of,O
alpha,B-IUPAC
-,I-IUPAC
heteroaromatic,I-IUPAC
aldoximes,I-IUPAC
",",O
RC,O
(,O
=,O
NOH,O
),O
H,O
",",O
and,O
thiohydroximates,O
",",O
RC,O
(,O
=,O
NOH,O
),O
S,O
-,O
(,O
CH2,O
),O
2N,O
(,O
C2H5,O
),O
2,O
",",O
where,O
R,O
represents,O
various,O
oxadiazole,O
and,O
thiadiazole,O
rings,O
.,O
Addition,O
of,O
4,B-PARTIUPAC
-,I-PARTIUPAC
methoxy,I-PARTIUPAC
-,I-PARTIUPAC
or,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
benzyloxy,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
Grignard,O
reagents,O
to,O
p,B-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
",",O
p,B-IUPAC
-,I-IUPAC
benzyloxy,I-IUPAC
",",O
or,O
unsubstituted,O
deoxybenzoins,O
",",O
followed,O
by,O
dehydration,O
of,O
the,O
resulting,O
carbinols,O
produced,O
a,O
mixture,O
of,O
E,O
and,O
Z,O
olefins,O
",",O
which,O
were,O
reacted,O
with,O
dichlorocarbene,O
to,O
give,O
O,O
-,O
protected,O
DTACs,O
.,O
ethanolamine,I-IUPAC
complex,B-MODIFIER
(,O
8,O
),O
",",O
and,O
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
adamantane,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
carbonyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
phenylpropionic,I-IUPAC
acid,I-IUPAC
(,O
15,O
),O
show,O
a,O
dose,O
-,O
dependent,O
",",O
astrocyte,O
-,O
selective,O
antiproliferative,O
activity,O
in,O
the,O
concentration,O
range,O
0.1-10,O
microM,O
.,O
The,O
phosphate,O
anion,O
",",O
derived,O
from,O
P,O
-,O
O,O
bond,O
cleavage,O
of,O
these,O
latter,O
compounds,O
",",O
is,O
only,O
observed,O
at,O
low,O
levels,O
after,O
a,O
long,O
period,O
of,O
hydrolysis,O
.,O
Several,O
compounds,O
prolonged,O
the,O
survival,O
time,O
of,O
mice,O
in,O
hypoxic,O
conditions,O
at,O
a,O
dose,O
of,O
30,O
mg,O
/,O
kg,O
(,O
sc,O
or,O
ip,O
),O
and,O
100,O
mg,O
/,O
kg,O
(,O
po,O
),O
.,O
Polyamines,O
containing,O
two,O
nitrogen,O
atoms,O
showed,O
optimal,O
binding,O
at,O
both,O
sigma,O
-,O
1,O
and,O
sigma,O
-,O
2,O
receptor,O
subtypes,O
.,O
A,O
series,O
of,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
naphthalenylsulfonyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
thiazolidinediones,I-IUPAC
were,O
synthesized,O
and,O
evaluated,O
for,O
antihyperglycemic,O
activity,O
in,O
an,O
insulin,O
-,O
resistant,O
",",O
genetically,O
diabetic,O
db,O
/,O
db,O
mouse,O
model,O
of,O
non,O
-,O
insulin,O
-,O
dependent,O
diabetes,O
mellitus,O
(,O
NIDDM,O
),O
.,O
The,O
hydroosmotic,O
activity,O
of,O
the,O
biotinyl,O
analogue,O
was,O
reversed,O
following,O
addition,O
of,O
avidin,O
",",O
whereas,O
the,O
photoaffinity,O
analogue,O
induced,O
a,O
persistent,O
response,O
following,O
UV,O
irradiation,O
that,O
was,O
not,O
reversed,O
upon,O
repeated,O
and,O
prolonged,O
periods,O
of,O
washout,O
.,O
The,O
(,O
1R,O
",",O
2R,O
),O
-,O
(,O
+,O
),O
-,O
enantiomer,O
",",O
(,O
+,O
),O
-,O
2,O
",",O
had,O
low,O
affinity,O
for,O
both,O
kappa,O
and,O
sigma,O
receptors,O
",",O
exhibiting,O
Ki,O
values,O
of,O
1298,O
+,O
/,O
-,O
49,O
nM,O
at,O
kappa,O
(,O
[,O
3H,O
],O
BREM,O
),O
and,O
1270,O
+,O
/,O
-,O
168,O
nM,O
at,O
sigma,O
[,O
[,O
3H,O
],O
-,O
(,O
+,O
),O
-,O
3,O
-,O
PPP,O
],O
.,O
The,O
compounds,O
"1,1",B-IUPAC
-,I-IUPAC
cyclobutanedicarboxylatobis,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenylazopyridine,I-IUPAC
),I-IUPAC
ruthenium,I-IUPAC
(,I-IUPAC
II,I-IUPAC
),I-IUPAC
",",O
alpha,O
-,O
[,O
Ru,O
(,O
azpy,O
),O
(,O
2,O
),O
(,O
cbdca,O
-,O
O,O
",",O
O',O
),O
],O
(,O
1,O
),O
",",O
oxalatobis,B-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenylazopyridine,I-IUPAC
),I-IUPAC
ruthenium,I-IUPAC
(,I-IUPAC
II,I-IUPAC
),I-IUPAC
",",O
alpha,O
-,O
[,O
Ru,O
(,O
azpy,O
),O
(,O
2,O
),O
(,O
ox,O
),O
],O
(,O
2,O
),O
",",O
and,O
malonatobis,B-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenylazopyridine,I-IUPAC
),I-IUPAC
ruthenium,I-IUPAC
(,I-IUPAC
II,I-IUPAC
),I-IUPAC
",",O
alpha,O
-,O
[,O
Ru,O
(,O
azpy,O
),O
(,O
2,O
),O
(,O
mal,O
),O
],O
(,O
3,O
),O
",",O
have,O
been,O
synthesized,O
and,O
fully,O
characterized,O
.,O
6beta,B-IUPAC
-,I-IUPAC
Acyloxy,I-IUPAC
(,I-IUPAC
nor,I-IUPAC
),I-IUPAC
tropane,I-IUPAC
",",O
two,O
other,O
(,O
nor,O
),O
tropanes,O
",",O
and,O
the,O
classical,O
muscarinic,O
agonists,O
had,O
higher,O
affinity,O
versus,O
agonist,O
binding,O
compared,O
to,O
antagonist,O
binding,O
for,O
transfected,O
m,O
(,O
4,O
),O
-,O
receptors,O
.,O
We,O
find,O
that,O
for,O
the,O
fluorine,O
-,O
substituted,O
derivatives,O
studied,O
",",O
the,O
position,O
of,O
the,O
fluorine,O
on,O
the,O
quinolone,O
nucleus,O
or,O
the,O
number,O
of,O
fluorine,O
atoms,O
does,O
not,O
seem,O
to,O
be,O
important,O
for,O
good,O
Gram,O
positive,O
activity,O
.,O
In,O
vitro,O
quantitative,O
autoradiography,O
determined,O
that,O
3,O
",",O
7,O
",",O
and,O
8,O
had,O
potent,O
binding,O
affinities,O
(,O
K,O
(,O
i,O
),O
=,O
0.07-0.19,O
nM,O
),O
for,O
PBR,O
in,O
the,O
rat,O
brain,O
.,O
The,O
replacement,O
of,O
the,O
[,O
Phe,O
(,O
3,O
),O
-,O
MePhe,O
(,O
4,O
),O
-,O
Pro,O
(,O
5,O
),O
],O
tripeptide,O
by,O
an,O
8,B-IUPAC
-,I-IUPAC
aminocaprylic,I-IUPAC
acid,I-IUPAC
or,O
the,O
N,O
(,O
7,O
),O
(,O
),O
-,O
desmethylation,O
of,O
MeVal,O
(,O
7,O
),O
led,O
to,O
only,O
a,O
3.3,O
-,O
fold,O
decreased,O
capacity,O
to,O
inhibit,O
Pgp,O
function,O
",",O
suggesting,O
that,O
the,O
Pgp,O
inhibitory,O
potential,O
of,O
aureobasidins,O
",",O
though,O
favored,O
by,O
the,O
establishment,O
of,O
an,O
antiparallel,O
beta,O
-,O
sheet,O
between,O
the,O
[,O
D,O
-,O
Hmp,O
(,O
1,O
),O
-,O
L,O
-,O
MeVal,O
(,O
2,O
),O
-,O
L,O
-,O
Phe,O
(,O
3,O
),O
],O
and,O
[,O
L,O
-,O
aIle,O
(,O
6,O
),O
-,O
L,O
-,O
MeVal,O
(,O
7,O
),O
-,O
L,O
-,O
Leu,O
(,O
8,O
),O
-,O
],O
tripeptides,O
",",O
does,O
not,O
critically,O
depend,O
on,O
the,O
occurrence,O
of,O
the,O
[,O
L,O
-,O
Phe,O
(,O
3,O
),O
-,O
L,O
-,O
MePhe,O
(,O
4,O
),O
-,O
L,O
-,O
Pro,O
(,O
5,O
),O
-,O
L,O
-,O
aIle,O
(,O
6,O
),O
],O
type,O
II,O
',O
beta,O
-,O
turn,O
secondary,O
structure,O
.,O
This,O
report,O
describes,O
the,O
synthesis,O
and,O
initial,O
biochemical,O
evaluation,O
of,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxyalkyl,I-IUPAC
),I-IUPAC
estrogens,I-IUPAC
and,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
aminoalkyl,I-IUPAC
),I-IUPAC
estradiols,I-IUPAC
.,O
The,O
inhibition,O
constants,O
",",O
alpha,O
(,O
the,O
ratio,O
of,O
the,O
molar,O
I50,O
of,O
theophylline,O
to,O
the,O
molar,O
I50,O
of,O
the,O
test,O
compounds,O
),O
",",O
were,O
subjected,O
to,O
a,O
Hansch,O
correlation,O
analysis,O
.,O
The,O
5,B-PARTIUPAC
-,I-PARTIUPAC
halo,I-PARTIUPAC
-,I-PARTIUPAC
6,I-PARTIUPAC
-,I-PARTIUPAC
alkoxy,I-PARTIUPAC
(,O
or,O
azido,B-PARTIUPAC
),O
-,B-PARTIUPAC
"5,6",I-PARTIUPAC
-,I-PARTIUPAC
dihydro,I-PARTIUPAC
-,I-PARTIUPAC
3',I-PARTIUPAC
-,I-PARTIUPAC
azido,I-PARTIUPAC
-,I-PARTIUPAC
3',I-PARTIUPAC
-,I-PARTIUPAC
deoxythymidines,I-PARTIUPAC
",",O
which,O
differ,O
in,O
configuration,O
at,O
the,O
C,O
-,O
5,O
and,O
C,O
-,O
6,O
positions,O
",",O
were,O
synthesized,O
by,O
the,O
regiospecific,O
addition,O
of,O
XR,O
(,O
X,O
=,O
Br,O
",",O
Cl,O
",",O
I,O
;,O
R,O
=,O
alkoxy,O
",",O
azido,O
),O
to,O
the,O
"5,6",O
-,O
olefinic,O
bond,O
of,O
AZT,O
.,O
Additional,O
small,O
substituents,O
on,O
the,O
guanidine,O
nitrogen,O
atoms,O
bearing,O
the,O
aryl,O
rings,O
resulted,O
in,O
tri,O
-,O
and,O
tetrasubstituted,O
guanidine,O
derivatives,O
which,O
retained,O
affinity,O
for,O
NMDA,O
receptor,O
ion,O
channel,O
sites,O
but,O
exhibited,O
a,O
significant,O
reduction,O
in,O
their,O
affinities,O
for,O
sigma,O
receptors,O
.,O
This,O
antiviral,O
activity,O
did,O
not,O
appear,O
to,O
be,O
related,O
to,O
the,O
decomposition,O
to,O
the,O
5,B-IUPAC
-,I-IUPAC
formyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
",",O
which,O
was,O
itself,O
devoid,O
of,O
anti,O
-,O
orthopoxvirus,O
activity,O
in,O
these,O
assays,O
.,O
As,O
hybrids,O
between,O
tropanes,O
and,O
quinuclidines,O
",",O
these,O
tropaquinuclidines,O
represent,O
a,O
significant,O
structural,O
departure,O
from,O
many,O
of,O
the,O
other,O
classes,O
of,O
tropane,O
ligands,O
synthesized,O
to,O
date,O
.,O
Confirmed,O
in,O
vitro,O
cytotoxic,O
activity,O
that,O
parallels,O
antimicrobial,O
activity,O
was,O
found,O
for,O
juncusol,O
(,O
1a,O
),O
",",O
desvinyljuncusol,O
(,O
2h,O
),O
",",O
2,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
"9,10",I-IUPAC
-,I-IUPAC
dihydrophenanthrene,I-IUPAC
(,O
3h,O
),O
",",O
and,O
the,O
quaternary,B-MODIFIER
dimethyl,B-IUPAC
[,I-IUPAC
(,I-IUPAC
phenylthio,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
ammonium,I-IUPAC
salts,B-MODIFIER
2d,O
and,O
3d,O
in,O
a,O
human,O
lymphoblastic,O
leukemia,O
cell,O
culture,O
(,O
CCRF,O
-,O
CEM,O
",",O
IC50,O
=,O
nt,O
",",O
9.3,O
",",O
nt,O
",",O
0.9,O
and,O
1.4,O
microgram,O
/,O
mL,O
",",O
respectively,O
),O
",",O
B,O
-,O
16,O
mouse,O
melanoma,O
cell,O
culture,O
(,O
IC50,O
=,O
12.5,O
",",O
17.5,O
",",O
27.7,O
",",O
0.3,O
",",O
and,O
0.5,O
microgram,O
/,O
mL,O
",",O
respectively,O
),O
",",O
and,O
L,O
-,O
1210,O
mouse,O
lymphocytic,O
leukemia,O
cell,O
culture,O
(,O
IC50,O
=,O
13.8,O
",",O
10.2,O
",",O
24.5,O
",",O
1.3,O
",",O
and,O
3.7,O
micrograms,O
/,O
mL,O
",",O
respectively,O
),O
.,O
The,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxyalkyl,I-IUPAC
),I-IUPAC
estrogens,I-IUPAC
were,O
prepared,O
by,O
oxidative,O
hydroboration,O
of,O
4,B-IUPAC
-,I-IUPAC
alkenylestradiols,I-IUPAC
.,O
On,O
the,O
basis,O
of,O
our,O
recent,O
findings,O
that,O
[,B-IUPAC
188Re,I-IUPAC
],I-IUPAC
tricarbonyl,I-IUPAC
(,I-IUPAC
cyclopentadienylcarbonate,I-IUPAC
),I-IUPAC
rhenium,I-IUPAC
(,O
[,O
188Re,O
],O
CpTR,O
-,O
COOH,O
),O
was,O
recognized,O
as,O
an,O
aromatic,O
compound,O
and,O
was,O
metabolized,O
as,O
such,O
in,O
the,O
body,O
",",O
[,O
99mTc,O
],O
cyclopentadienyltricarbonyltechnetium,O
(,O
[,O
99mTc,O
],O
CpTT,O
),O
was,O
conjugated,O
at,O
the,O
omega,O
-,O
position,O
of,O
pentadecanoic,O
acid,O
to,O
prepare,O
[,O
99mTc,O
],O
CpTT,O
-,O
PA,O
.,O
1-9,O
),O
",",O
a,O
75%,O
increase,O
in,O
survival,O
was,O
observed,O
relative,O
to,O
untreated,O
controls,O
",",O
and,O
there,O
was,O
no,O
evidence,O
of,O
any,O
host,O
toxicity,O
.,O
Most,O
compounds,O
were,O
potent,O
competitive,O
inhibitors,O
of,O
pol,O
IIIC,O
(,O
K,O
(,O
i,O
),O
s,O
0.02-0.5,O
microM,O
),O
",",O
and,O
those,O
with,O
neutral,O
",",O
moderately,O
polar,O
3,O
-,O
substituents,O
had,O
potent,O
antibacterial,O
activity,O
against,O
Gram+,O
organisms,O
in,O
culture,O
(,O
MICs,O
0.125-10,O
microg,O
/,O
mL,O
),O
.,O
In,O
the,O
series,O
of,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylamino,I-IUPAC
),I-IUPAC
",",O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
phenyloxy,I-IUPAC
),I-IUPAC
",",O
and,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylthio,I-IUPAC
),I-IUPAC
substitutions,B-MODIFIER
",",O
the,O
order,O
of,O
affinity,O
at,O
the,O
A,O
(,O
3,O
),O
AR,O
was,O
oxy,O
&,O
gt,O
;,O
or,O
=,O
amino,O
&,O
gt,O
;,O
thio,O
.,O
The,O
most,O
potent,O
broad,O
spectrum,O
agent,O
in,O
the,O
NCI,O
cell,O
panel,O
was,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methylphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
fluorobenzothiazole,I-IUPAC
(,O
10h,O
),O
which,O
",",O
unlike,O
the,O
6,B-IUPAC
-,I-IUPAC
fluoro,I-IUPAC
isomer,B-MODIFIER
(,O
10d,O
),O
",",O
produces,O
no,O
exportable,O
metabolites,O
in,O
the,O
presence,O
of,O
sensitive,O
MCF,O
-,O
7,O
cells,O
.,O
Fluoride,O
was,O
also,O
found,O
after,O
injection,O
of,O
[,O
18F,O
],O
4d,O
.,O
Sulfur,O
-,O
bridged,O
pregnanes,O
"6,19",B-IUPAC
-,I-IUPAC
epithioprogesterone,I-IUPAC
",",O
21,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
"6,19",I-IUPAC
-,I-IUPAC
epithioprogesterone,I-IUPAC
",",O
and,O
the,O
corresponding,O
sulfoxides,O
and,O
sulfones,O
were,O
synthesized,O
and,O
tested,O
as,O
blockers,O
of,O
the,O
immunosuppresive,O
activity,O
of,O
dexamethasone,O
in,O
rat,O
thymocytes,O
.,O
The,O
conclusion,O
was,O
reached,O
that,O
certain,O
conformations,O
",",O
which,O
do,O
not,O
resemble,O
those,O
of,O
lowest,O
potential,O
energy,O
",",O
cannot,O
be,O
adopted,O
by,O
the,O
inactive,O
compounds,O
.,O
The,O
affinity,O
of,O
6beta,B-IUPAC
-,I-IUPAC
benzoyloxynortropane,I-IUPAC
and,O
other,O
analogues,O
with,O
larger,O
acyl,O
moieties,O
was,O
little,O
affected,O
by,O
N,O
-,O
methylation,O
or,O
in,O
some,O
cases,O
was,O
increased,O
.,O
Indeed,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxyalkyl,I-IUPAC
),I-IUPAC
hydroxypyridinones,I-IUPAC
which,O
are,O
known,O
to,O
be,O
rapidly,O
converted,O
to,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
carboxyalkyl,I-IUPAC
),I-IUPAC
hydroxypyridinones,I-IUPAC
are,O
also,O
marginally,O
superior,O
to,O
Deferiprone,O
.,O
Compound,O
7n,O
is,O
a,O
13,O
-,O
fold,O
more,O
potent,O
inhibitor,O
than,O
7b,O
",",O
and,O
these,O
kinetic,O
studies,O
indicate,O
that,O
the,O
increase,O
in,O
inhibitory,O
activity,O
is,O
due,O
to,O
an,O
increase,O
in,O
initial,O
affinity,O
toward,O
the,O
enzyme,O
and,O
not,O
an,O
increase,O
in,O
chemical,O
reactivity,O
.,O
Zone,O
assays,O
in,O
several,O
tumor,O
cell,O
lines,O
show,O
that,O
active,O
compounds,O
are,O
cytotoxic,O
agents,O
with,O
little,O
selectivity,O
for,O
tumor,O
cells,O
.,O
Also,O
included,O
in,O
the,O
study,O
were,O
3,B-PARTIUPAC
-,I-PARTIUPAC
oxo,I-PARTIUPAC
-,I-PARTIUPAC
3H,I-PARTIUPAC
-,I-PARTIUPAC
naphtho,I-PARTIUPAC
[,I-PARTIUPAC
"2,1",I-PARTIUPAC
-,I-PARTIUPAC
b,I-PARTIUPAC
],I-PARTIUPAC
pyran,I-PARTIUPAC
-,I-PARTIUPAC
1,I-PARTIUPAC
-,I-PARTIUPAC
acetic,I-PARTIUPAC
",",O
2,B-PARTIUPAC
-,I-PARTIUPAC
oxo,I-PARTIUPAC
-,I-PARTIUPAC
2H,I-PARTIUPAC
-,I-PARTIUPAC
naphtho,I-PARTIUPAC
[,I-PARTIUPAC
"1,2",I-PARTIUPAC
-,I-PARTIUPAC
b,I-PARTIUPAC
],I-PARTIUPAC
pyran,I-PARTIUPAC
-,I-PARTIUPAC
4,I-PARTIUPAC
-,I-PARTIUPAC
acetic,I-PARTIUPAC
",",O
and,O
1,B-IUPAC
-,I-IUPAC
naphthylacetic,I-IUPAC
acids,I-IUPAC
.,O
Placement,O
of,O
the,O
epoxyalkyl,O
group,O
at,O
the,O
carboxy,O
terminus,O
led,O
to,O
potent,O
rapid,O
inactivation,O
.,O
These,O
results,O
suggest,O
that,O
the,O
potent,O
antagonistic,O
properties,O
of,O
the,O
bicyclic,O
analogues,O
[,O
Mpa1,O
",",O
cyclo,O
(,O
Glu4,O
",",O
Lys8,O
),O
],O
oxytocin,O
and,O
[,O
dPen1,O
",",O
cyclo,O
(,O
Glu4,O
",",O
Lys8,O
),O
],O
oxytocin,O
can,O
be,O
attributed,O
to,O
the,O
effect,O
of,O
the,O
lactam,O
bridge,O
on,O
the,O
conformational,O
flexibility,O
and,O
topographical,O
properties,O
of,O
the,O
analogues,O
",",O
rendering,O
them,O
more,O
favorable,O
for,O
binding,O
to,O
the,O
receptor,O
in,O
such,O
a,O
manner,O
as,O
to,O
prevent,O
transduction,O
of,O
a,O
biological,O
response,O
.,O
The,O
structure,O
-,O
activity,O
findings,O
led,O
to,O
a,O
refinement,O
of,O
a,O
model,O
of,O
the,O
nonprostanoid,O
PGI2,O
mimetic,O
pharmacophore,O
.,O
;,O
Cheatham,O
",",O
S,O
.,O
Previous,O
findings,O
suggesting,O
that,O
"5,10",B-IUPAC
-,I-IUPAC
dialkyl,I-IUPAC
-,O
substituted,B-MODIFIER
derivatives,I-MODIFIER
of,O
"5,10",B-IUPAC
-,I-IUPAC
dideazaaminopterin,I-IUPAC
warranted,O
study,O
as,O
potential,O
antifolates,O
prompted,O
synthesis,O
of,O
10,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
"5,10",I-IUPAC
-,I-IUPAC
dideazaaminopterin,I-IUPAC
(,O
12a,O
),O
.,O
2,B-IUPAC
-,I-IUPAC
Aminoadipic,I-IUPAC
acid,I-IUPAC
(,O
3,O
),O
",",O
which,O
shows,O
a,O
complex,O
excitatory,O
amino,O
acid,O
synaptic,O
pharmacology,O
",",O
was,O
an,O
agonist,O
at,O
mGlu6,O
as,O
well,O
as,O
mGlu2,O
.,O
The,O
peripheral,O
benzodiazepine,O
receptor,O
(,O
PBR,O
),O
is,O
widely,O
expressed,O
in,O
peripheral,O
tissues,O
",",O
blood,O
cells,O
",",O
and,O
in,O
glia,O
cells,O
in,O
the,O
brain,O
.,O
Contrary,O
to,O
the,O
literature,O
reports,O
",",O
no,O
enhancement,O
in,O
activity,O
due,O
to,O
the,O
presence,O
of,O
a,O
hydroxy,O
group,O
was,O
found,O
when,O
the,O
cytotoxicity,O
of,O
furanones,O
13a,O
",",O
b,O
",",O
d,O
and,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1',I-IUPAC
-,I-IUPAC
hydroxyalkyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methylenedihydrofuran,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
6a,O
",",O
b,O
",",O
d,O
was,O
compared,O
.,O
For,O
the,O
syntheses,O
",",O
"2,4",B-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
trimethylsily,I-IUPAC
),I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
fluorouracil,I-IUPAC
(,O
Me3Si,O
-,O
FU,O
",",O
1,O
),O
and,O
2,B-IUPAC
-,I-IUPAC
acetoxytetrahydrofuran,I-IUPAC
(,O
Thf,O
-,O
OAc,O
",",O
2,O
),O
were,O
condensed,O
in,O
the,O
presence,O
of,O
Friedel,O
-,O
Crafts,O
catalysts,O
",",O
such,O
as,O
SnCl4,O
and,O
BF3,O
-,O
Et2O,O
in,O
dichloromethane,O
",",O
or,O
in,O
the,O
presence,O
of,O
NaI,O
in,O
acetonitrile,O
to,O
give,O
Thf,O
-,O
Fu,O
or,O
Thf2,O
-,O
FU,O
depending,O
on,O
the,O
reaction,O
conditions,O
and,O
workup,O
procedure,O
.,O
The,O
4H,B-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
",",O
the,O
"2,3",B-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
4H,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
",",O
the,O
4H,B-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
",",O
and,O
the,O
"2,3",B-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
derivatives,B-MODIFIER
were,O
found,O
to,O
be,O
inactive,O
or,O
only,O
marginally,O
activate,O
as,O
receptor,O
ligands,O
or,O
estrogen,O
agonists,O
-,O
antagonists,O
.,O
Analogues,O
of,O
methotrexate,O
(,O
MTX,O
),O
and,O
aminopterin,O
(,O
AMT,O
),O
modified,O
at,O
the,O
gamma,O
-,O
position,O
of,O
the,O
glutamate,O
side,O
chain,O
were,O
synthesized,O
and,O
evaluated,O
as,O
dihydrofolate,O
reductase,O
(,O
DHFR,O
),O
inhibitors,O
and,O
tumor,O
cell,O
growth,O
inhibitors,O
.,O
A,O
series,O
of,O
4,B-IUPAC
(,I-IUPAC
5,I-IUPAC
),I-IUPAC
-,I-IUPAC
iodo,I-IUPAC
-,I-IUPAC
5,I-IUPAC
(,I-IUPAC
4,I-IUPAC
),I-IUPAC
-,I-IUPAC
nitro,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,O
substituted,B-MODIFIER
-,O
imidazoles,B-IUPAC
has,O
been,O
synthesized,O
and,O
tested,O
for,O
their,O
ability,O
to,O
selectively,O
radiosensitize,O
hypoxic,O
Chinese,O
hamster,O
cells,O
(,O
V,O
-,O
79,O
),O
to,O
the,O
lethal,O
effect,O
of,O
radiation,O
.,O
Moreover,O
",",O
in,O
vivo,O
binding,O
of,O
the,O
methyl,O
homologue,O
[,O
(,O
11,O
),O
C,O
],O
8,O
in,O
the,O
monkey,O
brain,O
could,O
be,O
inhibited,O
by,O
PBR,O
-,O
selective,O
2,O
or,O
1,O
",",O
indicating,O
that,O
some,O
of,O
the,O
[,O
(,O
11,O
),O
C,O
],O
8,O
binding,O
was,O
due,O
to,O
PBR,O
.,O
The,O
compounds,O
were,O
prepared,O
by,O
condensing,O
4,B-IUPAC
",",I-IUPAC
6,I-IUPAC
-,I-IUPAC
diaminonicotinaldehyde,I-IUPAC
with,O
"2,6",B-IUPAC
-,I-IUPAC
dichlorophenylacetonitrile,I-IUPAC
and,O
selectively,O
converting,O
the,O
2,O
-,O
and,O
7,O
-,O
amino,O
groups,O
of,O
the,O
product,O
to,O
hydroxy,O
and,O
fluoro,O
groups,O
",",O
respectively,O
",",O
by,O
prolonged,O
diazotization,O
in,O
50%,O
aqueous,O
fluoboric,O
acid,O
.,O
Both,O
12a,O
and,O
its,O
5,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,O
substituted,B-MODIFIER
analogue,B-MODIFIER
12b,O
were,O
converted,O
to,O
versatile,O
6,B-IUPAC
-,I-IUPAC
bromomethyl,I-IUPAC
intermediates,B-MODIFIER
13a,O
and,O
13b,O
from,O
which,O
important,O
antifolates,O
may,O
be,O
readily,O
derived,O
.,O
Analogous,O
peptides,O
with,O
a,O
tyrosine,O
at,O
position,O
11,O
(,O
31-36,O
),O
were,O
less,O
selective,O
than,O
the,O
corresponding,O
peptides,O
with,O
a,O
tyrosine,O
at,O
position,O
2,O
.,O
At,O
60,O
min,O
post,O
-,O
iv,O
-,O
injection,O
",",O
the,O
specific,O
uptakes,O
",",O
as,O
measured,O
by,O
[,O
striatum,O
-,O
cerebellum,O
],O
/,O
cerebellum,O
(,O
[,O
ST,O
-,O
CB,O
],O
/,O
CB,O
),O
ratio,O
",",O
were,O
1.72,O
and,O
2.79,O
for,O
2A,O
",",O
B,O
",",O
respectively,O
.,O
None,O
of,O
these,O
new,O
compounds,O
showed,O
detectable,O
effects,O
at,O
N,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
d,I-IUPAC
-,I-IUPAC
aspartic,I-IUPAC
acid,I-IUPAC
(,O
NMDA,O
),O
or,O
kainic,O
acid,O
receptors,O
in,O
vitro,O
.,O
Functionally,O
",",O
the,O
stereoisomers,O
displayed,O
a,O
similar,O
alpha,O
(,O
1,O
),O
-,O
selectivity,O
profile,O
",",O
that,O
is,O
alpha,O
(,O
1D,O
),O
&,O
gt,O
;,O
alpha,O
(,O
1B,O
),O
&,O
gt,O
;,O
alpha,O
(,O
1A,O
),O
",",O
which,O
is,O
different,O
from,O
that,O
exhibited,O
by,O
the,O
reference,O
compound,O
1,O
.,O
The,O
results,O
establish,O
that,O
alpha,B-IUPAC
-,I-IUPAC
naphthoflavone,I-IUPAC
is,O
the,O
most,O
effective,O
in,O
vitro,O
inhibitor,O
.,O
A,O
new,O
class,O
of,O
5,B-PARTIUPAC
-,I-PARTIUPAC
halo,I-PARTIUPAC
-,I-PARTIUPAC
6,I-PARTIUPAC
-,I-PARTIUPAC
alkoxy,I-PARTIUPAC
(,O
or,O
azido,B-PARTIUPAC
),O
-,B-PARTIUPAC
"5,6",I-PARTIUPAC
-,I-PARTIUPAC
dihydro,I-PARTIUPAC
-,I-PARTIUPAC
3',I-PARTIUPAC
-,I-PARTIUPAC
azido,I-PARTIUPAC
-,I-PARTIUPAC
3',I-PARTIUPAC
-,I-PARTIUPAC
deoxythymidines,I-PARTIUPAC
was,O
investigated,O
as,O
potential,O
anti,O
-,O
AIDS,O
drugs,O
.,O
Two,O
approaches,O
for,O
the,O
preparation,O
of,O
iodinated,O
versions,O
of,O
these,O
prostaglandins,O
were,O
evaluated,O
:,O
(,O
1,O
),O
iodination,O
of,O
a,O
phenyl,O
azide,O
bearing,O
an,O
activating,O
hydroxyl,O
group,O
and,O
(,O
2,O
),O
iodination,O
of,O
an,O
aniline,O
precursor,O
to,O
the,O
phenyl,O
azide,O
group,O
and,O
subsequent,O
conversion,O
of,O
the,O
aniline,O
to,O
the,O
phenyl,O
azide,O
.,O
Mainly,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
acyloxy,I-IUPAC
),I-IUPAC
alkyl,I-IUPAC
esters,I-IUPAC
and,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
alkoxycarbonyl,I-IUPAC
),I-IUPAC
oxy,I-IUPAC
],I-IUPAC
alkyl,I-IUPAC
esters,I-IUPAC
",",O
double,O
ester,O
derivatives,O
",",O
were,O
synthesized,O
.,O
In,O
contrast,O
",",O
high,O
activity,O
against,O
aminopyrine,O
demethylase,O
was,O
frequently,O
displayed,O
in,O
this,O
series,O
",",O
"3,5",B-IUPAC
-,I-IUPAC
dibromo,I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
dihydroxypropiophenone,I-IUPAC
(,O
36,O
),O
showing,O
greatest,O
inhibitory,O
potency,O
.,O
The,O
capacity,O
of,O
ligand,O
1,O
and,O
its,O
Ga,O
(,O
III,O
),O
and,O
Fe,O
(,O
III,O
),O
complexes,O
to,O
destroy,O
the,O
tyrosyl,O
radical,O
of,O
the,O
presumed,O
target,O
ribonucleotide,O
reductase,O
is,O
reported,O
.,O
It,O
is,O
suggested,O
that,O
nipecotamides,O
interact,O
with,O
anionic,O
platelet,O
sites,O
located,O
7,O
A,O
from,O
each,O
other,O
and,O
connected,O
by,O
a,O
hydrophobic,O
well,O
.,O
In,O
contrast,O
",",O
reaction,O
of,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
iodoethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
(,O
11a,O
),O
with,O
sodium,O
carbonate,O
in,O
methanol,O
afforded,O
a,O
mixture,O
of,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
methoxyethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
(,O
13,O
),O
and,O
"2,3",B-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
ribofuranosyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
furano,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidin,I-IUPAC
-,I-IUPAC
6,I-IUPAC
(,I-IUPAC
5H,I-IUPAC
),I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
14,O
),O
.,O
A,O
series,O
of,O
4,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
2,B-IUPAC
-,I-IUPAC
formylpyridine,I-IUPAC
thiosemicarbazones,I-IUPAC
has,O
been,O
synthesized,O
which,O
contain,O
a,O
tertiary,O
N,O
at,O
the,O
4,O
position,O
.,O
In,O
order,O
to,O
investigate,O
the,O
role,O
of,O
receptor,O
subtypes,O
",",O
we,O
have,O
carried,O
out,O
a,O
chemical,O
synthesis,O
program,O
to,O
seek,O
selective,O
retinoids,O
for,O
these,O
receptors,O
.,O
A,O
synthesis,O
scheme,O
for,O
3',B-IUPAC
-,I-IUPAC
C,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxynucleosides,I-IUPAC
and,O
3',B-IUPAC
-,I-IUPAC
C,I-IUPAC
-,I-IUPAC
methylidene,I-IUPAC
-,I-IUPAC
2',I-IUPAC
",",I-IUPAC
3',I-IUPAC
-,I-IUPAC
dideoxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyluridine,I-IUPAC
has,O
been,O
proposed,O
with,O
2,B-IUPAC
-,I-IUPAC
deoxyribose,I-IUPAC
as,O
the,O
starting,O
material,O
.,O
In,O
a,O
comparative,O
study,O
the,O
benzopyran,O
16,O
was,O
found,O
to,O
be,O
more,O
effective,O
antiestrogen,O
than,O
tamoxifen,O
while,O
being,O
as,O
effective,O
as,O
LY,O
-,O
117018,O
.,O
Hydrophilicity,O
of,O
these,O
analogues,O
",",O
a,O
potential,O
measure,O
of,O
their,O
ability,O
to,O
be,O
formulated,O
for,O
sustained,O
release,O
",",O
was,O
determined,O
using,O
RP,O
-,O
HPLC,O
at,O
neutral,O
pH,O
yielding,O
analogues,O
with,O
shorter,O
as,O
well,O
as,O
longer,O
retention,O
times,O
.,O
Potency,O
showed,O
a,O
marked,O
sensitivity,O
to,O
the,O
introduction,O
of,O
substituents,O
to,O
these,O
aromatic,O
rings,O
and,O
only,O
the,O
bis,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
derivative,B-MODIFIER
9j,O
",",O
IC50,O
=,O
0.34,O
microM,O
",",O
demonstrated,O
enhanced,O
potency,O
compared,O
to,O
the,O
parent,O
structure,O
3,O
",",O
IC50,O
=,O
1.2,O
microM,O
.,O
Results,O
of,O
these,O
studies,O
indicate,O
that,O
",",O
in,O
addition,O
to,O
the,O
2,B-IUPAC
-,I-IUPAC
[,I-IUPAC
methyl,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxoethyl,I-IUPAC
moiety,B-MODIFIER
",",O
the,O
presence,O
of,O
an,O
acid,O
group,O
and,O
a,O
lipophilic,O
side,O
chain,O
",",O
as,O
well,O
as,O
the,O
spatial,O
relationship,O
of,O
these,O
three,O
functions,O
",",O
is,O
crucial,O
for,O
high,O
binding,O
affinity,O
with,O
LTB4,O
receptors,O
.,O
They,O
combine,O
10,O
different,O
N,O
-,O
protecting,O
groups,O
(,O
R1,O
),O
",",O
3,O
amino,O
acids,O
residues,O
in,O
P1,O
(,O
AA,O
),O
",",O
and,O
44,O
distinct,O
substituents,O
on,O
the,O
alpha,O
-,O
keto,O
amide,O
nitrogen,O
(,O
R2,O
),O
.,O
A,O
comparison,O
of,O
the,O
brain,O
uptake,O
of,O
the,O
N,B-IUPAC
-,I-IUPAC
isopropyl,I-IUPAC
derivative,B-MODIFIER
with,O
the,O
2,B-IUPAC
(,I-IUPAC
RS,I-IUPAC
),I-IUPAC
-,I-IUPAC
aminopropyl,I-IUPAC
analogue,B-MODIFIER
demonstrated,O
higher,O
initial,O
brain,O
uptake,O
and,O
brain,O
to,O
blood,O
ratios,O
(,O
5,O
min,O
",",O
3.2%,O
dose,O
/,O
g,O
;,O
10.3/1,O
),O
but,O
more,O
rapid,O
washout,O
(,O
30,O
min,O
",",O
1.37%,O
dose,O
;,O
2.8/1,O
),O
.,O
The,O
N,B-MODIFIER
-,I-MODIFIER
6,I-MODIFIER
glycosylated,I-MODIFIER
imidazo,B-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
isothiazoles,I-IUPAC
were,O
completely,O
inactive,O
up,O
to,O
the,O
highest,O
concentration,O
tested,O
.,O
In,O
general,O
",",O
the,O
derivatives,O
were,O
found,O
to,O
be,O
considerably,O
more,O
potent,O
at,O
24,O
h,O
than,O
at,O
2,O
h,O
after,O
the,O
administration,O
.,O
The,O
introduction,O
of,O
a,O
cycloaliphatic,O
five,O
-,O
or,O
six,O
-,O
membered,O
ring,O
fused,O
at,O
the,O
thiophene,O
was,O
favorable,O
for,O
CEase,O
inhibition,O
.,O
Compounds,O
5,O
and,O
6,O
also,O
demonstrated,O
modest,O
anti,O
-,O
hepatitis,O
B,O
virus,O
activity,O
against,O
DHBV,O
(,O
EC,O
(,O
50,O
),O
=,O
19.9-23.6,O
microM,O
),O
.,O
Certain,O
derivatives,O
containing,O
the,O
"1,2",B-IUPAC
-,I-IUPAC
dihydropyrido,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
pyrazine,I-IUPAC
(,O
1,B-IUPAC
-,I-IUPAC
deaza,I-IUPAC
-,I-IUPAC
"7,8",I-IUPAC
-,I-IUPAC
dihydropteridine,I-IUPAC
),O
ring,B-MODIFIER
system,I-MODIFIER
are,O
active,O
against,O
experimental,O
neoplasms,O
in,O
mice,O
.,O
Reinforcement,O
of,O
the,O
characteristics,O
of,O
amphiphilicity,O
",",O
helicity,O
",",O
and,O
peptide,O
dipolar,O
effects,O
",",O
using,O
recognized,O
medicinal,O
chemistry,O
approaches,O
including,O
introduction,O
of,O
conformational,O
constraints,O
",",O
has,O
resulted,O
in,O
several,O
potent,O
GHRH,O
analogues,O
.,O
We,O
have,O
further,O
modified,O
the,O
flavone,O
structure,O
to,O
achieve,O
a,O
degree,O
of,O
selectivity,O
for,O
cloned,O
human,O
brain,O
A3,O
receptors,O
",",O
determined,O
in,O
competitive,O
binding,O
assays,O
versus,O
[,O
125I,O
],O
AB,O
-,O
MECA,O
[,O
N6,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
iodobenzyl,I-IUPAC
),I-IUPAC
adenosine,I-IUPAC
-,I-IUPAC
5',I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methylur,I-IUPAC
onamide,I-IUPAC
),I-IUPAC
],O
.,O
Structurally,O
",",O
this,O
series,O
of,O
analogues,O
has,O
novel,O
substitutions,O
at,O
positions,O
3,O
",",O
7,O
",",O
and,O
8,O
and,O
N,O
(,O
alpha,O
),O
-,O
methylation,O
at,O
positions,O
6,O
",",O
7,O
",",O
and,O
8,O
in,O
the,O
structure,O
of,O
degarelix,O
.,O
An,O
enantiospecific,O
method,O
was,O
developed,O
for,O
the,O
synthesis,O
of,O
3,B-PARTIUPAC
-,I-PARTIUPAC
fluoromethyl,I-PARTIUPAC
-,I-PARTIUPAC
",",O
3,B-PARTIUPAC
-,I-PARTIUPAC
hydroxymethyl,I-PARTIUPAC
-,I-PARTIUPAC
",",O
and,O
3,B-IUPAC
-,I-IUPAC
chloromethyl,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,O
substituted,B-MODIFIER
-,O
"1,2,3,4",B-IUPAC
-,I-IUPAC
tetrahydroisoquinolines,I-IUPAC
(,O
THIQs,O
),O
from,O
phenylalanine,O
.,O
In,O
the,O
linear,O
series,O
(,O
analogues,O
of,O
metoclopramide,O
),O
",",O
introduction,O
of,O
a,O
benzyl,B-IUPAC
group,B-MODIFIER
on,O
the,O
terminal,O
nitrogen,O
",",O
rather,O
than,O
an,O
ethyl,B-IUPAC
group,B-MODIFIER
",",O
and,O
a,O
methyl,B-IUPAC
group,B-MODIFIER
on,O
the,O
p,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
group,B-MODIFIER
of,O
metoclopramide,O
both,O
enhanced,O
the,O
activity,O
.,O
The,O
triethyl,O
and,O
tripropyl,O
ether,O
derivatives,O
of,O
the,O
flavonol,O
galangin,O
",",O
4,O
",",O
had,O
Ki,O
values,O
of,O
0.3,O
-,O
0.4,O
microM,O
at,O
human,O
A3,O
receptors,O
.,O
Treatment,O
of,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
bromo,I-IUPAC
-,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dicyanopyrrole,I-IUPAC
(,O
1,O
),O
with,O
triethyl,O
orthoformate,O
followed,O
by,O
alkylation,O
via,O
the,O
sodium,O
salt,O
method,O
with,O
a,O
variety,O
of,O
alkylating,O
agents,O
furnished,O
the,O
corresponding,O
1,O
-,O
substituted,O
pyrroles,O
2a,O
-,O
k,O
.,O
Med.,O
Chem.,O
1992,O
",",O
35,O
",",O
4334-4343,O
),O
we,O
conformationally,O
restricted,O
the,O
sigma,O
-,O
receptor,O
ligand,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
pyrrolidinyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichlorophenyl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methylethylamine,I-IUPAC
(,O
1,O
),O
by,O
incorporating,O
it,O
into,O
a,O
series,O
of,O
homologous,O
piperazines,O
3-9,O
and,O
homopiperazines,O
10,O
and,O
11,O
",",O
diazabicyclononanes,O
and,O
decanes,O
",",O
bridgehead,O
bicyclooctanes,O
and,O
nonanes,O
as,O
well,O
as,O
other,O
miscellaneous,O
compounds,O
.,O
The,O
cholesterol,O
-,O
lowering,O
sterols,O
did,O
not,O
significantly,O
alter,O
lipoprotein,O
levels,O
;,O
however,O
",",O
the,O
two,O
compounds,O
have,O
been,O
shown,O
to,O
inhibit,O
acyl,O
-,O
coenzyme,O
A,O
:,O
cholesterol,O
acyl,O
-,O
transferase,O
(,O
ACAT,O
),O
in,O
tissue,O
culture,O
studies,O
.,O
The,O
results,O
also,O
indicate,O
that,O
the,O
microsomal,O
monooxygenase,O
activities,O
induced,O
in,O
rat,O
liver,O
by,O
alpha,B-IUPAC
-,I-IUPAC
naphthoflavone,I-IUPAC
",",O
beta,B-IUPAC
-,I-IUPAC
naphthoflavone,I-IUPAC
",",O
and,O
3,B-IUPAC
-,I-IUPAC
methylcholanthrene,I-IUPAC
are,O
not,O
equivalent,O
.,O
Employing,O
a,O
recently,O
developed,O
q,O
-,O
jumping,O
molecular,O
dynamics,O
(,O
MD,O
),O
simulation,O
method,O
",",O
which,O
allows,O
us,O
to,O
consider,O
the,O
flexibility,O
of,O
both,O
the,O
ligands,O
and,O
the,O
receptor,O
in,O
docking,O
studies,O
",",O
we,O
predicted,O
the,O
binding,O
models,O
of,O
phorbol,B-IUPAC
-,I-IUPAC
13,I-IUPAC
-,I-IUPAC
acetate,I-IUPAC
",",O
phorbol,B-IUPAC
-,I-IUPAC
"12,13",I-IUPAC
-,I-IUPAC
dibutyrate,I-IUPAC
(,O
PDBu,O
),O
",",O
indolactam,O
V,O
(,O
ILV,O
),O
",",O
ingenol,B-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
benzoate,I-IUPAC
",",O
and,O
thymeleatoxin,O
to,O
PKC,O
.,O
Monoiodination,O
of,O
25,O
to,O
yield,O
26,O
and,O
of,O
27,O
to,O
yield,O
28,O
resulted,O
in,O
an,O
additional,O
4,O
-,O
fold,O
increase,O
in,O
affinity,O
at,O
sst1,O
.,O
These,O
compounds,O
are,O
not,O
inhibitors,O
of,O
thrombin,O
",",O
plasmin,O
t,O
-,O
PA,O
",",O
urokinase,O
",",O
and,O
factor,O
Xa,O
(,O
IC50,O
&,O
gt,O
;,O
33,O
microM,O
),O
.,O
In,O
this,O
displacement,O
assay,O
",",O
(,B-IUPAC
+,I-IUPAC
),I-IUPAC
-,I-IUPAC
pentazocine,I-IUPAC
exhibited,O
a,O
Ki,O
of,O
3.1,O
nM,O
while,O
DTG,O
and,O
haloperidol,O
showed,O
Ki,O
values,O
of,O
27.7,O
and,O
3.7,O
nM,O
",",O
respectively,O
.,O
These,O
cis,O
and,O
trans,O
analogs,O
of,O
"2,3,3",B-IUPAC
a,I-IUPAC
",",I-IUPAC
"4,9,9",I-IUPAC
a,I-IUPAC
-,I-IUPAC
hexahydro,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
benz,I-IUPAC
[,I-IUPAC
f,I-IUPAC
],I-IUPAC
indole,I-IUPAC
(,O
3,O
),O
",",O
where,O
a,O
five,O
-,O
membered,O
ring,O
is,O
fused,O
between,O
the,O
nitrogen,O
and,O
C,O
-,O
3,O
carbon,O
of,O
2,B-IUPAC
-,I-IUPAC
aminotetralin,I-IUPAC
",",O
were,O
synthesized,O
from,O
5,B-PARTIUPAC
-,I-PARTIUPAC
methoxy,I-PARTIUPAC
-,I-PARTIUPAC
and,O
8,B-IUPAC
-,I-IUPAC
methoxytetralones,I-IUPAC
.,O
Structure,O
-,O
activity,O
studies,O
using,O
potassium,O
-,O
depolarized,O
rabbit,O
aorta,O
show,O
that,O
ortho,B-IUPAC
",",O
meta,B-MODIFIER
-,I-MODIFIER
disubstituted,I-MODIFIER
aryl,B-IUPAC
derivatives,B-MODIFIER
are,O
more,O
potent,O
than,O
either,O
ortho,O
-,O
or,O
meta,O
-,O
monosubstituted,O
compounds,O
.,O
The,O
7,B-IUPAC
-,I-IUPAC
hydroxypyrazolo,I-IUPAC
[,I-IUPAC
"1,5",I-IUPAC
-,I-IUPAC
a,I-IUPAC
],I-IUPAC
-,I-IUPAC
pyrimidines,I-IUPAC
were,O
not,O
as,O
active,O
.,O
Screening,O
of,O
the,O
compounds,O
was,O
with,O
one,O
of,O
two,O
assays,O
.,O
b,O
.,O
Acta,O
1972,O
",",O
284,O
",",O
427-434,O
.,O
(,I-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
mandelate,I-IUPAC
.,O
Here,O
we,O
describe,O
the,O
synthesis,O
and,O
structure,O
-,O
activity,O
relationship,O
(,O
SAR,O
),O
studies,O
of,O
two,O
new,O
series,O
of,O
LTB4,O
receptor,O
antagonists,O
in,O
which,O
the,O
phenyl,O
ring,O
of,O
this,O
receptor,O
binding,O
domain,O
is,O
replaced,O
with,O
indole,O
and,O
naphthalene,O
",",O
respectively,O
.,O
A,O
novel,O
reagent,O
",",O
maleimidoethyl,B-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
tri,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
butylstannyl,I-IUPAC
),I-IUPAC
hippurate,I-IUPAC
(,O
MIH,O
),O
",",O
was,O
synthesized,O
by,O
reacting,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxyethyl,I-IUPAC
),I-IUPAC
maleimide,I-IUPAC
with,O
N,B-IUPAC
-,I-IUPAC
Boc,I-IUPAC
-,I-IUPAC
glycine,I-IUPAC
before,O
coupling,O
with,O
N,B-IUPAC
-,I-IUPAC
succinimidyl,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
tri,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
butylstannyl,I-IUPAC
),I-IUPAC
benzoate,I-IUPAC
(,O
ATE,O
),O
.,O
It,O
is,O
suggested,O
that,O
the,O
greater,O
conformational,O
flexibility,O
of,O
the,O
side,O
chain,O
allows,O
II,O
to,O
achieve,O
a,O
conformation,O
inaccessible,O
to,O
pirenzepine,O
",",O
which,O
allows,O
it,O
to,O
bind,O
preferentially,O
to,O
M2,O
receptors,O
.,O
Two,O
-,O
dimensional,O
nuclear,O
Overhauser,O
effect,O
(,O
NOESY,O
),O
spectra,O
of,O
the,O
tomaymycin,O
-,O
d,O
(,O
ATGCAT,O
),O
2,O
duplex,O
adduct,O
show,O
that,O
the,O
adducts,O
are,O
relatively,O
nondistortive,O
.,O
The,O
new,O
compounds,O
",",O
bearing,O
a,O
branched,O
(,O
4,O
),O
or,O
a,O
geometrically,O
constrained,O
benzyl,B-IUPAC
/,O
phenylethyl,B-IUPAC
amide,I-IUPAC
side,B-MODIFIER
chain,I-MODIFIER
(,O
5-8,O
),O
",",O
represent,O
the,O
continuation,O
of,O
our,O
research,O
on,O
N,B-IUPAC
-,I-IUPAC
benzylindol,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ylglyoxylylamides,I-IUPAC
1,O
(,O
Da,O
Settimo,O
et,O
al.,O
",",O
1996,O
),O
",",O
N',B-IUPAC
-,I-IUPAC
phenylindol,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ylglyoxylohydrazides,I-IUPAC
2,O
(,O
Da,O
Settimo,O
et,O
al.,O
",",O
1998,O
),O
",",O
and,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
indol,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ylglyoxylyl,I-IUPAC
),I-IUPAC
alanine,I-IUPAC
derivatives,B-MODIFIER
3,O
(,O
Primofiore,O
et,O
al.,O
",",O
1989,O
),O
.,O
The,O
most,O
active,O
were,O
analogues,O
4c,O
",",O
4d,O
",",O
4e,O
",",O
and,O
6e,O
(,O
IC50,O
10-20,O
microM,O
),O
.,O
carinii,O
DHFR,O
and,O
M,O
.,O
The,O
biological,O
profiles,O
of,O
reported,O
compounds,O
at,O
alpha,O
(,O
1,O
),O
-,O
adrenoreceptor,O
subtypes,O
were,O
assessed,O
by,O
functional,O
experiments,O
in,O
isolated,O
rat,O
vas,O
deferens,O
(,O
alpha,O
(,O
1A,O
),O
),O
",",O
spleen,O
(,O
alpha,O
(,O
1B,O
),O
),O
",",O
and,O
aorta,O
(,O
alpha,O
(,O
1D,O
),O
),O
and,O
by,O
binding,O
assays,O
in,O
CHO,O
and,O
HeLa,O
cells,O
membranes,O
expressing,O
the,O
human,O
cloned,O
alpha,O
(,O
1,O
),O
-,O
adrenoreceptor,O
subtypes,O
and,O
5,O
-,O
HT,O
(,O
1A,O
),O
receptors,O
",",O
respectively,O
.,O
Peptide,O
coupling,O
with,O
diethyl,O
L,O
-,O
glutamate,O
followed,O
by,O
ester,O
hydrolysis,O
at,O
room,O
temperature,O
afforded,O
the,O
new,O
"5,10",B-IUPAC
-,I-IUPAC
dideazaaminopterin,I-IUPAC
analogues,B-MODIFIER
.,O
The,O
same,O
reactions,O
with,O
the,O
alpha,O
-,O
keto,O
sugar,O
gave,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3',I-IUPAC
-,I-IUPAC
C,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
erythro,I-IUPAC
-,I-IUPAC
pentofuranosyl,I-IUPAC
),I-IUPAC
thymine,I-IUPAC
and,O
its,O
beta,O
-,O
anomer,O
.,O
Biochemistry,O
1986,O
",",O
25,O
",",O
3021-3031,O
),O
.,O
The,O
present,O
work,O
gives,O
new,O
insights,O
into,O
the,O
role,O
of,O
the,O
substituent,O
in,O
both,O
the,O
7,O
-,O
and,O
the,O
3,O
-,O
position,O
for,O
the,O
design,O
of,O
4H,B-IUPAC
-,I-IUPAC
"1,2,4",I-IUPAC
-,I-IUPAC
benzothiadiazine,I-IUPAC
"1,1",I-IUPAC
-,I-IUPAC
dioxide,I-IUPAC
potassium,O
channel,O
openers,O
exhibiting,O
different,O
tissue,O
selectivity,O
profiles,O
.,O
Since,O
thrombin,O
inhibitors,O
appear,O
to,O
be,O
effective,O
in,O
the,O
treatment,O
and,O
prevention,O
of,O
thrombotic,O
and,O
embolic,O
disorders,O
",",O
considerable,O
attention,O
has,O
been,O
focused,O
on,O
the,O
structure,O
and,O
interactions,O
of,O
this,O
enzyme,O
.,O
Nine,O
of,O
these,O
heterocycles,O
contained,O
a,O
thiochroman,O
group,O
",",O
two,O
had,O
a,O
chroman,O
group,O
",",O
and,O
two,O
others,O
had,O
a,O
benzothienyl,O
system,O
.,O
A,O
wide,O
range,O
of,O
IC50,O
values,O
were,O
observed,O
for,O
pyranones,O
and,O
thiopyranones,O
substituted,O
at,O
the,O
6,O
-,O
position,O
",",O
with,O
the,O
3,O
-,O
and,O
5,O
-,O
positions,O
proving,O
intolerant,O
to,O
substitution,O
.,O
Nearly,O
complete,O
loss,O
of,O
potency,O
was,O
seen,O
for,O
[,O
Ala1,O
],O
",",O
[,O
Ala3,O
],O
",",O
[,O
Ala5,O
],O
",",O
[,O
Ala6,O
],O
",",O
[,O
Ala10,O
],O
",",O
[,O
Ala11,O
],O
",",O
[,O
Ala13,O
],O
",",O
[,O
Ala14,O
],O
",",O
and,O
[,O
Ala23,O
],O
",",O
whereas,O
[,O
Ala16,O
],O
",",O
[,O
Ala18,O
],O
",",O
[,O
Ala24,O
],O
",",O
[,O
Ala25,O
],O
",",O
[,O
Ala26,O
],O
",",O
and,O
[,O
Ala29,O
],O
yielded,O
equipotent,O
analogues,O
and,O
[,O
Ala7,O
],O
",",O
[,O
Ala12,O
],O
",",O
[,O
Ala17,O
],O
",",O
[,O
Ala20,O
],O
",",O
[,O
Ala21,O
],O
",",O
and,O
[,O
Ala27,O
],O
gave,O
weak,O
agonists,O
with,O
potencies,O
15-40%,O
that,O
of,O
the,O
standard,O
.,O
6beta,B-IUPAC
-,I-IUPAC
Acetoxynortropane,I-IUPAC
had,O
K,O
(,O
i,O
),O
values,O
versus,O
oxotremorine,O
-,O
M,O
binding,O
at,O
m,O
(,O
1,O
),O
-,O
",",O
m,O
(,O
2,O
),O
-,O
",",O
and,O
m,O
(,O
4,O
),O
-,O
receptors,O
ranging,O
from,O
4,O
to,O
7,O
nM,O
.,O
Two,O
members,O
of,O
this,O
series,O
",",O
[,B-IUPAC
R,I-IUPAC
-,I-IUPAC
(,I-IUPAC
E,I-IUPAC
),I-IUPAC
],I-IUPAC
-,I-IUPAC
"5,5",I-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
pyridinyl,I-IUPAC
),I-IUPAC
butyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
pentadienamide,I-IUPAC
(,O
31,O
),O
and,O
[,B-IUPAC
R,I-IUPAC
-,I-IUPAC
(,I-IUPAC
E,I-IUPAC
",",I-IUPAC
E,I-IUPAC
),I-IUPAC
],I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methoxyphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
pyridinyl,I-IUPAC
),I-IUPAC
butyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
decadienamide,I-IUPAC
(,O
58,O
),O
",",O
were,O
selected,O
for,O
further,O
pharmacological,O
evaluation,O
.,O
The,O
data,O
provide,O
a,O
basis,O
for,O
identifying,O
muscarinic,O
receptor,O
subtypes,O
(,O
as,O
defined,O
through,O
cloning,O
procedures,O
),O
with,O
selective,O
ligands,O
.,O
Many,O
of,O
these,O
derivatives,O
exhibit,O
K,O
(,O
i,O
),O
values,O
for,O
PARP,O
inhibition,O
&,O
lt,O
;,O
10,O
nM,O
",",O
with,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxymethylphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
benzimidazole,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
(,O
78,O
",",O
K,O
(,O
i,O
),O
=,O
1.6,O
nM,O
),O
being,O
one,O
of,O
the,O
most,O
potent,O
.,O
This,O
mixture,O
was,O
rearranged,O
by,O
heating,O
with,O
molecular,O
sieve,O
in,O
refluxing,O
toluene,O
to,O
give,O
a,O
6,O
:,O
1,O
mixture,O
of,O
2,O
and,O
3,O
.,O
Out,O
of,O
the,O
33,O
novel,O
analogues,O
tested,O
for,O
the,O
duration,O
of,O
action,O
in,O
this,O
series,O
",",O
two,O
analogues,O
(,O
[,B-IUPAC
N,I-IUPAC
(,I-IUPAC
epsilon,I-IUPAC
),I-IUPAC
-,I-IUPAC
cyclohexyl,I-IUPAC
-,I-IUPAC
Lys,I-IUPAC
(,I-IUPAC
8,I-IUPAC
),I-IUPAC
],I-IUPAC
degarelix,I-IUPAC
",",O
IC,O
(,O
50,O
),O
=,O
1.50,O
nM,O
),O
(,O
23,O
),O
and,O
(,O
[,B-IUPAC
N,I-IUPAC
(,I-IUPAC
beta,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
IbetaAla,I-IUPAC
),I-IUPAC
Dap,I-IUPAC
(,I-IUPAC
8,I-IUPAC
),I-IUPAC
],I-IUPAC
degarelix,I-IUPAC
",",O
IC,O
(,O
50,O
),O
=,O
1.98,O
nM,O
),O
(,O
26,O
),O
had,O
antagonist,O
potencies,O
and,O
duration,O
of,O
action,O
similar,O
to,O
that,O
of,O
azaline,O
B,O
{,O
inhibited,O
LH,O
(,O
&,O
gt,O
;,O
80%,O
),O
release,O
for,O
&,O
gt,O
;,O
72,O
h,O
after,O
sc,O
injection,O
to,O
castrated,O
male,O
rats,O
at,O
a,O
standard,O
dose,O
of,O
50,O
mug,O
/,O
rat,O
in,O
5%,O
mannitol,O
},O
.,O
The,O
p,B-IUPAC
-,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
butylbenzyl,I-IUPAC
-,O
quaternized,B-MODIFIER
analogue,I-MODIFIER
very,O
strongly,O
inhibited,O
(,O
ED,O
(,O
50,O
),O
&,O
lt,O
;,O
1,O
microM,O
),O
growth,O
of,O
the,O
amastigote,O
stage,O
of,O
T,O
.,O
Since,O
chemical,O
carbethoxylating,O
agents,O
represented,O
by,O
the,O
O,B-MODIFIER
-,I-MODIFIER
carbethoxylated,I-MODIFIER
N,B-IUPAC
-,I-IUPAC
hydroxyphthalimide,I-IUPAC
",",O
1,B-IUPAC
-,I-IUPAC
hydroxybenzotriazole,I-IUPAC
",",O
and,O
N,B-IUPAC
-,I-IUPAC
hydroxysuccinimide,I-IUPAC
(,O
8,O
",",O
9,O
",",O
and,O
10,O
",",O
respectively,O
),O
likewise,O
inhibited,O
yeast,O
AlDH,O
",",O
albeit,O
with,O
IC50,O
's,O
1,O
order,O
of,O
magnitude,O
higher,O
",",O
we,O
postulate,O
that,O
1c,O
and,O
6,O
act,O
as,O
irreversible,O
inhibitors,O
of,O
AlDH,O
by,O
carbethoxylating,O
the,O
active,O
site,O
of,O
the,O
enzyme,O
.,O
When,O
acidolysis,O
was,O
preceded,O
by,O
catalytic,O
hydrogenation,O
",",O
the,O
final,O
product,O
was,O
the,O
corresponding,O
(,O
6R,O
",",O
6S,O
),O
-,O
tetrahydro,O
derivative,O
2,O
.,O
By,O
these,O
approaches,O
eight,O
new,O
diamidines,O
and,O
four,O
potential,O
prodrugs,O
were,O
prepared,O
.,O
The,O
affinity,O
for,O
A2,O
receptors,O
of,O
these,O
compounds,O
was,O
very,O
low,O
or,O
negligible,O
.,O
The,O
dicyclic,O
analogue,O
dicyclo,O
(,O
1-3/4-10,O
),O
[,O
Ac,O
-,O
DAsp,O
(,O
1,O
),O
",",O
DCpa,O
(,O
2,O
),O
",",O
DLys,O
(,O
3,O
),O
",",O
Asp,O
(,O
4,O
),O
",",O
DNal,O
(,O
6,O
),O
",",O
Dpr,O
(,O
10,O
),O
],O
GnRH,O
(,O
26,O
),O
was,O
fully,O
active,O
at,O
500,O
microgram,O
",",O
with,O
a,O
K,O
(,O
i,O
),O
value,O
of,O
1,O
nM,O
.,O
Interestingly,O
",",O
the,O
IC,O
(,O
50,O
),O
values,O
of,O
this,O
series,O
of,O
ruthenium,O
compounds,O
(,O
except,O
the,O
beta,O
isomeric,O
compounds,O
),O
are,O
similar,O
in,O
the,O
cisplatin,O
-,O
resistant,O
A2780cisR,O
cell,O
line,O
compared,O
to,O
the,O
normal,O
cell,O
line,O
A2780,O
",",O
suggesting,O
that,O
the,O
activity,O
of,O
these,O
compounds,O
might,O
not,O
be,O
influenced,O
by,O
the,O
multifactorial,O
resistance,O
mechanism,O
that,O
affect,O
platinum,O
anticancer,O
agents,O
.,O
Also,O
",",O
the,O
active,O
imidazo,B-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
pyridine,I-IUPAC
3,O
was,O
shown,O
to,O
cause,O
the,O
accumulation,O
of,O
cells,O
at,O
mitosis,O
.,O
The,O
multiple,O
-,O
alanine,O
-,O
substituted,O
peptides,O
[,O
MeTyr1,O
",",O
Ala15,O
",",O
22,O
",",O
Nle27,O
],O
-,O
hGHRH,O
(,O
1-29,O
),O
-,O
NH2,O
(,O
29,O
),O
and,O
[,O
MeTyr1,O
",",O
Ala8,O
",",O
"9,15,22,28",O
",",O
Nle,O
27,O
],O
-,O
hGHRH,O
(,O
1-29,O
),O
-,O
NH2,O
(,O
30,O
),O
released,O
growth,O
hormone,O
26,O
and,O
11,O
times,O
",",O
respectively,O
",",O
more,O
effectively,O
than,O
the,O
standard,O
in,O
vitro,O
.,O
Structure,O
proof,O
of,O
target,O
nucleosides,O
was,O
provided,O
by,O
independent,O
synthesis,O
",",O
1H,O
NMR,O
",",O
and,O
UV,O
.,O
The,O
trans,B-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
analogs,B-MODIFIER
showed,O
selective,O
5,O
-,O
HT1A,O
receptor,O
activity,O
in,O
vitro,O
but,O
displayed,O
mixed,O
5,O
-,O
HT1A,O
and,O
D2,O
agonist,O
properties,O
in,O
vivo,O
.,O
The,O
2,O
-,O
substituted,O
histamine,O
analogues,O
were,O
partial,O
H1,O
receptor,O
agonists,O
on,O
the,O
endothelium,O
-,O
denuded,O
isolated,O
guinea,O
pig,O
aorta,O
with,O
pEC50,O
values,O
generally,O
smaller,O
than,O
observed,O
on,O
the,O
guinea,O
pig,O
ileum,O
",",O
but,O
the,O
rank,O
order,O
of,O
potency,O
was,O
found,O
to,O
be,O
similar,O
.,O
Analogues,O
1-14,O
were,O
tested,O
for,O
agonistic,O
and,O
antagonistic,O
activities,O
by,O
antidiuretic,O
",",O
vasopressor,O
",",O
and,O
oxytocic,O
assays,O
in,O
rats,O
.,O
4,B-IUPAC
-,I-IUPAC
Butylhomoibotenic,I-IUPAC
acid,I-IUPAC
(,O
4c,O
),O
and,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxyethyl,I-IUPAC
),I-IUPAC
homoibotenic,I-IUPAC
acid,I-IUPAC
(,O
4e,O
),O
were,O
equipotent,O
as,O
inhibitors,O
of,O
[,O
3H,O
],O
AMPA,O
binding,O
(,O
IC50,O
=,O
2,O
microM,O
),O
and,O
showed,O
similar,O
excitatory,O
activity,O
in,O
the,O
rat,O
cortical,O
slice,O
preparation,O
.,O
On,O
the,O
other,O
hand,O
",",O
formamides,O
32,O
(,O
N,B-IUPAC
-,I-IUPAC
heptyl,I-IUPAC
),O
and,O
33,O
(,O
N,B-IUPAC
-,I-IUPAC
octyl,I-IUPAC
),O
",",O
in,O
addition,O
to,O
inhibiting,O
the,O
type,O
I,O
enzyme,O
(,O
IC50s,O
=,O
9.57,O
and,O
16.9,O
nM,O
",",O
respectively,O
),O
",",O
showed,O
also,O
strong,O
inhibitory,O
activity,O
(,O
IC50s,O
=,O
14.0,O
and,O
18.4,O
nM,O
",",O
respectively,O
),O
for,O
human,O
type,O
II,O
5,O
alpha,O
-,O
reductase,O
",",O
in,O
comparison,O
to,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1',I-IUPAC
",",I-IUPAC
1',I-IUPAC
-,I-IUPAC
dimethylethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
aza,I-IUPAC
-,I-IUPAC
5,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
androst,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
ene,I-IUPAC
-,I-IUPAC
17,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
(,O
MK,O
-,O
906,O
;,O
IC50,O
=,O
4.53,O
nM,O
),O
.,O
Glycosylation,O
of,O
ethyl,B-IUPAC
3,I-IUPAC
(,I-IUPAC
5,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
bromomethyl,I-IUPAC
),I-IUPAC
pyrazole,I-IUPAC
-,I-IUPAC
5,I-IUPAC
(,I-IUPAC
3,I-IUPAC
),I-IUPAC
-,I-IUPAC
carboxylate,I-IUPAC
(,O
3,O
),O
and,O
3,B-IUPAC
(,I-IUPAC
5,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
bromomethyl,I-IUPAC
),I-IUPAC
pyrazole,I-IUPAC
-,I-IUPAC
5,I-IUPAC
(,I-IUPAC
3,I-IUPAC
),I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
(,O
4,O
),O
with,O
poly,O
-,O
O,O
-,O
acetylated,O
sugars,O
via,O
an,O
acid,O
-,O
catalyzed,O
fusion,O
method,O
afforded,O
the,O
corresponding,O
ethyl,B-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
bromomethyl,I-IUPAC
),I-IUPAC
pyrazole,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxylate,I-IUPAC
and,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
bromomethyl,I-IUPAC
),I-IUPAC
pyrazole,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
substituted,B-MODIFIER
nucleosides,I-MODIFIER
5,I-MODIFIER
and,O
7,B-MODIFIER
",",O
respectively,O
.,O
An,O
examination,O
of,O
nitrogen,O
substitution,O
(,O
R2,O
in,O
3,O
),O
revealed,O
that,O
analogs,O
with,O
either,O
an,O
allyl,O
or,O
an,O
n,B-IUPAC
-,I-IUPAC
propyl,I-IUPAC
group,B-MODIFIER
displayed,O
equipotent,O
activities,O
.,O
Conformation,O
of,O
each,O
nucleoside,O
in,O
D,O
(,O
2,O
),O
O,O
solution,O
",",O
deduced,O
from,O
(,O
1,O
),O
H,O
NMR,O
spectra,O
and,O
confirmed,O
by,O
molecular,O
mechanics,O
calculations,O
",",O
showed,O
the,O
pentose,O
ring,O
to,O
exist,O
predominantly,O
in,O
the,O
conformation,O
S,O
(,O
C,O
-,O
2',O
-,O
endo,O
),O
and,O
the,O
N,O
(,O
4,O
),O
-,O
OH,O
group,O
as,O
the,O
cis,O
rotamer,O
.,O
Higher,O
binding,O
affinity,O
for,O
dopamine,O
transporters,O
was,O
observed,O
for,O
3B,O
(,O
Ki,O
=,O
13.87,O
and,O
8.42,O
nM,O
for,O
the,O
analogous,O
rhenium,O
complexes,O
3A,O
",",O
B,O
",",O
respectively,O
),O
.,O
Drugs,O
were,O
given,O
at,O
various,O
concentrations,O
on,O
days,O
0,O
",",O
5,O
",",O
and,O
9,O
.,O
Med.,O
Chem.,O
1982,O
",",O
25,O
",",O
337-339,O
),O
",",O
which,O
is,O
free,O
of,O
sedative,O
and,O
alcohol,O
interaction,O
potential,O
as,O
measured,O
by,O
the,O
test,O
procedures,O
described,O
.,O
A,O
study,O
of,O
ring,O
-,O
expanded,O
analogues,O
of,O
the,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
propananilido,I-IUPAC
),I-IUPAC
piperidine,I-IUPAC
analgesics,O
has,O
been,O
undertaken,O
in,O
order,O
to,O
evaluate,O
the,O
influence,O
of,O
this,O
structural,O
modification,O
on,O
both,O
analgesic,O
activity,O
and,O
physical,O
-,O
dependence,O
capacity,O
.,O
The,O
cytidine,O
conjugates,O
include,O
CDP,B-IUPAC
-,I-IUPAC
rac,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
S,I-IUPAC
-,I-IUPAC
octadecyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
palmitoyl,I-IUPAC
(,O
or,O
-,B-PARTIUPAC
methyl,I-PARTIUPAC
),O
-,B-PARTIUPAC
1,I-PARTIUPAC
-,I-PARTIUPAC
thioglycerols,I-PARTIUPAC
(,O
9a,O
and,O
9b,O
),O
.,O
In,O
contrast,O
with,O
type,O
I,O
mechanism,O
-,O
based,O
inactivation,O
",",O
reduction,O
of,O
enzyme,O
-,O
bound,O
NAD+,O
to,O
NADH,O
was,O
not,O
observed,O
.,O
Among,O
the,O
3,O
-,O
substituted,O
allopurinol,O
nucleosides,O
",",O
18b,O
and,O
18c,O
showed,O
significant,O
activity,O
against,O
Para,O
3,O
virus,O
and,O
were,O
found,O
to,O
be,O
potent,O
inhibitors,O
of,O
growth,O
of,O
L1210,O
and,O
P388,O
leukemia,O
.,O
Of,O
the,O
newly,O
synthesized,O
compounds,O
",",O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
cyanamido,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
iodoethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
(,O
6,O
),O
exhibited,O
the,O
most,O
potent,O
anti,O
-,O
HSV,O
-,O
1,O
activity,O
",",O
which,O
was,O
equipotent,O
to,O
acyclovir,O
and,O
superior,O
to,O
5,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
(,O
EDU,O
),O
.,O
Reaction,O
of,O
"2,3",B-IUPAC
-,I-IUPAC
dibromopropene,I-IUPAC
(,O
19,O
),O
with,O
adenine,O
(,O
18,O
),O
led,O
to,O
bromoalkene,O
20,O
",",O
which,O
was,O
benzoylated,O
to,O
give,O
N6,B-IUPAC
",",I-IUPAC
N6,I-IUPAC
-,I-IUPAC
dibenzoyl,I-IUPAC
derivative,B-MODIFIER
23,O
.,O
The,O
[,B-IUPAC
"1,2,4",I-IUPAC
],I-IUPAC
triazolo,I-IUPAC
[,I-IUPAC
"1,5",I-IUPAC
-,I-IUPAC
a,I-IUPAC
],I-IUPAC
triazine,I-IUPAC
derivative,B-MODIFIER
3,O
",",O
more,O
commonly,O
known,O
in,O
the,O
field,O
of,O
adenosine,O
research,O
as,O
ZM,O
-,O
241385,O
",",O
has,O
previously,O
been,O
demonstrated,O
to,O
be,O
a,O
potent,O
and,O
selective,O
adenosine,O
A2a,O
receptor,O
antagonist,O
",",O
although,O
with,O
limited,O
oral,O
bioavailability,O
.,O
Preference,O
for,O
the,O
Northern,O
(,O
N,O
),O
ring,O
conformation,O
of,O
the,O
ribose,O
moiety,O
of,O
nucleotide,O
5',O
-,O
triphosphate,O
agonists,O
at,O
P2Y,O
(,O
1,O
),O
",",O
P2Y,O
(,O
2,O
),O
",",O
P2Y,O
(,O
4,O
),O
",",O
and,O
P2Y,O
(,O
11,O
),O
receptors,O
",",O
but,O
not,O
P2Y,O
(,O
6,O
),O
receptors,O
",",O
was,O
established,O
using,O
a,O
ring,O
-,O
constrained,O
methanocarba,O
(,O
a,O
3.1.0,O
-,O
bicyclohexane,O
),O
ring,O
as,O
a,O
ribose,O
substitute,O
(,O
Kim,O
et,O
al.,O
J,O
.,O
A,O
residual,O
enzymatic,O
activity,O
at,O
an,O
infinite,O
inhibitor,O
concentration,O
and,O
thus,O
a,O
catalytically,O
active,O
ternary,O
enzyme,O
-,O
substrate,O
-,O
inhibitor,O
complex,O
was,O
concluded,O
.,O
In,O
accordance,O
with,O
this,O
disparity,O
",",O
compound,O
8a,O
was,O
found,O
to,O
inhibit,O
synaptosomal,O
[,O
3H,O
],O
D,O
-,O
aspartic,O
acid,O
uptake,O
(,O
IC,O
(,O
50,O
),O
=,O
93,O
+,O
/,O
-,O
25,O
microM,O
),O
",",O
as,O
well,O
as,O
excitatory,O
amino,O
acid,O
transporters,O
(,O
EAATs,O
),O
EAAT1,O
(,O
IC,O
(,O
50,O
),O
=,O
100,O
+,O
/,O
-,O
30,O
microM,O
),O
and,O
EAAT2,O
(,O
IC,O
(,O
50,O
),O
=,O
300,O
+,O
/,O
-,O
80,O
microM,O
),O
.,O
Compound,O
1a,O
",",O
the,O
most,O
potent,O
isomer,O
of,O
the,O
series,O
",",O
was,O
also,O
tested,O
in,O
vivo,O
on,O
pithed,O
rat,O
and,O
its,O
muscarinic,O
activity,O
at,O
the,O
M1,O
receptor,O
subtype,O
was,O
compared,O
with,O
that,O
of,O
muscarine,O
.,O
Potencies,O
at,O
central,O
pre,O
-,O
(,O
auto,O
-,O
),O
and,O
postsynaptic,O
DA,O
receptors,O
were,O
determined,O
by,O
a,O
biochemical,O
and,O
a,O
behavioral,O
method,O
",",O
respectively,O
.,O
Furthermore,O
",",O
the,O
functional,O
activity,O
of,O
(,O
-,O
),O
-,O
3,O
",",O
(,O
+,O
),O
-,O
3,O
",",O
(,O
-,O
),O
-,O
4,O
",",O
and,O
(,O
+,O
),O
-,O
4,O
toward,O
5,O
-,O
HT,O
(,O
1A,O
),O
receptors,O
was,O
evaluated,O
by,O
determining,O
the,O
induced,O
stimulation,O
of,O
[,O
(,O
35,O
),O
S,O
],O
GTPgammaS,O
binding,O
in,O
cell,O
membranes,O
from,O
HeLa,O
cells,O
transfected,O
with,O
human,O
cloned,O
5,O
-,O
HT,O
(,O
1A,O
),O
receptors,O
.,O
With,O
use,O
of,O
Heindel,O
's,O
triazene,O
method,O
for,O
introduction,O
of,O
the,O
radionuclide,O
",",O
the,O
iodine,O
-,O
125,O
-,O
labeled,O
substituted,O
benzamide,O
was,O
obtained,O
with,O
a,O
calculated,O
specific,O
activity,O
of,O
136,O
Ci,O
/,O
mmol,O
and,O
14%,O
radiochemical,O
yield,O
.,O
Further,O
biological,O
studies,O
with,O
these,O
compounds,O
are,O
described,O
.,O
These,O
observations,O
of,O
good,O
brain,O
penetration,O
and,O
high,O
affinity,O
and,O
selectivity,O
for,O
D,O
-,O
2,O
receptors,O
indicate,O
that,O
the,O
corresponding,O
iodine,O
-,O
123,O
-,O
labeled,O
benzamide,O
may,O
be,O
a,O
useful,O
ligand,O
for,O
the,O
noninvasive,O
visualization,O
study,O
of,O
dopamine,O
D,O
-,O
2,O
receptor,O
sites,O
in,O
vivo,O
by,O
single,O
photon,O
emission,O
computed,O
tomography,O
.,O
Inhibitors,O
of,O
PARP,O
have,O
clinical,O
potential,O
as,O
resistance,O
-,O
modifying,O
agents,O
capable,O
of,O
potentiating,O
radiotherapy,O
and,O
the,O
cytotoxicity,O
of,O
some,O
forms,O
of,O
cancer,O
chemotherapy,O
.,O
Both,O
systems,O
compare,O
the,O
ability,O
of,O
chelators,O
to,O
remove,O
iron,O
from,O
the,O
liver,O
",",O
the,O
prime,O
target,O
organ,O
in,O
thalassemia,O
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
enantiomers,O
(,O
+,O
),O
-,O
and,O
(,O
-,O
),O
-,O
14b,O
",",O
(,O
+,O
),O
-,O
and,O
(,O
-,O
),O
-,O
15b,O
displayed,O
high,O
affinity,O
and,O
selectivity,O
for,O
the,O
D1,O
receptor,O
.,O
All,O
derivatives,O
of,O
propargylfolate,O
were,O
active,O
against,O
the,O
growth,O
of,O
Streptococcus,O
faecium,O
",",O
but,O
with,O
the,O
exception,O
of,O
"7,8",B-IUPAC
-,I-IUPAC
dihydropropargylfolic,I-IUPAC
acid,I-IUPAC
",",O
all,O
were,O
inactive,O
against,O
L,O
.,O
Compounds,O
synthesized,O
in,O
this,O
study,O
inhibited,O
HIV,O
-,O
1,O
replication,O
in,O
MT,O
-,O
4,O
cells,O
in,O
the,O
submicromolar,O
to,O
namomolar,O
concentration,O
range,O
.,O
N,B-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
Bis,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
chloroethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
"2,11",I-IUPAC
-,I-IUPAC
dihyroxy,I-IUPAC
-,I-IUPAC
10,I-IUPAC
-,I-IUPAC
methoxynoraporphine,I-IUPAC
(,O
1b,O
),O
and,O
its,O
mono,O
-,O
and,O
diacetyl,O
ester,O
derivatives,O
(,O
1c,O
-,O
d,O
),O
were,O
prepared,O
from,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
chloroacetyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,11",I-IUPAC
-,I-IUPAC
diacetoxy,I-IUPAC
-,I-IUPAC
10,I-IUPAC
-,I-IUPAC
methoxynoraporphine,I-IUPAC
(,O
2,O
),O
.,O
The,O
polyamine,O
spacer,O
units,O
ranged,O
from,O
generic,O
(,O
"4,4",B-IUPAC
-,I-IUPAC
triamine,I-IUPAC
",",O
"4,3",B-IUPAC
-,I-IUPAC
triamine,I-IUPAC
",",O
and,O
diaminooctane,O
),O
spacers,O
to,O
more,O
exotic,O
[,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
ethoxy,I-IUPAC
),I-IUPAC
ethanoxy,I-IUPAC
-,I-IUPAC
containing,B-MODIFIER
diamine,B-IUPAC
",",O
hydroxylated,B-MODIFIER
"4,3",B-IUPAC
-,I-IUPAC
triamine,I-IUPAC
",",O
and,O
cyclohexylene,O
-,O
containing,O
triamine,O
],O
spacers,O
.,O
The,O
observed,O
relationships,O
between,O
nonquaternary,O
compound,O
structure,O
",",O
reactivation,O
potency,O
",",O
and,O
anti,O
-,O
AChE,O
activity,O
reveal,O
important,O
molecular,O
requirements,O
for,O
high,O
reactivity,O
toward,O
phosphonylated,O
AChE,O
.,O
In,O
addition,O
",",O
replacement,O
of,O
the,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
group,B-MODIFIER
with,O
other,O
substituents,O
destroyed,O
activity,O
.,O
We,O
also,O
noted,O
that,O
further,O
deletions,O
(,O
residues,O
8-14,O
),O
produced,O
antagonists,O
such,O
as,O
astressin,O
\C2,O
\BF,O
cyclo,O
(,O
30-33,O
),O
[,O
DPhe12,O
",",O
Nle21,O
",",O
38,O
",",O
Glu30,O
",",O
Lys33,O
],O
hCRF,O
(,O
12-41,O
),O
\C2,O
\BF,O
(,O
1,O
),O
.,O
Under,O
the,O
same,O
conditions,O
",",O
nitroxyl,B-IUPAC
generation,O
from,O
6,O
was,O
minimal,O
",",O
a,O
result,O
compatible,O
with,O
a,O
previous,O
observation,O
that,O
nitroxyl,O
generation,O
from,O
N,B-IUPAC
-,I-IUPAC
hydroxysaccharin,I-IUPAC
(,O
7,O
),O
",",O
the,O
product,O
of,O
the,O
hydrolysis,O
of,O
the,O
carbethoxy,B-IUPAC
group,B-MODIFIER
of,O
6,O
",",O
was,O
minimal,O
at,O
physiological,O
pH,O
.,O
By,O
means,O
of,O
the,O
pharmacological,O
results,O
obtained,O
on,O
pancreatic,O
B,O
-,O
cells,O
",",O
structure,O
-,O
-,O
activity,O
relationships,O
were,O
deduced,O
and,O
a,O
pharmacophoric,O
model,O
for,O
the,O
interaction,O
of,O
these,O
drugs,O
with,O
their,O
receptor,O
site,O
associated,O
to,O
the,O
pancreatic,O
K,O
(,O
ATP,O
),O
channel,O
was,O
proposed,O
.,O
A,O
comparison,O
of,O
the,O
biological,O
properties,O
of,O
these,O
compounds,O
clearly,O
demonstrates,O
that,O
the,O
tetraamines,O
must,O
be,O
charged,O
to,O
be,O
"""",O
recognized,O
"""",O
by,O
the,O
cell,O
.,O
These,O
compounds,O
were,O
generally,O
more,O
toxic,O
to,O
V,O
-,O
79,O
cells,O
than,O
the,O
2,B-IUPAC
-,I-IUPAC
nitroimidazole,I-IUPAC
derivatives,B-MODIFIER
and,O
were,O
found,O
to,O
be,O
more,O
effective,O
radiosensitizers,O
in,O
vitro,O
.,O
Substitution,O
at,O
position,O
1,O
or,O
3,O
with,O
methyl,O
or,O
fluorine,O
atoms,O
always,O
led,O
to,O
more,O
active,O
compounds,O
.,O
Condensation,O
of,O
the,O
appropriate,O
"2,4",B-IUPAC
-,I-IUPAC
dichloroquinazoline,I-IUPAC
(,O
IV,O
),O
with,O
the,O
requisite,O
N,B-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
dialkylalkylenediamine,I-IUPAC
afforded,O
a,O
series,O
of,O
2,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
dialkylamino,I-IUPAC
),I-IUPAC
alkyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
quinazolinamines,I-IUPAC
(,O
V,O
),O
which,O
were,O
condensed,O
with,O
the,O
appropriate,O
arylamine,O
to,O
provide,O
the,O
corresponding,O
N2,B-IUPAC
-,I-IUPAC
aryl,I-IUPAC
-,I-IUPAC
N4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
dialkylamino,I-IUPAC
),I-IUPAC
alkyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
quinazolinediamines,I-IUPAC
(,O
VI,O
),O
.,O
A,O
series,O
of,O
28,O
4,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
and,O
"4,5",B-MODIFIER
-,I-MODIFIER
disubstituted,I-MODIFIER
2,B-IUPAC
-,I-IUPAC
pyridylimidazoles,I-IUPAC
was,O
synthesized,O
and,O
evaluated,O
in,O
vitro,O
for,O
inhibition,O
of,O
xanthine,O
oxidase,O
.,O
The,O
antiviral,O
activity,O
of,O
both,O
compounds,O
was,O
well,O
separated,O
from,O
cytotoxicity,O
in,O
KB,O
",",O
HFF,O
",",O
and,O
L1210,O
cells,O
.,O
Antiimmunosuppresive,O
activity,O
was,O
evaluated,O
by,O
the,O
ability,O
of,O
the,O
different,O
steroids,O
to,O
block,O
dexamethasone,O
-,O
mediated,O
apoptosis,O
in,O
thymocytes,O
and,O
dexamethasone,O
-,O
mediated,O
inhibition,O
of,O
the,O
NFkappa,O
-,O
B,O
transcription,O
factor,O
activity,O
.,O
Compound,O
5h,O
was,O
also,O
active,O
against,O
T,O
.,O
The,O
N,O
(,O
1,O
),O
-,O
substituents,O
evaluated,O
ranged,O
in,O
size,O
from,O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
",",O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
naphthalen,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
ylmethyl,I-IUPAC
",",O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
naphthalen,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
",",O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
naphthalen,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
",",O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
anthracen,I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
ylmethyl,I-IUPAC
",",O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
anthracen,I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
",",O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
anthracen,I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
",",O
and,O
pyren,B-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
ylmethyl,I-IUPAC
.,O
Cell,O
culture,O
toxicity,O
reversal,O
studies,O
and,O
enzyme,O
inhibition,O
tests,O
showed,O
that,O
1,O
was,O
cytotoxic,O
but,O
not,O
by,O
the,O
mechanism,O
of,O
the,O
dihydrofolate,O
reductase,O
inhibitor,O
aminopterin,O
.,O
At,O
6,O
h,O
postinjection,O
of,O
[,O
131I,O
],O
MIH,O
-,O
NGA,O
",",O
80%,O
of,O
the,O
injected,O
radioactivity,O
was,O
recovered,O
in,O
the,O
urine,O
.,O
One,O
compound,O
",",O
(,B-IUPAC
Z,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,1",I-IUPAC
-,I-IUPAC
dichloro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
ethoxy,I-IUPAC
],I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methoxyphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
phenylcyclopropane,I-IUPAC
(,O
7b,O
),O
",",O
elicited,O
a,O
dose,O
-,O
dependent,O
decrease,O
in,O
vivo,O
comparable,O
to,O
MER,O
25,O
.,O
None,O
of,O
the,O
compounds,O
improved,O
upon,O
1a,O
in,O
inhibiting,O
the,O
growth,O
of,O
L1210,O
cells,O
in,O
culture,O
.,O
Remaining,O
steps,O
were,O
ester,O
hydrolysis,O
of,O
9a,O
",",O
b,O
to,O
give,O
carboxylic,O
acids,O
10a,O
",",O
b,O
followed,O
by,O
standard,O
peptide,O
coupling,O
with,O
diethyl,O
L,O
-,O
glutamate,O
to,O
produce,O
diethyl,O
esters,O
11a,O
",",O
b,O
",",O
which,O
on,O
hydrolysis,O
gave,O
12a,O
and,O
10,O
-,O
EDAM,O
(,O
12b,O
),O
",",O
respectively,O
.,O
The,O
synthesis,O
",",O
physical,O
properties,O
",",O
antitumor,O
activity,O
",",O
structure,O
-,O
activity,O
relationships,O
",",O
and,O
nephrotoxicity,O
of,O
a,O
series,O
of,O
[,O
2,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
-,O
"4,5",B-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
aminomethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,3",I-IUPAC
-,I-IUPAC
dioxolane,I-IUPAC
],I-IUPAC
platinum,I-IUPAC
(,I-IUPAC
II,I-IUPAC
),I-IUPAC
complexes,B-MODIFIER
are,O
described,O
.,O
An,O
alternate,O
route,O
",",O
using,O
the,O
dibenzyloxyfluoroaldehyde,B-IUPAC
",",O
was,O
also,O
used,O
to,O
prepare,O
6,B-IUPAC
-,I-IUPAC
fluoronorepinephrine,I-IUPAC
.,O
All,O
these,O
peptides,O
share,O
a,O
common,O
rigid,O
tripeptide,O
cycle,O
with,O
a,O
single,O
energetically,O
preferred,O
backbone,O
conformation,O
and,O
three,O
different,O
conformers,O
of,O
the,O
D,O
-,O
Cys,O
",",O
D,O
-,O
Pen,O
disulfide,O
bridge,O
",",O
two,O
of,O
which,O
are,O
observed,O
in,O
the,O
solid,O
state,O
and,O
in,O
aqueous,O
solution,O
",",O
as,O
previously,O
determined,O
from,O
X,O
-,O
ray,O
crystallography,O
and,O
1H,O
NMR,O
spectroscopy,O
data,O
(,O
Lomize,O
",",O
A,O
;,O
et,O
al.,O
J,O
.,O
Novel,O
A,O
(,O
1,O
),O
agonists,O
with,O
potent,O
central,O
nervous,O
system,O
effects,O
and,O
diminished,O
influence,O
on,O
the,O
cardiovascular,O
system,O
are,O
reported,O
and,O
compared,O
to,O
selected,O
reference,O
adenosine,O
agonists,O
.,O
We,O
are,O
able,O
to,O
rationalize,O
the,O
observed,O
selectivities,O
by,O
comparing,O
the,O
docking,O
of,O
4,O
and,O
6,O
to,O
subtype,O
constructs,O
",",O
i.e.,O
",",O
a,O
crystal,O
structure,O
of,O
the,O
extracellular,O
binding,O
domain,O
of,O
GluR2,O
and,O
a,O
homology,O
model,O
of,O
GluR5,O
.,O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
8,I-IUPAC
-,I-IUPAC
Aza,I-IUPAC
-,I-IUPAC
7,I-IUPAC
",",I-IUPAC
9,I-IUPAC
-,I-IUPAC
dioxospiro,I-IUPAC
[,I-IUPAC
4.5,I-IUPAC
],I-IUPAC
decan,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
butyl,I-IUPAC
],I-IUPAC
propylamino,I-IUPAC
],I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
fluorote,I-IUPAC
tralin,I-IUPAC
(,O
18,O
),O
bound,O
with,O
very,O
high,O
affinity,O
to,O
both,O
DA,O
D3,O
and,O
5,O
-,O
HT1A,O
receptors,O
(,O
Ki,O
=,O
0.2,O
nM,O
),O
and,O
was,O
also,O
characterized,O
as,O
a,O
dopaminergic,O
antagonist,O
.,O
The,O
prepared,O
compounds,O
are,O
heterocyclic,O
analogues,O
of,O
glutamic,O
acid,O
with,O
differing,O
chain,O
lengths,O
.,O
The,O
unselective,O
excitatory,O
amino,O
acid,O
activity,O
of,O
21,O
is,O
comparable,O
with,O
"6,7",B-IUPAC
-,I-IUPAC
dichloro,I-IUPAC
-,I-IUPAC
quinoxaline,I-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dione,I-IUPAC
and,O
"6,7",B-IUPAC
-,I-IUPAC
dichloroquinoxalic,I-IUPAC
acid,I-IUPAC
and,O
this,O
suggests,O
similarities,O
in,O
their,O
modes,O
of,O
binding,O
to,O
excitatory,O
amino,O
acid,O
receptors,O
.,O
Unlike,O
the,O
case,O
for,O
theophylline,O
",",O
the,O
presence,O
of,O
a,O
phenyl,O
substituent,O
in,O
the,O
five,O
-,O
membered,O
ring,O
did,O
not,O
enhance,O
the,O
potency,O
of,O
a,O
mesoionic,O
thiadiazolopyrimidine,O
.,O
The,O
somatostatin,O
receptor,O
binding,O
affinities,O
of,O
synthetic,O
DTPA,O
-,O
D,O
-,O
Phe1,O
-,O
octreotide,O
and,O
CPTA,O
-,O
D,O
-,O
Phe1,O
-,O
octreotide,O
to,O
AtT,O
-,O
20,O
mouse,O
pituitary,O
carcinoma,O
cell,O
membranes,O
were,O
examined,O
by,O
labeling,O
with,O
111In,O
and,O
64Cu,O
",",O
respectively,O
",",O
and,O
performing,O
Scatchard,O
analyses,O
.,O
Compound,O
11,O
was,O
found,O
to,O
have,O
the,O
most,O
significant,O
and,O
selective,O
antiviral,O
activity,O
against,O
herpes,O
simplex,O
virus,O
.,O
[,B-IUPAC
1,I-IUPAC
],I-IUPAC
Benzothieno,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
c,I-IUPAC
],I-IUPAC
pyridines,I-IUPAC
(,O
10a,O
-,O
c,O
",",O
11,O
",",O
12a,O
-,O
t,O
",",O
and,O
13a,O
",",O
b,O
),O
and,O
"1,2,3,4",B-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
[,I-IUPAC
1,I-IUPAC
],I-IUPAC
benzothieno,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
c,I-IUPAC
],I-IUPAC
pyridines,I-IUPAC
(,O
3a,O
-,O
c,O
",",O
7,O
",",O
8a,O
-,O
c,O
",",O
and,O
9,O
),O
were,O
synthesized,O
.,O
Biol.,O
Chem.,O
1983,O
",",O
258,O
",",O
15046-15053,O
.,O
The,O
pharmacology,O
of,O
THHBADs,O
was,O
characterized,O
by,O
electrical,O
recordings,O
in,O
Xenopus,O
oocytes,O
expressing,O
rat,O
brain,O
NMDA,O
and,O
AMPA,O
receptors,O
.,O
Pharmacological,O
evaluation,O
of,O
these,O
compounds,O
demonstrated,O
central,O
nervous,O
system,O
depressant,O
activity,O
",",O
potential,O
anticonvulsant,O
properties,O
",",O
and,O
a,O
low,O
order,O
of,O
acute,O
toxicity,O
.,O
The,O
compounds,O
are,O
related,O
to,O
Lu,O
28-179,O
(,O
1',B-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
fluorophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
indol,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
butyl,I-IUPAC
],I-IUPAC
spiro,I-IUPAC
[,I-IUPAC
isobenzofuran,I-IUPAC
-,I-IUPAC
1,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
",",I-IUPAC
4',I-IUPAC
-,I-IUPAC
piperidine,I-IUPAC
],I-IUPAC
),O
that,O
has,O
been,O
demonstrated,O
to,O
be,O
a,O
selective,O
sigma,O
2,O
ligand,O
with,O
affinity,O
in,O
the,O
subnanomolar,O
range,O
.,O
Such,O
inhibitors,O
may,O
be,O
useful,O
in,O
elucidating,O
the,O
physiological,O
and,O
pathological,O
events,O
involving,O
these,O
proteases,O
and,O
may,O
become,O
possible,O
therapeutic,O
agents,O
.,O
Chemical,O
and,O
biological,O
similarities,O
of,O
plutonium,O
(,O
IV,O
),O
and,O
iron,O
(,O
III,O
),O
suggested,O
that,O
octadentate,O
ligands,O
containing,O
hydroxamate,O
or,O
catecholate,O
functional,O
groups,O
",",O
which,O
are,O
found,O
in,O
microbial,O
iron,O
chelating,O
agents,O
(,O
siderophores,O
),O
",",O
would,O
be,O
effective,O
and,O
relatively,O
selective,O
complexing,O
agents,O
for,O
actinide,O
(,O
IV,O
),O
ions,O
.,O
This,O
compound,O
binds,O
to,O
the,O
ETA,O
receptor,O
with,O
an,O
affinity,O
(,O
Ki,O
),O
of,O
0,O
.,O
Some,O
of,O
the,O
reported,O
analogues,O
",",O
namely,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
mercapto,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methylcyclohexaneacetic,I-IUPAC
acid,I-IUPAC
),I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
arginine,I-IUPAC
-,I-IUPAC
vasopressin,I-IUPAC
",",O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
mercapto,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methylcyclohexaneacetic,I-IUPAC
acid,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
methyltryosine,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
arginine,I-IUPAC
-,I-IUPAC
vasopressin,I-IUPAC
",",O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
butyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
mercaptocyclohexaneacetic,I-IUPAC
acid,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
methyltyrosine,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
arginine,I-IUPAC
-,I-IUPAC
vasopressin,I-IUPAC
",",O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
mercapto,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
phenylcyclohexaneacetic,I-IUPAC
acid,I-IUPAC
),I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
arginine,I-IUPAC
-,I-IUPAC
vasopressin,I-IUPAC
and,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
mercapto,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
phenylcyclohexaneacetic,I-IUPAC
acid,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
methyltyrosine,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
arginine,I-IUPAC
-,I-IUPAC
vasopressin,I-IUPAC
",",O
are,O
among,O
the,O
most,O
potent,O
and,O
selective,O
antagonists,O
of,O
the,O
vasopressor,O
response,O
to,O
arginine,O
-,O
vasopressin,O
reported,O
to,O
date,O
.,O
for,O
the,O
PAF,O
-,O
induced,O
mortality,O
test,O
in,O
mice,O
),O
.,O
It,O
was,O
found,O
that,O
polar,O
functional,O
groups,O
suitable,O
for,O
the,O
attachment,O
of,O
a,O
prodrug,O
moiety,O
were,O
tolerated,O
on,O
the,O
styryl,O
ring,O
and,O
even,O
better,O
on,O
the,O
3,O
-,O
substituent,O
.,O
In,O
fact,O
",",O
[,O
Tyr,O
(,O
7,O
),O
],O
-,O
2,O
(,O
6,O
),O
and,O
[,O
Tyr,O
(,O
7,O
),O
],O
-,O
3,O
(,O
7,O
),O
show,O
ca.,O
5,O
-,O
fold,O
selectivity,O
for,O
sst,O
(,O
4,O
),O
",",O
and,O
[,O
Aph,O
(,O
7,O
),O
],O
-,O
2,O
(,O
8,O
),O
and,O
[,O
Aph,O
(,O
7,O
),O
],O
-,O
3,O
(,O
9,O
),O
have,O
high,O
sst,O
(,O
4,O
),O
affinity,O
(,O
IC,O
(,O
50,O
),O
=,O
1.2,O
and,O
0.88,O
nM,O
",",O
respectively,O
),O
and,O
selectivity,O
",",O
suggesting,O
that,O
indeed,O
an,O
l,O
-,O
residue,O
at,O
position,O
8,O
will,O
direct,O
selectivity,O
toward,O
sst,O
(,O
4,O
),O
.,O
Leukemia,O
and,O
colorectal,O
carcinoma,O
cell,O
lines,O
were,O
generally,O
most,O
sensitive,O
",",O
though,O
good,O
activity,O
was,O
also,O
observed,O
against,O
CNS,O
tumors,O
and,O
carcinomas,O
of,O
the,O
breast,O
and,O
prostate,O
.,O
However,O
",",O
the,O
heterocycles,O
and,O
several,O
of,O
the,O
N,O
-,O
4,O
glycosylated,O
derivatives,O
were,O
toxic,O
to,O
HFF,O
",",O
KB,O
and,O
L1210,O
cells,O
;,O
compounds,O
with,O
5,B-IUPAC
-,I-IUPAC
benzylthio,I-IUPAC
substituents,B-MODIFIER
were,O
the,O
most,O
cytotoxic,O
agents,O
in,O
this,O
series,O
.,O
Although,O
less,O
potent,O
than,O
PDDF,O
",",O
marked,O
inhibition,O
of,O
thymidylate,O
synthase,O
by,O
2,O
was,O
observed,O
in,O
permeabilized,O
L1210,O
cells,O
.,O
Substitution,O
at,O
the,O
1,O
-,O
position,O
was,O
necessary,O
for,O
high,O
affinity,O
at,O
adenosine,O
receptors,O
.,O
"1,4",B-IUPAC
-,I-IUPAC
Di,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
allyl,I-IUPAC
-,I-IUPAC
myo,I-IUPAC
-,I-IUPAC
inositol,I-IUPAC
was,O
regioselectively,O
p,O
-,O
methoxybenzylated,O
at,O
the,O
3,O
-,O
position,O
to,O
give,O
"1,4",B-IUPAC
-,I-IUPAC
di,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
allyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
(,I-IUPAC
p,I-IUPAC
-,I-IUPAC
methoxybenzyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
myo,I-IUPAC
-,I-IUPAC
inositol,I-IUPAC
followed,O
by,O
benzylation,O
of,O
the,O
remaining,O
free,O
hydroxyl,B-IUPAC
groups,B-MODIFIER
to,O
give,O
the,O
key,O
intermediate,O
"1,4",B-IUPAC
-,I-IUPAC
di,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
allyl,I-IUPAC
-,I-IUPAC
"2,5,6",I-IUPAC
-,I-IUPAC
tri,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
(,I-IUPAC
p,I-IUPAC
-,I-IUPAC
methoxybenzyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
myo,I-IUPAC
-,I-IUPAC
inositol,I-IUPAC
.,O
Treatment,O
of,O
2,O
or,O
3,O
with,O
the,O
appropriate,O
nucleophiles,O
at,O
room,O
temperature,O
gave,O
6,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
8,B-IUPAC
-,I-IUPAC
azapurine,I-IUPAC
ribonucleosides,I-IUPAC
(,O
7,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
2,B-PARTIUPAC
-,I-PARTIUPAC
or,O
3,B-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
ribofuranosyl,I-IUPAC
-,I-IUPAC
3H,I-IUPAC
-,I-IUPAC
"1,2,3",I-IUPAC
-,I-IUPAC
triazolo,I-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidines,I-IUPAC
),O
4-13,O
.,O
All,O
analogues,O
were,O
tested,O
in,O
rats,O
for,O
agonistic,O
and,O
antagonistic,O
activities,O
in,O
oxytocic,O
(,O
in,O
vitro,O
",",O
without,O
and,O
with,O
Mg2+,O
",",O
and,O
in,O
vivo,O
),O
assays,O
as,O
well,O
as,O
by,O
antidiuretic,O
and,O
vasopressor,O
assays,O
.,O
The,O
conjugates,O
can,O
use,O
bacterial,O
iron,O
siderophore,O
uptake,O
routes,O
to,O
penetrate,O
the,O
Gram,O
-,O
negative,O
outer,O
membrane,O
permeability,O
barrier,O
.,O
Of,O
the,O
compounds,O
tested,O
for,O
duration,O
of,O
action,O
(,O
1,O
",",O
3-6,O
",",O
8,O
),O
",",O
we,O
found,O
6,O
and,O
8,O
to,O
be,O
slightly,O
longer,O
-,O
acting,O
than,O
astressin,O
or,O
[,O
DHis32,O
],O
astressin,O
",",O
while,O
their,O
potencies,O
in,O
vitro,O
were,O
not,O
significantly,O
different,O
from,O
that,O
of,O
3,O
.,O
A,O
novel,O
class,O
of,O
5,O
-,O
substituted,O
acyclic,O
pyrimidine,O
nucleosides,O
",",O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxyethoxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
azidovinyl,I-IUPAC
),I-IUPAC
uracil,I-IUPAC
(,O
9a,O
),O
",",O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxymethyl,I-IUPAC
),I-IUPAC
ethoxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
azidovinyl,I-IUPAC
),I-IUPAC
uracil,I-IUPAC
(,O
9b,O
),O
",",O
and,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxymethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
butyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
azidovinyl,I-IUPAC
),I-IUPAC
uracil,I-IUPAC
(,O
9c,O
),O
",",O
were,O
synthesized,O
by,O
regiospecific,O
addition,O
of,O
bromine,O
azide,O
to,O
the,O
5,B-IUPAC
-,I-IUPAC
vinyl,I-IUPAC
substituent,B-MODIFIER
of,O
the,O
respective,O
5,B-IUPAC
-,I-IUPAC
vinyluracils,I-IUPAC
(,O
2a,O
-,O
c,O
),O
followed,O
by,O
treatment,O
of,O
the,O
obtained,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
azido,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
bromoethyl,I-IUPAC
),I-IUPAC
compounds,B-MODIFIER
(,O
3a,O
-,O
c,O
),O
with,O
t,O
-,O
BuOK,O
",",O
to,O
affect,O
the,O
base,O
-,O
catalyzed,O
elimination,O
of,O
HBr,O
.,O
In,O
order,O
to,O
improve,O
the,O
oral,O
bioavailability,O
(,O
BA,O
),O
of,O
2,B-IUPAC
-,I-IUPAC
butyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
2',I-IUPAC
-,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
tetrazol,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
biphenyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
benzimid,I-IUPAC
azole,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acid,I-IUPAC
(,O
3,O
:,O
CV,O
-,O
11194,O
),O
and,O
2,B-IUPAC
-,I-IUPAC
ethoxy,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
2',I-IUPAC
-,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
tetrazol,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
biphenyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
benzimidazole,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acid,I-IUPAC
(,O
4,O
:,O
CV,O
-,O
11974,O
),O
",",O
novel,O
angiotensin,O
II,O
(,O
AII,O
),O
receptor,O
antagonists,O
",",O
chemical,O
modification,O
to,O
yield,O
prodrugs,O
has,O
been,O
examined,O
.,O
In,O
general,O
",",O
the,O
antiproliferative,O
activity,O
correlated,O
with,O
inhibition,O
of,O
tubulin,O
polymerization,O
.,O
Examination,O
of,O
initial,O
rate,O
kinetics,O
of,O
carbonic,O
anhydrase,O
catalyzed,O
p,B-IUPAC
-,I-IUPAC
nitrophenyl,I-IUPAC
acetate,I-IUPAC
hydrolysis,O
showed,O
that,O
N,B-IUPAC
-,I-IUPAC
methylacetazolamide,I-IUPAC
was,O
a,O
competitive,O
inhibitor,O
",",O
in,O
contrast,O
to,O
noncompetitive,O
inhibition,O
seen,O
with,O
acetazolamide,O
and,O
other,O
primary,O
sulfonamide,O
inhibitors,O
.,O
Treatment,O
of,O
1,O
with,O
benzyl,B-IUPAC
bromide,I-IUPAC
gave,O
4,B-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
benzylpyrazofurin,I-IUPAC
(,O
4,O
),O
.,O
2,B-PARTIUPAC
-,I-PARTIUPAC
Chloro,I-PARTIUPAC
-,I-PARTIUPAC
",",O
2,B-PARTIUPAC
-,I-PARTIUPAC
bromo,I-PARTIUPAC
-,I-PARTIUPAC
",",O
and,O
2,B-IUPAC
-,I-IUPAC
iodo,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
fucose,I-IUPAC
(,O
9a,O
",",O
9b,O
",",O
and,O
13,O
",",O
respectively,O
),O
have,O
been,O
prepared,O
by,O
addition,O
of,O
the,O
appropriate,O
halogen,O
to,O
"3,4",B-IUPAC
-,I-IUPAC
di,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
fucal,I-IUPAC
",",O
followed,O
by,O
hydrolysis,O
of,O
the,O
anomeric,O
halogen,O
and,O
the,O
acetyl,O
groups,O
.,O
Biological,O
evaluation,O
in,O
Limulus,O
photoreceptors,O
showed,O
that,O
1L,B-IUPAC
-,I-IUPAC
myo,I-IUPAC
-,I-IUPAC
inositol,I-IUPAC
"1,3,4",I-IUPAC
-,I-IUPAC
trisphosphate,I-IUPAC
was,O
much,O
more,O
active,O
than,O
the,O
D,O
-,O
enantiomer,O
",",O
producing,O
repetitive,O
bursts,O
of,O
depolarization,O
due,O
to,O
mobilization,O
of,O
intracellular,O
calcium,O
.,O
Thus,O
replacement,O
of,O
the,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
imidazolidinon,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
side,B-MODIFIER
chain,I-MODIFIER
with,O
a,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
"1,3",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
ureido,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
or,O
methyl,B-IUPAC
substituent,B-MODIFIER
resulted,O
in,O
unchanged,O
affinity,O
and,O
selectivity,O
for,O
5,O
-,O
HT2,O
receptors,O
.,O
Four,O
polyamine,O
conjugates,O
are,O
synthesized,O
",",O
two,O
of,O
terephthalic,O
acid,O
[,O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
),I-IUPAC
benzoylspermine,I-IUPAC
(,O
7,O
),O
and,O
its,O
methyl,O
ester,O
(,O
6,O
),O
],O
and,O
two,O
of,O
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
dihydroxyphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
thiazolecarboxylic,I-IUPAC
acid,I-IUPAC
[,O
(,O
S,O
),O
-,O
4',O
-,O
(,O
HO,O
),O
-,O
DADFT,O
],O
[,O
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
12,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
"5,9",I-IUPAC
-,I-IUPAC
diazadodecyl,I-IUPAC
-,I-IUPAC
oxy,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
thiazolecarboxylic,I-IUPAC
acid,I-IUPAC
(,O
10,O
),O
and,O
its,O
ethyl,O
ester,O
(,O
9,O
),O
],O
.,O
Good,O
penetration,O
into,O
the,O
CNS,O
was,O
documented,O
both,O
after,O
subcutaneous,O
and,O
peroral,O
administration,O
of,O
Lu,O
28-179,O
by,O
ex,O
vivo,O
binding,O
studies,O
.,O
Whereas,O
compounds,O
4-6,O
and,O
8,O
did,O
not,O
exhibit,O
a,O
selective,O
antiviral,O
effect,O
",",O
compounds,O
1-3,O
and,O
7,O
proved,O
almost,O
as,O
active,O
as,O
the,O
reference,O
compound,O
BVDU,O
.,O
The,O
remaining,O
trans,O
-,O
"4,5",O
-,O
di,O
-,O
Me,O
-,O
substituted,O
",",O
cis,O
-,O
and,O
trans,O
-,O
"4,7",O
-,O
di,O
-,O
Me,O
-,O
substituted,O
",",O
and,O
all,O
"4,5",O
-,O
",",O
"5,6",O
-,O
",",O
"6,7",O
-,O
",",O
and,O
"7,8",O
-,O
fused,O
disubstituted,O
analogues,O
of,O
1,O
possessed,O
no,O
noticeable,O
desired,O
activity,O
.,O
f,O
.,O
A,O
number,O
of,O
novel,O
dihydropyridine,O
derivatives,O
based,O
upon,O
1,B-IUPAC
",",I-IUPAC
4,I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
methoxycarbonyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
",",I-IUPAC
6,I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
nitrophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
",",I-IUPAC
4,I-IUPAC
-,I-IUPAC
diphenylpiperidin,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
),I-IUPAC
aminocarbonyl,I-IUPAC
),I-IUPAC
pyridine,I-IUPAC
(,O
4,O
),O
have,O
been,O
synthesized,O
and,O
tested,O
at,O
cloned,O
human,O
alpha,O
adrenoceptors,O
as,O
well,O
as,O
the,O
rat,O
L,O
-,O
type,O
calcium,O
channel,O
.,O
In,O
this,O
regard,O
",",O
a,O
cytotoxicity,O
model,O
was,O
proposed,O
",",O
which,O
describes,O
a,O
hydrophobic,O
pocket,O
of,O
set,O
dimensions,O
adjacent,O
to,O
the,O
putative,O
PAT,O
polyamine,O
-,O
binding,O
site,O
.,O
In,O
vitro,O
compounds,O
35,O
and,O
39,O
bound,O
to,O
[,O
3H,O
],O
mepyramine,O
-,O
labeled,O
guinea,O
pig,O
cerebellar,O
membranes,O
with,O
a,O
pKi,O
of,O
6.1,O
and,O
5.9,O
",",O
respectively,O
.,O
The,O
N,B-PARTIUPAC
(,I-PARTIUPAC
1,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
naphthalenylmethyl,I-PARTIUPAC
",",O
N,B-PARTIUPAC
(,I-PARTIUPAC
1,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
anthracenylmethyl,I-PARTIUPAC
",",O
and,O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
pyrenylmethyl,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
triamines,I-IUPAC
had,O
similar,O
toxicity,O
(,O
IC,O
(,O
50,O
),O
s,O
:,O
approximately,O
0.5,O
microM,O
),O
in,O
CHO,O
cells,O
",",O
which,O
have,O
an,O
active,O
polyamine,O
transporter,O
(,O
PAT,O
),O
.,O
N3,B-IUPAC
-,I-IUPAC
Methylquinazolinones,I-IUPAC
42,O
and,O
43,O
were,O
essentially,O
devoid,O
of,O
activity,O
(,O
IC50,O
values,O
&,O
gt,O
;,O
100,O
microM,O
),O
.,O
Other,O
amino,O
acid,O
substitutions,O
in,O
this,O
series,O
",",O
such,O
as,O
those,O
with,O
Amp,O
(,O
25,O
",",O
26,O
),O
",",O
Orn,O
(,O
27,O
),O
",",O
or,O
IAmp,O
(,O
29,O
),O
at,O
position,O
7,O
",",O
were,O
also,O
tolerated,O
but,O
with,O
a,O
2,O
-,O
to,O
3,O
-,O
fold,O
loss,O
of,O
affinity,O
and,O
concomitant,O
loss,O
of,O
selectivity,O
.,O
Treatment,O
of,O
3,O
with,O
sodium,O
methoxide,O
in,O
methanol,O
provided,O
a,O
good,O
yield,O
of,O
methyl,B-IUPAC
4,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxyethoxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
pyrazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
formimidate,I-IUPAC
(,O
4,O
),O
.,O
A,O
number,O
of,O
N,B-IUPAC
",",I-IUPAC
N,I-IUPAC
:,I-IUPAC
N',I-IUPAC
",",I-IUPAC
N',I-IUPAC
:,I-IUPAC
N,I-IUPAC
"""",I-IUPAC
",",I-IUPAC
N,I-IUPAC
"""",I-IUPAC
-,I-IUPAC
tri,I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
ethanediylphosphoric,I-IUPAC
triamide,I-IUPAC
(,O
TEPA,O
),O
and,O
N,B-IUPAC
",",I-IUPAC
N,I-IUPAC
:,I-IUPAC
N',I-IUPAC
",",I-IUPAC
N',I-IUPAC
:,I-IUPAC
N,I-IUPAC
"""",I-IUPAC
",",I-IUPAC
N,I-IUPAC
"""",I-IUPAC
-,I-IUPAC
tri,I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
ethanediylphosphorothioic,I-IUPAC
triamide,I-IUPAC
(,O
thio,O
-,O
TEPA,O
),O
derivatives,O
containing,O
either,O
two,O
aziridine,B-IUPAC
moieties,B-MODIFIER
(,O
1a,O
),O
or,O
two,O
(,B-IUPAC
2,I-IUPAC
-,I-IUPAC
chloroethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
functions,B-MODIFIER
(,O
1b,O
),O
and,O
either,O
a,O
"2,2,6,6",B-IUPAC
-,I-IUPAC
tetramethylpiperidine,I-IUPAC
",",O
1,B-IUPAC
-,I-IUPAC
oxy,I-IUPAC
-,I-IUPAC
"2,2,6,6",I-IUPAC
-,I-IUPAC
tetramethylpiperidine,I-IUPAC
or,O
1,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
"2,2,6,6",I-IUPAC
-,I-IUPAC
tetramethylpiperidine,I-IUPAC
component,B-MODIFIER
were,O
synthesized,O
and,O
tested,O
against,O
lymphocytic,O
leukemia,O
P388,O
in,O
mice,O
.,O
Reaction,O
of,O
alpha,O
",",O
omega,O
-,O
diaminoalkanes,O
with,O
8,O
-,O
Br,O
-,O
ATP,O
gave,O
8,O
-,O
NH,O
(,O
CH2,O
),O
nNH2,O
derivatives,O
of,O
ATP,O
",",O
which,O
upon,O
iodoacetylation,O
gave,O
8,O
-,O
NH,O
(,O
CH2,O
),O
nNHCOCH2I,O
derivatives,O
of,O
ATP,O
(,O
n,O
=,O
2,O
",",O
4,O
",",O
6,O
",",O
or,O
8,O
),O
.,O
Compound,O
6a,O
produced,O
cures,O
at,O
an,O
oral,O
dosage,O
of,O
5,O
mg,O
/,O
kg,O
.,O
The,O
"""",O
predicted,O
"""",O
binding,O
model,O
for,O
phorbol,B-IUPAC
-,I-IUPAC
13,I-IUPAC
-,I-IUPAC
acetate,I-IUPAC
is,O
virtually,O
identical,O
to,O
the,O
experimentally,O
determined,O
binding,O
model,O
for,O
this,O
ligand,O
.,O
CD81,O
is,O
a,O
member,O
of,O
the,O
tetraspanin,O
family,O
of,O
membrane,O
proteins,O
found,O
in,O
all,O
cell,O
lineages,O
in,O
the,O
liver,O
.,O
A,O
series,O
of,O
aporphine,O
nitrogen,O
mustards,O
and,O
their,O
congeners,O
(,O
1b,O
-,O
g,O
),O
has,O
been,O
prepared,O
.,O
A,O
series,O
of,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxyphenethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
aryloxy,I-IUPAC
),I-IUPAC
propan,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
ols,I-IUPAC
was,O
synthesized,O
together,O
with,O
several,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dimethoxyphenethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
aryloxy,I-IUPAC
),I-IUPAC
propan,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
ols,I-IUPAC
.,O
The,O
results,O
obtained,O
suggest,O
that,O
(,O
a,O
),O
analogs,O
I,O
and,O
VI,O
are,O
potent,O
antagonists,O
of,O
the,O
pressor,O
response,O
of,O
angiotensin,O
II,O
in,O
normal,O
rat,O
",",O
VI,O
being,O
the,O
most,O
potent,O
antagonist,O
thus,O
far,O
synthesized,O
;,O
(,O
b,O
),O
replacement,O
of,O
position,O
4,O
(,O
Tyr,O
),O
with,O
MeTyr,O
or,O
position,O
5,O
and,O
/,O
or,O
8,O
(,O
Ile,O
),O
with,O
Melle,O
in,O
[,B-IUPAC
1,I-IUPAC
-,I-IUPAC
sarcosine,I-IUPAC
",",I-IUPAC
8,I-IUPAC
-,I-IUPAC
isoleucine,I-IUPAC
],I-IUPAC
angiotensin,I-IUPAC
II,I-IUPAC
reduced,O
the,O
antagonist,O
activity,O
of,O
this,O
peptide,O
(,O
rabbit,O
aortic,O
strips,O
and,O
rats,O
),O
",",O
indicating,O
that,O
steric,O
hindrance,O
imposed,O
due,O
to,O
N,O
-,O
methylation,O
in,O
positions,O
4,O
",",O
5,O
",",O
or,O
8,O
was,O
not,O
favorable,O
in,O
eliminating,O
the,O
initial,O
pressor,O
activity,O
or,O
prolonging,O
the,O
duration,O
of,O
action,O
of,O
[,O
Sar1,O
",",O
Ile8,O
],O
angiotensin,O
II,O
without,O
reducing,O
its,O
antagonistic,O
properties,O
;,O
(,O
c,O
),O
except,O
II,O
",",O
none,O
of,O
the,O
analogs,O
showed,O
any,O
enhanced,O
duration,O
of,O
action,O
",",O
suggesting,O
that,O
N,O
-,O
methylation,O
in,O
positions,O
5,O
or,O
8,O
did,O
not,O
afford,O
protection,O
against,O
proteolytic,O
enzymes,O
;,O
and,O
(,O
d,O
),O
perfusion,O
studies,O
in,O
cat,O
adrenals,O
indicated,O
that,O
all,O
of,O
these,O
analogs,O
are,O
only,O
very,O
weak,O
secretagogues,O
.,O
A,O
series,O
of,O
dialkyl,B-MODIFIER
N,B-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
(,I-IUPAC
m,I-IUPAC
-,I-IUPAC
phenylene,I-IUPAC
),I-IUPAC
dioxamates,I-IUPAC
was,O
synthesized,O
by,O
treatment,O
of,O
the,O
requisite,O
m,B-IUPAC
-,I-IUPAC
phenylenediamines,I-IUPAC
with,O
an,O
alkyloxalyl,O
chloride,O
in,O
the,O
presence,O
of,O
triethylamine,O
.,O
Reaction,O
of,O
2,O
with,O
diethanolamine,O
under,O
various,O
conditions,O
and,O
different,O
solvents,O
resulted,O
in,O
the,O
corresponding,O
N,B-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxyethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
acetyl,I-IUPAC
],I-IUPAC
precursors,O
",",O
which,O
were,O
subsequently,O
treated,O
with,O
SOCl2,O
to,O
yield,O
the,O
target,O
compounds,O
.,O
Furthermore,O
",",O
"2,4",B-IUPAC
-,I-IUPAC
oxazolidinediones,I-IUPAC
and,O
hydantoins,O
must,O
either,O
orient,O
differently,O
in,O
the,O
same,O
binding,O
site,O
or,O
interact,O
with,O
different,O
sites,O
on,O
the,O
neuronal,O
voltage,O
-,O
dependent,O
sodium,O
channel,O
.,O
The,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
cyanamido,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
haloethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
"7,8",I-IUPAC
),I-IUPAC
analogues,B-MODIFIER
of,O
arabinouridine,O
were,O
moderately,O
inhibitory,O
for,O
VZV,O
and,O
HSV,O
-,O
1,O
(,O
strain,O
KOS,O
),O
",",O
whereas,O
compounds,O
10,O
and,O
11,O
were,O
inactive,O
against,O
herpes,O
viruses,O
.,O
Three,O
were,O
bromoacetamides,O
differing,O
at,O
the,O
alkyl,O
substituent,O
(,O
methyl,O
",",O
ethyl,O
",",O
or,O
propyl,O
),O
",",O
and,O
the,O
last,O
was,O
an,O
[,B-IUPAC
(,I-IUPAC
iodoacetamido,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
],I-IUPAC
estradiol,I-IUPAC
prepared,O
under,O
both,O
nonradioactive,O
and,O
3H,O
-,O
labeled,O
forms,O
.,O
The,O
nisoxetine,O
derivatives,O
8,O
(,O
rac,B-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methylamino,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
naphthale,I-IUPAC
nesulfonamide,I-IUPAC
),O
and,O
9,O
(,O
rac,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methylamino,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
nitro,I-IUPAC
-,I-IUPAC
"2,1",I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
benzoxadiazole,I-IUPAC
),O
and,O
especially,O
the,O
guanidine,O
derivative,O
4,O
(,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
"1,3",I-IUPAC
-,I-IUPAC
butadienyl,I-IUPAC
),I-IUPAC
benzyl,I-IUPAC
],I-IUPAC
guanidinium,I-IUPAC
sulfate,I-IUPAC
),O
which,O
are,O
characterized,O
by,O
intermediate,O
affinity,O
for,O
the,O
NET,O
(,O
IC,O
(,O
50,O
),O
370-850,O
nM,O
),O
caused,O
significant,O
and,O
nisoxetine,O
-,O
sensitive,O
cell,O
fluorescence,O
.,O
Most,O
of,O
the,O
tested,O
compounds,O
19-31,O
proved,O
to,O
be,O
much,O
more,O
active,O
than,O
THA,O
in,O
reversing,O
the,O
neuromuscular,O
blockade,O
induced,O
by,O
d,O
-,O
tubocurarine,O
.,O
No,O
ATP,O
-,O
site,O
-,O
directed,O
inactivations,O
resulted,O
when,O
the,O
M,O
",",O
L,O
",",O
or,O
K,O
isozymes,O
of,O
PK,O
were,O
exposed,O
for,O
8,O
h,O
",",O
22,O
degrees,O
C,O
",",O
to,O
5,O
mM,O
levels,O
of,O
18,O
ATP,O
derivatives,O
or,O
6,O
analogous,O
ADP,O
derivatives,O
or,O
when,O
yeast,O
HK,O
or,O
rat,O
KH,O
I,O
",",O
II,O
",",O
or,O
III,O
was,O
exposed,O
for,O
6,O
h,O
",",O
22,O
degrees,O
C,O
",",O
to,O
5,O
mM,O
levels,O
of,O
28,O
ATP,O
derivatives,O
.,O
Three,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
diaminopteridin,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
(,I-IUPAC
omega,I-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
alkynyl,I-IUPAC
),I-IUPAC
dibenz,I-IUPAC
[,I-IUPAC
b,I-IUPAC
",",I-IUPAC
f,I-IUPAC
],I-IUPAC
azepines,I-IUPAC
(,O
19-21,O
),O
were,O
also,O
synthesized,O
and,O
tested,O
.,O
The,O
newly,O
prepared,O
[,O
125I,O
],O
iodoproxyfan,O
(,O
23,O
),O
possesses,O
advantageous,O
pharmacological,O
properties,O
and,O
fulfills,O
all,O
criteria,O
of,O
a,O
useful,O
radioligand,O
.,O
They,O
were,O
tested,O
in,O
radioligand,O
binding,O
assays,O
on,O
sigma,O
(,O
[,O
3H,O
],O
DTG,O
and,O
[,O
3H,O
],O
-,O
(,O
+,O
),O
-,O
pentazocine,O
),O
",",O
D,O
-,O
2,O
dopaminergic,O
",",O
5,O
-,O
HT1A,O
and,O
5,O
-,O
HT2,O
serotonergic,O
",",O
and,O
PCP,O
(,O
phencyclidine,O
),O
receptors,O
.,O
N,B-IUPAC
-,I-IUPAC
Acetyl,I-IUPAC
-,I-IUPAC
"2,6",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
benzoquinone,I-IUPAC
imine,I-IUPAC
and,O
N,B-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
"3,5",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
benzoquinone,I-IUPAC
imine,I-IUPAC
were,O
prepared,O
from,O
"2,6",B-IUPAC
-,I-IUPAC
dimethylacetaminophen,I-IUPAC
and,O
"3,5",B-IUPAC
-,I-IUPAC
dimethylacetaminophen,I-IUPAC
by,O
oxidation,O
with,O
lead,O
tetraacetate,O
.,O
However,O
",",O
the,O
intrinsic,O
receptor,O
-,O
alkylating,O
activities,O
of,O
these,O
compounds,O
were,O
probably,O
very,O
hampered,O
by,O
their,O
poor,O
hydrolytic,O
stability,O
in,O
estrogen,O
receptor,O
-,O
containing,O
tissue,O
extracts,O
.,O
The,O
cis,B-IUPAC
-,I-IUPAC
"1,3",I-IUPAC
-,I-IUPAC
dimethylindolin,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
imidazoline,I-IUPAC
6a,O
is,O
an,O
alpha,O
2,O
-,O
adrenergic,O
agonist,O
equal,O
in,O
potency,O
to,O
clonidine,O
in,O
vitro,O
",",O
while,O
the,O
trans,B-IUPAC
-,I-IUPAC
"1,3",I-IUPAC
-,I-IUPAC
dimethylindolin,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
imidazoline,I-IUPAC
6b,O
is,O
a,O
moderately,O
potent,O
alpha,O
2,O
-,O
adrenergic,O
antagonist,O
.,O
Among,O
all,O
the,O
synthesized,O
compounds,O
",",O
only,O
12,O
compounds,O
",",O
namely,O
3a,O
",",O
3c,O
",",O
3d,O
",",O
3f,O
",",O
4c,O
",",O
4d,O
",",O
4f,O
",",O
5a,O
",",O
6f,O
",",O
6h,O
",",O
6i,O
",",O
and,O
7h,O
",",O
have,O
exhibited,O
either,O
&,O
gt,O
;,O
90%,O
micro,O
-,O
or,O
macrofilaricidal,O
activity,O
or,O
sterlization,O
of,O
female,O
worms,O
.,O
For,O
the,O
latter,O
complexes,O
",",O
cis,O
isomers,O
seem,O
to,O
be,O
somewhat,O
more,O
active,O
than,O
trans,O
isomers,O
.,O
The,O
"1,2",B-IUPAC
-,I-IUPAC
dihydropyrido,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
pyrazines,I-IUPAC
(,O
1,O
),O
are,O
mitotic,O
inhibitors,O
with,O
significant,O
antitumor,O
activity,O
in,O
mice,O
.,O
The,O
combination,O
of,O
Tyr,O
(,O
2,O
),O
and,O
dTrp,O
(,O
8,O
),O
in,O
analogues,O
14,O
and,O
22,O
did,O
not,O
affect,O
the,O
affinity,O
of,O
the,O
analogues,O
for,O
sst,O
(,O
4,O
),O
(,O
IC,O
(,O
50,O
),O
=,O
1.2,O
and,O
1.1,O
nM,O
",",O
respectively,O
),O
but,O
resulted,O
in,O
loss,O
of,O
selectivity,O
",",O
whereas,O
the,O
combination,O
of,O
Tyr,O
(,O
2,O
),O
and,O
LTrp,O
(,O
8,O
),O
in,O
H,O
-,O
Tyr,O
-,O
c,O
[,O
Cys,O
-,O
Phe,O
-,O
Aph,O
-,O
Trp,O
-,O
Lys,O
-,O
Thr,O
-,O
Phe,O
-,O
Cys,O
],O
-,O
OH,O
(,O
13,O
),O
and,O
H,O
-,O
Tyr,O
-,O
c,O
[,O
Cys,O
-,O
Phe,O
-,O
Ala,O
-,O
Trp,O
-,O
Lys,O
-,O
Thr,O
-,O
Phe,O
-,O
Cys,O
],O
-,O
OH,O
(,O
19,O
),O
retained,O
high,O
affinity,O
(,O
IC,O
(,O
50,O
),O
=,O
1.9,O
and,O
1.98,O
nM,O
",",O
respectively,O
),O
and,O
sst,O
(,O
4,O
),O
selectivity,O
(,O
&,O
gt,O
;,O
50,O
and,O
&,O
gt,O
;,O
250,O
",",O
respectively,O
),O
.,O
Similarly,O
",",O
H,O
-,O
Dmt,O
-,O
Tic,O
-,O
Gly,O
-,O
NH,O
-,O
Ph,O
(,O
5,O
),O
had,O
nearly,O
equivalent,O
high,O
delta,O
-,O
agonism,O
(,O
pEC,O
(,O
50,O
),O
",",O
8.52,O
),O
and,O
mu,O
-,O
agonism,O
(,O
pEC,O
(,O
50,O
),O
",",O
8.59,O
),O
",",O
while,O
H,O
-,O
Dmt,O
-,O
Tic,O
-,O
Gly,O
-,O
NH,O
-,O
CH,O
(,O
2,O
),O
-,O
Ph,O
(,O
6,O
),O
whose,O
spacer,O
was,O
longer,O
by,O
a,O
single,O
methylene,O
group,O
exhibited,O
potent,O
delta,O
-,O
antagonism,O
(,O
pA,O
(,O
2,O
),O
",",O
9.25,O
),O
and,O
very,O
high,O
mu,O
-,O
agonism,O
(,O
pEC,O
(,O
50,O
),O
",",O
8.57,O
),O
.,O
The,O
kinetic,O
parameters,O
of,O
the,O
HLE,O
inhibition,O
were,O
determined,O
.,O
New,O
siderophore,O
penicillin,O
V,O
conjugates,O
with,O
the,O
siderophore,O
component,O
attached,O
to,O
the,O
phenyl,O
ring,O
of,O
penicillin,O
V,O
are,O
inactive,O
against,O
these,O
Gram,O
-,O
negative,O
bacteria,O
.,O
In,O
this,O
article,O
",",O
we,O
report,O
synthesis,O
and,O
cytotoxicity,O
of,O
a,O
series,O
of,O
new,O
pyrido,B-IUPAC
[,I-IUPAC
2,I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
nucleosides,B-MODIFIER
.,O
The,O
key,O
intermediate,O
was,O
the,O
protected,O
nonapeptide,O
N,B-IUPAC
-,I-IUPAC
carbobenzoxy,I-IUPAC
-,I-IUPAC
S,I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
cysteinyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
tyrosyldihydrophenyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
alanyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
glutaminyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
asparaginyl,I-IUPAC
-,I-IUPAC
S,I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
cysteinyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
prolyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
epsilon,I-IUPAC
-,I-IUPAC
tosyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
lysylglycinamide,I-IUPAC
that,O
was,O
synthesized,O
stepwise,O
by,O
the,O
solid,O
-,O
phase,O
technique,O
.,O
Related,O
pyran,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
",",O
pyran,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
",",O
and,O
thiopyran,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
showed,O
similar,O
IC50,O
values,O
against,O
DNA,O
-,O
PK,O
",",O
whereas,O
the,O
pyridin,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
system,B-MODIFIER
proved,O
",",O
in,O
general,O
",",O
ineffective,O
at,O
inhibiting,O
DNA,O
-,O
PK,O
.,O
Hydrolysis,O
of,O
the,O
lactone,O
ring,O
of,O
the,O
1H,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
one,I-IUPAC
skeleton,B-MODIFIER
",",O
to,O
give,O
6,B-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxyphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methylhex,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
4,I-IUPAC
",",I-IUPAC
5,I-IUPAC
-,I-IUPAC
dihydroxy,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ammoniohexanoate,I-IUPAC
(,O
5,O
),O
",",O
led,O
to,O
a,O
considerable,O
decrease,O
in,O
activity,O
.,O
Against,O
Ma,O
DHFR,O
",",O
28,O
had,O
IC,O
(,O
50,O
),O
and,O
SI,O
values,O
of,O
1.5,O
nM,O
and,O
430,O
",",O
respectively,O
",",O
compared,O
with,O
300,O
nM,O
and,O
610,O
for,O
TMP,O
.,O
A,O
series,O
of,O
N,B-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
4,I-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
3,I-PARTIUPAC
-,I-PARTIUPAC
pyridinyl,I-PARTIUPAC
),I-PARTIUPAC
butyl,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
"5,5",I-PARTIUPAC
-,O
disubstituted,B-MODIFIER
-,O
pentadienamides,B-PARTIUPAC
was,O
prepared,O
and,O
evaluated,O
for,O
PAF,O
-,O
antagonist,O
activity,O
.,O
In,O
an,O
in,O
vivo,O
mouse,O
model,O
for,O
T,O
.,O
The,O
analogue,O
[,O
CalphaMe,O
-,O
Leu27,O
",",O
DHis32,O
],O
astressin,O
(,O
16,O
),O
was,O
more,O
potent,O
(,O
although,O
not,O
statistically,O
in,O
all,O
cases,O
),O
than,O
the,O
other,O
four,O
analogues,O
in,O
vitro,O
.,O
Both,O
43,O
(,O
ED,O
(,O
50,O
),O
=,O
150,O
micromol,O
/,O
kg,O
),O
and,O
44,O
(,O
ED,O
(,O
50,O
),O
=,O
220,O
micromol,O
/,O
kg,O
),O
showed,O
anticonvulsant,O
effects,O
",",O
and,O
this,O
effect,O
of,O
43,O
was,O
shown,O
to,O
reside,O
in,O
the,O
(,O
R,O
),O
-,O
(,O
+,O
),O
-,O
enantiomer,O
",",O
45,O
(,O
ED,O
(,O
50,O
),O
=,O
44,O
micromol,O
/,O
kg,O
),O
.,O
Selective,O
protection,O
of,O
the,O
5',B-IUPAC
-,I-IUPAC
hydroxyl,I-IUPAC
group,B-MODIFIER
of,O
14,O
with,O
tert,B-IUPAC
-,I-IUPAC
butyldimethylsilyl,I-IUPAC
chloride,I-IUPAC
followed,O
by,O
a,O
Barton,O
type,O
deoxygenation,O
sequence,O
of,O
the,O
3',B-IUPAC
-,I-IUPAC
hydroxyl,I-IUPAC
groups,B-MODIFIER
afforded,O
ethyl,B-IUPAC
3,I-IUPAC
-,I-IUPAC
cyano,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dideoxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
butyldimethylsilyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
glycero,I-IUPAC
-,I-IUPAC
pentofuranosyl,I-IUPAC
],I-IUPAC
pyrrole,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
carboxylate,I-IUPAC
(,O
18,O
),O
.,O
A,O
number,O
of,O
derivatives,O
structurally,O
related,O
to,O
cirazoline,O
(,O
1,O
),O
were,O
synthesized,O
and,O
studied,O
with,O
the,O
purpose,O
of,O
modulating,O
alpha2,O
-,O
adrenoreceptors,O
selectivity,O
versus,O
both,O
alpha1,O
-,O
adrenoreceptors,O
and,O
I2,O
imidazoline,O
binding,O
sites,O
.,O
This,O
publication,O
describes,O
the,O
synthesis,O
and,O
optimization,O
of,O
a,O
novel,O
series,O
of,O
stilbene,O
endothelin,O
antagonists,O
.,O
The,O
activity,O
of,O
the,O
title,O
compounds,O
was,O
determined,O
in,O
vitro,O
against,O
Gram,O
-,O
positive,O
and,O
Gram,O
-,O
negative,O
bacteria,O
",",O
and,O
the,O
in,O
vivo,O
efficacy,O
of,O
selected,O
derivatives,O
was,O
determined,O
using,O
a,O
mouse,O
infection,O
model,O
.,O
Molecular,O
interactions,O
between,O
RGD,O
peptides,O
and,O
integrins,O
are,O
known,O
to,O
mediate,O
many,O
biological,O
and,O
pathological,O
processes,O
.,O
C,O
.,O
carinii,O
at,O
30,O
mg,O
/,O
kg,O
x,O
5,O
days,O
(,O
ip,O
),O
and,O
against,O
B,O
.,O
A,O
series,O
of,O
7,B-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
"2,3",B-MODIFIER
-,I-MODIFIER
disubstituted,I-MODIFIER
-,O
1,B-IUPAC
-,I-IUPAC
azetidinyl,I-IUPAC
),B-PARTIUPAC
-,I-PARTIUPAC
"1,4",I-PARTIUPAC
-,I-PARTIUPAC
dihydro,I-PARTIUPAC
-,I-PARTIUPAC
6,I-PARTIUPAC
-,I-PARTIUPAC
fluoro,I-PARTIUPAC
-,I-PARTIUPAC
4,I-PARTIUPAC
-,I-PARTIUPAC
oxoquinoline,I-PARTIUPAC
-,I-PARTIUPAC
and,O
-,B-PARTIUPAC
"1,8",I-PARTIUPAC
-,I-PARTIUPAC
naphthyridine,I-PARTIUPAC
-,I-PARTIUPAC
3,I-PARTIUPAC
-,I-PARTIUPAC
carboxylic,I-PARTIUPAC
acids,I-PARTIUPAC
",",O
with,O
varied,O
substituents,O
at,O
the,O
1,O
-,O
",",O
5,O
-,O
",",O
and,O
8,O
-,O
positions,O
",",O
was,O
prepared,O
to,O
study,O
the,O
effects,O
on,O
potency,O
and,O
physicochemical,O
properties,O
of,O
the,O
substituent,O
at,O
position,O
2,O
of,O
the,O
azetidine,O
moiety,O
.,O
Structure,O
-,O
activity,O
relationships,O
have,O
been,O
investigated,O
for,O
inhibition,O
of,O
DNA,O
-,O
dependent,O
protein,O
kinase,O
(,O
DNA,O
-,O
PK,O
),O
and,O
ATM,O
kinase,O
by,O
a,O
series,O
of,O
pyran,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
",",O
pyran,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
",",O
thiopyran,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
",",O
and,O
pyridin,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
.,O
A,O
good,O
correlation,O
was,O
found,O
between,O
the,O
electronic,O
properties,O
of,O
the,O
substituent,O
and,O
the,O
inhibitory,O
activity,O
and,O
stability,O
.,O
In,O
this,O
series,O
",",O
DA,O
agonist,O
activity,O
was,O
found,O
to,O
be,O
highly,O
dependent,O
on,O
the,O
size,O
of,O
the,O
N,B-IUPAC
-,I-IUPAC
alkyl,I-IUPAC
substituent,B-MODIFIER
",",O
the,O
saturation,O
level,O
of,O
the,O
six,O
-,O
membered,O
ring,O
",",O
and,O
the,O
mode,O
of,O
attachment,O
of,O
the,O
2,B-IUPAC
-,I-IUPAC
aminothiazole,I-IUPAC
ring,B-MODIFIER
.,O
Reaction,O
of,O
2,O
with,O
ethylene,O
oxide,O
resulted,O
in,O
a,O
mixture,O
of,O
two,O
compounds,O
",",O
the,O
"2,4",B-IUPAC
-,I-IUPAC
dinitroimidazole,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
ethanol,I-IUPAC
(,O
4,O
),O
and,O
"2,3",B-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
nitroimidazo,I-IUPAC
[,I-IUPAC
"2,1",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
oxazole,I-IUPAC
(,O
5,O
),O
.,O
At,O
least,O
the,O
guanidine,O
derivative,O
4,O
might,O
represent,O
a,O
potentially,O
useful,O
agent,O
for,O
imaging,O
of,O
neuroblastoma,O
cells,O
.,O
A,O
number,O
of,O
N9,O
-,O
alkyl,O
-,O
substituted,O
purines,O
and,O
purine,O
ribonucleosides,O
have,O
been,O
synthesized,O
as,O
congeners,O
of,O
sulfinosine,O
and,O
evaluated,O
for,O
their,O
antileukemic,O
activity,O
in,O
mice,O
.,O
With,O
the,O
exception,O
of,O
II,O
and,O
III,O
",",O
all,O
the,O
other,O
analogs,O
had,O
very,O
low,O
intrinsic,O
activities,O
",",O
per,O
se,O
.,O
IV,O
",",O
[,O
des,O
-,O
Asp1,O
],O
angiotensin,O
II,O
(,O
III,O
),O
",",O
[,O
des,O
-,O
(,O
Asp1,O
",",O
Arg2,O
),O
],O
angiotensin,O
II,O
(,O
V,O
),O
",",O
[,O
des,O
-,O
(,O
Asp1,O
",",O
Arg2,O
",",O
Val3,O
),O
],O
angiotensin,O
II,O
(,O
VI,O
),O
",",O
[,O
Sar1,O
",",O
Ile8,O
],O
angiotensin,O
II,O
(,O
VII,O
),O
",",O
and,O
[,O
des,O
-,O
Asp1,O
",",O
Ile8,O
],O
angiotensin,O
II,O
(,O
VIII,O
),O
possessed,O
0.5,O
",",O
20,O
",",O
2,O
",",O
0,O
less,O
than,O
0.1,O
",",O
and,O
less,O
than,O
0.01%,O
of,O
the,O
inotropic,O
activity,O
(,O
rabbit,O
atria,O
),O
",",O
1,O
",",O
15,O
",",O
5,O
",",O
0,O
",",O
3,O
",",O
and,O
0%,O
secretory,O
activity,O
of,O
the,O
cat,O
adrenal,O
medulla,O
",",O
and,O
0.0,O
",",O
150,O
",",O
0.5,O
",",O
3,O
",",O
and,O
10%,O
of,O
the,O
adrenal,O
steroidogenic,O
activity,O
of,O
angiotensin,O
II,O
",",O
respectively,O
.,O
These,O
investigations,O
prompted,O
the,O
synthesis,O
and,O
evaluation,O
of,O
additional,O
diazepine,O
derivatives,O
",",O
which,O
are,O
described,O
in,O
the,O
following,O
paper,O
.,O
Given,O
significant,O
binding,O
to,O
one,O
or,O
more,O
EAA,O
receptors,O
",",O
5,O
would,O
offer,O
unique,O
modeling,O
and,O
perhaps,O
biological,O
opportunities,O
.,O
In,O
direct,O
contrast,O
",",O
nearly,O
all,O
of,O
the,O
thioamide,B-IUPAC
derivates,B-MODIFIER
6a,O
-,O
1,O
",",O
including,O
the,O
aglycone,O
of,O
thiosangivamycin,O
(,O
6m,O
),O
",",O
were,O
good,O
inhibitors,O
of,O
HCMV,O
and,O
HSV,O
-,O
1,O
.,O
More,O
interestingly,O
",",O
the,O
intermediate,O
compound,O
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
benzyloxyphenyl,I-IUPAC
),I-IUPAC
propenoic,I-IUPAC
acid,I-IUPAC
5,O
was,O
equiactive,O
with,O
3,O
.,O
The,O
novel,O
semirigid,O
derivatives,O
(,B-IUPAC
+,I-IUPAC
),I-IUPAC
-,I-IUPAC
cis,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
bicyclo,I-IUPAC
[,I-IUPAC
3.1.0,I-IUPAC
],I-IUPAC
hexyl,I-IUPAC
],I-IUPAC
piperidine,I-IUPAC
[,O
(,O
+,O
),O
-,O
8,O
],O
",",O
its,O
enantiomer,O
(,B-PARTIUPAC
-,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
8,I-PARTIUPAC
",",O
and,O
(,B-IUPAC
+,I-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
trans,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
bicyclo,I-IUPAC
[,I-IUPAC
3.1.0,I-IUPAC
],I-IUPAC
hexyl,I-IUPAC
],I-IUPAC
piperidine,I-IUPAC
[,O
(,O
+,O
/,O
-,O
),O
-,O
9,O
],O
were,O
synthesized,O
as,O
probes,O
to,O
investigate,O
the,O
mode,O
of,O
interaction,O
of,O
phencyclidine,O
(,O
PCP,O
),O
with,O
its,O
binding,O
site,O
on,O
the,O
N,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
aspartate,I-IUPAC
receptor,O
complex,O
.,O
Both,O
cyclopropyl,B-PARTIUPAC
compounds,B-MODIFIER
reduced,O
putrescine,O
and,O
spermidine,O
pools,O
",",O
but,O
less,O
effectively,O
than,O
did,O
DENSPM,O
and,O
its,O
derivatives,O
.,O
Different,O
substituents,O
were,O
introduced,O
in,O
the,O
1,O
-,O
position,O
of,O
the,O
piperidine,O
ring,O
in,O
the,O
5,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,O
substituted,B-MODIFIER
derivative,I-MODIFIER
.,O
These,O
compounds,O
and,O
the,O
corresponding,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,O
and,O
4,B-IUPAC
-,I-IUPAC
hydroxyimidazol,I-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
c,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,2,6",I-IUPAC
],I-IUPAC
thiadiazine,I-IUPAC
"2,2",I-IUPAC
-,I-IUPAC
dioxides,I-IUPAC
were,O
examined,O
as,O
potential,O
transition,O
-,O
state,O
analogue,O
inhibitors,O
of,O
xanthine,O
oxidase,O
and,O
guanine,O
aminohydrolase,O
.,O
The,O
Trp,O
(,O
DNPS,O
),O
-,O
containing,O
analogue,O
was,O
neurotoxic,O
.,O
mol,O
-,O
1,O
),O
between,O
the,O
most,O
and,O
the,O
least,O
favorable,O
conformations,O
.,O
The,O
resulting,O
1,B-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
[,I-PARTIUPAC
(,I-PARTIUPAC
dialkylamino,I-PARTIUPAC
),I-PARTIUPAC
alkyl,I-PARTIUPAC
],I-PARTIUPAC
amino,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
4,I-PARTIUPAC
-,I-PARTIUPAC
methyl,I-PARTIUPAC
-,I-PARTIUPAC
5H,I-PARTIUPAC
-,I-PARTIUPAC
pyrido,I-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
"4,3",I-PARTIUPAC
-,I-PARTIUPAC
b,I-PARTIUPAC
],I-PARTIUPAC
benzo,I-PARTIUPAC
[,I-PARTIUPAC
e,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
and,O
-,B-PARTIUPAC
benzo,I-PARTIUPAC
[,I-PARTIUPAC
g,I-PARTIUPAC
],I-PARTIUPAC
indoles,I-PARTIUPAC
",",O
as,O
well,O
as,O
hydroxy,O
derivatives,O
obtained,O
by,O
demethylation,O
of,O
methoxylated,O
compounds,O
with,O
hydrobromic,O
acid,O
",",O
were,O
tested,O
for,O
antitumor,O
activity,O
in,O
vitro,O
(,O
leukemic,O
and,O
solid,O
tumor,O
cells,O
),O
and,O
in,O
vivo,O
on,O
various,O
experimental,O
tumor,O
models,O
using,O
the,O
standard,O
NCI,O
protocols,O
.,O
This,O
has,O
led,O
to,O
an,O
increased,O
interest,O
in,O
the,O
development,O
of,O
RGD,O
compounds,O
with,O
high,O
affinity,O
and,O
improved,O
selectivity,O
for,O
integrin,O
receptors,O
.,O
Med.,O
Chem.,O
",",O
preceding,O
paper,O
in,O
this,O
issue,O
),O
(,O
11,O
),O
and,O
that,O
H,O
-,O
c,O
[,O
Cys,O
-,O
Phe,O
-,O
Phe,O
-,O
DTrp,O
-,O
Lys,O
-,O
Thr,O
-,O
Phe,O
-,O
Cys,O
],O
-,O
OH,O
(,O
ODT,O
-,O
8,O
",",O
3,O
),O
had,O
high,O
affinity,O
and,O
marginal,O
selectivity,O
for,O
human,O
sst,O
(,O
4,O
),O
",",O
that,O
H,O
-,O
c,O
[,O
Cys,O
-,O
Phe,O
-,O
Tyr,O
-,O
D,O
-,O
threo,O
-,O
beta,O
-,O
Me2Nal,O
-,O
Lys,O
-,O
Thr,O
-,O
Phe,O
-,O
Cys,O
],O
-,O
OH,O
had,O
high,O
affinity,O
for,O
all,O
sst,O
's,O
except,O
for,O
sst,O
(,O
1,O
),O
",",O
and,O
that,O
H,O
-,O
c,O
[,O
Cys,O
-,O
Phe,O
-,O
Tyr,O
-,O
L,O
-,O
threo,O
-,O
beta,O
-,O
Me2Nal,O
-,O
Lys,O
-,O
Thr,O
-,O
Phe,O
-,O
Cys,O
],O
-,O
OH,O
had,O
high,O
affinity,O
for,O
sst,O
(,O
4,O
),O
(,O
IC,O
(,O
50,O
),O
=,O
2.1,O
nM,O
),O
",",O
with,O
more,O
than,O
50,O
-,O
fold,O
selectivity,O
toward,O
the,O
other,O
receptors,O
(,O
parts,O
1,O
and,O
2,O
of,O
this,O
series,O
:,O
Rivier,O
et,O
al.,O
and,O
Erchegyi,O
et,O
al.,O
J,O
.,O
Aromatic,O
substitution,O
patterns,O
were,O
varied,O
with,O
the,O
goal,O
of,O
identifying,O
a,O
compound,O
having,O
affinities,O
for,O
the,O
D,O
(,O
2,O
),O
and,O
D,O
(,O
4,O
),O
receptors,O
in,O
a,O
ratio,O
similar,O
to,O
that,O
observed,O
for,O
the,O
atypical,O
neuroleptic,O
clozapine,O
.,O
The,O
k,O
(,O
cat,O
),O
value,O
for,O
NOS,O
II,O
-,O
catalyzed,O
oxidation,O
of,O
N,B-IUPAC
-,I-IUPAC
para,I-IUPAC
-,I-IUPAC
fluorophenyl,I-IUPAC
N',I-IUPAC
-,I-IUPAC
hydroxyguanidine,I-IUPAC
was,O
80%,O
of,O
that,O
found,O
for,O
NOHA,O
",",O
and,O
its,O
k,O
(,O
cat,O
),O
/,O
K,O
(,O
m,O
),O
value,O
was,O
only,O
9,O
-,O
fold,O
lower,O
than,O
that,O
of,O
NOHA,O
.,O
4,B-IUPAC
-,I-IUPAC
Morpholino,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
formylpyridine,I-IUPAC
thiosemicarbazone,I-IUPAC
was,O
the,O
most,O
active,O
antineoplastic,O
agent,O
of,O
this,O
series,O
in,O
mice,O
bearing,O
Sarcoma,O
180,O
ascites,O
cells,O
and,O
was,O
significantly,O
superior,O
to,O
5,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
formylpyridine,I-IUPAC
thiosemicarbazone,I-IUPAC
in,O
this,O
test,O
system,O
.,O
Benzoate,O
substitutions,O
in,O
the,O
ortho,O
position,O
relative,O
to,O
the,O
terminal,O
carboxylate,O
(,O
9d,O
",",O
k,O
",",O
r,O
),O
are,O
well,O
-,O
tolerated,O
;,O
however,O
",",O
a,O
methoxy,O
substituent,O
meta,O
relative,O
to,O
the,O
terminal,O
carboxylate,O
gives,O
rise,O
to,O
only,O
weakly,O
active,O
analogues,O
(,O
9x,O
),O
.,O
1c,O
might,O
also,O
penetrate,O
cells,O
directly,O
and,O
undergo,O
the,O
same,O
degradation,O
sequence,O
after,O
hydrolysis,O
by,O
cellular,O
esterases,O
.,O
The,O
hydrogen,O
-,O
bond,O
-,O
acceptor,O
properties,O
of,O
the,O
carbonyl,B-IUPAC
moiety,B-MODIFIER
in,O
the,O
17beta,B-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
group,B-MODIFIER
on,O
the,O
D,O
-,O
ring,O
of,O
the,O
anesthetic,O
steroids,O
(,B-PARTIUPAC
3alpha,I-PARTIUPAC
",",I-PARTIUPAC
5alpha,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
and,O
(,B-IUPAC
3alpha,I-IUPAC
",",I-IUPAC
5beta,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxypregan,I-IUPAC
-,I-IUPAC
20,I-IUPAC
-,I-IUPAC
one,I-IUPAC
form,O
an,O
important,O
part,O
of,O
the,O
anesthetic,O
steroid,O
pharmacophore,O
.,O
A,O
broad,O
screening,O
of,O
phytochemicals,O
has,O
demonstrated,O
that,O
certain,O
flavone,O
and,O
flavonol,O
derivatives,O
have,O
a,O
relatively,O
high,O
affinity,O
at,O
A3,O
adenosine,O
receptors,O
",",O
with,O
Ki,O
values,O
of,O
&,O
gt,O
;,O
or,O
=,O
1,O
microM,O
(,O
Ji,O
et,O
al.,O
J,O
.,O
The,O
insertion,O
of,O
substituents,O
on,O
the,O
furan,O
ring,O
of,O
3,O
",",O
as,O
in,O
compounds,O
4,O
and,O
5,O
",",O
did,O
not,O
improve,O
the,O
selectivity,O
profile,O
.,O
By,O
a,O
variety,O
of,O
synthetic,O
routes,O
",",O
we,O
have,O
synthesized,O
a,O
series,O
of,O
"3,4,5",B-MODIFIER
-,I-MODIFIER
trisubstituted,I-MODIFIER
4H,B-IUPAC
-,I-IUPAC
"1,2,4",I-IUPAC
-,I-IUPAC
triazoles,I-IUPAC
and,O
a,O
related,O
series,O
of,O
3H,B-IUPAC
-,I-IUPAC
imidazo,I-IUPAC
[,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,2,4",I-IUPAC
],I-IUPAC
triazoles,I-IUPAC
and,O
evaluated,O
them,O
in,O
vitro,O
and,O
in,O
vivo,O
as,O
angiotensin,O
II,O
(,O
AII,O
),O
antagonists,O
.,O
Most,O
of,O
the,O
target,O
compounds,O
were,O
more,O
potent,O
than,O
the,O
corresponding,O
secondary,O
amides,O
and,O
had,O
improved,O
therapeutic,O
margins,O
toward,O
CNS,O
toxicity,O
.,O
All,O
analogues,O
",",O
with,O
the,O
exception,O
of,O
the,O
Pro4,O
-,O
containing,O
analogue,O
",",O
are,O
antidiuretic,O
antagonists,O
.,O
Condensation,O
of,O
N6,B-IUPAC
-,I-IUPAC
(,I-IUPAC
omega,I-IUPAC
-,I-IUPAC
aminoalkyl,I-IUPAC
),I-IUPAC
derivatives,B-MODIFIER
of,O
AMP,O
with,O
N,B-IUPAC
-,I-IUPAC
hydroxysuccinimide,I-IUPAC
esters,I-IUPAC
of,O
omega,B-IUPAC
-,I-IUPAC
[,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
carbobenzyloxy,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
carboxylic,I-IUPAC
acids,I-IUPAC
gave,O
N6,O
-,O
(,O
CH2,O
),O
nNHCO,O
(,O
CH2,O
),O
mNH,O
-,O
Cbz,O
derivatives,O
of,O
AMP,O
which,O
",",O
upon,O
conversion,O
to,O
the,O
corresponding,O
derivatives,O
of,O
ATP,O
",",O
followed,O
by,O
removal,O
of,O
the,O
carbobenzyloxy,B-IUPAC
group,B-MODIFIER
and,O
iodoacetylation,O
",",O
as,O
described,O
above,O
",",O
gave,O
N6,O
-,O
(,O
CH2,O
),O
nNHCO,O
(,O
CH2,O
),O
mNHCOCH2I,O
-,O
ATP,O
derivatives,O
(,O
n,O
=,O
3,O
",",O
m,O
=,O
5,O
or,O
6,O
;,O
n,O
=,O
4,O
",",O
m,O
=,O
5,O
;,O
n,O
=,O
6,O
",",O
m,O
=,O
1,O
-,O
-,O
6,O
),O
.,O
The,O
intrinsic,O
activity,O
of,O
the,O
compounds,O
was,O
evaluated,O
by,O
measuring,O
their,O
effect,O
on,O
VIP,O
-,O
stimulated,O
cAMP,O
production,O
in,O
GH4ZD10,O
cells,O
stably,O
transfected,O
with,O
the,O
5,O
-,O
HT1A,O
receptor,O
.,O
"2,3",B-IUPAC
-,I-IUPAC
Dimethylputrescine,I-IUPAC
however,O
",",O
was,O
transported,O
into,O
the,O
cells,O
and,O
significantly,O
decreased,O
its,O
ODC,O
activity,O
.,O
From,O
the,O
findings,O
of,O
this,O
study,O
",",O
it,O
appears,O
that,O
norepinephrine,O
has,O
a,O
different,O
active,O
site,O
binding,O
orientation,O
than,O
most,O
known,O
substrates,O
and,O
competitive,O
inhibitors,O
of,O
PNMT,O
.,O
In,O
vivo,O
experiments,O
with,O
rats,O
show,O
that,O
[,O
125I,O
],O
(,O
S,O
),O
-,O
6b,O
penetrates,O
readily,O
into,O
the,O
brain,O
and,O
is,O
preferentially,O
localized,O
in,O
the,O
striatum,O
as,O
compared,O
to,O
the,O
cerebellum,O
",",O
the,O
ratio,O
of,O
uptake,O
being,O
7.2,O
to,O
1,O
",",O
60,O
min,O
after,O
injection,O
.,O
A,O
series,B-MODIFIER
of,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
fluorophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
indoles,I-IUPAC
substituted,B-MODIFIER
in,I-MODIFIER
the,I-MODIFIER
1,I-MODIFIER
-,I-MODIFIER
position,I-MODIFIER
with,O
4,B-IUPAC
-,I-IUPAC
piperidinyl,I-IUPAC
",",O
"1,2,3,6",B-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
pyridinyl,I-IUPAC
",",O
and,O
4,B-IUPAC
-,I-IUPAC
piperazinyl,I-IUPAC
was,O
synthesized,O
.,O
As,O
far,O
as,O
the,O
potency,O
at,O
the,O
A,O
(,O
2B,O
),O
receptor,O
",",O
the,O
type,O
of,O
2,O
-,O
alkynyl,O
chain,O
and,O
the,O
presence,O
of,O
the,O
ethylcarboxamido,O
group,O
on,O
the,O
sugar,O
seem,O
to,O
be,O
very,O
important,O
;,O
in,O
fact,O
",",O
the,O
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenylhydroxypropynyl,I-IUPAC
NECA,O
[,O
(,O
S,O
),O
-,O
PHPNECA,O
",",O
1e,O
",",O
EC,O
(,O
50,O
),O
(,O
A,O
(,O
2B,O
),O
),O
=,O
0.22,O
microM,O
],O
proved,O
to,O
be,O
one,O
of,O
the,O
most,O
potent,O
A,O
(,O
2B,O
),O
agonist,O
reported,O
so,O
far,O
.,O
Incorporation,O
of,O
substituted,B-MODIFIER
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
benzylidene,I-IUPAC
moieties,B-MODIFIER
onto,O
the,O
7,O
-,O
keto,O
precursor,O
of,O
(,B-IUPAC
+,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxyphenyl,I-IUPAC
),I-IUPAC
morphan,I-IUPAC
",",O
(,O
+,O
),O
-,O
1,O
",",O
produces,O
compounds,O
(,O
-,O
),O
-,O
2,O
through,O
(,O
-,O
),O
-,O
7,O
(,O
5.8-32.0,O
nM,O
",",O
sigma,O
1,O
),O
",",O
which,O
have,O
between,O
a,O
25,O
-,O
and,O
131,O
-,O
fold,O
increase,O
in,O
affinity,O
for,O
the,O
sigma,O
1,O
receptor,O
subtype,O
relative,O
to,O
the,O
keto,O
precursor,O
(,O
+,O
),O
-,O
1,O
(,O
Ki,O
=,O
762,O
nM,O
",",O
sigma,O
1,O
),O
.,O
The,O
affinity,O
of,O
ZIENT,O
and,O
EIENT,O
for,O
DAT,O
was,O
69,O
and,O
1.6,O
-,O
fold,O
lower,O
",",O
respectively,O
",",O
than,O
for,O
SERT,O
.,O
Binding,O
potencies,O
of,O
these,O
compounds,O
to,O
receptor,O
sites,O
labeled,O
with,O
[,O
3H,O
],O
dextromethorphan,O
(,O
[,O
3H,O
],O
1,O
),O
",",O
in,O
rat,O
brain,O
and,O
guinea,O
pig,O
brain,O
subcellular,O
fractions,O
",",O
and,O
[,O
3H,O
],O
thienylcyclohexylpiperidine,O
(,O
TCP,O
),O
and,O
[,O
3H,O
],O
glycine,O
in,O
rat,O
brain,O
",",O
were,O
determined,O
.,O
Highly,O
potent,O
antagonists,O
",",O
4,B-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
isoquinolone,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
benzylcarboxamides,I-IUPAC
(,O
11,O
),O
",",O
were,O
discovered,O
from,O
the,O
structure,O
-,O
activity,O
relationship,O
studies,O
on,O
the,O
isoquinolone,O
-,O
urea,O
lead,O
1a,O
.,O
The,O
monocylic,O
analogue,O
[,O
dPen1,O
",",O
(,O
Glu4,O
",",O
Lys8,O
),O
],O
oxytocin,O
was,O
a,O
weak,O
oxytocin,O
antagonist,O
with,O
a,O
pA2,O
value,O
of,O
5.8,O
in,O
the,O
uterotonic,O
assay,O
.,O
[,O
18F,O
],O
4c,O
was,O
superior,O
to,O
[,O
18F,O
],O
4b,O
since,O
its,O
specific,O
binding,O
was,O
more,O
readily,O
blocked,O
by,O
4a,O
.,O
Although,O
without,O
significant,O
antiviral,O
activity,O
in,O
cell,O
cultures,O
",",O
the,O
2,B-IUPAC
-,I-IUPAC
aminopurines,I-IUPAC
(,O
13,O
",",O
14-16,O
",",O
26-29,O
),O
and,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
alkoxypurines,I-IUPAC
(,O
12,O
",",O
23-25,O
),O
are,O
well,O
absorbed,O
after,O
oral,O
administration,O
to,O
mice,O
and,O
are,O
converted,O
efficiently,O
to,O
the,O
antiviral,O
guanine,O
derivatives,O
(,O
8,O
",",O
21,O
),O
in,O
vivo,O
.,O
Tumorigenicity,O
assays,O
indicate,O
that,O
the,O
"9,10",B-IUPAC
-,I-IUPAC
dihydrodiol,I-IUPAC
derivatives,B-MODIFIER
of,O
cholanthrene,O
and,O
its,O
3,B-PARTIUPAC
-,I-PARTIUPAC
and,O
6,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
derivatives,B-MODIFIER
are,O
all,O
potent,O
tumor,O
initiators,O
on,O
mouse,O
skin,O
.,O
Compounds,O
with,O
substituents,O
(,O
F,O
",",O
CF3,O
",",O
Me,O
),O
in,O
the,O
5,O
-,O
or,O
6,O
-,O
position,O
of,O
the,O
isobenzofuran,O
exert,O
increased,O
affinity,O
for,O
sigma,O
1,O
binding,O
sites,O
(,O
IC50,O
(,O
sigma,O
1,O
),O
=,O
5-30,O
nM,O
",",O
IC50,O
(,O
sigma,O
2,O
),O
=,O
0.3-7,O
nM,O
),O
",",O
thus,O
rendering,O
unselective,O
compounds,O
.,O
When,O
injected,O
into,O
rats,O
",",O
[,O
99mTc,O
],O
CpTT,O
-,O
PA,O
exhibited,O
the,O
maximum,O
myocardial,O
accumulation,O
and,O
heart,O
-,O
to,O
-,O
blood,O
ratio,O
of,O
3.85,O
%,O
ID,O
/,O
g,O
at,O
1,O
min,O
and,O
4.60,O
at,O
10,O
min,O
postinjection,O
",",O
respectively,O
.,O
However,O
",",O
exo,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
hydroxybenzonorbornene,I-IUPAC
(,O
8,O
),O
and,O
anti,B-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
hydroxybenzonorbornene,I-IUPAC
(,O
12,O
),O
displayed,O
significant,O
activity,O
as,O
inhibitors,O
toward,O
PNMT,O
.,O
(,O
N,O
),O
-,O
Methanocarba,O
-,O
T,O
(,O
2,O
),O
was,O
further,O
evaluated,O
as,O
a,O
component,O
of,O
a,O
short,O
oligodeoxynucleotide,O
(,O
ODN,O
),O
phosphorothioate,O
(,O
5',O
-,O
CTTCATTTTTTCTTC,O
-,O
3',O
),O
where,O
all,O
thymidines,O
were,O
replaced,O
by,O
2,O
.,O
The,O
amines,O
(,O
+,O
),O
-,O
and,O
(,O
-,O
),O
-,O
14a,O
",",O
incorporating,O
the,O
D1,O
pharmacophore,O
2,B-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxyphenyl,I-IUPAC
),I-IUPAC
ethylamine,I-IUPAC
in,O
a,O
trans,O
extended,O
conformation,O
",",O
and,O
their,O
derivatives,O
displayed,O
D1,O
and,O
D2,O
affinity,O
in,O
the,O
nanomolar,O
range,O
.,O
The,O
metabolite,O
-,O
corrected,O
blood,O
radioactivity,O
had,O
a,O
half,O
-,O
life,O
of,O
29,O
min,O
.,O
In,O
the,O
present,O
work,O
",",O
we,O
describe,O
how,O
the,O
bicyclo,B-IUPAC
[,I-IUPAC
3.1.0,I-IUPAC
],I-IUPAC
hexane,I-IUPAC
template,O
fixes,O
the,O
ring,O
pucker,O
of,O
2',B-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
methanocarba,I-IUPAC
-,I-IUPAC
nucleosides,I-IUPAC
1-5,O
and,O
12,O
to,O
values,O
corresponding,O
to,O
either,O
one,O
of,O
these,O
two,O
extreme,O
conformations,O
that,O
are,O
typical,O
of,O
nucleosides,O
.,O
These,O
compounds,O
proved,O
to,O
be,O
selective,O
CB1,O
cannabinoid,O
receptor,O
ligands,O
",",O
acting,O
as,O
inverse,O
agonists,O
in,O
a,O
[,O
35S,O
],O
-,O
GTPgammaS,O
assay,O
.,O
The,O
order,O
of,O
anti,O
-,O
HIV,O
potency,O
of,O
pyrimidine,O
analogues,O
was,O
as,O
follows,O
:,O
5,B-IUPAC
-,I-IUPAC
fluorocytosine,I-IUPAC
(,O
beta,O
-,O
isomer,O
),O
&,O
gt,O
;,O
cytosine,O
(,O
beta,O
-,O
isomer,O
),O
&,O
gt,O
;,O
5,B-IUPAC
-,I-IUPAC
fluorocytosine,I-IUPAC
(,O
alpha,O
-,O
isomer,O
),O
&,O
gt,O
;,O
5,B-IUPAC
-,I-IUPAC
iodocytosine,I-IUPAC
(,O
beta,O
-,O
isomer,O
),O
&,O
gt,O
;,O
cytosine,O
(,O
alpha,O
-,O
isomer,O
),O
&,O
gt,O
;,O
5,B-IUPAC
-,I-IUPAC
bromocytosine,I-IUPAC
(,O
beta,O
-,O
isomer,O
),O
&,O
gt,O
;,O
thymine,O
(,O
beta,O
-,O
isomer,O
),O
&,O
gt,O
;,O
5,B-IUPAC
-,I-IUPAC
methylcytosine,I-IUPAC
(,O
alpha,O
-,O
isomer,O
),O
&,O
gt,O
;,O
5,B-IUPAC
-,I-IUPAC
iodocytosine,I-IUPAC
(,O
alpha,O
-,O
isomer,O
),O
&,O
gt,O
;,O
5,B-IUPAC
-,I-IUPAC
chlorocytosine,I-IUPAC
(,O
beta,O
-,O
isomer,O
),O
.,O
We,O
have,O
prepared,O
the,O
radiolabeled,O
des,O
-,O
AA,O
(,O
"1,2,5",O
),O
-,O
[,O
DTrp,O
(,O
8,O
),O
",",O
IAmp,O
(,O
9,O
),O
",",O
(,O
125,O
),O
ITyr,O
(,O
11,O
),O
],O
-,O
SRIF,O
(,O
(,O
125,O
),O
I,O
-,O
25,O
),O
and,O
des,O
-,O
AA,O
(,O
"1,2,5",O
),O
-,O
[,O
DTrp,O
(,O
8,O
),O
",",O
IAmp,O
(,O
9,O
),O
",",O
(,O
125,O
),O
ITyr,O
(,O
11,O
),O
],O
-,O
Cbm,O
-,O
SRIF,O
(,O
(,O
125,O
),O
I,O
-,O
27,O
),O
",",O
used,O
them,O
as,O
in,O
vitro,O
tracers,O
",",O
and,O
found,O
them,O
to,O
be,O
superior,O
to,O
des,O
-,O
AA,O
(,O
"1,5",O
),O
-,O
[,O
(,O
125,O
),O
ITyr,O
(,O
2,O
),O
",",O
DTrp,O
(,O
8,O
),O
",",O
IAmp,O
(,O
9,O
),O
],O
-,O
SRIF,O
(,O
(,O
125,O
),O
I,O
-,O
16,O
),O
for,O
the,O
detection,O
of,O
sst1,O
tumors,O
in,O
receptor,O
autoradiography,O
studies,O
.,O
Thrombin,O
is,O
a,O
serine,O
protease,O
responsible,O
for,O
blood,O
coagulation,O
.,O
These,O
results,O
suggest,O
that,O
the,O
hydroxyl,O
group,O
of,O
7,O
functions,O
as,O
an,O
H,O
-,O
bond,O
acceptor,O
",",O
rather,O
than,O
a,O
donor,O
",",O
and,O
that,O
on,O
interaction,O
of,O
7,O
",",O
and,O
the,O
pyrido,O
analogues,O
9,O
",",O
with,O
a,O
common,O
receptor,O
",",O
an,O
orbital,O
occupied,O
by,O
one,O
of,O
the,O
oxygen,O
lone,O
pair,O
electrons,O
of,O
7,O
must,O
assume,O
the,O
same,O
orientation,O
as,O
the,O
orbital,O
occupied,O
by,O
the,O
pyridine,O
nitrogen,O
lone,O
pair,O
.,O
The,O
remaining,O
target,O
compounds,O
",",O
11-17,O
",",O
were,O
very,O
weak,O
or,O
inactive,O
as,O
inhibitors,O
of,O
both,O
uptake,O
systems,O
.,O
Oxidative,O
cyclization,O
of,O
either,O
"4,5",B-PARTIUPAC
-,I-PARTIUPAC
or,O
"5,6",B-IUPAC
-,I-IUPAC
diaminopyridines,I-IUPAC
with,O
aryl,O
aldehydes,O
produced,O
the,O
[,O
"4,5",O
-,O
c,O
],O
and,O
[,O
"4,5",O
-,O
b,O
],O
imidazopyridine,O
ring,O
systems,O
",",O
respectively,O
.,O
In,O
some,O
cases,O
",",O
C,O
-,O
alkylation,O
also,O
occurred,O
.,O
On,O
the,O
basis,O
of,O
these,O
results,O
",",O
a,O
model,O
accounting,O
for,O
glycine,O
receptor,O
binding,O
of,O
the,O
1,O
derived,O
antagonists,O
is,O
proposed,O
",",O
comprising,O
(,O
a,O
),O
size,O
-,O
limited,O
",",O
hydrophobic,O
binding,O
of,O
the,O
benzene,O
ring,O
",",O
(,O
b,O
),O
hydrogen,O
-,O
bond,O
acceptance,O
by,O
the,O
4,B-IUPAC
-,I-IUPAC
oxo,I-IUPAC
group,B-MODIFIER
",",O
(,O
c,O
),O
hydrogen,O
-,O
bond,O
donation,O
by,O
the,O
1,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
group,B-MODIFIER
",",O
and,O
(,O
d,O
),O
a,O
Coulombic,O
attraction,O
of,O
the,O
2,B-IUPAC
-,I-IUPAC
carboxylate,I-IUPAC
.,O
Compound,O
13,O
",",O
which,O
showed,O
the,O
highest,O
5,O
-,O
HT,O
(,O
1A,O
),O
receptor,O
affinity,O
(,O
K,O
(,O
i,O
),O
=,O
1.1,O
nM,O
),O
",",O
was,O
50,O
-,O
fold,O
selective,O
in,O
relation,O
to,O
alpha,O
(,O
1,O
),O
adrenoceptors,O
and,O
at,O
least,O
250,O
-,O
fold,O
over,O
5,O
-,O
HT,O
(,O
2A,O
),O
and,O
D,O
(,O
2,O
),O
sites,O
.,O
The,O
major,O
structural,O
differences,O
between,O
2a,O
and,O
(,O
3S,O
",",O
4R,O
),O
-,O
3,O
are,O
that,O
2a,O
possesses,O
a,O
different,O
absolute,O
stereochemistry,O
and,O
has,O
an,O
ethylene,O
bridge,O
not,O
present,O
in,O
3,O
.,O
Of,O
the,O
four,O
gem,O
diether,O
nucleosides,O
",",O
only,O
the,O
dimethyl,O
gem,O
diether,O
congener,O
showed,O
significant,O
antiviral,O
activity,O
against,O
both,O
viruses,O
.,O
Moreover,O
",",O
compound,O
13,O
",",O
a,O
1,B-IUPAC
-,I-IUPAC
benzylpiperazine,I-IUPAC
analogue,B-MODIFIER
of,O
14,O
",",O
preserved,O
a,O
dual,O
high,O
5,O
-,O
HT1A,O
and,O
sigma,O
affinity,O
(,O
Ki,O
=,O
3.6,O
nM,O
on,O
[,O
3H,O
],O
-,O
5,O
-,O
HT,O
and,O
Ki,O
=,O
7.0,O
nM,O
on,O
[,O
3H,O
],O
DTG,O
),O
.,O
This,O
derivative,O
",",O
(,B-IUPAC
S,I-IUPAC
*,I-IUPAC
",",I-IUPAC
R,I-IUPAC
*,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
mercaptopropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
leucyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
isoquinolinyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
carbonyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
glutamine,I-IUPAC
",",O
was,O
evaluated,O
in,O
vivo,O
along,O
with,O
(,B-IUPAC
S,I-IUPAC
*,I-IUPAC
",",I-IUPAC
R,I-IUPAC
*,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
mercaptopropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
leucyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
isoquinolinyl,I-IUPAC
],I-IUPAC
carbonyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
methionine,I-IUPAC
methyl,I-IUPAC
ester,I-IUPAC
for,O
antitumor,O
activity,O
in,O
an,O
athymic,O
mouse,O
model,O
implanted,O
ip,O
with,O
H,O
-,O
ras,O
-,O
transformed,O
rat,O
-,O
1,O
tumor,O
cells,O
.,O
These,O
agents,O
were,O
tested,O
for,O
their,O
ability,O
to,O
sensitize,O
hypoxic,O
Escherichia,O
coli,O
cells,O
to,O
killing,O
by,O
ionizing,O
radiation,O
.,O
Replacement,O
of,O
a,O
hydroxyl,B-IUPAC
group,B-MODIFIER
for,O
a,O
fluorine,O
atom,O
in,O
the,O
4,O
position,O
of,O
muscarine,O
produces,O
1,O
order,O
of,O
magnitude,O
increase,O
in,O
affinity,O
for,O
cardiac,O
M2,O
muscarinic,O
receptors,O
controlling,O
rate,O
",",O
while,O
the,O
affinity,O
at,O
cardiac,O
M2,O
muscarinic,O
receptors,O
controlling,O
force,O
is,O
unchanged,O
",",O
opening,O
the,O
possibility,O
of,O
a,O
further,O
classification,O
of,O
cardiac,O
muscarinic,O
receptors,O
.,O
Compound,O
2,O
did,O
not,O
exhibit,O
any,O
antifolate,O
activity,O
against,O
Lactobacillus,O
casei,O
or,O
Streptococcus,O
faecium,O
.,O
This,O
selectivity,O
was,O
more,O
pronounced,O
for,O
9,O
",",O
which,O
showed,O
IC,O
(,O
50,O
),O
values,O
of,O
40,O
and,O
500,O
microM,O
as,O
an,O
inhibitor,O
of,O
glial,O
and,O
neuronal,O
GABA,O
uptake,O
",",O
respectively,O
.,O
Compound,O
13,O
(,O
methylhistaprodifen,O
;,O
N,B-IUPAC
(,I-IUPAC
alpha,I-IUPAC
),I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
diphenylpropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
imidazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
ethanamine,I-IUPAC
),O
is,O
the,O
most,O
potent,O
histamine,O
H,O
(,O
1,O
),O
-,O
receptor,O
agonist,O
reported,O
so,O
far,O
in,O
the,O
literature,O
and,O
may,O
become,O
a,O
valuable,O
tool,O
for,O
the,O
study,O
of,O
physiological,O
and,O
pathophysiological,O
H,O
(,O
1,O
),O
-,O
receptor,O
-,O
mediated,O
effects,O
.,O
A,O
new,O
class,O
of,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
cyanamido,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
haloethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridines,I-IUPAC
(,O
4-6,O
),O
and,O
arabinouridines,O
(,O
7,O
",",O
8,O
),O
were,O
synthesized,O
by,O
the,O
regiospecific,O
addition,O
of,O
halogenocyanamides,O
(,O
X,O
-,O
NHCN,O
),O
to,O
the,O
5,B-IUPAC
-,I-IUPAC
vinyl,I-IUPAC
substituent,B-MODIFIER
of,O
the,O
respective,O
5,B-IUPAC
-,I-IUPAC
vinyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
(,O
2,O
),O
and,O
2',B-IUPAC
-,I-IUPAC
arabinouridine,I-IUPAC
(,O
3,O
),O
.,O
Assuming,O
that,O
the,O
interaction,O
between,O
these,O
racemic,O
compounds,O
and,O
PK,O
-,O
C,O
is,O
stereospecific,O
",",O
the,O
potency,O
of,O
the,O
active,O
enantiomer,O
is,O
anticipated,O
to,O
double,O
.,O
This,O
structure,O
class,O
is,O
characterized,O
by,O
the,O
boat,O
conformation,O
of,O
the,O
tropane,O
ring,O
and,O
the,O
orientation,O
of,O
the,O
additional,O
bridge,O
(,O
and,O
therefore,O
of,O
the,O
nitrogen,O
lone,O
pair,O
),O
together,O
with,O
the,O
unusual,O
placement,O
of,O
the,O
aromatic,O
moiety,O
.,O
Tomaymycin,O
is,O
a,O
member,O
of,O
the,O
pyrrolo,B-IUPAC
[,I-IUPAC
"1,4",I-IUPAC
],I-IUPAC
benzodiazepine,I-IUPAC
antitumor,O
-,O
antibiotic,O
group,O
that,O
binds,O
covalently,O
to,O
the,O
exocyclic,B-MODIFIER
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
group,B-MODIFIER
of,O
guanine,O
in,O
DNA,O
.,O
In,O
a,O
sequence,O
of,O
reactions,O
",",O
methyl,O
mesopyropheophorbide,O
a,O
",",O
mesochlorin,B-IUPAC
e,I-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
trimethyl,I-IUPAC
ester,I-IUPAC
",",O
mesochlorin,B-IUPAC
p,I-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
trimethyl,I-IUPAC
ester,I-IUPAC
",",O
mesopurpurin,B-IUPAC
-,I-IUPAC
18,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
hexylimide,I-IUPAC
methyl,I-IUPAC
ester,I-IUPAC
",",O
and,O
mesopurpurin,B-IUPAC
-,I-IUPAC
18,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
"3,5",I-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
trifluoromethyl,I-IUPAC
),I-IUPAC
benzylimide,I-IUPAC
methyl,I-IUPAC
ester,I-IUPAC
were,O
synthesized,O
from,O
chlorophyll,O
-,O
a,O
.,O
A,O
similar,O
dehydration,O
of,O
the,O
precursor,O
tetraacetyl,B-IUPAC
derivative,B-MODIFIER
of,O
4,O
gave,O
the,O
corresponding,O
carbonitrile,O
",",O
which,O
on,O
deprotection,O
and,O
subsequent,O
treatment,O
with,O
hydroxylamine,O
furnished,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
benzyloxy,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
ribofuranosylpyrazole,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxamidoxime,I-IUPAC
(,O
13,O
),O
.,O
The,O
fluorine,O
substituent,O
markedly,O
increases,O
the,O
phenolic,O
acidities,O
of,O
these,O
analogues,O
.,O
However,O
",",O
for,O
all,O
compounds,O
there,O
was,O
a,O
good,O
correlation,O
(,O
R,O
&,O
gt,O
;,O
0.97,O
),O
between,O
the,O
differential,O
uptake,O
ratio,O
(,O
DUR,O
",",O
(,O
%,O
ID,O
/,O
g,O
),O
x,O
body,O
weight,O
(,O
g,O
),O
/,O
100,O
),O
in,O
individual,O
rat,O
brain,O
regions,O
at,O
30,O
min,O
after,O
injection,O
and,O
the,O
concentration,O
of,O
receptors,O
as,O
determined,O
by,O
in,O
vitro,O
quantitative,O
autoradiography,O
in,O
rat,O
.,O
In,O
the,O
presence,O
of,O
2,B-IUPAC
-,I-IUPAC
mercaptoehtanesulfonic,I-IUPAC
acid,I-IUPAC
",",O
an,O
acrolein,O
scavenger,O
",",O
1c,O
was,O
equally,O
effective,O
against,O
a,O
P,O
-,O
388,O
mutant,O
cell,O
line,O
that,O
was,O
resistant,O
to,O
FU,O
.,O
Deprotection,O
of,O
ethyl,B-IUPAC
3,I-IUPAC
-,I-IUPAC
cyano,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
"3,5",I-IUPAC
-,I-IUPAC
di,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
toluoyl,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
erythro,I-IUPAC
-,I-IUPAC
pentofuranosyl,I-IUPAC
),I-IUPAC
pyrr,I-IUPAC
ole,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
carboxylate,I-IUPAC
(,O
12,O
),O
using,O
sodium,O
ethoxide,O
furnished,O
ethyl,B-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
erythro,I-IUPAC
-,I-IUPAC
pentofuranosyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
cyanopyrrole,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
late,I-IUPAC
(,O
14,O
),O
which,O
served,O
as,O
the,O
starting,O
material,O
for,O
the,O
preparation,O
of,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dideoxy,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
glycero,I-IUPAC
-,I-IUPAC
pentofuranosyl,I-IUPAC
),I-IUPAC
pyrrolo,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyridazin,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
20,O
),O
.,O
In,O
the,O
binding,O
assay,O
",",O
the,O
relative,O
order,O
of,O
potencies,O
for,O
the,O
analogues,O
in,O
the,O
5alpha,O
-,O
and,O
5beta,O
-,O
series,O
is,O
identical,O
.,O
Last,O
",",O
neither,O
compound,O
displayed,O
dose,O
-,O
dependent,O
activation,O
of,O
alpha4beta2,O
nAChRs,O
.,O
Neuroprotective,O
properties,O
assessed,O
after,O
postischemic,O
dosing,O
in,O
a,O
Mongolian,O
gerbil,O
severe,O
temporary,O
forebrain,O
ischemia,O
paradigm,O
",",O
using,O
hippocampal,O
CA1,O
damage,O
endpoints,O
",",O
and,O
the,O
efficacy,O
of,O
these,O
agonists,O
in,O
an,O
A,O
(,O
1,O
),O
functional,O
assay,O
show,O
similarities,O
to,O
some,O
reference,O
adenosine,O
agonists,O
.,O
For,O
9,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
RS,I-IUPAC
),I-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
diazidopropyl,I-IUPAC
],I-IUPAC
adenine,I-IUPAC
and,O
some,O
di,B-MODIFIER
-,I-MODIFIER
and,O
trihydroxybutyl,B-MODIFIER
analogues,I-MODIFIER
of,O
DHPA,O
",",O
viz,O
.,O
Condensation,O
of,O
1,O
with,O
dibenzoylmethane,B-IUPAC
gave,O
15,O
.,O
The,O
conformationally,O
restricted,O
linear,O
tricyclic,O
analogs,O
of,O
5,B-PARTIUPAC
-,I-PARTIUPAC
and,O
8,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
di,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
propylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
tetralins,I-IUPAC
were,O
investigated,O
for,O
their,O
serotonergic,O
and,O
dopaminergic,O
properties,O
.,O
The,O
most,O
active,O
compound,O
was,O
dl,B-IUPAC
-,I-IUPAC
erythro,I-IUPAC
-,I-IUPAC
4',I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"1,4",I-IUPAC
-,I-IUPAC
benzodioxan,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxyethyl,I-IUPAC
],I-IUPAC
spiro,I-IUPAC
[,I-IUPAC
4H,I-IUPAC
-,I-IUPAC
"3,1",I-IUPAC
-,I-IUPAC
benzoxazine,I-IUPAC
-,I-IUPAC
"4,4",I-IUPAC
',I-IUPAC
-,I-IUPAC
piperidin,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
),I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
9,O
),O
",",O
and,O
various,O
modifications,O
of,O
this,O
compound,O
were,O
made,O
in,O
order,O
to,O
elucidate,O
the,O
structure,O
-,O
activity,O
relationships,O
in,O
the,O
series,O
.,O
Dose,O
ratios,O
(,O
ratio,O
of,O
ED20,O
of,O
angiotensin,O
II,O
during,O
infusion,O
of,O
the,O
antagonist,O
and,O
before,O
infusion,O
of,O
the,O
antagonist,O
),O
in,O
vagotomized,O
",",O
ganglion,O
-,O
blocked,O
rats,O
",",O
infused,O
at,O
250,O
ng,O
/,O
kg,O
/,O
min,O
",",O
were,O
33.43,O
",",O
2.14,O
",",O
3.26,O
",",O
2.99,O
",",O
0.62,O
",",O
62.52,O
",",O
incalculable,O
",",O
and,O
11.15,O
",",O
respectively,O
.,O
(,O
+,O
),O
-,O
1,O
and,O
(,O
-,O
),O
-,O
1,O
were,O
synthesized,O
from,O
(,B-IUPAC
+,I-IUPAC
/,I-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
trans,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
aminocyclohexanol,I-IUPAC
[,O
(,O
+,O
/,O
-,O
),O
-,O
3,O
],O
.,O
The,O
pKa,O
values,O
of,O
respective,O
ligands,O
and,O
the,O
stability,O
constants,O
of,O
their,O
iron,O
(,O
III,O
),O
complexes,O
are,O
presented,O
.,O
The,O
structure,O
-,O
activity,O
relationships,O
of,O
these,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
oxochroman,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
amides,I-IUPAC
and,O
related,O
compounds,O
are,O
discussed,O
on,O
the,O
basis,O
of,O
these,O
two,O
assays,O
.,O
(,O
all,O
-,O
E,O
),O
-,O
1,O
was,O
further,O
evaluated,O
for,O
its,O
ability,O
to,O
prevent,O
the,O
induction,O
of,O
mouse,O
skin,O
papillomas,O
and,O
to,O
induce,O
signs,O
of,O
vitamin,O
A,O
toxicity,O
in,O
mice,O
.,O
Analogues,O
of,O
1t,O
(,O
3,O
),O
",",O
which,O
have,O
(,B-PARTIUPAC
S,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
and,O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
groups,B-MODIFIER
at,O
the,O
benzylic,O
methylene,O
portion,O
of,O
1t,O
",",O
were,O
prepared,O
and,O
separated,O
into,O
the,O
diastereomeric,O
atropisomers,O
",",O
3a,O
-,O
A,O
",",O
3a,O
-,O
B,O
and,O
3b,O
-,O
A,O
",",O
3b,O
-,O
B,O
",",O
in,O
enantiomerically,O
pure,O
forms,O
.,O
Comparison,O
of,O
the,O
binding,O
data,O
of,O
different,O
N,O
-,O
substituted,O
homologues,O
of,O
1,O
with,O
those,O
of,O
the,O
1,B-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichlorophenyl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
alkylpiperazines,I-IUPAC
suggests,O
that,O
the,O
two,O
nitrogen,O
atoms,O
of,O
1,O
are,O
working,O
in,O
opposition,O
to,O
one,O
another,O
in,O
terms,O
of,O
their,O
sensitivity,O
to,O
steric,O
bulk,O
.,O
On,O
incubation,O
with,O
rat,O
plasma,O
",",O
1c,O
liberated,O
nitroxyl,B-IUPAC
",",O
a,O
potent,O
inhibitor,O
of,O
AlDH,O
.,O
Preliminary,O
stroke,O
results,O
from,O
1,B-PARTIUPAC
-,I-PARTIUPAC
and,O
2,B-IUPAC
-,I-IUPAC
aza,I-IUPAC
-,I-IUPAC
5,I-IUPAC
[,I-IUPAC
H,I-IUPAC
],I-IUPAC
-,I-IUPAC
phenanthridin,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
one,I-IUPAC
prompted,O
structure,O
-,O
activity,O
relationships,O
to,O
be,O
established,O
for,O
several,O
2,B-MODIFIER
-,I-MODIFIER
and,O
3,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
1,B-IUPAC
-,I-IUPAC
aza,I-IUPAC
-,I-IUPAC
5,I-IUPAC
[,I-IUPAC
H,I-IUPAC
],I-IUPAC
-,I-IUPAC
phenanthridin,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
.,O
A,O
possible,O
receptor,O
-,O
active,O
conformation,O
is,O
suggested,O
.,O
Regression,O
analysis,O
suggested,O
a,O
requirement,O
for,O
optimally,O
sized,O
",",O
hydrophobic,O
5,O
-,O
and,O
7,O
-,O
substituents,O
",",O
with,O
bulk,O
tolerance,O
being,O
greater,O
at,O
the,O
5,O
-,O
position,O
.,O
Additional,O
bioassay,O
data,O
for,O
these,O
compounds,O
are,O
also,O
reported,O
.,O
This,O
leads,O
to,O
the,O
formation,O
of,O
a,O
2,B-IUPAC
-,I-IUPAC
hydroxyoxazaphosphorine,I-IUPAC
ring,O
with,O
R,O
=,O
H,O
(,O
3a,O
coming,O
from,O
compounds,O
2a,O
",",O
c,O
),O
or,O
(,O
CH,O
(,O
2,O
),O
),O
(,O
2,O
),O
Cl,O
(,O
3b,O
coming,O
from,O
compounds,O
2b,O
",",O
d,O
),O
and,O
to,O
the,O
release,O
of,O
ammonia,O
or,O
chloroethylamine,O
.,O
Further,O
modifications,O
of,O
the,O
intermediate,O
led,O
to,O
the,O
syntheses,O
of,O
(,B-IUPAC
9R,I-IUPAC
),I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
deoxo,I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
"12,21",I-IUPAC
-,I-IUPAC
epoxyerythromycin,I-IUPAC
B,I-IUPAC
",",O
(,B-IUPAC
9R,I-IUPAC
),I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
deoxo,I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
21,I-IUPAC
-,I-IUPAC
hydroxyerythromycin,I-IUPAC
A,I-IUPAC
",",O
and,O
(,B-IUPAC
9R,I-IUPAC
),I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
deoxo,I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
21,I-IUPAC
-,I-IUPAC
hydroxyerythromycin,I-IUPAC
B,I-IUPAC
.,O
In,O
the,O
latter,O
assay,O
",",O
both,O
enantiomers,O
of,O
6,O
had,O
identical,O
potencies,O
",",O
but,O
their,O
dose,O
-,O
response,O
curves,O
were,O
not,O
parallel,O
.,O
On,O
the,O
basis,O
of,O
inhibition,O
of,O
HIV,O
-,O
1',O
s,O
cytopathic,O
effects,O
in,O
MT,O
-,O
4,O
cells,O
",",O
we,O
found,O
that,O
5,O
-,O
mono,O
-,O
Me,O
-,O
substituted,O
analogues,O
",",O
the,O
original,O
substitution,O
in,O
the,O
early,O
lead,O
compounds,O
",",O
and,O
7,O
-,O
mono,O
-,O
Me,O
-,O
substituted,O
analogues,O
of,O
1,O
were,O
comparable,O
as,O
being,O
consistently,O
the,O
most,O
active,O
compounds,O
.,O
Convenient,O
procedures,O
are,O
described,O
for,O
the,O
synthesis,O
of,O
5,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
N,B-IUPAC
(,I-IUPAC
4,I-IUPAC
),I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxycytidines,I-IUPAC
5a,O
",",O
b,O
",",O
d,O
-,O
h,O
via,O
transformation,O
of,O
the,O
respective,O
5,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
3',B-IUPAC
",",I-IUPAC
5',I-IUPAC
-,I-IUPAC
di,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridines,I-IUPAC
1a,O
-,O
c,O
",",O
e,O
-,O
h,O
.,O
Thus,O
",",O
none,O
of,O
the,O
compounds,O
showed,O
an,O
advantage,O
over,O
CGS,O
9896,O
(,O
Yokoyama,O
et,O
al.,O
J,O
.,O
At,O
P2X,O
-,O
receptors,O
",",O
no,O
activity,O
was,O
observed,O
in,O
the,O
rabbit,O
saphenous,O
artery,O
",",O
but,O
variable,O
degrees,O
of,O
activity,O
were,O
observed,O
in,O
the,O
guinea,O
pig,O
vas,O
deferens,O
and,O
bladder,O
depending,O
on,O
distal,O
substituents,O
of,O
the,O
thioether,O
moiety,O
.,O
Nucleosides,O
5a,O
",",O
b,O
",",O
d,O
-,O
h,O
were,O
selectively,O
converted,O
to,O
the,O
corresponding,O
5',O
-,O
monophosphates,O
6a,O
",",O
b,O
",",O
d,O
-,O
h,O
with,O
the,O
aid,O
of,O
the,O
wheat,O
shoot,O
phosphotransferase,O
system,O
.,O
Thus,O
(,O
S,O
),O
-,O
6b,O
has,O
a,O
lipophilicity,O
that,O
will,O
allow,O
a,O
relatively,O
higher,O
uptake,O
into,O
the,O
brain,O
compared,O
to,O
sulpiride,O
.,O
All,O
the,O
furoxan,O
and,O
furazan,O
derivatives,O
showed,O
activity,O
as,O
inhibitors,O
of,O
platelet,O
aggregation,O
.,O
Conversion,O
to,O
the,O
4,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
derivatives,B-MODIFIER
and,O
condensation,O
with,O
3,B-IUPAC
-,I-IUPAC
chloroaniline,I-IUPAC
gave,O
the,O
corresponding,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
chloroanilino,I-IUPAC
),I-IUPAC
derivatives,B-MODIFIER
.,O
8,O
was,O
shown,O
to,O
be,O
photochemically,O
active,O
and,O
is,O
a,O
potential,O
photoaffinity,O
label,O
for,O
the,O
recognition,O
site,O
of,O
the,O
AMPA,O
receptors,O
.,O
Some,O
functional,O
groups,O
were,O
introduced,O
that,O
were,O
hypothesized,O
to,O
influence,O
the,O
phamacokinetic,O
properties,O
of,O
the,O
analogues,O
such,O
as,O
bioavailability,O
",",O
solubility,O
",",O
intra,O
-,O
or,O
intermolecular,O
hydrogen,O
bond,O
forming,O
capacity,O
",",O
and,O
ability,O
to,O
bind,O
carrier,O
proteins,O
.,O
In,O
in,O
vivo,O
tests,O
against,O
L1210,O
in,O
mice,O
",",O
4,O
failed,O
to,O
show,O
therapeutic,O
effect,O
.,O
Compounds,O
3a,O
",",O
b,O
are,O
transient,O
intermediates,O
",",O
which,O
in,O
strongly,O
acidic,O
medium,O
are,O
not,O
observed,O
with,O
(,O
31,O
),O
P,O
NMR,O
.,O
These,O
data,O
confirm,O
that,O
the,O
distance,O
between,O
the,O
Dmt,O
-,O
Tic,O
pharmacophore,O
and,O
a,O
third,O
aromatic,O
nucleus,O
is,O
an,O
important,O
criterion,O
in,O
converting,O
Dmt,O
-,O
Tic,O
from,O
a,O
highly,O
potent,O
delta,O
-,O
antagonist,O
into,O
a,O
potent,O
delta,O
-,O
agonist,O
or,O
into,O
ligands,O
with,O
mixed,O
delta,O
-,O
and,O
mu,O
-,O
opioid,O
properties,O
.,O
In,O
some,O
cases,O
",",O
the,O
positional,O
isomers,O
6,O
and,O
8,O
were,O
also,O
obtained,O
.,O
Orally,O
administered,O
"3,4,3",O
-,O
LI,O
-,O
(,O
diCAM,O
-,O
diHOPO,O
),O
promoted,O
significantly,O
more,O
Pu,O
excretion,O
than,O
an,O
equimolar,O
amount,O
of,O
CaNa3DTPA,O
.,O
Of,O
the,O
compounds,O
examined,O
",",O
the,O
greatest,O
degree,O
of,O
activity,O
in,O
vitro,O
was,O
found,O
with,O
the,O
7,B-IUPAC
-,I-IUPAC
mercaptopyrazolo,I-IUPAC
[,I-IUPAC
"1,5",I-IUPAC
-,I-IUPAC
a,I-IUPAC
],I-IUPAC
pyrimidines,I-IUPAC
.,O
The,O
compounds,O
were,O
prepared,O
by,O
two,O
methods,O
:,O
(,O
1,O
),O
direct,O
alkylation,O
of,O
adenosine,O
with,O
an,O
appropriately,O
substituted,O
benzyl,O
bromide,O
to,O
give,O
the,O
N1,O
-,O
substituted,O
derivative,O
which,O
was,O
then,O
rearranged,O
in,O
base,O
to,O
give,O
the,O
N6,O
-,O
substituted,O
compound,O
",",O
and,O
(,O
2,O
),O
by,O
nucleophilic,O
displacement,O
of,O
chlorine,O
in,O
6,B-IUPAC
-,I-IUPAC
chloropurine,I-IUPAC
ribonucleoside,B-MODIFIER
",",O
6,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
aminopurine,I-IUPAC
ribonucleoside,B-MODIFIER
",",O
and,O
6,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
aminopurine,I-IUPAC
with,O
an,O
amine,O
.,O
When,O
the,O
p,O
-,O
anisyl,O
group,O
of,O
1,O
was,O
replaced,O
by,O
an,O
n,O
-,O
pentyl,O
group,O
",",O
the,O
resultant,O
antagonist,O
3,O
exhibited,O
substantially,O
increased,O
ETB,O
/,O
ETA,O
activity,O
ratio,O
",",O
but,O
a,O
decreased,O
ETA,O
affinity,O
.,O
gondii,O
DHFR,O
",",O
with,O
an,O
IC50,O
of,O
0.0064,O
microM,O
corresponding,O
again,O
to,O
a,O
minor,O
increase,O
in,O
activity,O
over,O
TMQ,O
and,O
PTX,O
.,O
In,O
contrast,O
",",O
the,O
(,B-IUPAC
diethylamino,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
substituent,B-MODIFIER
on,O
the,O
piperidine,O
ring,O
conferred,O
a,O
much,O
larger,O
set,O
of,O
minimum,O
-,O
energy,O
conformations,O
on,O
II,O
.,O
The,O
total,O
synthesis,O
time,O
was,O
50-53,O
min,O
from,O
the,O
end,O
of,O
cyclotron,O
fluorine,O
-,O
18,O
production,O
(,O
EOB,O
),O
.,O
Inhibition,O
of,O
macromolecular,O
synthesis,O
with,O
compounds,O
4c,O
",",O
4d,O
",",O
6e,O
",",O
9c,O
",",O
and,O
9d,O
follows,O
the,O
order,O
:,O
DNA,O
greater,O
than,O
RNA,O
greater,O
than,O
or,O
equal,O
to,O
protein,O
.,O
The,O
latter,O
is,O
presumably,O
formed,O
by,O
dephosphorylation,O
of,O
FdUMP,O
by,O
plasma,O
5',O
-,O
nucleotidases,O
or,O
phosphatases,O
.,O
Compound,O
4,O
was,O
also,O
relatively,O
neurotoxic,O
(,O
TD50,O
=,O
124,O
mg,O
/,O
kg,O
),O
.,O
Results,O
presented,O
in,O
this,O
paper,O
confirm,O
the,O
first,O
assignment,O
and,O
establish,O
that,O
",",O
although,O
the,O
proposed,O
6,O
-,O
cyano,O
adduct,O
is,O
initially,O
formed,O
",",O
the,O
product,O
that,O
was,O
isolated,O
from,O
the,O
mitochondrial,O
incubation,O
mixtures,O
of,O
MPTP,O
and,O
sodium,O
cyanide,O
actually,O
is,O
the,O
isomeric,O
2,B-IUPAC
-,I-IUPAC
cyano,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
"1,2,3,6",I-IUPAC
-,I-IUPAC
tetrahydropyridine,I-IUPAC
.,O
Various,O
4,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
3,B-PARTIUPAC
-,I-PARTIUPAC
alkylamino,I-PARTIUPAC
-,I-PARTIUPAC
",",O
3,B-PARTIUPAC
-,I-PARTIUPAC
alkoxy,I-PARTIUPAC
-,I-PARTIUPAC
",",O
3,B-PARTIUPAC
-,I-PARTIUPAC
alkylthio,I-PARTIUPAC
-,I-PARTIUPAC
",",O
and,O
3,B-IUPAC
-,I-IUPAC
alkyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
sulfamoylbenzoic,I-IUPAC
acids,I-IUPAC
related,O
to,O
known,O
aminobenzoic,O
acid,O
diuretics,O
were,O
synthesized,O
and,O
screened,O
for,O
their,O
diuretic,O
properties,O
in,O
dogs,O
.,O
Each,O
configurational,O
isomer,O
of,O
1,O
was,O
evaluated,O
for,O
its,O
ability,O
to,O
inhibit,O
the,O
binding,O
of,O
retinoic,O
acid,O
to,O
CRABP,O
(,O
chick,O
skin,O
),O
and,O
to,O
inhibit,O
the,O
chemical,O
induction,O
of,O
ornithine,O
decarboxylase,O
in,O
mouse,O
skin,O
.,O
The,O
[,O
125I,O
],O
-,O
radiolabeled,O
congeners,O
of,O
10,O
and,O
14,O
were,O
prepared,O
as,O
potential,O
metabolic,O
markers,O
.,O
N,B-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
[,I-IUPAC
N',I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
Chloroethyl,I-IUPAC
),I-IUPAC
carbamyl,I-IUPAC
],I-IUPAC
oxy,I-IUPAC
],I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
norapocodeine,I-IUPAC
(,O
1g,O
),O
and,O
its,O
11,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
chloroethyl,I-IUPAC
),I-IUPAC
carbamyl,I-IUPAC
derivative,B-MODIFIER
(,O
1h,O
),O
were,O
also,O
prepared,O
.,O
The,O
binding,O
activity,O
for,O
the,O
more,O
potent,O
bicyclic,O
hydantoin,O
",",O
"1,8",B-IUPAC
-,I-IUPAC
diaza,I-IUPAC
-,I-IUPAC
"9,10",I-IUPAC
-,I-IUPAC
dioxo,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
phenylbicyclo,I-IUPAC
[,I-IUPAC
5.2.1,I-IUPAC
],I-IUPAC
decane,I-IUPAC
(,O
4,O
),O
(,O
IC50,O
=,O
427,O
microM,O
),O
",",O
was,O
comparable,O
to,O
that,O
of,O
the,O
ring,O
-,O
opened,O
",",O
N3,O
-,O
methylated,O
monocyclic,O
hydantoin,O
model,O
",",O
5,B-IUPAC
-,I-IUPAC
butyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
phenylhydantoin,I-IUPAC
(,O
9,O
),O
(,O
IC50,O
=,O
285,O
microM,O
),O
",",O
and,O
these,O
were,O
8-11,O
times,O
less,O
potent,O
than,O
the,O
monocyclic,O
model,O
8,O
",",O
which,O
contains,O
a,O
free,O
imide,O
NH,O
.,O
The,O
ethyl,O
esters,O
were,O
further,O
reacted,O
with,O
3,B-IUPAC
-,I-IUPAC
picolylamine,I-IUPAC
to,O
produce,O
corresponding,O
amides,O
.,O
In,O
addition,O
",",O
selected,O
compounds,O
showed,O
potential,O
antipsychotic,O
effects,O
.,O
This,O
study,O
indicates,O
that,O
the,O
substitutions,O
with,O
none,O
or,O
low,O
polar,O
functional,O
groups,O
at,O
the,O
1,O
-,O
position,O
could,O
improve,O
the,O
selectivity,O
and,O
duration,O
of,O
the,O
bronchodilator,O
effects,O
of,O
xanthines,O
.,O
Several,O
of,O
these,O
compounds,O
",",O
such,O
as,O
6b,O
",",O
e,O
",",O
were,O
particularly,O
interesting,O
inhibitors,O
of,O
HCMV,O
with,O
IC,O
(,O
50,O
),O
's,O
ranging,O
from,O
0.1,O
to,O
1.3,O
muM,O
.,O
It,O
is,O
well,O
known,O
that,O
1,O
is,O
metabolized,O
to,O
its,O
phenolic,O
derivative,O
dextrorphan,O
(,O
2,O
),O
and,O
this,O
metabolite,O
is,O
also,O
a,O
potent,O
anticonvulsant,O
.,O
The,O
conversion,O
of,O
the,O
monophenols,O
into,O
catecholic,O
metabolites,O
is,O
only,O
1-5%,O
",",O
and,O
the,O
further,O
conversion,O
of,O
these,O
catecholic,O
metabolites,O
into,O
methoxylated,O
analogues,O
is,O
very,O
rapid,O
.,O
Compounds,O
1a,O
-,O
c,O
and,O
some,O
of,O
their,O
hydrolytic,O
degradation,O
products,O
(,O
4b,O
-,O
1,O
",",O
4b,O
-,O
2,O
",",O
diphosphoric,O
diester,O
[,O
Cl,O
(,O
CH,O
(,O
2,O
),O
),O
(,O
2,O
),O
NH,O
(,O
CH,O
(,O
2,O
),O
),O
(,O
3,O
),O
OP,O
(,O
O,O
),O
(,O
OH,O
),O
],O
(,O
2,O
),O
O,O
(,O
5,O
),O
",",O
and,O
chloroethylamine,O
),O
did,O
not,O
exhibit,O
",",O
as,O
expected,O
",",O
any,O
antitumor,O
efficacy,O
in,O
vivo,O
against,O
P388,O
leukemia,O
.,O
Further,O
molecular,O
modifications,O
involve,O
the,O
pendant,O
phenyl,O
ring,O
as,O
well,O
as,O
quaternary,O
amine,O
compounds,O
.,O
A,O
series,O
of,O
erythro,B-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
nonyl,I-IUPAC
),I-IUPAC
azole,I-IUPAC
derivatives,B-MODIFIER
have,O
been,O
synthesized,O
and,O
evaluated,O
for,O
adenosine,O
deaminase,O
(,O
ADA,O
),O
inhibitory,O
activity,O
",",O
in,O
order,O
to,O
introduce,O
simplifications,O
in,O
the,O
ADA,O
inhibitor,O
erythro,B-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
nonyl,I-IUPAC
),I-IUPAC
adenine,I-IUPAC
(,O
EHNA,O
",",O
1a,O
),O
.,O
2,B-IUPAC
-,I-IUPAC
Deoxy,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
arabino,I-IUPAC
-,I-IUPAC
hexopyranoside,I-IUPAC
2,O
was,O
also,O
an,O
effective,O
growth,O
inhibitor,O
of,O
two,O
drug,O
-,O
resistant,O
leukemic,O
cell,O
lines,O
",",O
P388,O
/,O
Adr,O
and,O
L1210,O
/,O
vmdr,O
.,O
The,O
synthesis,O
of,O
several,O
analogues,O
of,O
(,B-IUPAC
8R,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
erythro,I-IUPAC
-,I-IUPAC
pentofuranosyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"3,6,7,8",I-IUPAC
-,I-IUPAC
tetrahydroimidazo,I-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,3",I-IUPAC
],I-IUPAC
diazepin,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
ol,I-IUPAC
(,O
pentostatin,O
",",O
1a,O
),O
is,O
described,O
.,O
This,O
study,O
emphasizes,O
the,O
importance,O
of,O
the,O
metabolic,O
conversion,O
of,O
the,O
enantiomers,O
of,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxyphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
propylpiperidine,I-IUPAC
(,O
3,O
-,O
PPP,O
),O
into,O
their,O
catechol,O
analogues,O
",",O
the,O
enantiomers,O
of,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dihydroxyphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
propylpiperidine,I-IUPAC
.,O
The,O
GAELs,O
differ,O
from,O
1,O
in,O
having,O
the,O
sn,B-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
phosphocholine,I-IUPAC
residue,O
replaced,O
by,O
one,O
of,O
the,O
following,O
monosaccharide,O
residues,O
:,O
beta,B-PARTIUPAC
-,I-PARTIUPAC
and,O
alpha,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
arabino,I-IUPAC
-,I-IUPAC
hexopyranosyl,I-IUPAC
",",O
alpha,B-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
mannopyranosyl,I-IUPAC
",",O
2,B-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
glucopyranosyl,I-IUPAC
",",O
and,O
2,B-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
mannopyranosyl,I-IUPAC
.,O
Hydroxymethyl,O
compound,O
14,O
was,O
obtained,O
by,O
deamination,O
of,O
reported,O
"2,4",B-IUPAC
-,I-IUPAC
diaminopyrido,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
methanol,I-IUPAC
(,O
12a,O
),O
in,O
refluxing,O
1,O
N,O
NaOH,O
.,O
A,O
new,O
means,O
of,O
accessing,O
N,B-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
cyclopropylmethyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
(,I-IUPAC
11,I-IUPAC
),I-IUPAC
-,I-IUPAC
ethylnorspermine,I-IUPAC
(,O
CPMENSPM,O
),O
and,O
the,O
first,O
synthesis,O
of,O
(,B-IUPAC
2R,I-IUPAC
",",I-IUPAC
10S,I-IUPAC
),I-IUPAC
-,I-IUPAC
N,I-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
cyclopropylmethyl,I-IUPAC
-,I-IUPAC
"2,10",I-IUPAC
-,I-IUPAC
dihydroxy,I-IUPAC
-,I-IUPAC
N,I-IUPAC
(,I-IUPAC
11,I-IUPAC
),I-IUPAC
-,I-IUPAC
ethylnorspermine,I-IUPAC
[,O
(,O
2R,O
",",O
10S,O
),O
-,O
(,O
HO,O
),O
(,O
2,O
),O
CPMENSPM,O
],O
are,O
described,O
.,O
BTCP,O
and,O
7,O
were,O
the,O
most,O
potent,O
of,O
all,O
the,O
compounds,O
tested,O
in,O
terms,O
of,O
their,O
ability,O
to,O
inhibit,O
uptake,O
of,O
[,O
3H,O
],O
DA,O
.,O
The,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxyalkyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxypyridin,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
are,O
demonstrated,O
to,O
be,O
orally,O
active,O
under,O
the,O
in,O
vivo,O
conditions,O
adopted,O
.,O
This,O
was,O
converted,O
to,O
(,B-IUPAC
+,I-IUPAC
/,I-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
"5,12",I-IUPAC
-,I-IUPAC
dimethoxy,I-IUPAC
-,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
azanaphthacene,I-IUPAC
-,I-IUPAC
"6,11",I-IUPAC
-,I-IUPAC
dione,I-IUPAC
by,O
dehydration,O
to,O
the,O
4,B-IUPAC
-,I-IUPAC
keto,I-IUPAC
analogue,B-MODIFIER
followed,O
by,O
cyanoborohydride,O
reduction,O
either,O
stepwise,O
or,O
in,O
situ,O
.,O
The,O
5,B-IUPAC
-,I-IUPAC
fluorocytosine,I-IUPAC
analogue,B-MODIFIER
12,O
was,O
inactive,O
at,O
up,O
to,O
1,O
x,O
10,O
(,O
-,O
4,O
),O
M,O
",",O
and,O
the,O
other,O
halogenated,O
derivatives,O
10,O
and,O
11,O
had,O
no,O
effect,O
even,O
at,O
1,O
x,O
10,O
(,O
-,O
3,O
),O
M,O
.,O
Unlike,O
the,O
hydroxylated,O
DENSPM,O
compounds,O
",",O
both,O
cyclopropyl,O
norspermines,O
substantially,O
upregulated,O
spermidine,O
/,O
spermine,O
N,O
(,O
1,O
),O
-,O
acetyltransferase,O
.,O
In,O
addition,O
to,O
their,O
5,O
alpha,O
-,O
reductase,O
activities,O
",",O
17,B-IUPAC
beta,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
alkylformamides,I-IUPAC
),I-IUPAC
were,O
also,O
studied,O
for,O
their,O
inhibitory,O
activities,O
on,O
dihydrotestosterone,O
(,O
DHT,O
),O
-,O
stimulated,O
proliferation,O
of,O
androgen,O
-,O
sensitive,O
Shionogi,O
mouse,O
mammary,O
carcinoma,O
cells,O
(,O
clone,O
SEM,O
-,O
107,O
),O
.,O
The,O
simplest,O
target,O
compound,O
(,O
9c,O
),O
derived,O
from,O
the,O
ineffective,O
"4,4",B-IUPAC
-,I-IUPAC
bis,I-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxymethyl,I-IUPAC
),I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
furanone,I-IUPAC
template,O
was,O
investigated,O
only,O
with,O
a,O
myristoyl,O
acyl,O
chain,O
.,O
In,O
contrast,O
",",O
3,B-PARTIUPAC
-,I-PARTIUPAC
alkylamino,I-PARTIUPAC
-,I-PARTIUPAC
7,I-PARTIUPAC
-,I-PARTIUPAC
trifluoromethyl,I-PARTIUPAC
-,I-PARTIUPAC
(,O
20a,O
-,O
c,O
),O
and,O
3,B-IUPAC
-,I-IUPAC
alkylamino,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
pentyl,I-IUPAC
-,I-IUPAC
4H,I-IUPAC
-,I-IUPAC
"1,2,4",I-IUPAC
-,I-IUPAC
benzothiadiazine,I-IUPAC
"1,1",I-IUPAC
-,I-IUPAC
dioxides,I-IUPAC
(,O
11a,O
",",O
b,O
),O
expressed,O
a,O
marked,O
myorelaxant,O
activity,O
on,O
rat,O
aorta,O
ring,O
.,O
3,O
-,O
Deoxy,O
-,O
"2,5",O
-,O
di,O
-,O
O,O
-,O
p,O
-,O
nitrobenzoyl,O
-,O
alpha,O
-,O
D,O
-,O
threo,O
-,O
entofuranosyl,O
bromide,O
(,O
1,O
),O
reacted,O
with,O
mercuric,O
cyanide,O
to,O
give,O
"2,5",B-IUPAC
-,I-IUPAC
anhydro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
lyxo,I-IUPAC
-,I-IUPAC
hexononitrile,I-IUPAC
(,O
2,O
),O
which,O
upon,O
acid,O
hydrolysis,O
of,O
the,O
CN,O
group,O
gave,O
acid,O
3,O
.,O
Noteworthy,O
are,O
the,O
tissue,O
-,O
selective,O
bronchodilator,O
activity,O
of,O
N,B-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
PGE2,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
and,O
the,O
selectivity,O
for,O
uterine,O
tissue,O
of,O
N,B-IUPAC
-,I-IUPAC
methanesulfonyl,I-IUPAC
-,I-IUPAC
PGE2,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
",",O
2,B-IUPAC
-,I-IUPAC
decarboxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
tetrazol,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"16,16",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
PGE2,I-IUPAC
",",O
N,B-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
"16,16",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
PGE2,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
",",O
and,O
N,B-IUPAC
-,I-IUPAC
methanesulfonyl,I-IUPAC
-,I-IUPAC
"16,16",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
PGE2,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
.,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
Benzyloxy,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
phenylpiperidines,I-IUPAC
and,O
4,B-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
arylmethyl,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
piperidinols,I-IUPAC
and,O
the,O
corresponding,O
methyl,O
ethers,O
and,O
esters,O
display,O
weak,O
to,O
modest,O
antitetrabenazine,O
activity,O
.,O
Compounds,O
7a,O
-,O
c,O
failed,O
to,O
increase,O
the,O
life,O
span,O
of,O
mice,O
infected,O
with,O
B16,O
melanoma,O
.,O
All,O
of,O
the,O
isozymes,O
tested,O
possessed,O
measurable,O
activity,O
with,O
phenethyl,O
chloride,O
.,O
Analogues,O
1-9,O
and,O
14,O
are,O
potent,O
AVP,O
V1,O
antagonists,O
.,O
A,O
series,O
of,O
4,B-IUPAC
-,I-IUPAC
phenylisoquinolone,I-IUPAC
derivatives,B-MODIFIER
were,O
synthesized,O
and,O
evaluated,O
for,O
NK1,O
(,O
substance,O
P,O
),O
antagonist,O
activity,O
.,O
The,O
aim,O
of,O
this,O
project,O
was,O
to,O
further,O
investigate,O
whether,O
it,O
is,O
possible,O
to,O
differentiate,O
between,O
these,O
compounds,O
with,O
respect,O
to,O
their,O
affinity,O
for,O
alpha,O
(,O
1,O
),O
-,O
adrenoreceptor,O
subtypes,O
and,O
the,O
affinity,O
for,O
5,O
-,O
HT,O
(,O
1A,O
),O
receptors,O
",",O
as,O
1,O
binds,O
with,O
high,O
affinity,O
at,O
both,O
receptor,O
systems,O
.,O
Their,O
structures,O
of,O
platinum,O
complexes,O
were,O
elucidated,O
from,O
circular,O
dichroism,O
and,O
13C,O
NMR,O
spectral,O
analyses,O
",",O
and,O
it,O
has,O
been,O
concluded,O
that,O
the,O
cyclohexane,O
ring,O
of,O
cis,B-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
cyclohexanediamine,I-IUPAC
is,O
nearly,O
perpendicular,O
to,O
the,O
chelate,O
ring,O
",",O
while,O
both,O
rings,O
of,O
trans,B-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
cyclohexanediamine,I-IUPAC
and,O
trans,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
aminomethyl,I-IUPAC
),I-IUPAC
cyclohexylamine,I-IUPAC
complexes,B-MODIFIER
lie,O
in,O
a,O
common,O
plane,O
.,O
When,O
compounds,O
2,O
and,O
9b,O
were,O
tested,O
in,O
combination,O
with,O
vidarabine,O
against,O
herpes,O
simplex,O
virus,O
",",O
type,O
1,O
",",O
in,O
an,O
HEp,O
-,O
2,O
plaque,O
reduction,O
assay,O
",",O
only,O
compound,O
2,O
was,O
able,O
to,O
potentiate,O
the,O
antiviral,O
activity,O
of,O
vidarabine,O
.,O
The,O
effects,O
on,O
biological,O
activity,O
of,O
substitution,O
and,O
structural,O
modification,O
of,O
the,O
4,B-PARTIUPAC
-,I-PARTIUPAC
and,O
5,B-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
rings,B-MODIFIER
of,O
3,O
was,O
examined,O
.,O
Preferred,O
substituents,O
on,O
the,O
triazolinone,O
ring,O
were,O
n,B-IUPAC
-,I-IUPAC
butyl,I-IUPAC
at,O
C5,O
and,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
trifluoromethyl,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
at,O
N2,O
.,O
Friedel,O
-,O
Crafts,O
reaction,O
of,O
5,O
led,O
to,O
"2,4",B-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
chloromethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
acetylbenzylamine,I-IUPAC
(,O
6,O
),O
which,O
on,O
treatment,O
with,O
KCN,O
",",O
hydrolysis,O
of,O
the,O
resultant,O
nitrile,O
",",O
and,O
subsequent,O
esterification,O
afforded,O
6,B-IUPAC
-,I-IUPAC
carbethoxymethyl,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
"1,2,3,4",I-IUPAC
-,I-IUPAC
tetrahydroisoquinolin,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
9,O
),O
.,O
THHBADs,O
are,O
antagonists,O
of,O
NMDA,O
and,O
AMPA,O
receptors,O
with,O
functional,O
potency,O
being,O
dependent,O
upon,O
the,O
substitution,O
pattern,O
on,O
the,O
tetrahydrobenzene,O
moiety,O
.,O
Furthermore,O
",",O
it,O
antagonized,O
in,O
vivo,O
seizures,O
induced,O
by,O
icv,O
administration,O
of,O
AMPA,O
or,O
kainate,O
(,O
KA,O
),O
.,O
It,O
is,O
transported,O
into,O
the,O
tumor,O
cells,O
by,O
the,O
neuronal,O
norepinephrine,O
(,O
NE,O
),O
transporter,O
(,O
NET,O
),O
which,O
is,O
expressed,O
in,O
almost,O
all,O
neuroblastoma,O
cells,O
.,O
Compound,O
1e,O
produced,O
an,O
ILS,O
of,O
71%,O
at,O
100,O
mg,O
/,O
kg,O
per,O
day,O
X,O
5,O
(,O
ip,O
),O
in,O
BDF,O
mice,O
inoculated,O
ip,O
with,O
10,O
(,O
6,O
),O
L,O
-,O
1210,O
cells,O
.,O
Compound,O
3,O
was,O
obtained,O
via,O
a,O
Wittig,O
reaction,O
of,O
the,O
tributylphosphonium,O
salt,O
of,O
"2,4",B-IUPAC
-,I-IUPAC
diamino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
chloromethyl,I-IUPAC
),I-IUPAC
furo,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
(,O
5,O
),O
and,O
methyl,B-IUPAC
4,I-IUPAC
-,I-IUPAC
formylbenzoate,I-IUPAC
(,O
6,O
),O
followed,O
by,O
reduction,O
and,O
coupling,O
with,O
the,O
diethyl,O
ester,O
of,O
L,B-IUPAC
-,I-IUPAC
glutamic,I-IUPAC
acid,I-IUPAC
.,O
Cold,O
monoiodination,O
of,O
19,O
yielded,O
21,O
",",O
with,O
retention,O
of,O
high,O
sst,O
(,O
4,O
),O
selectivity,O
and,O
affinity,O
(,O
IC,O
(,O
50,O
),O
=,O
3.5,O
nM,O
),O
.,O
These,O
nucleosides,O
were,O
evaluated,O
for,O
in,O
vitro,O
cytotoxicity,O
to,O
human,O
prostate,O
cancer,O
(,O
HTB,O
-,O
81,O
),O
and,O
mouse,O
melanoma,O
(,O
B16,O
),O
cells,O
as,O
well,O
as,O
normal,O
human,O
fibroblasts,O
(,O
NHF,O
),O
.,O
On,O
the,O
other,O
hand,O
",",O
compounds,O
7d,O
and,O
7n,O
are,O
time,O
-,O
dependent,O
inhibitors,O
with,O
a,O
saturable,O
initial,O
complex,O
.,O
We,O
have,O
designed,O
and,O
synthesized,O
16,O
new,O
olean,B-PARTIUPAC
-,I-PARTIUPAC
and,O
urs,B-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
en,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
one,I-IUPAC
triterpenoids,I-IUPAC
with,O
various,O
modified,O
rings,O
C,O
as,O
potential,O
antiinflammatory,O
and,O
cancer,O
chemopreventive,O
agents,O
and,O
evaluated,O
their,O
inhibitory,O
activities,O
against,O
production,O
of,O
nitric,O
oxide,O
induced,O
by,O
interferon,O
-,O
gamma,O
in,O
mouse,O
macrophages,O
.,O
carinii,O
enzyme,O
",",O
with,O
most,O
of,O
the,O
analogues,O
giving,O
IC50,O
values,O
of,O
0.01-0.1,O
microM,O
.,O
Thus,O
5,B-IUPAC
-,I-IUPAC
propyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
deazaaminopterin,I-IUPAC
",",O
5,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
10,I-IUPAC
-,I-IUPAC
propargyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
deazaaminopterin,I-IUPAC
",",O
5,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
10,I-IUPAC
-,I-IUPAC
allyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
deazaaminopterin,I-IUPAC
",",O
5,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
deazamethotrexate,I-IUPAC
",",O
and,O
"2,5",B-MODIFIER
-,I-MODIFIER
disubstituted,I-MODIFIER
thiophene,B-IUPAC
analogue,B-MODIFIER
of,O
5,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
deazaaminopterin,I-IUPAC
showed,O
potencies,O
greater,O
than,O
methotrexate,O
by,O
intraperitoneal,O
or,O
oral,O
administration,O
and,O
were,O
active,O
over,O
a,O
considerably,O
broader,O
dose,O
range,O
.,O
cruzi,O
.,O
Because,O
of,O
the,O
high,O
potency,O
and,O
selectivity,O
of,O
19,O
",",O
this,O
compound,O
has,O
also,O
been,O
prepared,O
in,O
the,O
[,O
125I,O
],O
-,O
iodinated,O
form,O
by,O
a,O
nucleophilic,O
halogen,O
exchange,O
reaction,O
using,O
the,O
corresponding,O
bromo,O
derivative,O
22,O
as,O
a,O
precursor,O
.,O
Thus,O
",",O
the,O
derivatives,O
39,O
",",O
46,O
",",O
and,O
61,O
bound,O
with,O
higher,O
affinity,O
and,O
selectivity,O
to,O
5,O
-,O
HT1A,O
receptors,O
(,O
versus,O
dopaminergic,O
D2,O
and,O
adrenergic,O
alpha1,O
receptors,O
),O
and,O
displayed,O
more,O
potent,O
5,O
-,O
HT1A,O
agonist,O
activity,O
in,O
vitro,O
and,O
in,O
vivo,O
than,O
their,O
C,O
-,O
4,O
desfluoro,O
analogues,O
.,O
The,O
induction,O
of,O
7,B-IUPAC
-,I-IUPAC
ethoxycoumarin,I-IUPAC
deethylase,O
activity,O
in,O
the,O
microsomal,O
fraction,O
from,O
rat,O
liver,O
by,O
alpha,B-IUPAC
-,I-IUPAC
naphthoflavone,I-IUPAC
",",O
beta,B-IUPAC
-,I-IUPAC
naphthoflavone,I-IUPAC
",",O
and,O
3,B-IUPAC
-,I-IUPAC
methylcholanthrene,I-IUPAC
and,O
the,O
inhibition,O
of,O
these,O
activities,O
by,O
flavone,O
and,O
alpha,B-PARTIUPAC
-,I-PARTIUPAC
",",O
beta,B-PARTIUPAC
",",O
and,O
gamma,B-IUPAC
-,I-IUPAC
naphthoflavone,I-IUPAC
have,O
also,O
been,O
examined,O
.,O
This,O
series,O
of,O
compounds,O
were,O
slightly,O
less,O
potent,O
at,O
A2,O
receptors,O
.,O
However,O
",",O
in,O
biological,O
investigations,O
using,O
a,O
subcutaneous,O
B16,O
(,O
hypoxic,O
),O
melanoma,O
tumor,O
in,O
BDF1,O
hybrid,O
mice,O
with,O
cyclophosphamide,O
as,O
positive,O
control,O
the,O
most,O
interesting,O
series,O
of,O
structurally,O
related,O
analogues,O
were,O
the,O
potentially,O
monoalkylating,O
monoquinones,O
of,O
the,O
2,B-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
(,O
leaving,O
group,O
),O
methyl,B-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
"1,4",I-PARTIUPAC
-,I-PARTIUPAC
benzoquinone,I-PARTIUPAC
type,B-MODIFIER
(,O
i.e.,O
",",O
14,O
and,O
15,O
),O
having,O
water,O
-,O
insoluble,O
(,O
acetoxy,O
),O
and,O
water,O
-,O
solubilizing,O
(,O
succinate,O
),O
groups,O
.,O
A,O
series,O
of,O
PGE2,O
",",O
"16,16",B-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
PGE2,I-IUPAC
",",O
and,O
PGF2,O
alpha,O
analogues,O
modified,O
at,O
the,O
carboxyl,O
terminus,O
with,O
tetrazole,O
",",O
amide,O
",",O
acylurea,O
",",O
imide,O
",",O
and,O
sulfonimide,O
functionalities,O
was,O
evaluated,O
for,O
uterine,O
stimulant,O
",",O
bronchodilator,O
",",O
hypotensive,O
",",O
gastric,O
antisecretory,O
",",O
and,O
diarrheal,O
activity,O
.,O
The,O
release,O
of,O
5,O
from,O
6,O
following,O
metabolism,O
was,O
confirmed,O
and,O
shown,O
by,O
use,O
of,O
the,O
bioassay,O
system,O
to,O
be,O
an,O
event,O
of,O
similar,O
toxicity,O
to,O
release,O
of,O
4,O
from,O
18,O
;,O
in,O
vivo,O
",",O
however,O
",",O
6,O
(,O
LD50,O
330,O
mg,O
/,O
kg,O
),O
was,O
more,O
toxic,O
to,O
mice,O
than,O
18,O
(,O
LD50,O
greater,O
than,O
500,O
mg,O
/,O
kg,O
),O
.,O
After,O
selective,O
tritylation,O
of,O
the,O
tetrazole,O
rings,O
in,O
3,O
and,O
4,O
",",O
treatment,O
of,O
N,B-MODIFIER
-,I-MODIFIER
tritylated,I-MODIFIER
benzimidazole,B-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acids,I-IUPAC
(,O
6,O
",",O
7,O
),O
with,O
a,O
variety,O
of,O
alkyl,O
halides,O
",",O
followed,O
by,O
deprotection,O
with,O
hydrochloric,O
acid,O
",",O
afforded,O
esters,O
of,O
3,O
and,O
4,O
.,O
Together,O
with,O
the,O
X,O
-,O
ray,O
structure,O
of,O
phorbol,B-IUPAC
-,I-IUPAC
13,I-IUPAC
-,I-IUPAC
acetate,I-IUPAC
in,O
complex,O
with,O
PKCdelta,O
C1b,O
",",O
the,O
predicted,O
binding,O
models,O
of,O
PDBu,O
",",O
ILV,O
",",O
ingenol,B-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
benzoate,I-IUPAC
",",O
and,O
thymeleatoxin,O
in,O
complex,O
with,O
PKC,O
showed,O
that,O
the,O
binding,O
of,O
these,O
ligands,O
to,O
PKC,O
is,O
governed,O
by,O
a,O
combination,O
of,O
several,O
highly,O
specific,O
and,O
optimal,O
hydrogen,O
bonds,O
and,O
hydrophobic,O
contacts,O
.,O
Thus,O
",",O
(,B-IUPAC
1S,I-IUPAC
",",I-IUPAC
3R,I-IUPAC
",",I-IUPAC
6S,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
Z,I-IUPAC
),I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
biphenylylmethylene,I-IUPAC
),I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
azatricyclo,I-IUPAC
[,I-IUPAC
4.3.1,I-IUPAC
.,I-IUPAC
PET,O
brain,O
imaging,O
studies,O
in,O
monkeys,O
demonstrated,O
high,O
[,O
(,O
18,O
),O
F,O
],O
(,O
R,O
),O
-,O
FIPCT,O
and,O
[,O
(,O
18,O
),O
F,O
],O
(,O
S,O
),O
-,O
FIPCT,O
uptake,O
in,O
the,O
caudate,O
and,O
putamen,O
which,O
resulted,O
in,O
caudate,O
-,O
to,O
-,O
cerebellum,O
and,O
putamen,O
-,O
to,O
-,O
cerebellum,O
ratios,O
of,O
2.5-3.5,O
at,O
115,O
min,O
.,O
The,O
results,O
favor,O
the,O
hypothesis,O
that,O
weakly,O
polar,O
pi,O
-,O
pi,O
interactions,O
exist,O
between,O
the,O
aromatic,O
group,O
and,O
the,O
receptor,O
.,O
Important,O
hydrogen,O
-,O
bonding,O
and,O
hydrophobic,O
interactions,O
with,O
the,O
protein,O
have,O
been,O
identified,O
for,O
this,O
inhibitor,O
.,O
More,O
convenient,O
one,O
-,O
pot,O
alkylation,O
-,O
elimination,O
of,O
adenine,O
(,O
18,O
),O
or,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
chloropurine,I-IUPAC
(,O
30,O
),O
with,O
24,O
+,O
25,O
afforded,O
(,B-PARTIUPAC
Z,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
and,O
(,B-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
methylenecyclopropane,I-IUPAC
derivatives,B-MODIFIER
26,O
+,O
27,O
and,O
31,O
+,O
32,O
.,O
In,O
this,O
case,O
",",O
highest,O
inhibitory,O
activity,O
was,O
obtained,O
by,O
N,B-IUPAC
-,I-IUPAC
[,I-IUPAC
7,I-IUPAC
-,I-IUPAC
(,I-IUPAC
decyloxy,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
oxochroman,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"2,2",I-IUPAC
-,I-IUPAC
dimethylpropanamid,I-IUPAC
e,I-IUPAC
(,O
65,O
),O
.,O
Variable,O
-,O
temperature,O
proton,O
nuclear,O
magnetic,O
resonance,O
studies,O
have,O
shown,O
that,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
propylidene,I-IUPAC
),I-IUPAC
-,I-IUPAC
10,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methylpiperazino,I-IUPAC
),I-IUPAC
-,I-IUPAC
5H,I-IUPAC
-,I-IUPAC
dibenzo,I-IUPAC
[,I-IUPAC
a,I-IUPAC
",",I-IUPAC
d,I-IUPAC
],I-IUPAC
cycloheptene,I-IUPAC
",",O
a,O
"5,11",B-IUPAC
-,I-IUPAC
dicarbo,I-IUPAC
analogue,B-MODIFIER
of,O
the,O
atypical,O
neuroleptic,O
agent,O
clozapine,B-IUPAC
[,I-IUPAC
8,I-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
11,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methylpiperazino,I-IUPAC
),I-IUPAC
-,I-IUPAC
5H,I-IUPAC
-,I-IUPAC
dibenzo,I-IUPAC
[,I-IUPAC
b,I-IUPAC
",",I-IUPAC
e,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,4",I-IUPAC
],I-IUPAC
diazepine,I-IUPAC
],I-IUPAC
",",O
exists,O
as,O
thermally,O
stable,O
configurational,O
isomers,O
.,O
The,O
absolute,O
bioavailability,O
of,O
5q,O
has,O
been,O
found,O
to,O
be,O
28%,O
in,O
the,O
rat,O
",",O
as,O
compared,O
to,O
68%,O
for,O
ICI,O
"204,219",O
",",O
with,O
significant,O
levels,O
of,O
5q,O
observed,O
in,O
the,O
blood,O
of,O
rats,O
up,O
to,O
24,O
h,O
postdose,O
.,O
Subsequent,O
modification,O
of,O
the,O
amino,O
terminal,O
into,O
N,B-IUPAC
alpha,I-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
threonine,I-IUPAC
led,O
to,O
the,O
most,O
potent,O
compound,O
",",O
N,B-IUPAC
alpha,I-IUPAC
-,I-IUPAC
[,I-IUPAC
N,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
acetyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
threonyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
N1,I-IUPAC
-,I-IUPAC
formyl,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
tryptophyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylmethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
phenylalaninamide,I-IUPAC
[,O
Ac,O
-,O
Thr,O
-,O
D,O
-,O
Trp,O
(,O
CHO,O
),O
-,O
Phe,O
-,O
NMeBzl,O
(,O
5a,O
",",O
FR113680,O
),O
],O
.,O
Acetate,O
salt,O
of,O
2,B-IUPAC
-,I-IUPAC
[,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
amidinophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
furan,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
-,I-IUPAC
imidazo,I-IUPAC
[,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
a,I-IUPAC
],I-IUPAC
pyridine,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
carboxamidine,I-IUPAC
(,O
8a,O
),O
was,O
obtained,O
from,O
4a,O
",",O
through,O
the,O
bis,B-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
acetoxyamidoxime,I-IUPAC
followed,O
by,O
hydrogenation,O
in,O
a,O
mixture,O
of,O
ethanol,O
/,O
ethyl,O
acetate,O
.,O
Contribution,O
of,O
both,O
an,O
N,B-PARTIUPAC
-,I-PARTIUPAC
n,I-PARTIUPAC
-,I-PARTIUPAC
propyl,I-PARTIUPAC
and,O
a,O
2,B-PARTIUPAC
-,I-PARTIUPAC
hydroxy,I-PARTIUPAC
in,O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
propylnorapomorphine,I-IUPAC
(,O
R,O
(,O
-,O
),O
-,O
2,O
-,O
OH,O
-,O
NPA,O
",",O
R,O
-,O
7,O
),O
or,O
a,O
methoxy,O
group,O
in,O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
propylnorapomorphine,I-IUPAC
(,O
R,O
(,O
-,O
),O
-,O
2,O
-,O
OCH3,O
-,O
NPA,O
",",O
R,O
-,O
9,O
),O
produced,O
the,O
highest,O
D2,O
affinity,O
(,O
0.053,O
and,O
0.17,O
nM,O
),O
and,O
D2,O
over,O
D1,O
selectivity,O
(,O
"17,300",O
and,O
"10,500",O
times,O
),O
of,O
the,O
compounds,O
evaluated,O
.,O
The,O
novel,O
compounds,O
were,O
characterized,O
as,O
dopaminergic,O
antagonists,O
or,O
inverse,O
agonists,O
.,O
4beta,B-IUPAC
",",I-IUPAC
19,I-IUPAC
-,I-IUPAC
Diol,I-IUPAC
27,O
",",O
previously,O
synthesized,O
",",O
was,O
identified,O
as,O
an,O
extremely,O
powerful,O
competitive,O
inhibitor,O
of,O
aromatase,O
(,O
K,O
(,O
i,O
),O
=,O
3.4,O
nM,O
),O
.,O
Thus,O
",",O
the,O
binding,O
data,O
show,O
that,O
this,O
conformation,O
is,O
recognized,O
by,O
the,O
DAT,O
-,O
associated,O
binding,O
site,O
and,O
also,O
suggest,O
that,O
this,O
conformation,O
of,O
paroxetine,O
is,O
recognized,O
by,O
the,O
5,O
-,O
HTT,O
-,O
associated,O
binding,O
site,O
.,O
Fluorescence,O
measurements,O
show,O
that,O
there,O
are,O
two,O
species,O
of,O
tomaymycin,O
bound,O
to,O
d,O
(,O
ATGCAT,O
),O
2,O
",",O
which,O
are,O
tentatively,O
identified,O
as,O
the,O
11R,O
",",O
11aS,O
and,O
11S,O
",",O
11aS,O
diastereomers,O
.,O
The,O
absolute,O
configurations,O
of,O
the,O
latter,O
were,O
established,O
by,O
conversion,O
of,O
1L,B-IUPAC
-,I-IUPAC
"2,5,6",I-IUPAC
-,I-IUPAC
tri,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
(,I-IUPAC
p,I-IUPAC
-,I-IUPAC
methoxybenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
myo,I-IUPAC
-,I-IUPAC
inositol,I-IUPAC
to,O
the,O
known,O
1L,B-IUPAC
-,I-IUPAC
"1,2,4,5,6",I-IUPAC
-,I-IUPAC
penta,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
benzyl,I-IUPAC
-,I-IUPAC
myo,I-IUPAC
-,I-IUPAC
inositol,I-IUPAC
.,O
In,O
rat,O
experiments,O
",",O
the,O
(,O
18,O
),O
F,O
-,O
labeled,O
candidate,O
showed,O
desirable,O
properties,O
for,O
PET,O
AChE,O
measurement,O
:,O
high,O
brain,O
uptake,O
of,O
the,O
authentic,O
ester,O
",",O
high,O
AChE,O
specificity,O
",",O
a,O
moderate,O
hydrolysis,O
rate,O
",",O
and,O
low,O
membrane,O
permeability,O
(,O
metabolic,O
trapping,O
),O
of,O
the,O
metabolite,O
.,O
Apyrogenic,O
samples,O
of,O
[,B-IUPAC
3,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
11,I-IUPAC
),I-IUPAC
C,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
],I-IUPAC
temozolomide,I-IUPAC
(,O
9,O
),O
and,O
[,B-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
11,I-IUPAC
),I-IUPAC
C,I-IUPAC
-,I-IUPAC
carbonyl,I-IUPAC
],I-IUPAC
temozolomide,I-IUPAC
(,O
11,O
),O
",",O
with,O
good,O
chemical,O
and,O
radiochemical,O
purities,O
",",O
have,O
been,O
prepared,O
and,O
used,O
in,O
human,O
PET,O
studies,O
.,O
Various,O
substituted,O
isoquinoline,B-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
carboxaldehyde,I-IUPAC
thiosemicarbazones,I-IUPAC
(,O
12,O
compounds,O
),O
have,O
been,O
synthesized,O
and,O
evaluated,O
for,O
antineoplastic,O
activity,O
in,O
mice,O
bearing,O
the,O
L1210,O
leukemia,O
.,O
Approximately,O
one,O
-,O
third,O
of,O
the,O
compounds,O
examined,O
exhibited,O
activity,O
against,O
both,O
maximal,O
electroshock,O
-,O
and,O
pentylenetetrazole,O
-,O
induced,O
seizures,O
in,O
mice,O
.,O
However,O
",",O
two,O
hydantoin,O
derivatives,O
",",O
5,O
and,O
8,O
",",O
were,O
totally,O
inactive,O
in,O
inhibiting,O
AlDH,O
in,O
vivo,O
.,O
Most,O
members,O
of,O
this,O
series,O
showed,O
the,O
excellent,O
antitumor,O
activity,O
against,O
murine,O
L1210,O
leukemia,O
cells,O
transplanted,O
in,O
mice,O
and,O
were,O
superior,O
to,O
cisplatin,O
and,O
carboplatin,O
.,O
This,O
study,O
should,O
be,O
applicable,O
to,O
other,O
biologically,O
active,O
peptides,O
.,O
The,O
thermal,O
Fischer,O
indolization,O
of,O
hydrazones,O
resulting,O
from,O
4,B-IUPAC
-,I-IUPAC
hydrazino,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
pyridin,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
one,I-IUPAC
and,O
various,O
beta,B-PARTIUPAC
-,I-PARTIUPAC
and,O
alpha,B-IUPAC
-,I-IUPAC
tetralones,I-IUPAC
led,O
to,O
4,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
"6,7",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
2H,I-IUPAC
",",I-IUPAC
5H,I-IUPAC
-,I-IUPAC
pyrido,I-IUPAC
[,I-IUPAC
"4,3",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
benzo,I-IUPAC
[,I-IUPAC
e,I-IUPAC
],I-IUPAC
indol,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
and,O
4,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
11,I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
2H,I-IUPAC
",",I-IUPAC
5H,I-IUPAC
-,I-IUPAC
pyrido,I-IUPAC
[,I-IUPAC
"4,3",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
benzo,I-IUPAC
[,I-IUPAC
g,I-IUPAC
],I-IUPAC
indol,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
ones,I-IUPAC
",",O
respectively,O
.,O
The,O
11,B-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
mesylate,I-IUPAC
of,O
5,O
on,O
LiAlH4,O
reduction,O
followed,O
by,O
mild,O
acid,O
treatment,O
and,O
demethylation,O
under,O
alkaline,O
conditions,O
gave,O
9,O
.,O
Fourteen,O
125I,O
-,O
labeled,O
aralkylguanidines,O
were,O
synthesized,O
and,O
evaluated,O
as,O
potential,O
imaging,O
agents,O
for,O
the,O
adrenal,O
medullae,O
and,O
tumors,O
of,O
adrenomedullary,O
origin,O
.,O
All,O
these,O
imidazole,O
nucleosides,O
were,O
tested,O
in,O
HeLa,O
cell,O
cultures,O
against,O
type,O
1,O
herpes,O
simplex,O
and,O
vesicular,O
stomatitis,O
viruses,O
.,O
Direct,O
alkylation,O
of,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
"4,6",I-IUPAC
-,I-IUPAC
dihydroxypyrimidine,I-IUPAC
afforded,O
a,O
mixture,O
of,O
2,B-PARTIUPAC
-,I-PARTIUPAC
amino,I-PARTIUPAC
-,I-PARTIUPAC
"4,6",I-PARTIUPAC
-,I-PARTIUPAC
bis,I-PARTIUPAC
[,I-PARTIUPAC
2,I-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
phosphonomethoxy,I-PARTIUPAC
),I-PARTIUPAC
ethyl,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
and,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
"1,4",I-IUPAC
-,I-IUPAC
bis,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phosphonomethoxy,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
.,O
The,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxyphenyl,I-IUPAC
),I-IUPAC
and,O
the,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxyphenyl,I-IUPAC
),I-IUPAC
isomer,B-MODIFIER
possessed,O
similar,O
potencies,O
as,O
D,O
-,O
1,O
antagonists,O
.,O
"3,4",O
-,O
Dihydro,O
-,O
2,O
(,O
1H,O
),O
-,O
quinolones,O
",",O
evolved,O
from,O
2,B-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
"1,2,3,4",I-IUPAC
",",I-IUPAC
-,I-IUPAC
tetrahydroquinolines,I-IUPAC
and,O
3,B-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
),I-IUPAC
-,I-IUPAC
quinolones,I-IUPAC
",",O
have,O
been,O
synthesized,O
and,O
evaluated,O
in,O
vitro,O
for,O
antagonist,O
activity,O
at,O
the,O
glycine,O
site,O
on,O
the,O
NMDA,O
receptor,O
and,O
for,O
AMPA,O
[,O
(,B-IUPAC
RS,I-IUPAC
),I-IUPAC
-,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
isoxazolepropionic,I-IUPAC
acid,I-IUPAC
],O
antagonist,O
activity,O
.,O
This,O
investigation,O
was,O
conducted,O
to,O
study,O
the,O
role,O
of,O
phenylalanine,O
at,O
position,O
6,O
on,O
the,O
glucagon,O
mechanism,O
of,O
action,O
.,O
Synthesis,O
of,O
new,O
analogues,O
of,O
1,O
",",O
modified,O
only,O
in,O
the,O
heterocyclic,O
moiety,O
(,O
five,O
-,O
",",O
six,O
-,O
",",O
or,O
seven,O
-,O
membered,O
rings,O
with,O
NH,O
",",O
S,O
",",O
O,O
",",O
and,O
CH2,O
substituents,O
),O
",",O
gave,O
compounds,O
varying,O
from,O
4,O
-,O
fold,O
higher,O
potency,O
(,B-IUPAC
2,I-IUPAC
-,I-IUPAC
iminothiazole,I-IUPAC
analogue,O
10,O
),O
to,O
&,O
gt,O
;,O
6000,O
-,O
fold,O
less,O
active,O
than,O
(,B-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
nicotine,I-IUPAC
.,O
The,O
sigma,O
receptor,O
binding,O
affinities,O
of,O
these,O
compounds,O
were,O
determined,O
using,O
[,B-IUPAC
3H,I-IUPAC
],I-IUPAC
(,I-IUPAC
+,I-IUPAC
),I-IUPAC
-,I-IUPAC
pentazocine,I-IUPAC
in,O
guinea,O
pig,O
brain,O
homogenates,O
.,O
The,O
effects,O
of,O
some,O
compounds,O
on,O
hexobarbital,O
sleeping,O
times,O
and,O
zoxazolamine,O
paralysis,O
times,O
in,O
mice,O
were,O
also,O
examined,O
.,O
Antagonistic,O
and,O
agonistic,O
properties,O
of,O
the,O
analogues,O
were,O
studied,O
using,O
an,O
in,O
vitro,O
functional,O
assay,O
with,O
hamster,O
tracheal,O
rings,O
.,O
The,O
compound,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
isoxazolyl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
3a,O
),O
(,O
IC,O
(,O
50,O
),O
=,O
0.11,O
microM,O
;,O
EC,O
(,O
50,O
),O
=,O
1.2,O
microM,O
),O
",",O
which,O
is,O
a,O
regioisostere,O
of,O
2,O
with,O
a,O
methoxy,O
group,O
substituted,O
for,O
the,O
methyl,B-IUPAC
group,B-MODIFIER
",",O
was,O
approximately,O
equipotent,O
with,O
2,O
(,O
IC,O
(,O
50,O
),O
=,O
0.020,O
microM,O
;,O
EC,O
(,O
50,O
),O
=,O
1.0,O
microM,O
),O
as,O
an,O
inhibitor,O
of,O
[,O
(,O
3,O
),O
H,O
],O
AMPA,O
binding,O
and,O
as,O
an,O
AMPA,O
agonist,O
",",O
respectively,O
",",O
whereas,O
the,O
corresponding,O
3,O
-,O
ethoxy,O
analogue,O
3b,O
(,O
IC,O
(,O
50,O
),O
=,O
1.0,O
microM,O
;,O
EC,O
(,O
50,O
),O
=,O
4.8,O
microM,O
),O
was,O
slightly,O
weaker,O
.,O
The,O
structural,O
basis,O
of,O
protein,O
kinase,O
C,O
(,O
PKC,O
),O
binding,O
to,O
several,O
classes,O
of,O
high,O
-,O
affinity,O
ligands,O
has,O
been,O
investigated,O
through,O
complementary,O
computational,O
and,O
experimental,O
methods,O
.,O
Further,O
modification,O
of,O
this,O
series,O
produced,O
benzoic,O
acid,O
derivative,O
(,B-IUPAC
1,I-IUPAC
",",I-IUPAC
1,I-IUPAC
-,I-IUPAC
dioxido,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
benzisothiazol,I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
(,I-IUPAC
phenylmethoxy,I-IUPAC
),I-IUPAC
carbonyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
benzoate,I-IUPAC
(,O
7n,O
),O
which,O
is,O
the,O
most,O
potent,O
inhibitor,O
identified,O
in,O
this,O
series,O
(,O
IC50,O
=,O
0.064,O
microM,O
),O
.,O
For,O
the,O
former,O
complexes,O
",",O
trans,O
isomers,O
are,O
more,O
efficacious,O
than,O
the,O
corresponding,O
cis,O
isomers,O
.,O
From,O
earlier,O
work,O
",",O
we,O
concluded,O
that,O
an,O
l,O
-,O
amino,O
acid,O
at,O
position,O
8,O
and,O
a,O
tyrosine,B-IUPAC
or,O
4,B-IUPAC
-,I-IUPAC
aminophenylalanine,I-IUPAC
substitution,B-MODIFIER
at,O
position,O
7,O
may,O
lead,O
to,O
high,O
sst,O
(,O
4,O
),O
selectivity,O
.,O
"5,10",B-IUPAC
-,I-IUPAC
Dideazaaminopterins,I-IUPAC
were,O
synthesized,O
by,O
similar,O
alkylation,O
of,O
the,O
carbanions,O
of,O
appropriate,O
4,B-PARTIUPAC
-,I-PARTIUPAC
carboxyphenylacetic,I-PARTIUPAC
",",O
(,B-PARTIUPAC
5,I-PARTIUPAC
-,I-PARTIUPAC
carboxy,I-PARTIUPAC
-,I-PARTIUPAC
2,I-PARTIUPAC
-,I-PARTIUPAC
thienyl,I-PARTIUPAC
),I-PARTIUPAC
acetic,I-PARTIUPAC
",",O
or,O
(,B-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
pyridyl,I-IUPAC
),I-IUPAC
acetic,I-IUPAC
acid,I-IUPAC
dimethyl,I-IUPAC
esters,I-IUPAC
.,O
These,O
two,O
derivatives,O
reduced,O
KA,O
and,O
ATPA,O
currents,O
to,O
a,O
larger,O
extent,O
than,O
that,O
shown,O
by,O
reference,O
compound,O
1,O
.,O
With,O
the,O
exception,O
of,O
3e,O
and,O
3f,O
",",O
which,O
have,O
no,O
substituent,O
on,O
the,O
2beta,B-IUPAC
-,I-IUPAC
(,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
isoxazole,I-IUPAC
),I-IUPAC
ring,B-MODIFIER
",",O
all,O
compounds,O
were,O
selective,O
for,O
the,O
DAT,O
relative,O
to,O
the,O
5,O
-,O
HTT,O
and,O
NET,O
.,O
Synthetic,O
procedures,O
for,O
the,O
preparation,O
of,O
various,O
3,B-MODIFIER
-,I-MODIFIER
unsubstituted,I-MODIFIER
xanthines,B-IUPAC
",",O
including,O
paraxanthine,O
analogs,O
(,O
"1,7",B-MODIFIER
-,I-MODIFIER
disubstituted,I-MODIFIER
xanthines,B-IUPAC
),O
and,O
"1,8",B-MODIFIER
-,I-MODIFIER
disubstituted,I-MODIFIER
xanthines,B-IUPAC
",",O
were,O
developed,O
.,O
In,O
the,O
first,O
part,O
of,O
the,O
paper,O
",",O
we,O
report,O
the,O
synthesis,O
of,O
mimetics,O
of,O
the,O
constrained,O
(,O
alpha,O
-,O
Me,O
),O
phosphotyrosine,O
residue,O
such,O
as,O
(,B-MODIFIER
alpha,I-MODIFIER
-,I-MODIFIER
Me,I-MODIFIER
),I-MODIFIER
-,O
4,B-IUPAC
-,I-IUPAC
phosphonomethylphenylalanine,I-IUPAC
(,O
-,O
CH2PO3H2,O
),O
",",O
(,B-MODIFIER
alpha,I-MODIFIER
-,I-MODIFIER
Me,I-MODIFIER
),I-MODIFIER
4,B-IUPAC
-,I-IUPAC
phosphonodifluoromethylphenylalanine,I-IUPAC
(,O
-,O
CF2PO3H2,O
),O
",",O
and,O
(,B-MODIFIER
alpha,I-MODIFIER
-,I-MODIFIER
Me,I-MODIFIER
),I-MODIFIER
-,O
4,B-IUPAC
-,I-IUPAC
phosphonophenylalanine,I-IUPAC
(,O
-,O
PO3H2,O
),O
.,O
A,O
series,O
of,O
"2,4",B-PARTIUPAC
-,I-PARTIUPAC
diamino,I-PARTIUPAC
-,I-PARTIUPAC
6,I-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
(,I-PARTIUPAC
aralkyl,I-PARTIUPAC
and,O
alicyclic,B-PARTIUPAC
),I-PARTIUPAC
thio,I-PARTIUPAC
-,I-PARTIUPAC
",",O
sulfinyl,B-PARTIUPAC
-,I-PARTIUPAC
",",O
and,O
sulfonyl,B-PARTIUPAC
],I-PARTIUPAC
quinazolines,I-PARTIUPAC
was,O
prepared,O
via,O
condensation,O
of,O
5,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
nitrobenzonitrile,I-IUPAC
or,O
"5,6",B-IUPAC
-,I-IUPAC
dichloro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
nitrobenzonitrile,I-IUPAC
with,O
the,O
appropriate,O
aralkyl,O
or,O
alicyclic,O
thiopseudourea,O
",",O
reduction,O
of,O
the,O
resulting,O
2,B-IUPAC
-,I-IUPAC
nitro,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
aralkyl,I-IUPAC
or,I-IUPAC
alicyclic,I-IUPAC
),I-IUPAC
thio,I-IUPAC
],I-IUPAC
benzonitrile,I-IUPAC
with,O
stannous,O
chloride,O
to,O
the,O
amine,O
",",O
and,O
cyclization,O
with,O
chloroformamidine,B-IUPAC
hydrochloride,I-IUPAC
.,O
The,O
most,O
active,O
compounds,O
are,O
2,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
methyl,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxoethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylmethoxy,I-IUPAC
),I-IUPAC
indol,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
propenoic+,I-IUPAC
+,I-IUPAC
+,I-IUPAC
acid,I-IUPAC
(,O
4g,O
),O
of,O
the,O
indolyl,O
series,O
and,O
4,B-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
methyl,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenethyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
oxoethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phenylmethoxy,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
naphthalenecarboxylic,I-IUPAC
acid,I-IUPAC
(,O
2a,O
),O
or,O
the,O
naphthyl,B-IUPAC
series,B-MODIFIER
",",O
with,O
IC50,O
of,O
8,O
and,O
4.7,O
nM,O
respectively,O
",",O
in,O
the,O
receptor,O
binding,O
assay,O
using,O
intact,O
human,O
neutrophils,O
.,O
The,O
substitution,O
of,O
an,O
n,B-IUPAC
-,I-IUPAC
propyl,I-IUPAC
group,B-MODIFIER
with,O
different,O
alkylphenyl,O
groups,O
",",O
to,O
give,O
compounds,O
18b,O
-,O
e,O
",",O
increases,O
the,O
affinity,O
for,O
the,O
D,O
-,O
2,O
subtype,O
from,O
19,O
-,O
fold,O
to,O
36,O
-,O
fold,O
.,O
Selective,O
methylation,O
of,O
the,O
phenolic,B-MODIFIER
hydroxyl,B-IUPAC
group,B-MODIFIER
of,O
to,O
give,O
1,B-IUPAC
",",I-IUPAC
6,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methylbutyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
-,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
dihydroxy,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ammoniohexanoate,I-IUPAC
(,O
15,O
),O
",",O
resulted,O
in,O
a,O
small,O
decrease,O
in,O
activity,O
.,O
gondii,O
),O
was,O
ca.,O
30,O
-,O
fold,O
higher,O
than,O
that,O
of,O
TMQ,O
or,O
PTX,O
.,O
High,O
specific,O
activity,O
[,O
(,O
123,O
),O
I,O
],O
ZIENT,O
and,O
[,O
(,O
123,O
),O
I,O
],O
EIENT,O
were,O
synthesized,O
in,O
45%,O
(,O
n,O
=,O
5,O
),O
and,O
42%,O
(,O
n,O
=,O
4,O
),O
radiochemical,O
yield,O
(,O
decay,O
-,O
corrected,O
to,O
end,O
of,O
bombardment,O
(,O
EOB,O
),O
),O
",",O
respectively,O
",",O
by,O
preparation,O
of,O
the,O
precursor,O
carbomethoxy,B-IUPAC
-,I-IUPAC
3beta,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4',I-IUPAC
-,I-IUPAC
(,I-IUPAC
(,I-IUPAC
Z,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
trimethylstannylethenyl,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
),I-IUPAC
nortropane,I-IUPAC
(,O
7,O
),O
and,O
2beta,B-IUPAC
-,I-IUPAC
carbomethoxy,I-IUPAC
-,I-IUPAC
3beta,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4',I-IUPAC
-,I-IUPAC
(,I-IUPAC
(,I-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
tributylstannylethenyl,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
),I-IUPAC
nortropane,I-IUPAC
(,O
9,O
),O
",",O
respectively,O
",",O
followed,O
by,O
treatment,O
with,O
no,O
carrier,O
-,O
added,O
sodium,O
[,O
(,O
123,O
),O
I,O
],O
iodide,O
and,O
hydrogen,O
peroxide,O
in,O
ethanolic,O
HCl,O
.,O
The,O
affinities,O
of,O
these,O
ligands,O
for,O
PK,O
-,O
C,O
were,O
assessed,O
in,O
terms,O
of,O
their,O
ability,O
to,O
displace,O
bound,O
[,B-IUPAC
3H,I-IUPAC
-,I-IUPAC
20,I-IUPAC
],I-IUPAC
phorbol,I-IUPAC
"12,13",I-IUPAC
-,I-IUPAC
dibutyrate,I-IUPAC
(,O
PDBU,O
),O
from,O
the,O
single,O
isozyme,O
PK,O
-,O
C,O
alpha,O
.,O
A,O
series,O
of,O
28,O
new,O
pyrrolo,B-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
amines,I-IUPAC
",",O
pyrimido,B-IUPAC
[,I-IUPAC
4,I-IUPAC
",",I-IUPAC
5,I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
indole,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
amines,I-IUPAC
",",O
and,O
tetrahydropyrimido,B-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
indole,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
amines,I-IUPAC
was,O
synthesized,O
and,O
their,O
adenosine,O
receptor,O
affinity,O
determined,O
in,O
radioligand,O
binding,O
assays,O
at,O
rat,O
A,O
(,O
1,O
),O
and,O
A,O
(,O
2A,O
),O
adenosine,O
receptors,O
(,O
ARs,O
),O
.,O
From,O
the,O
reaction,O
of,O
silylated,B-MODIFIER
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,3",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
triazeno,I-IUPAC
),I-IUPAC
imidazole,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
(,O
DTIC,O
",",O
5,O
),O
and,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,3",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
triazeno,I-IUPAC
),I-IUPAC
pyrazole,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
(,O
DTPC,O
",",O
9,O
),O
with,O
2,B-IUPAC
-,I-IUPAC
chlorotetrahydrofuran,I-IUPAC
",",O
we,O
have,O
isolated,O
in,O
both,O
cases,O
a,O
single,O
tetrahydrofuran,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
derivative,B-MODIFIER
.,O
This,O
inactivation,O
was,O
very,O
rapid,O
but,O
reversible,O
",",O
with,O
regeneration,O
of,O
enzyme,O
activity,O
being,O
spontaneous,O
and,O
hydrazine,O
-,O
accelerated,O
",",O
suggestive,O
of,O
the,O
intermediacy,O
of,O
a,O
stable,O
acyl,O
enzyme,O
.,O
The,O
new,O
leads,O
with,O
potent,O
H3,O
receptor,O
antagonist,O
activity,O
belong,O
to,O
a,O
series,O
of,O
derivatives,O
of,O
3,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
imidazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propanol,I-IUPAC
with,O
carbamate,O
(,O
4-7,O
),O
",",O
ester,O
(,O
8-16,O
),O
",",O
and,O
ether,O
(,O
17-22,O
),O
as,O
functional,O
groups,O
.,O
These,O
analogues,O
when,O
examined,O
for,O
suppressive,O
activity,O
against,O
drug,O
-,O
sensitive,O
lines,O
of,O
Plasmodium,O
berghei,O
in,O
mice,O
were,O
not,O
as,O
active,O
as,O
"2,4",B-IUPAC
-,I-IUPAC
diamino,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichlorobenzyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
quinazoline,I-IUPAC
(,O
Ia,O
),O
.,O
The,O
3,B-IUPAC
-,I-IUPAC
isoxazolol,I-IUPAC
amino,I-IUPAC
acid,I-IUPAC
(,B-IUPAC
RS,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methylisoxazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
AMPA,O
",",O
2,O
),O
and,O
the,O
isomeric,O
compound,O
(,B-IUPAC
RS,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methylisoxazol,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
4,B-IUPAC
-,I-IUPAC
methylhomoibotenic,I-IUPAC
acid,I-IUPAC
",",O
4a,O
),O
are,O
potent,O
agonists,O
at,O
the,O
AMPA,O
subtype,O
of,O
central,O
excitatory,O
amino,O
acid,O
receptors,O
.,O
Systematic,O
point,O
mutations,O
led,O
to,O
cyclo,O
[,O
"21,29",O
],O
[,O
D,O
-,O
Cys,O
(,O
21,O
),O
Nle,O
(,O
23,O
),O
Cys,O
(,O
29,O
),O
],O
-,O
uPA,O
(,O
21,O
),O
(,O
-,O
),O
(,O
30,O
),O
",",O
which,O
still,O
binds,O
to,O
uPAR,O
but,O
is,O
resistant,O
to,O
proteolytic,O
cleavage,O
",",O
e.g.,O
",",O
by,O
the,O
tumor,O
-,O
associated,O
serine,O
proteases,O
uPA,O
and,O
plasmin,O
",",O
and,O
is,O
stable,O
in,O
blood,O
serum,O
or,O
plasma,O
.,O
Differential,O
scanning,O
calorimetry,O
has,O
been,O
used,O
to,O
investigate,O
the,O
phase,O
behavior,O
of,O
the,O
lipid,O
bilayers,O
.,O
When,O
assayed,O
in,O
vivo,O
",",O
it,O
was,O
found,O
to,O
decrease,O
ODC,O
activity,O
by,O
60%,O
",",O
when,O
the,O
latter,O
was,O
measured,O
1,O
h,O
after,O
administration,O
.,O
One,O
compound,O
(,O
5l,O
),O
was,O
tested,O
for,O
antiproliferative,O
activity,O
against,O
P,O
.,O
The,O
derivatives,O
were,O
evaluated,O
for,O
in,O
vitro,O
cytoxicity,O
against,O
five,O
human,O
tumor,O
cell,O
lines,O
",",O
including,O
HepG2,O
",",O
TSGH,O
8302,O
",",O
COLO,O
205,O
",",O
KB,O
",",O
and,O
MOLT,O
-,O
4,O
.,O
The,O
therapeutic,O
indices,O
(,O
LD50,O
-,O
/,O
ID90,O
),O
for,O
2,O
against,O
the,O
ADJ,O
/,O
PC6,O
mouse,O
tumor,O
and,O
the,O
Walker,O
256,O
tumor,O
in,O
the,O
rat,O
were,O
28.6,O
and,O
7.7,O
",",O
respectively,O
",",O
and,O
were,O
lower,O
than,O
the,O
corresponding,O
values,O
for,O
1,O
(,O
91.8,O
and,O
33.2,O
",",O
respectively,O
),O
although,O
the,O
toxicities,O
toward,O
Walker,O
cells,O
in,O
a,O
bioassay,O
system,O
of,O
1,O
and,O
2,O
following,O
microsomal,O
metabolism,O
were,O
similar,O
.,O
Any,O
substitution,O
on,O
the,O
piperazine,O
ring,O
of,O
type,O
7,O
compounds,O
led,O
to,O
a,O
decline,O
in,O
activity,O
",",O
the,O
most,O
active,O
analog,B-MODIFIER
being,O
N,B-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
decylnipecotoyl,I-IUPAC
),I-IUPAC
piperazine,I-IUPAC
(,O
7a,O
),O
.,O
All,O
were,O
thus,O
less,O
inhibitory,O
than,O
1a,O
.,O
A,O
family,O
of,O
analogues,O
of,O
des,O
-,O
AA,O
(,O
"1,2,5",O
),O
-,O
[,O
DTrp,O
(,O
8,O
),O
/,O
D2Nal,O
(,O
8,O
),O
],O
-,O
SRIF,O
that,O
contain,O
a,O
4,B-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
isopropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
aminomethylphenylalanine,I-IUPAC
(,O
IAmp,O
),O
at,O
position,O
9,O
was,O
identified,O
that,O
has,O
high,O
affinity,O
and,O
selectivity,O
for,O
human,O
somatostatin,O
receptor,O
subtype,O
1,O
(,O
sst1,O
),O
.,O
The,O
suppressive,O
effect,O
of,O
5l,O
was,O
the,O
same,O
as,O
that,O
of,O
trimethoprim,O
(,O
10,O
microgram,O
/,O
mL,O
),O
+,O
sulfamethoxazole,O
(,O
250,O
microgram,O
/,O
mL,O
),O
",",O
a,O
standard,O
clinical,O
combination,O
for,O
the,O
treatment,O
of,O
P,O
.,O
Accordingly,O
",",O
antitumor,O
agents,O
can,O
be,O
made,O
selective,O
for,O
tumors,O
by,O
virtue,O
of,O
high,O
activity,O
under,O
hypoxic,O
conditions,O
.,O
In,O
the,O
second,O
approach,O
",",O
the,O
iodination,O
of,O
a,O
17,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
aminophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"18,19,20",I-IUPAC
-,I-IUPAC
trinorprostaglandin,I-IUPAC
F2,I-IUPAC
alpha,I-IUPAC
derivative,B-MODIFIER
delivered,O
17,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
azido,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
iodophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"18,19,20",I-IUPAC
-,I-IUPAC
trinorprostaglandin,I-IUPAC
F2,I-IUPAC
alpha,I-IUPAC
",",O
which,O
exhibited,O
competitive,O
binding,O
with,O
natural,O
[,O
3H,O
],O
PGF2,O
alpha,O
to,O
ovine,O
luteal,O
cells,O
and,O
to,O
plasma,O
membranes,O
of,O
bovine,O
corpora,O
lutea,O
.,O
The,O
results,O
obtained,O
with,O
different,O
3,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
4,B-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
sulfamoylbenzoic,I-IUPAC
acids,I-IUPAC
supported,O
the,O
earlier,O
concept,O
regarding,O
the,O
steric,O
influence,O
of,O
the,O
4,O
-,O
substituent,O
on,O
the,O
diuretic,O
potency,O
of,O
sulfamoylbenzoic,O
acid,O
diuretics,O
.,O
1-4,O
are,O
analogues,O
of,O
A,O
",",O
5-10,O
are,O
analogues,O
of,O
B,O
",",O
and,O
11-16,O
are,O
analogues,O
of,O
C,O
.,O
Their,O
pharmacological,O
activity,O
was,O
evaluated,O
in,O
a,O
water,O
lick,O
conflict,O
test,O
in,O
rats,O
and,O
a,O
passive,O
avoidance,O
test,O
in,O
mice,O
.,O
Finally,O
",",O
two,O
tripeptides,O
containing,O
O',B-IUPAC
-,I-IUPAC
(,I-IUPAC
epoxyalkyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
tryosines,I-IUPAC
were,O
synthesized,O
[,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
tert,I-IUPAC
-,I-IUPAC
butoxycarbonyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
alanyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
alanyl,I-IUPAC
-,I-IUPAC
O',I-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
epoxypropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
tyrosi,I-IUPAC
ne,I-IUPAC
ethyl,I-IUPAC
ester,I-IUPAC
and,O
N,B-IUPAC
-,I-IUPAC
(,I-IUPAC
trifluoroacetyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
valyl,I-IUPAC
-,I-IUPAC
O',I-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
epoxypropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
tyrosyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
valine,I-IUPAC
methyl,I-IUPAC
ester,I-IUPAC
],O
as,O
potential,O
elastase,O
inhibitors,O
and,O
were,O
found,O
to,O
reversibly,O
and,O
competitively,O
inhibit,O
porcine,O
pancreatic,O
elastase,O
.,O
In,O
general,O
",",O
moderate,O
affinities,O
for,O
the,O
polyamine,O
transporter,O
were,O
observed,O
for,O
the,O
N,B-IUPAC
-,I-IUPAC
arylmethyl,I-IUPAC
"4,4",I-IUPAC
-,I-IUPAC
triamine,I-IUPAC
series,B-MODIFIER
with,O
their,O
L1210,O
K,O
(,O
i,O
),O
values,O
all,O
near,O
3,O
microM,O
.,O
These,O
studies,O
suggest,O
that,O
[,O
18F,O
],O
4c,O
should,O
be,O
a,O
useful,O
compound,O
to,O
assess,O
dynamic,O
changes,O
in,O
serotonin,O
levels,O
while,O
[,O
18F,O
],O
4d,O
",",O
with,O
its,O
high,O
contrast,O
and,O
F,O
-,O
18,O
label,O
",",O
should,O
provide,O
better,O
statistics,O
and,O
quantification,O
for,O
static,O
measurement,O
of,O
5,O
-,O
HT1A,O
receptor,O
distribution,O
.,O
Compound,O
139,O
",",O
"3,4",B-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
fluorophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,2,4",I-IUPAC
-,I-IUPAC
oxadiazol,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
phthalazineacetic,I-IUPAC
acid,I-IUPAC
",",O
with,O
IC50,O
less,O
than,O
1.0,O
x,O
10,O
(,O
-,O
8,O
),O
M,O
",",O
caused,O
a,O
69%,O
reduction,O
in,O
sorbitol,O
accumulation,O
in,O
rat,O
sciatic,O
nerve,O
at,O
an,O
oral,O
dose,O
of,O
25,O
mg,O
/,O
kg,O
.,O
Two,O
chemical,O
series,O
derived,O
from,O
the,O
general,O
structures,O
6,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
tertioalkylphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
naphthoic,I-IUPAC
acid,I-IUPAC
(,O
series,O
I,O
),O
and,O
4,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
E,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
tertioalkylphenyl,I-IUPAC
),I-IUPAC
propenyl,I-IUPAC
],I-IUPAC
benzoic,I-IUPAC
acid,I-IUPAC
(,O
series,O
II,O
),O
were,O
developed,O
.,O
All,O
members,O
of,O
the,O
series,O
were,O
designed,O
to,O
have,O
a,O
"1,3",O
-,O
dioxolane,O
ring,O
moiety,O
in,O
their,O
carrier,O
ligands,O
to,O
increase,O
water,O
solubility,O
.,O
The,O
selectivity,O
index,O
(,O
SI,O
),O
of,O
each,O
compound,O
was,O
obtained,O
by,O
dividing,O
its,O
50%,O
inhibitory,O
concentration,O
(,O
IC,O
(,O
50,O
),O
),O
against,O
Pc,O
",",O
Tg,O
",",O
or,O
Ma,O
DHFR,O
by,O
its,O
IC,O
(,O
50,O
),O
against,O
rat,O
DHFR,O
.,O
The,O
stereochemistry,O
of,O
a,O
hydroxy,O
group,O
at,O
C,O
-,O
4,O
of,O
compound,O
25,O
and,O
that,O
at,O
C,O
-,O
6,O
of,O
compounds,O
36,O
and,O
37,O
were,O
determined,O
on,O
the,O
basis,O
of,O
(,O
1,O
),O
H,O
NMR,O
spectroscopy,O
in,O
each,O
case,O
.,O
avium,O
DHFR,O
relative,O
to,O
rat,O
DHFR,O
.,O
All,O
S,O
enantiomers,O
were,O
less,O
potent,O
than,O
the,O
R,O
ones,O
.,O
3',B-IUPAC
-,I-IUPAC
C,I-IUPAC
-,I-IUPAC
Methyl,I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyluridine,I-IUPAC
did,O
not,O
suppress,O
HIV,O
-,O
1,O
replication,O
in,O
MT,O
-,O
4,O
cells,O
at,O
500,O
microM,O
while,O
its,O
5',B-IUPAC
-,I-IUPAC
phosphite,I-IUPAC
derivative,B-MODIFIER
exhibited,O
modest,O
anti,O
-,O
HIV,O
-,O
1,O
activity,O
.,O
The,O
epimers,O
(,O
-,O
),O
-,O
3,O
and,O
(,O
+,O
),O
-,O
4,O
proved,O
to,O
be,O
agonists,O
at,O
the,O
5,O
-,O
HT,O
(,O
1A,O
),O
receptors,O
",",O
with,O
a,O
potency,O
comparable,O
to,O
that,O
of,O
5,B-IUPAC
-,I-IUPAC
hydroxytryptamine,I-IUPAC
.,O
(,B-IUPAC
m,I-IUPAC
-,I-IUPAC
[,I-IUPAC
125I,I-IUPAC
],I-IUPAC
Iodobenzyl,I-IUPAC
),I-IUPAC
guanidine,I-IUPAC
(,O
m,O
-,O
IBG,O
",",O
2b,O
),O
gave,O
the,O
best,O
combination,O
of,O
high,O
concentration,O
and,O
selectivity,O
.,O
Inhibitory,O
activity,O
of,O
cytosine,O
derivative,O
9c,O
is,O
reversed,O
with,O
uridine,O
and,O
2',B-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
but,O
not,O
with,O
the,O
corresponding,O
cytosine,O
nucleosides,O
.,O
The,O
in,O
vitro,O
screening,O
for,O
trypanocidal,O
activity,O
against,O
Trypanosoma,O
brucei,O
rhodesiense,O
of,O
an,O
in,O
-,O
house,O
library,O
of,O
62,O
compounds,O
[,O
i.e.,O
alkane,O
",",O
diphenyl,O
",",O
and,O
azaalkane,O
bisguanidines,O
and,O
bis,B-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
aminoimidazolines,I-IUPAC
),I-IUPAC
],O
",",O
which,O
were,O
chosen,O
for,O
their,O
structural,O
similarity,O
to,O
the,O
trypanocidal,O
agents,O
synthalin,O
(,O
"1,10",B-IUPAC
-,I-IUPAC
decanediguanidine,I-IUPAC
),O
and,O
"4,4",B-IUPAC
',I-IUPAC
-,I-IUPAC
diguanidinodiphenylmethane,I-IUPAC
and,O
the,O
polyamine,B-IUPAC
N,I-IUPAC
(,I-IUPAC
1,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
propyl,I-IUPAC
),I-IUPAC
propane,I-IUPAC
-,I-IUPAC
"1,3",I-IUPAC
-,I-IUPAC
diamine,I-IUPAC
",",O
respectively,O
",",O
is,O
reported,O
.,O
Sonicated,O
solutions,O
of,O
the,O
conjugates,O
existed,O
in,O
the,O
form,O
of,O
micellar,O
disks,O
(,O
size,O
0.01-0.04,O
microns,O
),O
.,O
(,O
S,O
),O
-,O
11a,O
was,O
evaluated,O
as,O
a,O
substrate,O
for,O
P815,O
tryptophan,O
hydroxylase,O
and,O
determined,O
to,O
have,O
an,O
apparent,O
Km,O
of,O
4.31,O
+,O
/,O
-,O
1.07,O
mM,O
",",O
essentially,O
half,O
the,O
value,O
previously,O
reported,O
for,O
the,O
racemic,O
mixture,O
of,O
11a,O
with,O
rat,O
brain,O
stem,O
tryptophan,O
hydroxylase,O
.,O
These,O
structure,O
-,O
affinity,O
findings,O
were,O
exploited,O
to,O
produce,O
nicotinamides,O
(,O
e.g.,O
13ii,O
and,O
25x,O
),O
and,O
pyrazolo,B-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
pyridines,I-IUPAC
(,O
e.g.,O
37f,O
and,O
37y,O
),O
ligands,O
with,O
nanomolar,O
affinity,O
at,O
the,O
alpha,O
1,O
-,O
AR,O
subtype,O
prevalent,O
in,O
the,O
human,O
lower,O
urinary,O
tract,O
(,O
pA2,O
values,O
:,O
8.8,O
",",O
10.7,O
",",O
9.3,O
",",O
and,O
9.9,O
",",O
respectively,O
),O
and,O
displaying,O
2-3,O
orders,O
of,O
magnitude,O
selectivity,O
over,O
the,O
alpha,O
1D,O
-,O
AR,O
.,O
Condensation,O
of,O
3,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
bromomethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
pyrazinecarbonitrile,I-IUPAC
4,I-IUPAC
-,I-IUPAC
oxide,I-IUPAC
(,O
V,O
),O
with,O
the,O
appropriately,O
substituted,O
amine,O
afforded,O
a,O
series,O
of,O
3,B-PARTIUPAC
-,I-PARTIUPAC
amino,I-PARTIUPAC
-,I-PARTIUPAC
6,I-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
[,I-PARTIUPAC
(,I-PARTIUPAC
aryl,I-PARTIUPAC
and,O
aralkyl,B-PARTIUPAC
),I-PARTIUPAC
amino,I-PARTIUPAC
],I-PARTIUPAC
methyl,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
2,I-PARTIUPAC
-,I-PARTIUPAC
pyrazinecarbonitrile,I-PARTIUPAC
4,I-PARTIUPAC
-,I-PARTIUPAC
oxides,I-PARTIUPAC
VI,O
.,O
Bioassay,O
results,O
from,O
guinea,O
pig,O
ileum,O
and,O
mouse,O
vas,O
deferens,O
preparations,O
are,O
in,O
general,O
agreement,O
with,O
the,O
binding,O
results,O
;,O
however,O
some,O
potency,O
discrepancies,O
are,O
observed,O
.,O
The,O
first,O
involved,O
substitution,O
of,O
the,O
N1,O
-,O
position,O
while,O
the,O
second,O
involved,O
substitution,O
of,O
the,O
N5,O
-,O
position,O
.,O
Extensive,O
evidence,O
gathered,O
from,O
structure,O
-,O
activity,O
relationship,O
analysis,O
has,O
identified,O
and,O
confirmed,O
specific,O
positions,O
in,O
the,O
glucagon,O
sequence,O
that,O
are,O
important,O
either,O
for,O
binding,O
to,O
its,O
receptor,O
or,O
for,O
signal,O
transduction,O
.,O
Consistent,O
with,O
earlier,O
results,O
with,O
polyamine,O
analogues,O
",",O
these,O
studies,O
underscore,O
the,O
importance,O
of,O
charge,O
in,O
the,O
design,O
of,O
polyamine,O
-,O
vectored,O
chelators,O
.,O
coli,O
thymidine,O
kinase,O
(,O
TK,O
),O
",",O
and,O
of,O
yeast,O
hexokinase,O
(,O
HK,O
),O
and,O
rat,O
KH,O
I,O
",",O
II,O
",",O
and,O
III,O
isozymes,O
.,O
The,O
high,O
acidity,O
of,O
HOPO,O
ligands,O
and,O
the,O
much,O
lower,O
acidity,O
of,O
catechol,O
(,O
CAM,O
),O
ligands,O
suggested,O
that,O
mixed,O
octadentate,O
(,O
CAM,O
-,O
HOPO,O
),O
ligands,O
containing,O
one,O
or,O
two,O
"1,2",O
-,O
HOPO,O
and,O
three,O
(,O
or,O
two,O
),O
catechol,O
(,O
CAM,O
),O
groups,O
might,O
be,O
as,O
effective,O
for,O
Pu,O
removal,O
[,O
fully,O
eight,O
-,O
coordinated,O
Pu,O
(,O
IV,O
),O
complexes,O
formed,O
at,O
pH,O
&,O
gt,O
;,O
or,O
=,O
6,O
],O
and,O
less,O
toxic,O
than,O
"3,4,3",O
-,O
LIHOPO,O
.,O
Reducing,O
the,O
long,O
acyl,O
chain,O
to,O
an,O
acetyl,O
moiety,O
and,O
attaching,O
a,O
compensating,O
lipophilic,O
chain,O
to,O
the,O
lactone,O
ring,O
as,O
an,O
alpha,B-IUPAC
-,I-IUPAC
alkylidene,I-IUPAC
moiety,B-MODIFIER
produced,O
compounds,O
10e,O
and,O
10f,O
(,O
Z,O
-,O
isomers,O
),O
and,O
11e,O
and,O
11f,O
(,O
E,O
-,O
isomers,O
),O
",",O
which,O
were,O
constructed,O
on,O
the,O
more,O
effective,O
"5,5",B-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
hydroxymethyl,I-IUPAC
),I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
furanone,I-IUPAC
template,O
.,O
Ligands,O
[,O
(,O
11,O
),O
C,O
],O
3,O
",",O
[,O
(,O
11,O
),O
C,O
],O
7,O
",",O
and,O
[,O
(,O
11,O
),O
C,O
],O
8,O
were,O
synthesized,O
by,O
alkylation,O
of,O
phenol,O
precursor,O
9,O
with,O
2,B-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
11,I-IUPAC
),I-IUPAC
C,I-IUPAC
],I-IUPAC
iodopropane,I-IUPAC
(,O
[,O
(,O
11,O
),O
C,O
],O
10,O
),O
",",O
[,B-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
11,I-IUPAC
),I-IUPAC
C,I-IUPAC
],I-IUPAC
iodoethane,I-IUPAC
(,O
[,O
(,O
11,O
),O
C,O
],O
11,O
),O
",",O
and,O
[,B-IUPAC
(,I-IUPAC
11,I-IUPAC
),I-IUPAC
C,I-IUPAC
],I-IUPAC
iodomethane,I-IUPAC
(,O
[,O
(,O
11,O
),O
C,O
],O
12,O
),O
",",O
respectively,O
.,O
Bromomethyl,O
intermediate,O
15,O
was,O
prepared,O
from,O
the,O
corresponding,O
hydroxymethyl,B-IUPAC
precursor,B-MODIFIER
14,O
by,O
treatment,O
with,O
48%,O
HBr,O
.,O
Generally,O
",",O
the,O
(,O
R,O
),O
-,O
enantiomers,O
displayed,O
higher,O
affinity,O
for,O
the,O
5,O
-,O
HT1A,O
receptor,O
than,O
the,O
corresponding,O
(,O
S,O
),O
-,O
enantiomers,O
.,O
For,O
the,O
preparation,O
of,O
the,O
iodine,O
-,O
125,O
-,O
labeled,O
benzamide,O
with,O
higher,O
specific,O
activity,O
",",O
this,O
method,O
was,O
unsuccessful,O
and,O
utilization,O
of,O
the,O
corresponding,O
tri,B-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
butyltin,I-IUPAC
derivative,B-MODIFIER
was,O
required,O
.,O
The,O
thione,O
11,O
rearranges,O
to,O
N,B-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
ribofuranosyl,I-IUPAC
[,I-IUPAC
"1,2,3",I-IUPAC
],I-IUPAC
thiadiazolo,I-IUPAC
[,I-IUPAC
"5,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidin,I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
amine,I-IUPAC
(,O
14,O
),O
in,O
the,O
solid,O
state,O
or,O
in,O
solution,O
.,O
More,O
detailed,O
biological,O
studies,O
conducted,O
with,O
the,O
most,O
potent,O
inhibitor,O
NU7163,O
(,O
48,O
;,O
IC,O
(,O
50,O
),O
=,O
0.19,O
microM,O
),O
demonstrated,O
ATP,O
-,O
competitive,O
DNA,O
-,O
PK,O
inhibition,O
",",O
with,O
a,O
K,O
(,O
i,O
),O
value,O
of,O
24,O
nM,O
",",O
and,O
48,O
exhibited,O
selectivity,O
for,O
DNA,O
-,O
PK,O
compared,O
with,O
the,O
related,O
enzymes,O
ATM,O
",",O
ATR,O
",",O
mTOR,O
",",O
and,O
PI,O
3,O
-,O
K,O
(,O
p110alpha,O
),O
.,O
The,O
absolute,O
stereochemical,O
requirements,O
for,O
binding,O
were,O
found,O
to,O
be,O
2S,O
",",O
4R,O
",",O
showing,O
that,O
",",O
in,O
common,O
with,O
other,O
glycine,O
-,O
site,O
NMDA,O
receptor,O
ligands,O
",",O
the,O
unnatural,O
configuration,O
at,O
the,O
alpha,O
-,O
amino,O
acid,O
center,O
is,O
required,O
.,O
Their,O
anti,O
-,O
V1,O
pA2,O
values,O
range,O
from,O
7.92,O
to,O
8.45,O
.,O
These,O
results,O
are,O
in,O
agreement,O
with,O
other,O
studies,O
suggesting,O
the,O
presence,O
of,O
a,O
lipophilic,O
pocket,O
in,O
the,O
AR,O
binding,O
site,O
that,O
is,O
filled,O
by,O
moderately,O
sized,O
cycloalkyl,O
rings,O
at,O
the,O
N,O
(,O
6,O
),O
position,O
of,O
both,O
adenine,O
and,O
adenosine,O
derivatives,O
.,O
The,O
most,O
active,O
and,O
selective,O
compound,O
we,O
found,O
in,O
the,O
present,O
series,O
is,O
compound,O
8b,O
[,O
(,B-IUPAC
1S,I-IUPAC
",",I-IUPAC
3R,I-IUPAC
",",I-IUPAC
6S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
acetoxymethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
Z,I-IUPAC
),I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
",",I-IUPAC
4,I-IUPAC
-,I-IUPAC
dichlorophenylmethylene,I-IUPAC
),I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
azatricyclo,I-IUPAC
[,I-IUPAC
4.3.1.0,I-IUPAC
(,I-IUPAC
"3,7",I-IUPAC
),I-IUPAC
],I-IUPAC
decane,I-IUPAC
],O
.,O
In,O
this,O
cisplatin,O
-,O
sensitive,O
cell,O
line,O
the,O
complexes,O
containing,O
cyclohexane,B-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
diamine,I-IUPAC
(,O
chxn,O
),O
displayed,O
a,O
high,O
activity,O
in,O
comparison,O
to,O
the,O
diammine,B-IUPAC
and,O
ethane,B-IUPAC
-,I-IUPAC
"1,2",I-IUPAC
-,I-IUPAC
diamine,I-IUPAC
counterparts,O
.,O
These,O
analogues,O
are,O
1,O
",",O
d,O
-,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Ile4AVP,O
;,O
2,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Abu4AVP,O
;,O
3,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Thr4AVP,O
;,O
4,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Ala4AVP,O
;,O
5,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2AVP,O
;,O
6,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Lys4AVP,O
;,O
7,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Cha4AVP,O
;,O
8,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Nle4AVP,O
;,O
9,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Nva4AVP,O
;,O
10,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Phe4AVP,O
;,O
11,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Leu4AVP,O
;,O
12,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Gly4AVP,O
;,O
13,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Tyr4AVP,O
;,O
14,O
",",O
d,O
(,O
CH2,O
),O
5,O
-,O
D,O
-,O
Phe2,O
",",O
Pro4AVP,O
.,O
Careful,O
analysis,O
of,O
the,O
NMR,O
structures,O
of,O
cyclo,O
(,O
4-10,O
),O
[,O
Ac,O
-,O
Delta,O
(,O
3,O
),O
Pro,O
(,O
1,O
),O
",",O
DFpa,O
(,O
2,O
),O
",",O
DTrp,O
(,O
3,O
),O
",",O
Asp,O
(,O
4,O
),O
",",O
DNal,O
(,O
6,O
),O
",",O
Dpr,O
(,O
10,O
),O
],O
GnRH,O
",",O
dicyclo,O
(,O
4-10/5-8,O
),O
[,O
Ac,O
-,O
DNal,O
(,O
1,O
),O
",",O
DCpa,O
(,O
2,O
),O
",",O
DTrp,O
(,O
3,O
),O
",",O
Asp,O
(,O
4,O
),O
",",O
Glu,O
(,O
5,O
),O
",",O
DArg,O
(,O
6,O
),O
",",O
Lys,O
(,O
8,O
),O
",",O
Dpr,O
(,O
10,O
),O
],O
GnRH,O
",",O
and,O
dicyclo,O
(,O
4-10/5,O
",",O
5',O
-,O
8,O
),O
[,O
Ac,O
-,O
DNal,O
(,O
1,O
),O
",",O
DCpa,O
(,O
2,O
),O
",",O
DPal,O
(,O
3,O
),O
",",O
Asp,O
(,O
4,O
),O
",",O
Glu,O
(,O
5,O
),O
(,O
Gly,O
),O
",",O
DArg,O
(,O
6,O
),O
",",O
Dbu,O
(,O
8,O
),O
",",O
Dpr,O
(,O
10,O
),O
],O
GnRH,O
showed,O
that,O
",",O
in,O
the,O
N,O
-,O
terminal,O
tripeptide,O
",",O
a,O
type,O
II,O
beta,O
-,O
turn,O
around,O
residues,O
1,O
and,O
2,O
was,O
probable,O
along,O
with,O
a,O
gamma,O
-,O
turn,O
around,O
DTrp,O
(,O
3,O
),O
/,O
DPal,O
(,O
3,O
),O
.,O
The,O
sodium,O
salt,O
of,O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
cyanopyrazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
(,O
1,O
),O
was,O
condensed,O
with,O
(,B-IUPAC
2,I-IUPAC
-,I-IUPAC
acetoxyethoxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
bromide,I-IUPAC
(,O
2,O
),O
to,O
provide,O
the,O
corresponding,O
protected,O
acyclic,O
nucleoside,O
",",O
4,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
cyano,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
acetoxyethoxy,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
pyrazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimid,I-IUPAC
ine,I-IUPAC
(,O
3,O
),O
.,O
Similar,O
relative,O
orders,O
of,O
potencies,O
are,O
also,O
found,O
in,O
the,O
other,O
two,O
bioassays,O
.,O
"6,7",B-IUPAC
-,I-IUPAC
Dihydro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
4H,I-IUPAC
",",I-IUPAC
5H,I-IUPAC
-,I-IUPAC
cyclopenta,I-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
],I-IUPAC
thieno,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,3",I-IUPAC
],I-IUPAC
oxazin,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
33,O
),O
exhibited,O
a,O
K,O
(,O
i,O
),O
value,O
of,O
630,O
nM,O
and,O
excelled,O
in,O
its,O
low,O
susceptibility,O
to,O
CEase,O
-,O
catalyzed,O
degradation,O
.,O
In,O
addition,O
",",O
2a,O
possesses,O
a,O
carbomethoxy,O
substituent,O
adjacent,O
to,O
the,O
aryl,O
ring,O
",",O
whereas,O
(,O
3S,O
",",O
4R,O
),O
-,O
3,O
contains,O
a,O
[,B-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
(,I-IUPAC
methylenedioxy,I-IUPAC
),I-IUPAC
phenoxy,I-IUPAC
],I-IUPAC
methyl,I-IUPAC
group,B-MODIFIER
.,O
Other,O
compounds,O
in,O
this,O
series,O
showed,O
moderate,O
activities,O
(,O
IC50,O
&,O
gt,O
;,O
100,O
nM,O
),O
on,O
the,O
type,O
II,O
enzyme,O
.,O
Changing,O
the,O
2',B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
group,B-MODIFIER
of,O
(,O
+,O
),O
-,O
1f,O
to,O
an,O
H,O
",",O
F,O
",",O
Cl,O
",",O
Br,O
",",O
I,O
",",O
NHAc,O
",",O
or,O
NHSO2CH3,O
resulted,O
in,O
a,O
5,O
-,O
fold,O
or,O
greater,O
loss,O
in,O
potency,O
.,O
carinii,O
trophozoites,O
in,O
culture,O
at,O
a,O
concentration,O
of,O
10,O
microgram,O
/,O
mL,O
and,O
was,O
found,O
to,O
completely,O
suppress,O
growth,O
over,O
7,O
days,O
.,O
The,O
brominated,O
primary,O
amines,O
4c,O
",",O
d,O
were,O
assayed,O
initially,O
for,O
activity,O
in,O
the,O
two,O
-,O
lever,O
drug,O
discrimination,O
(,O
DD,O
),O
paradigm,O
in,O
rats,O
trained,O
to,O
discriminate,O
saline,O
from,O
LSD,O
tartrate,O
(,O
0,O
.,O
The,O
aim,O
of,O
the,O
current,O
study,O
concerns,O
the,O
synthesis,O
of,O
amantidine,O
analogues,O
by,O
appending,O
primary,O
amines,O
to,O
1,B-IUPAC
-,I-IUPAC
boraadamantane,I-IUPAC
to,O
evaluate,O
such,O
compounds,O
for,O
CD81,O
-,O
dependent,O
antiproliferation,O
of,O
CD81,O
-,O
enriched,O
cell,O
lines,O
(,O
astrocyte,O
),O
vs,O
CD81,O
-,O
deficient,O
cell,O
lines,O
(,O
C6,O
glioma,O
),O
.,O
Two,O
3,B-IUPAC
-,I-IUPAC
carboxythiophene,I-IUPAC
3,I-IUPAC
-,I-IUPAC
trifluoromethylbenzyl,I-IUPAC
esters,I-IUPAC
",",O
3d,O
(,O
49%,O
),O
and,O
3f,O
(,O
63%,O
),O
",",O
had,O
substantial,O
AE,O
activity,O
.,O
Affinity,O
labeling,O
was,O
directly,O
demonstrated,O
by,O
ethanol,O
-,O
resistant,O
binding,O
of,O
[,B-IUPAC
3H,I-IUPAC
],I-IUPAC
[,I-IUPAC
(,I-IUPAC
iodoacetamido,I-IUPAC
),I-IUPAC
propyl,I-IUPAC
],I-IUPAC
estradiol,I-IUPAC
to,O
the,O
receptor,O
.,O
Further,O
",",O
selected,O
analogues,O
were,O
potent,O
inhibitors,O
of,O
the,O
growth,O
of,O
tumor,O
cells,O
in,O
culture,O
in,O
the,O
in,O
vitro,O
screening,O
program,O
of,O
the,O
National,O
Cancer,O
Institute,O
with,O
GI50s,O
in,O
the,O
nanomolar,O
and,O
subnanomolar,O
range,O
.,O
Compounds,O
having,O
an,O
i,O
-,O
Pr,O
ester,O
substituent,O
acted,O
as,O
dual,O
cardioselective,O
calcium,O
channel,O
agonists,O
(,O
GPLA,O
),O
/,O
smooth,O
muscle,O
-,O
selective,O
calcium,O
channel,O
antagonists,O
(,O
GPILSM,O
),O
",",O
except,O
for,O
the,O
C,O
-,O
4,O
3,B-IUPAC
-,I-IUPAC
nitro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
pyridyl,I-IUPAC
compound,B-MODIFIER
which,O
exhibited,O
an,O
antagonist,O
effect,O
on,O
both,O
GPLA,O
and,O
GPILSM,O
.,O
Ep,O
.,O
These,O
results,O
indicate,O
that,O
this,O
non,O
-,O
amino,O
acid,O
structure,O
of,O
inhibitors,O
meets,O
the,O
ACE,O
active,O
site,O
requirements,O
for,O
the,O
binding,O
.,O
The,O
optimal,O
ratios,O
of,O
Me3Si,O
-,O
FU,O
",",O
Thf,O
-,O
OAc,O
",",O
and,O
SnCl4,O
or,O
NaI,O
for,O
preparation,O
of,O
Thf,O
-,O
FU,O
and,O
Thf2,O
-,O
FU,O
were,O
determined,O
.,O
Among,O
the,O
thymine,O
",",O
uracil,O
",",O
and,O
5,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
uracil,B-IUPAC
derivatives,B-MODIFIER
",",O
thymine,O
(,O
alpha,O
-,O
isomer,O
),O
and,O
uracil,O
(,O
beta,O
-,O
isomer,O
),O
derivatives,O
exhibited,O
moderate,O
anti,O
-,O
HIV,O
activity,O
.,O
This,O
report,O
focuses,O
on,O
the,O
synthesis,O
and,O
structure,O
-,O
activity,O
relationships,O
of,O
these,O
compounds,O
.,O
Several,O
compounds,O
display,O
high,O
affinity,O
to,O
serotonin,O
5,O
-,O
HT1A,O
receptors,O
in,O
spite,O
of,O
major,O
differences,O
in,O
steric,O
bulk,O
and,O
electronic,O
properties,O
of,O
the,O
various,O
C11,O
-,O
substituents,O
.,O
However,O
",",O
like,O
4c,O
",",O
e,O
",",O
4d,O
did,O
not,O
significantly,O
affect,O
the,O
binding,O
of,O
the,O
competitive,O
NMDA,O
antagonist,O
",",O
[,O
3H,O
],O
CPP,O
",",O
or,O
the,O
noncompetitive,O
NMDA,O
antagonist,O
",",O
[,O
3H,O
],O
MK,O
-,O
801,O
.,O
From,O
these,O
studies,O
",",O
an,O
initial,O
rate,O
constant,O
",",O
Ki,O
",",O
for,O
7d,O
and,O
7n,O
was,O
found,O
to,O
be,O
345,O
and,O
465,O
nM,O
",",O
respectively,O
.,O
Analogues,O
22,O
and,O
23,O
were,O
also,O
more,O
potent,O
than,O
astressin,O
at,O
reversing,O
intracisternal,O
CRF,O
-,O
and,O
abdominal,O
surgery,O
-,O
induced,O
delay,O
of,O
gastric,O
emptying,O
in,O
conscious,O
rats,O
.,O
The,O
most,O
active,O
compounds,O
are,O
the,O
alkyl,O
derivatives,O
of,O
the,O
2,B-IUPAC
-,I-IUPAC
mesitylamino,I-IUPAC
/,O
2,B-IUPAC
-,I-IUPAC
mesitylimino,I-IUPAC
tautomeric,B-MODIFIER
forms,I-MODIFIER
.,O
Optimization,O
of,O
the,O
activity,O
in,O
this,O
series,O
resulted,O
in,O
the,O
development,O
of,O
5,B-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
pyrido,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
pyridine,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
benzylcarboxamides,I-IUPAC
(,O
30,O
),O
which,O
are,O
highly,O
potent,O
orally,O
active,O
NK1,O
antagonists,O
.,O
Previous,O
correlation,O
of,O
fluorescence,O
and,O
NMR,O
data,O
suggested,O
that,O
the,O
11R,O
",",O
11aS,O
and,O
the,O
11S,O
",",O
11aS,O
diastereomers,O
of,O
tomaymycin,O
could,O
bind,O
to,O
DNA,O
in,O
two,O
orientations,O
relative,O
to,O
the,O
covalently,O
modified,O
guanine,O
(,O
Barkley,O
",",O
M,O
.,O
7,B-IUPAC
-,I-IUPAC
Benzyl,I-IUPAC
-,I-IUPAC
"5,6,7,8",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dimethoxybenzyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
methylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
4H,I-IUPAC
-,I-IUPAC
pyrido,I-IUPAC
[,I-IUPAC
4',I-IUPAC
",",I-IUPAC
3',I-IUPAC
:,I-IUPAC
"4,5",I-IUPAC
],I-IUPAC
thieno,I-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,3",I-IUPAC
],I-IUPAC
oxazin,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
21,O
),O
had,O
the,O
IC,O
(,O
50,O
),O
value,O
of,O
330,O
nM,O
for,O
AChE,O
inhibition,O
.,O
All,O
of,O
the,O
analogues,O
are,O
weak,O
agonists,O
at,O
the,O
A1,O
receptor,O
",",O
requiring,O
concentrations,O
greater,O
than,O
9,O
microM,O
to,O
cause,O
second,O
degree,O
heart,O
block,O
.,O
The,O
products,O
were,O
tested,O
for,O
in,O
vivo,O
antitumor,O
activity,O
against,O
L1210,O
leukemia,O
in,O
mice,O
to,O
test,O
whether,O
all,O
MTX,O
and,O
DCM,O
diesters,O
are,O
therapeutically,O
equivalent,O
in,O
this,O
species,O
.,O
The,O
diphenylmethyl,O
moiety,O
functioned,O
as,O
an,O
effective,O
isostere,O
for,O
"4,5",O
-,O
diphenylated,O
heterocycles,O
since,O
13aad,O
showed,O
similar,O
platelet,O
inhibitory,O
activity,O
to,O
3,O
.,O
In,O
comparison,O
to,O
N,B-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
diethyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
aza,I-IUPAC
-,I-IUPAC
5,I-IUPAC
alpha,I-IUPAC
-,I-IUPAC
androstane,I-IUPAC
-,I-IUPAC
17,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
(,O
4,O
-,O
MA,O
;,O
IC50,O
=,O
4.15,O
nM,O
),O
",",O
17,B-IUPAC
beta,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
alkylformamido,I-IUPAC
),I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
azasteroids,I-IUPAC
were,O
potent,O
inhibitors,O
of,O
human,O
type,O
I,O
5,O
alpha,O
-,O
reductase,O
",",O
IC50,O
values,O
of,O
compounds,O
29,O
",",O
30,O
",",O
36,O
",",O
and,O
37,O
being,O
measured,O
as,O
3.05,O
",",O
0.91,O
",",O
2.19,O
",",O
and,O
2.35,O
nM,O
",",O
respectively,O
.,O
In,O
addition,O
",",O
it,O
was,O
significantly,O
inhibitory,O
for,O
thymidine,O
kinase,O
deficient,O
strain,O
of,O
HSV,O
-,O
1,O
(,O
EC,O
(,O
50,O
),O
=,O
2.3-15.3,O
microM,O
),O
.,O
The,O
N,B-MODIFIER
-,I-MODIFIER
6,I-MODIFIER
glycosylated,I-MODIFIER
imidazo,B-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
isothiazoles,I-IUPAC
also,O
were,O
inactive,O
in,O
antiproliferative,O
and,O
cytotoxicity,O
assays,O
",",O
except,O
for,O
3,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
ribofuranosylimidazo,I-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
isothiazole,I-IUPAC
(,O
15a,O
),O
and,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
benzylthio,I-IUPAC
),I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
deoxy,I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
D,I-IUPAC
-,I-IUPAC
ribofuranosyl,I-IUPAC
),I-IUPAC
imidazo,I-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
isothiaz,I-IUPAC
ole,I-IUPAC
(,O
5e,O
),O
",",O
which,O
showed,O
moderate,O
inhibition,O
of,O
L1210,O
cell,O
growth,O
.,O
avium,O
DHFR,O
",",O
and,O
55,O
nM,O
against,O
rat,O
DHFR,O
.,O
Thiazolo,B-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
pyridin,I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
-,I-IUPAC
ones,I-IUPAC
35,O
were,O
prepared,O
from,O
6,B-IUPAC
-,I-IUPAC
bromo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
',I-IUPAC
-,I-IUPAC
bipyridin,I-IUPAC
],I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
amines,I-IUPAC
30,O
and,O
32,O
via,O
a,O
four,O
-,O
step,O
sequence,O
.,O
Stannic,O
chloride,O
catalyzed,O
condensation,O
of,O
the,O
pertrimethylsilyl,O
derivatives,O
of,O
4b,O
and,O
4c,O
with,O
a,O
protected,O
glycosyl,O
halide,O
afforded,O
anomeric,O
mixtures,O
of,O
ketonucleosides,O
3,B-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
2,I-PARTIUPAC
-,I-PARTIUPAC
deoxy,I-PARTIUPAC
-,I-PARTIUPAC
"3,5",I-PARTIUPAC
-,I-PARTIUPAC
di,I-PARTIUPAC
-,I-PARTIUPAC
O,I-PARTIUPAC
-,I-PARTIUPAC
p,I-PARTIUPAC
-,I-PARTIUPAC
toluoyl,I-PARTIUPAC
-,I-PARTIUPAC
beta,I-PARTIUPAC
-,I-PARTIUPAC
and,O
-,B-PARTIUPAC
alpha,I-PARTIUPAC
-,I-PARTIUPAC
D,I-PARTIUPAC
-,I-PARTIUPAC
erythro,I-PARTIUPAC
-,I-PARTIUPAC
pentofuranosyl,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
"6,7",I-PARTIUPAC
-,I-PARTIUPAC
dihydro,I-PARTIUPAC
-,I-PARTIUPAC
5,I-PARTIUPAC
-,I-PARTIUPAC
methylimidazo,I-PARTIUPAC
[,I-PARTIUPAC
"4,5",I-PARTIUPAC
-,I-PARTIUPAC
d,I-PARTIUPAC
],I-PARTIUPAC
[,I-PARTIUPAC
"1,3",I-PARTIUPAC
],I-PARTIUPAC
diazepin,I-PARTIUPAC
-,I-PARTIUPAC
8,I-PARTIUPAC
(,I-PARTIUPAC
3H,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
one,I-PARTIUPAC
(,O
5b,O
and,O
6b,O
),O
and,O
3,B-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
2,I-PARTIUPAC
-,I-PARTIUPAC
deoxy,I-PARTIUPAC
-,I-PARTIUPAC
"3,5",I-PARTIUPAC
-,I-PARTIUPAC
di,I-PARTIUPAC
-,I-PARTIUPAC
O,I-PARTIUPAC
-,I-PARTIUPAC
p,I-PARTIUPAC
-,I-PARTIUPAC
toluoyl,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
beta,I-PARTIUPAC
-,I-PARTIUPAC
and,O
-,B-PARTIUPAC
alpha,I-PARTIUPAC
-,I-PARTIUPAC
D,I-PARTIUPAC
-,I-PARTIUPAC
erythro,I-PARTIUPAC
-,I-PARTIUPAC
pentofuranosyl,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
5,I-PARTIUPAC
-,I-PARTIUPAC
ethyl,I-PARTIUPAC
-,I-PARTIUPAC
"6,7",I-PARTIUPAC
-,I-PARTIUPAC
dihydroimidazo,I-PARTIUPAC
[,I-PARTIUPAC
"4,5",I-PARTIUPAC
-,I-PARTIUPAC
d,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
"1,3",I-PARTIUPAC
],I-PARTIUPAC
diazepin,I-PARTIUPAC
-,I-PARTIUPAC
8,I-PARTIUPAC
(,I-PARTIUPAC
3H,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
one,I-PARTIUPAC
(,O
5c,O
and,O
6c,O
),O
",",O
respectively,O
.,O
v,O
.,O
All,O
three,O
compounds,O
retained,O
antibacterial,O
activity,O
against,O
several,O
organisms,O
normally,O
susceptible,O
to,O
(,B-IUPAC
9R,I-IUPAC
),I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
deoxo,I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
erythromycin,I-IUPAC
A,I-IUPAC
.,O
Other,O
analogs,O
from,O
this,O
series,O
",",O
including,O
(,B-IUPAC
3S,I-IUPAC
",",I-IUPAC
4aR,I-IUPAC
",",I-IUPAC
6S,I-IUPAC
",",I-IUPAC
8aR,I-IUPAC
),I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
tetrazol,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
methyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,2,3,4,4",I-IUPAC
a,I-IUPAC
",",I-IUPAC
"5,6,7,8,8",I-IUPAC
a,I-IUPAC
-,I-IUPAC
decahydroisoquinoline,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acid,I-IUPAC
(,O
32,O
),O
and,O
(,B-IUPAC
3S,I-IUPAC
",",I-IUPAC
4aR,I-IUPAC
",",I-IUPAC
6S,I-IUPAC
",",I-IUPAC
8aR,I-IUPAC
),I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
(,I-IUPAC
phosphonomethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,2,3,4,4",I-IUPAC
a,I-IUPAC
",",I-IUPAC
"5,6,7,8,8",I-IUPAC
a,I-IUPAC
-,I-IUPAC
decahydroisoquinoline,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ca,I-IUPAC
rboxylic,I-IUPAC
acid,I-IUPAC
(,O
61,O
),O
are,O
potent,O
",",O
selective,O
",",O
and,O
systemically,O
active,O
NMDA,O
antagonists,O
.,O
034,O
nM,O
and,O
with,O
a,O
2000,O
-,O
fold,O
selectivity,O
for,O
the,O
ETA,O
receptor,O
versus,O
the,O
ETB,O
receptor,O
.,O
A,O
series,O
of,O
new,O
dipeptidyl,O
alpha,O
-,O
keto,O
amides,O
of,O
the,O
general,O
structure,O
R1,O
-,O
L,O
-,O
Leu,O
-,O
D,O
",",O
L,O
-,O
AA,O
-,O
CONH,O
-,O
R2,O
were,O
synthesized,O
and,O
evaluated,O
as,O
inhibitors,O
for,O
the,O
cysteine,O
proteases,O
calpain,O
I,O
",",O
calpain,O
II,O
",",O
and,O
cathepsin,O
B,O
.,O
The,O
absolute,O
configuration,O
of,O
(,O
-,O
),O
-,O
10,O
and,O
(,O
+,O
),O
-,O
10,O
was,O
determined,O
by,O
single,O
-,O
crystal,O
X,O
-,O
ray,O
diffractometry,O
of,O
the,O
bis,B-IUPAC
-,I-IUPAC
(,I-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
mandelate,I-IUPAC
salt,B-MODIFIER
.,O
Furthermore,O
",",O
(,B-IUPAC
3RS,I-IUPAC
",",I-IUPAC
4SR,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxypiperidine,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acid,I-IUPAC
(,O
14,O
),O
",",O
related,O
to,O
the,O
specific,O
GABA,O
agonist,O
piperidine,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxylic,I-IUPAC
acid,I-IUPAC
(,O
isonipecotic,O
acid,O
),O
",",O
has,O
been,O
synthesized,O
.,O
(,B-IUPAC
5,I-IUPAC
-,I-IUPAC
Amino,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
pyrazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
chlorophenyl,I-IUPAC
),I-IUPAC
methanone,I-IUPAC
(,O
21,O
),O
was,O
the,O
most,O
active,O
compound,O
against,O
pentylenetetrazole,O
-,O
induced,O
convulsions,O
.,O
All,O
three,O
compounds,O
fully,O
antagonized,O
the,O
effects,O
of,O
carbachol,O
at,O
the,O
M1,O
receptor,O
",",O
while,O
only,O
4d,O
completely,O
antagonized,O
carbachol,O
at,O
the,O
M2,O
receptor,O
.,O
2,B-IUPAC
-,I-IUPAC
Phenylquinazolinones,I-IUPAC
were,O
marginally,O
less,O
potent,O
than,O
the,O
corresponding,O
2,B-IUPAC
-,I-IUPAC
methylquinazolinones,I-IUPAC
",",O
but,O
the,O
introduction,O
of,O
an,O
electron,O
-,O
withdrawing,O
or,O
electron,O
-,O
donating,O
4',O
-,O
substituent,O
on,O
the,O
2,B-IUPAC
-,I-IUPAC
aryl,I-IUPAC
ring,B-MODIFIER
invariably,O
increased,O
potency,O
.,O
By,O
contrast,O
",",O
the,O
4,B-IUPAC
-,I-IUPAC
phenyltetrahydropyranone,I-IUPAC
(,O
3,O
),O
inactivated,O
alpha,O
-,O
chymotrypsin,O
in,O
a,O
time,O
-,O
dependent,O
manner,O
.,O
The,O
enantiomers,O
of,O
trans,B-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
n,I-IUPAC
-,I-IUPAC
propyl,I-IUPAC
and,O
-,B-PARTIUPAC
N,I-PARTIUPAC
-,I-PARTIUPAC
allyl,I-PARTIUPAC
analogs,B-MODIFIER
were,O
obtained,O
via,O
fractional,O
recrystallization,O
of,O
their,O
di,B-IUPAC
-,I-IUPAC
p,I-IUPAC
-,I-IUPAC
toluoyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
(,O
or,O
D,B-PARTIUPAC
),O
tartaric,B-IUPAC
acid,I-IUPAC
salts,I-IUPAC
.,O
In,O
general,O
",",O
the,O
compounds,O
structurally,O
related,O
to,O
BTCP,O
exhibited,O
greater,O
selectivity,O
for,O
sites,O
labeled,O
by,O
[,O
3H,O
],O
BTCP,O
.,O
A,O
potent,O
and,O
orally,O
active,O
NK1,O
antagonist,O
",",O
trans,B-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
3,I-IUPAC
",",I-IUPAC
5,I-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
trifluoromethyl,I-IUPAC
),I-IUPAC
benzyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"7,8",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
N,I-IUPAC
",",I-IUPAC
7,I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
methylphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
8,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
"1,7",I-IUPAC
-,I-IUPAC
naphthyridine,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
(,O
1t,O
),O
",",O
was,O
shown,O
to,O
exist,O
as,O
a,O
mixture,O
of,O
separable,O
and,O
stable,O
(,O
R,O
),O
-,O
and,O
(,O
S,O
),O
-,O
atropisomers,O
(,O
1t,O
-,O
A,O
and,O
1t,O
-,O
B,O
),O
originating,O
from,O
the,O
restricted,O
rotation,O
around,O
the,O
-,O
C,O
(,O
6,O
),O
-,O
C,O
(,O
=,O
O,O
),O
-,O
bond,O
;,O
the,O
antagonistic,O
activities,O
of,O
1t,O
-,O
A,O
were,O
ca.,O
6-13,O
-,O
fold,O
higher,O
than,O
those,O
of,O
1t,O
-,O
B,O
.,O
Analogues,O
1,O
",",O
2,O
",",O
and,O
4-6,O
exhibit,O
no,O
detectable,O
antidiuretic,O
agonistic,O
activity,O
.,O
The,O
results,O
showed,O
stereospecificity,O
of,O
the,O
furnidipine,O
isomers,O
in,O
brain,O
",",O
ileum,O
",",O
and,O
cardiac,O
tissues,O
",",O
the,O
(,O
SS,O
),O
-,O
and,O
(,O
SR,O
),O
-,O
isomers,O
clearly,O
being,O
more,O
potent,O
than,O
their,O
(,O
RR,O
),O
-,O
and,O
(,O
RS,O
),O
-,O
enantiomers,O
.,O
casei,O
and,O
were,O
of,O
low,O
activity,O
(,O
IC50,O
10,O
(,O
-,O
5,O
),O
M,O
),O
.,O
Deblocking,O
of,O
6a,O
-,O
c,O
gave,O
the,O
corresponding,O
amino,B-IUPAC
acids,I-IUPAC
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
bromoacetamido,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
hydrobromide,I-IUPAC
(,O
7a,O
),O
",",O
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"2,2",I-IUPAC
-,I-IUPAC
dichloroacetamido,I-IUPAC
),I-IUPAC
propionic,I-IUPAC
acid,I-IUPAC
(,O
7b,O
),O
",",O
and,O
ethyl,B-IUPAC
N,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
carboxyethyl,I-IUPAC
],I-IUPAC
fumarate,I-IUPAC
(,O
7c,O
),O
.,O
The,O
resulting,O
diastereoisomers,O
were,O
separated,O
by,O
column,O
chromatography,O
and,O
their,O
structures,O
established,O
by,O
CD,O
and,O
NMR,O
spectroscopy,O
.,O
In,O
tissue,O
culture,O
assays,O
",",O
22,B-IUPAC
-,I-IUPAC
hydroxycholesterol,I-IUPAC
as,O
well,O
as,O
the,O
side,O
chain,O
modified,O
analogues,O
were,O
potent,O
inhibitors,O
of,O
HMG,O
CoA,O
reductase,O
.,O
N1,B-IUPAC
-,I-IUPAC
Allylchlorpropamide,I-IUPAC
3,O
was,O
",",O
as,O
expected,O
",",O
a,O
potent,O
inhibitor,O
of,O
hepatic,O
AlDH,O
in,O
rats,O
",",O
as,O
indicated,O
by,O
the,O
4,O
-,O
fold,O
increase,O
in,O
the,O
levels,O
of,O
ethanol,O
-,O
derived,O
blood,O
acetaldehyde,O
relative,O
to,O
that,O
elicited,O
by,O
chlorpropamide,O
itself,O
.,O
Thus,O
",",O
4d,O
is,O
an,O
effective,O
and,O
highly,O
selective,O
inhibitor,O
of,O
calcium,O
chloride,O
-,O
dependent,O
[,O
3H,O
],O
glutamic,O
acid,O
binding,O
and,O
may,O
be,O
a,O
useful,O
tool,O
for,O
studies,O
of,O
the,O
physiological,O
relevance,O
and,O
pharmacological,O
importance,O
of,O
this,O
binding,O
affinity,O
.,O
gondii,O
enzyme,O
were,O
those,O
with,O
an,O
ArCH2,O
-,O
NH,O
or,O
ArNHCH2,O
side,O
chain,O
.,O
tuberculosis,O
.,O
The,O
syntheses,O
and,O
anthelmintic,O
activities,O
of,O
31,O
3,B-PARTIUPAC
-,I-PARTIUPAC
and,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
isothiocyanatophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,2,4",I-IUPAC
-,I-IUPAC
oxadiazoles,I-IUPAC
are,O
reported,O
.,O
A,O
change,O
of,O
the,O
N,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
group,B-MODIFIER
of,O
the,O
nonselective,O
3,O
to,O
H,O
[,O
23,O
",",O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
11,I-IUPAC
-,I-IUPAC
hydroxynoraporphine,I-IUPAC
],O
or,O
propyl,O
[,O
2,O
",",O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
11,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
propylnoraporphine,I-IUPAC
],O
increases,O
the,O
selectivity,O
for,O
5,O
-,O
HT1A,O
receptors,O
(,O
100,O
-,O
fold,O
),O
and,O
dopamine,O
D2A,O
receptors,O
(,O
3,O
-,O
fold,O
),O
",",O
respectively,O
.,O
In,O
addition,O
",",O
45,O
also,O
protected,O
gerbils,O
from,O
hippocampal,O
neuronal,O
degeneration,O
produced,O
by,O
either,O
hypoxia,O
or,O
intrastriatal,O
quinolinic,O
acid,O
injection,O
.,O
Furthermore,O
",",O
several,O
of,O
the,O
"2,4",B-IUPAC
-,I-IUPAC
pteridinediamines,I-IUPAC
exhibited,O
potent,O
prophylactic,O
activity,O
against,O
Plasmodium,O
gallinaceum,O
infections,O
in,O
the,O
chick,O
and,O
also,O
showed,O
strong,O
antibacterial,O
action,O
against,O
Streptococcus,O
faecalis,O
and,O
Staphylococcus,O
aureus,O
.,O
The,O
most,O
active,O
compounds,O
strongly,O
displaced,O
[,O
(,O
3,O
),O
H,O
],O
colchicine,O
from,O
its,O
binding,O
site,O
in,O
the,O
tubulin,O
",",O
yielding,O
IC,O
(,O
50,O
),O
values,O
3,O
-,O
to,O
4,O
-,O
fold,O
lower,O
than,O
that,O
of,O
colchicine,O
.,O
In,O
contrast,O
",",O
II,O
bound,O
with,O
higher,O
affinity,O
to,O
muscarinic,O
receptors,O
in,O
brainstem,O
",",O
cerebellar,O
",",O
and,O
hypothalamic,O
nuclei,O
(,O
IC50,O
values,O
less,O
than,O
0.5,O
microM,O
),O
than,O
to,O
receptors,O
in,O
thalamic,O
nuclei,O
(,O
IC50,O
values,O
between,O
0.5,O
and,O
2.0,O
microM,O
),O
.,O
Substituted,B-MODIFIER
9H,B-IUPAC
-,I-IUPAC
pyrido,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
b,I-IUPAC
],I-IUPAC
indoles,I-IUPAC
(,O
beta,O
-,O
carbolines,O
),O
",",O
identified,O
in,O
our,O
laboratory,O
as,O
potential,O
pharmacophores,O
for,O
designing,O
macrofilaricidal,O
agents,O
",",O
have,O
been,O
explored,O
further,O
for,O
identifying,O
the,O
pharmacophore,O
responsible,O
for,O
the,O
high,O
order,O
of,O
adulticidal,O
activity,O
.,O
The,O
disodium,O
salts,O
of,O
the,O
phosphate,O
prodrugs,O
exhibited,O
high,O
water,O
solubility,O
(,B-IUPAC
8,I-IUPAC
-,I-IUPAC
(,I-IUPAC
m,I-IUPAC
-,I-IUPAC
methoxystyryl,I-IUPAC
),I-IUPAC
-,I-IUPAC
7,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
[,I-IUPAC
3,I-IUPAC
-,I-IUPAC
O,I-IUPAC
-,I-IUPAC
phosphatylpropyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
propargylxan,I-IUPAC
thine,I-IUPAC
disodium,I-IUPAC
salt,I-IUPAC
",",O
9b,O
:,O
17,O
mM,O
",",O
9,O
mg,O
/,O
mL,O
),O
.,O
The,O
binding,O
data,O
suggests,O
that,O
this,O
conformation,O
in,O
1,O
favors,O
strong,O
binding,O
interaction,O
at,O
sigma,O
-,O
receptors,O
.,O
Several,O
of,O
the,O
more,O
potent,O
derivatives,O
effectively,O
antagonized,O
the,O
effects,O
of,O
an,O
agonist,O
in,O
a,O
functional,O
A3,O
receptor,O
assay,O
",",O
i.e.,O
inhibition,O
of,O
adenylyl,B-IUPAC
cyclase,I-IUPAC
in,O
CHO,O
cells,O
expressing,O
cloned,O
rat,O
A3,O
receptors,O
.,O
A,O
series,O
of,O
esters,O
of,O
6beta,B-IUPAC
-,I-IUPAC
hydroxynortropane,I-IUPAC
and,O
the,O
N,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
analogue,B-MODIFIER
6beta,B-IUPAC
-,I-IUPAC
tropanol,I-IUPAC
were,O
synthesized,O
and,O
screened,O
versus,O
binding,O
of,O
an,O
antagonist,O
(,O
quinuclidinyl,B-IUPAC
benzilate,I-IUPAC
),O
and,O
an,O
agonist,O
(,O
oxotremorine,O
-,O
M,O
),O
at,O
sites,O
on,O
human,O
m,O
(,O
1,O
),O
-,O
",",O
m,O
(,O
2,O
),O
-,O
",",O
m,O
(,O
3,O
),O
-,O
",",O
and,O
m,O
(,O
4,O
),O
-,O
muscarinic,O
receptors,O
in,O
transfected,O
cell,O
membranes,O
and,O
on,O
native,O
M,O
(,O
1,O
),O
-,O
muscarinic,O
receptors,O
in,O
rat,O
brain,O
membranes,O
and,O
native,O
M,O
(,O
2,O
),O
-,O
muscarinic,O
receptors,O
in,O
rat,O
heart,O
membranes,O
.,O
The,O
title,O
compounds,O
displayed,O
partial,O
agonism,O
on,O
contractile,O
H,O
(,O
1,O
),O
receptors,O
of,O
the,O
guinea,O
-,O
pig,O
ileum,O
and,O
endothelium,O
-,O
denuded,O
aorta,O
",",O
respectively,O
",",O
except,O
10,O
(,O
histaprodifen,O
;,O
2,B-IUPAC
-,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
diphenylpropyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
imidazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
],I-IUPAC
ethanamine,I-IUPAC
),O
which,O
was,O
a,O
full,O
agonist,O
in,O
the,O
ileum,O
assay,O
.,O
The,O
object,O
of,O
the,O
study,O
was,O
to,O
determine,O
the,O
structural,O
factors,O
governing,O
sigma,O
1,O
/,O
sigma,O
2,O
affinity,O
and,O
selectivity,O
within,O
this,O
class,O
of,O
compounds,O
.,O
The,O
synthesis,O
of,O
"6,7",B-IUPAC
-,I-IUPAC
dichloro,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
pyrrolidinyl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
tetralin,I-IUPAC
(,O
19,O
),O
and,O
its,O
desmethyl,B-IUPAC
derivative,I-IUPAC
20,O
permitted,O
constraint,O
of,O
the,O
"3,4",B-IUPAC
-,I-IUPAC
dichlorophenyl,I-IUPAC
and,O
N,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
moieties,B-MODIFIER
of,O
1,O
into,O
a,O
gauche,O
orientation,O
.,O
x,O
4,O
),O
or,O
240,O
mg,O
/,O
kg,O
(,O
q,O
.,O
New,O
compounds,O
of,O
the,O
nitroimidazole,O
series,O
have,O
been,O
synthesized,O
as,O
radiosensitizers,O
which,O
selectively,O
sensitize,O
hypoxic,O
cells,O
to,O
the,O
lethal,O
effect,O
of,O
radiation,O
.,O
The,O
electron,O
-,O
withdrawing,O
chloroethyl,B-IUPAC
group,B-MODIFIER
at,O
the,O
endocyclic,O
and,O
/,O
or,O
exocyclic,O
nitrogens,O
counteracts,O
the,O
endocyclic,O
P,O
-,O
N,O
bond,O
hydrolysis,O
.,O
The,O
1,B-IUPAC
",",I-IUPAC
6,I-IUPAC
-,I-IUPAC
naphthyridin,I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
),I-IUPAC
-,I-IUPAC
ones,I-IUPAC
showed,O
broadly,O
similar,O
activity,O
to,O
the,O
analogous,B-MODIFIER
pyrido,B-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidin,I-IUPAC
-,I-IUPAC
7,I-IUPAC
(,I-IUPAC
8H,I-IUPAC
),I-IUPAC
-,I-IUPAC
ones,I-IUPAC
",",O
whereas,O
the,O
1,B-IUPAC
",",I-IUPAC
8,I-IUPAC
-,I-IUPAC
naphthyridin,I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
),I-IUPAC
-,I-IUPAC
ones,I-IUPAC
were,O
at,O
least,O
10,O
(,O
3,O
),O
-,O
fold,O
less,O
potent,O
.,O
In,O
contrast,O
",",O
3',B-IUPAC
-,I-IUPAC
C,I-IUPAC
-,I-IUPAC
methylidene,I-IUPAC
-,I-IUPAC
2',I-IUPAC
",",I-IUPAC
3',I-IUPAC
-,I-IUPAC
dideoxy,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methyluridine,I-IUPAC
5',I-IUPAC
-,I-IUPAC
triphosphate,I-IUPAC
was,O
found,O
to,O
be,O
incorporated,O
at,O
the,O
3',O
-,O
end,O
of,O
the,O
DNA,O
chain,O
by,O
HIV,O
-,O
1,O
reverse,O
transcriptase,O
",",O
albeit,O
with,O
very,O
low,O
efficiency,O
.,O
The,O
inhibitions,O
of,O
cytochrome,O
P,O
-,O
450,O
dependent,O
monooxygenase,O
activity,O
in,O
microsomes,O
from,O
rat,O
liver,O
by,O
1,B-IUPAC
-,I-IUPAC
phenylpyrrole,I-IUPAC
",",O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
isopropylphenyl,I-IUPAC
),I-IUPAC
pyrrole,I-IUPAC
",",O
4,B-IUPAC
(,I-IUPAC
5,I-IUPAC
),I-IUPAC
-,I-IUPAC
phenylimidazole,I-IUPAC
",",O
and,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
isopropylphenyl,I-IUPAC
),I-IUPAC
imidazole,I-IUPAC
have,O
been,O
compared,O
.,O
The,O
characteristics,O
of,O
these,O
reactions,O
were,O
very,O
similar,O
to,O
those,O
previously,O
reported,O
for,O
the,O
oxidation,O
of,O
NOHA,O
by,O
NOS,O
:,O
(,O
i,O
),O
the,O
strict,O
requirement,O
of,O
NOS,O
containing,O
(,B-IUPAC
6R,I-IUPAC
),I-IUPAC
-,I-IUPAC
"5,6,7,8",I-IUPAC
-,I-IUPAC
tetrahydro,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
biopterin,I-IUPAC
",",O
reduced,O
nicotinamide,O
adenine,O
dinucleotide,O
phosphate,O
",",O
and,O
O,O
(,O
2,O
),O
for,O
the,O
oxidation,O
to,O
occur,O
",",O
(,O
ii,O
),O
the,O
formation,O
of,O
NO,O
and,O
the,O
corresponding,O
urea,O
in,O
a,O
1,O
:,O
1,O
molar,O
ratio,O
",",O
and,O
(,O
iii,O
),O
a,O
strong,O
inhibitory,O
effect,O
of,O
the,O
classical,O
NOS,O
inhibitors,O
such,O
as,O
N,B-IUPAC
(,I-IUPAC
omega,I-IUPAC
),I-IUPAC
-,I-IUPAC
nitro,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
arginine,I-IUPAC
and,O
S,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
iso,I-IUPAC
-,I-IUPAC
thiourea,I-IUPAC
.,O
In,O
this,O
assay,O
",",O
PCP,O
exhibited,O
affinities,O
of,O
64.5,O
nM,O
at,O
PCP,O
and,O
1090,O
nM,O
at,O
sigma,O
sites,O
.,O
Our,O
studies,O
identify,O
an,O
absolute,O
requirement,O
for,O
the,O
carboxylic,O
acid,O
moiety,O
on,O
the,O
aromatic,O
ring,O
to,O
be,O
para,O
relative,O
to,O
the,O
amide,O
linkage,O
for,O
activity,O
.,O
Primary,O
and,O
secondary,O
amines,O
bound,O
with,O
lower,O
affinity,O
than,O
tertiary,O
amines,O
.,O
These,O
compounds,O
will,O
allow,O
further,O
study,O
of,O
the,O
structure,O
and,O
function,O
of,O
the,O
"""",O
cocaine,O
"""",O
receptor,O
as,O
well,O
as,O
the,O
development,O
of,O
potential,O
cocaine,O
antagonists,O
.,O
It,O
is,O
likely,O
that,O
they,O
exert,O
their,O
antiviral,O
effect,O
via,O
selective,O
inhibition,O
of,O
the,O
methyltransferases,O
which,O
are,O
required,O
for,O
the,O
maturation,O
of,O
viral,O
mRNAs,O
.,O
These,O
tetraamines,O
include,O
a,O
simple,O
linear,O
analogue,O
of,O
DESPM,O
",",O
N1,B-IUPAC
",",I-IUPAC
N12,I-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
"2,2,2",I-IUPAC
-,I-IUPAC
trifluoroethyl,I-IUPAC
),I-IUPAC
spermine,I-IUPAC
(,O
FDESPM,O
),O
",",O
the,O
cyclic,O
analogues,O
of,O
DESPM,O
",",O
N,B-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
piperidinylmethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,4",I-IUPAC
-,I-IUPAC
diaminobutane,I-IUPAC
[,O
PIP,O
(,O
"4,4,4",O
),O
],O
and,O
N,B-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
bis,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
piperidinyl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"1,4",I-IUPAC
-,I-IUPAC
diaminobutane,I-IUPAC
[,O
PIP,O
(,O
"5,4,5",O
),O
],O
",",O
and,O
their,O
aromatic,O
counterparts,O
",",O
N,B-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
bis,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
pyridylmethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
"1,4",I-IUPAC
-,I-IUPAC
diaminobutane,I-IUPAC
[,O
PYR,O
(,O
"4,4,4",O
),O
],O
and,O
N,B-IUPAC
",",I-IUPAC
N',I-IUPAC
-,I-IUPAC
bis,I-IUPAC
[,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
pyridyl,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"1,4",I-IUPAC
-,I-IUPAC
diaminobutane,I-IUPAC
[,O
PYR,O
(,O
"5,4,5",O
),O
],O
.,O
Nine,O
compounds,O
with,O
BZ,O
receptor,O
IC50,O
binding,O
affinity,O
values,O
equal,O
or,O
superior,O
to,O
diazepam,O
were,O
evaluated,O
in,O
secondary,O
screening,O
.,O
A,O
series,O
of,O
bis,O
(,O
hydroxymethyl,O
),O
-,O
substituted,O
heterocycles,O
were,O
synthesized,O
and,O
converted,O
to,O
the,O
corresponding,O
bis,B-IUPAC
(,I-IUPAC
methylcarbamate,I-IUPAC
),I-IUPAC
derivatives,B-MODIFIER
.,O
Of,O
the,O
four,O
compounds,O
examined,O
",",O
only,O
compound,O
2,O
showed,O
significant,O
direct,O
activity,O
on,O
beta1,O
-,O
and,O
beta2,O
-,O
adrenergic,O
receptors,O
.,O
In,O
fact,O
",",O
1,B-IUPAC
-,I-IUPAC
boraadamantane,I-IUPAC
.,I-IUPAC
Additionally,O
",",O
we,O
introduced,O
CalphaMe,O
-,O
leucine,O
residues,O
in,O
lieu,O
of,O
leucine,O
at,O
positions,O
14,O
",",O
15,O
",",O
19,O
",",O
27,O
",",O
and,O
37,O
in,O
[,O
DHis32,O
],O
astressin,O
.,O
By,O
contrast,O
",",O
alpha,O
-,O
chymotrypsin,O
inactivated,O
with,O
N,B-IUPAC
-,I-IUPAC
benzoyl,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
Phe,I-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
epoxypropyl,I-IUPAC
ester,I-IUPAC
then,O
subjected,O
to,O
amino,O
acid,O
analysis,O
showed,O
no,O
change,O
in,O
the,O
content,O
of,O
any,O
amino,O
acid,O
that,O
would,O
serve,O
as,O
a,O
potential,O
nucleophile,O
to,O
the,O
inhibitor,O
.,O
The,O
activities,O
of,O
the,O
24,O
-,O
one,O
and,O
delta,O
(,O
22,O
),O
-,O
24,O
-,O
one,O
compounds,O
were,O
expected,O
to,O
be,O
very,O
low,O
",",O
because,O
the,O
carbonyl,B-IUPAC
group,B-MODIFIER
in,O
these,O
compounds,O
is,O
located,O
over,O
the,O
steroid,O
C,O
-,O
ring,O
and,O
oriented,O
toward,O
C,O
-,O
8,O
.,O
v,O
.,O
Adenosine,O
monophosphate,O
analogues,O
were,O
full,O
agonists,O
",",O
although,O
generally,O
4,O
orders,O
of,O
magnitude,O
less,O
potent,O
.,O
In,O
this,O
model,O
",",O
ICI,O
"204,219",O
was,O
active,O
at,O
0.4,O
mg,O
/,O
kg,O
.,O
administration,O
of,O
a,O
single,O
dose,O
of,O
1,O
mg,O
/,O
kg,O
and,O
also,O
provided,O
100%,O
inhibition,O
of,O
PAF,O
-,O
induced,O
aggregation,O
in,O
dog,O
whole,O
blood,O
6,O
h,O
after,O
i,O
.,O
Reaction,O
of,O
8,O
with,O
dimethyl,B-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
aminobenzoyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
glutamate,I-IUPAC
gave,O
the,O
"2,4",B-IUPAC
-,I-IUPAC
bis,I-IUPAC
(,I-IUPAC
acetylamino,I-IUPAC
),I-IUPAC
derivative,B-MODIFIER
11,O
",",O
which,O
was,O
hydrolyzed,O
with,O
1,O
N,O
sodium,O
hydroxide,O
to,O
give,O
1,O
;,O
the,O
glycine,O
analogue,O
16,O
was,O
prepared,O
in,O
a,O
similar,O
manner,O
.,O
The,O
coplanarity,O
of,O
trans,O
isomers,O
and,O
the,O
flexibility,O
of,O
cis,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
(,I-IUPAC
aminomethyl,I-IUPAC
),I-IUPAC
cyclohexylamine,I-IUPAC
complexes,B-MODIFIER
allow,O
them,O
easy,O
approach,O
to,O
the,O
target,O
DNA,O
.,O
Formylation,O
of,O
6,B-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichlorophenyl,I-IUPAC
),I-IUPAC
amino,I-IUPAC
],I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
pteridinediamine,I-IUPAC
gave,O
N,B-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
"2,4",I-IUPAC
-,I-IUPAC
diamino,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
pteridinyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dichlorophenyl,I-IUPAC
),I-IUPAC
formamide,I-IUPAC
.,O
A,O
diverse,O
range,O
of,O
chromen,B-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
one,I-IUPAC
",",O
chromen,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
and,O
pyrimidoisoquinolin,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
one,I-IUPAC
derivatives,B-MODIFIER
was,O
synthesized,O
and,O
evaluated,O
for,O
inhibitory,O
activity,O
against,O
the,O
DNA,O
repair,O
enzyme,O
DNA,O
-,O
dependent,O
protein,O
kinase,O
(,O
DNA,O
-,O
PK,O
),O
",",O
with,O
a,O
view,O
to,O
elucidating,O
structure,O
-,O
activity,O
relationships,O
for,O
potency,O
and,O
kinase,O
selectivity,O
.,O
Finally,O
",",O
there,O
was,O
no,O
correlation,O
between,O
the,O
SAR,O
for,O
the,O
human,O
MDR1,O
Pgp,O
inhibition,O
and,O
the,O
SAR,O
for,O
Saccharomyces,O
cerevisiae,O
antifungal,O
activity,O
",",O
which,O
is,O
mediated,O
by,O
an,O
inositol,O
phosphoceramide,O
synthase,O
activity,O
.,O
The,O
structure,O
-,O
activity,O
relationship,O
(,O
SAR,O
),O
associated,O
with,O
position,O
1,O
and,O
3,O
substituents,O
in,O
beta,O
-,O
carbolines,O
has,O
been,O
discussed,O
.,O
In,O
view,O
of,O
the,O
fact,O
that,O
3,O
and,O
its,O
B,O
-,O
ring,O
analogues,O
cannot,O
form,O
polyglutamates,O
",",O
their,O
high,O
cytotoxicity,O
relative,O
to,O
the,O
corresponding,O
B,O
-,O
ring,O
analogues,O
of,O
AMT,O
is,O
noteworthy,O
.,O
Selectivity,O
for,O
the,O
NMDA,O
receptor,O
ion,O
channel,O
sites,O
over,O
sigma,O
receptors,O
appears,O
to,O
be,O
dependent,O
upon,O
the,O
structure,O
of,O
the,O
additional,O
substituents,O
on,O
the,O
guanidine,O
nitrogen,O
atoms,O
bearing,O
the,O
aryl,O
groups,O
.,O
These,O
novel,O
compounds,O
are,O
derivatives,O
of,O
nipecotic,O
acid,O
",",O
guvacine,O
",",O
and,O
homo,B-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
proline,I-IUPAC
",",O
substituted,O
at,O
the,O
nitrogen,O
of,O
these,O
amino,O
acids,O
by,O
various,O
lipophilic,O
moieties,O
such,O
as,O
(,B-IUPAC
"10,11",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
5H,I-IUPAC
-,I-IUPAC
dibenz,I-IUPAC
[,I-IUPAC
b,I-IUPAC
",",I-IUPAC
f,I-IUPAC
],I-IUPAC
azepin,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
alkoxyalkyl,I-IUPAC
or,O
(,B-IUPAC
"10,11",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
5H,I-IUPAC
-,I-IUPAC
dibenzo,I-IUPAC
[,I-IUPAC
a,I-IUPAC
",",I-IUPAC
d,I-IUPAC
],I-IUPAC
cyclohepten,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
ylidene,I-IUPAC
),I-IUPAC
alkoxyalkyl,I-IUPAC
.,O
The,O
model,O
can,O
also,O
account,O
for,O
the,O
binding,O
of,O
quinoxaline,B-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
diones,I-IUPAC
",",O
quinoxalic,B-IUPAC
acids,I-IUPAC
",",O
and,O
2,B-IUPAC
-,I-IUPAC
carboxybenzimidazoles,I-IUPAC
.,O
The,O
"""",O
pharmacophore,O
"""",O
for,O
selective,O
dopamine,O
D,O
-,O
1,O
antagonist,O
activity,O
appears,O
to,O
be,O
a,O
tertiary,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
hydroxyphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenethylamine,I-IUPAC
.,O
In,O
order,O
to,O
selectively,O
determine,O
affinities,O
for,O
the,O
high,O
-,O
affinity,O
agonist,O
binding,O
site,O
at,O
DA,O
D2,O
receptors,O
",",O
the,O
agonist,O
[,O
3H,O
],O
quinpirole,O
was,O
used,O
.,O
Optimization,O
of,O
6,O
resulted,O
in,O
the,O
preparation,O
of,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
methylphenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
cyano,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
(,I-IUPAC
thien,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
ylmethyl,I-IUPAC
),I-IUPAC
phenyl,I-IUPAC
),I-IUPAC
pro,I-IUPAC
p,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
enol,I-IUPAC
33,O
with,O
an,O
IC50,O
of,O
300,O
nM,O
on,O
the,O
ETA,O
receptor,O
.,O
THMNDs,O
were,O
prepared,O
via,O
a,O
Diels,O
-,O
Alder,O
reaction,O
with,O
2,B-IUPAC
-,I-IUPAC
methoxybenzoquinone,I-IUPAC
(,O
5,O
),O
or,O
2,B-IUPAC
-,I-IUPAC
bromo,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methoxybenzoquinone,I-IUPAC
(,O
14,O
),O
and,O
substituted,B-MODIFIER
"1,3",B-IUPAC
-,I-IUPAC
butadienes,I-IUPAC
.,O
The,O
in,O
vitro,O
inotropic,O
activity,O
of,O
these,O
compounds,O
",",O
as,O
well,O
as,O
the,O
known,O
cardiotonics,O
amrinone,O
and,O
7,B-IUPAC
-,I-IUPAC
hydroxycyclindole,I-IUPAC
(,O
7,O
),O
",",O
was,O
investigated,O
.,O
The,O
comparable,O
potency,O
and,O
spectrum,O
of,O
activity,O
of,O
juncusol,O
(,O
1a,O
),O
",",O
desvinyljuncusol,O
(,O
2h,O
),O
",",O
and,O
2,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
"9,10",I-IUPAC
-,I-IUPAC
dihydrophenanthrene,I-IUPAC
(,O
3h,O
),O
suggest,O
that,O
the,O
agents,O
are,O
acting,O
as,O
simple,O
phenols,O
in,O
exerting,O
their,O
antimicrobial,O
and,O
cytotoxic,O
effects,O
.,O
Using,O
the,O
patch,O
-,O
clamp,O
technique,O
",",O
the,O
capability,O
of,O
derivatives,O
16,O
and,O
21,O
to,O
antagonize,O
KA,O
-,O
evoked,O
currents,O
in,O
primary,O
cultures,O
of,O
granule,O
neurons,O
was,O
tested,O
.,O
Antibacterial,O
efficacy,O
and,O
pharmacokinetic,O
and,O
physicochemical,O
properties,O
of,O
selected,O
derivatives,O
were,O
compared,O
to,O
the,O
relevant,O
7,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
azetidinyl,I-IUPAC
),I-IUPAC
and,O
7,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
azetidinyl,I-IUPAC
),I-IUPAC
analogues,B-MODIFIER
(,O
for,O
Part,O
1,O
",",O
see,O
:,O
J,O
.,O
The,O
structurally,O
similar,O
monoprotic,O
and,O
more,O
acidic,O
1,B-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
),I-IUPAC
-,I-IUPAC
pyridinone,I-IUPAC
(,O
"1,2",O
-,O
HOPO,O
),O
group,O
was,O
",",O
therefore,O
",",O
incorporated,O
into,O
multidentate,O
ligands,O
.,O
Comparison,O
of,O
the,O
HPLC,O
retention,O
times,O
",",O
diode,O
array,O
UV,O
",",O
and,O
chemical,O
ion,O
mass,O
spectral,O
characteristics,O
of,O
these,O
products,O
with,O
those,O
of,O
synthetic,O
standards,O
led,O
us,O
to,O
propose,O
the,O
1,B-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
dihydropyridinium,I-IUPAC
species,O
"2,3",O
-,O
MPDP+,O
and,O
6,B-IUPAC
-,I-IUPAC
cyano,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
phenyl,I-IUPAC
-,I-IUPAC
"1,2,3,6",I-IUPAC
-,I-IUPAC
tetrahydropyridine,I-IUPAC
as,O
tentative,O
structure,O
assignments,O
for,O
the,O
dihydropyridinium,O
metabolite,O
and,O
the,O
cyano,O
adduct,O
",",O
respectively,O
.,O
We,O
were,O
able,O
to,O
confirm,O
the,O
substantial,O
cardioselectivity,O
of,O
1,B-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
"3,4",I-PARTIUPAC
-,I-PARTIUPAC
dimethoxyphenethyl,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
3,I-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
(,I-PARTIUPAC
4,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
aryl,B-IUPAC
),B-PARTIUPAC
oxy,I-PARTIUPAC
],I-PARTIUPAC
propan,I-PARTIUPAC
-,I-PARTIUPAC
2,I-PARTIUPAC
-,I-PARTIUPAC
ols,I-PARTIUPAC
when,O
compared,O
to,O
those,O
with,O
a,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxyphenethyl,I-IUPAC
),I-IUPAC
group,B-MODIFIER
.,O
Its,O
efficiency,O
in,O
inhibition,O
of,O
microvascular,O
permeability,O
was,O
assessed,O
in,O
two,O
rhinitis,O
models,O
;,O
ovalbumin,O
and,O
capsaicin,O
-,O
induced,O
rhinorrhea,O
could,O
be,O
prevented,O
after,O
topical,O
application,O
of,O
submicromolar,O
concentrations,O
of,O
45,O
(,O
IC50,O
=,O
0.25,O
and,O
0.30,O
microM,O
),O
;,O
and,O
it,O
also,O
exerted,O
significant,O
inhibitory,O
effect,O
in,O
the,O
first,O
test,O
after,O
iv,O
and,O
oral,O
administration,O
",",O
with,O
ID50,O
=,O
0.005,O
and,O
0.46,O
mg,O
/,O
kg,O
.,O
In,O
addition,O
",",O
39,O
was,O
also,O
found,O
to,O
be,O
active,O
against,O
hookworms,O
in,O
dogs,O
at,O
a,O
single,O
",",O
oral,O
dose,O
of,O
200,O
mg,O
/,O
kg,O
.,O
omega,O
-,O
Hydroxylation,O
was,O
a,O
minor,O
metabolic,O
pathway,O
in,O
the,O
microsomal,O
incubation,O
.,O
A,O
series,O
of,O
N,B-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
-,I-IUPAC
alkyl,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
alkynyl,I-IUPAC
derivatives,B-MODIFIER
of,O
adenosine,O
(,O
Ado,O
),O
have,O
been,O
synthesized,O
and,O
evaluated,O
for,O
their,O
affinity,O
at,O
human,O
A,O
(,O
1,O
),O
",",O
A,O
(,O
2A,O
),O
",",O
and,O
A,O
(,O
3,O
),O
receptors,O
and,O
for,O
their,O
potency,O
at,O
A,O
(,O
2B,O
),O
adenosine,O
receptor,O
subtypes,O
.,O
The,O
most,O
active,O
compound,O
",",O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
iodoethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
2',I-IUPAC
-,I-IUPAC
deoxyuridine,I-IUPAC
(,O
12a,O
",",O
ID50,O
=,O
0.1,O
micrograms,O
/,O
mL,O
),O
",",O
which,O
exhibited,O
antiviral,O
activity,O
(,O
HSV,O
-,O
1,O
),O
100,O
-,O
fold,O
higher,O
than,O
that,O
of,O
the,O
5,B-IUPAC
-,I-IUPAC
(,I-IUPAC
1,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
iodoethyl,I-IUPAC
),I-IUPAC
analogue,B-MODIFIER
(,O
11a,O
),O
",",O
was,O
less,O
active,O
than,O
IVDU,O
or,O
acyclovir,O
(,O
ID50,O
=,O
0.01-0.1,O
micrograms,O
/,O
mL,O
range,O
),O
.,O
1c,O
was,O
moderately,O
stable,O
in,O
aqueous,O
buffers,O
over,O
the,O
pH,O
range,O
1-7.4,O
(,O
T1/2,O
&,O
gt,O
;,O
30,O
h,O
),O
.,O
Two,O
lower,O
homologues,O
of,O
10,O
were,O
weak,O
partial,O
H,O
(,O
1,O
),O
-,O
receptor,O
agonists,O
while,O
two,O
higher,O
homologues,O
of,O
10,O
were,O
silent,O
antagonists,O
endowed,O
with,O
micromolar,O
affinity,O
for,O
rat,O
and,O
guinea,O
-,O
pig,O
H,O
(,O
1,O
),O
receptors,O
.,O
With,O
the,O
exception,O
of,O
the,O
"3,4,5",B-IUPAC
-,I-IUPAC
triphenylpyrazole,I-IUPAC
derivative,B-MODIFIER
13g,O
",",O
compounds,O
presenting,O
the,O
(,B-IUPAC
m,I-IUPAC
-,I-IUPAC
ethylphenoxy,I-IUPAC
),I-IUPAC
acetic,I-IUPAC
acid,I-IUPAC
side,B-MODIFIER
chain,I-MODIFIER
discovered,O
with,O
3,O
demonstrated,O
enhanced,O
potency,O
compared,O
to,O
the,O
analogously,O
substituted,O
alkanoic,O
acid,O
derivative,O
.,O
Many,O
of,O
these,O
5,B-IUPAC
-,I-IUPAC
thio,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
pyridinecarboxylic,I-IUPAC
acid,I-IUPAC
derivatives,B-MODIFIER
were,O
orally,O
active,O
antihypertensive,O
agents,O
in,O
the,O
spontaneously,O
hypertensive,O
rat,O
.,O
Compound,O
4a,O
was,O
prepared,O
via,O
selective,O
bromination,O
of,O
6,B-IUPAC
-,I-IUPAC
(,I-IUPAC
furan,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
nicotinonitrile,I-IUPAC
(,O
2a,O
),O
with,O
N,B-IUPAC
-,I-IUPAC
bromosuccinimide,I-IUPAC
",",O
followed,O
by,O
Suzuki,O
coupling,O
with,O
4,B-IUPAC
-,I-IUPAC
cyanophenylboronic,I-IUPAC
acid,I-IUPAC
.,O
On,O
the,O
other,O
hand,O
",",O
the,O
(,B-IUPAC
S,I-IUPAC
),I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
phenylhydroxypropynyl,I-IUPAC
-,I-IUPAC
N,I-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
Ado,O
(,O
9e,O
",",O
EC,O
(,O
50,O
),O
(,O
A,O
(,O
2B,O
),O
),O
=,O
0.73,O
microM,O
),O
showed,O
a,O
significantly,O
increase,O
of,O
potency,O
at,O
the,O
A,O
(,O
2B,O
),O
subtype,O
in,O
comparison,O
with,O
the,O
N,B-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
",",O
N,B-IUPAC
(,I-IUPAC
6,I-IUPAC
),I-IUPAC
-,I-IUPAC
isopropyl,I-IUPAC
",",O
and,O
the,O
unsubstituted,O
adenosine,O
derivatives,O
",",O
although,O
it,O
resulted,O
in,O
being,O
less,O
potent,O
than,O
(,O
S,O
),O
-,O
PHPNECA,O
(,O
1e,O
",",O
EC,O
(,O
50,O
),O
(,O
A,O
(,O
2B,O
),O
),O
=,O
0.22,O
microM,O
),O
.,O
Compound,O
6,O
thus,O
represents,O
a,O
new,O
structural,O
class,O
of,O
GluR5,O
agonists,O
.,O
The,O
absolute,O
configuration,O
of,O
the,O
respective,O
(,O
R,O
),O
-,O
and,O
(,O
S,O
),O
-,O
enantiomers,O
was,O
deduced,O
from,O
X,O
-,O
ray,O
crystallography,O
of,O
(,B-IUPAC
R,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
isopropylamino,I-IUPAC
),I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methoxy,I-IUPAC
-,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
2H,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
benzopyran,I-IUPAC
",",O
(,O
R,O
),O
-,O
9a,O
.,O
The,O
structure,O
of,O
the,O
new,O
heterocyclic,O
compound,O
5,O
was,O
confirmed,O
by,O
1H,O
NMR,O
",",O
mass,O
spectrum,O
",",O
and,O
X,O
-,O
ray,O
crystallography,O
.,O
Potency,O
of,O
the,O
CAM,O
-,O
HOPO,O
ligands,O
for,O
in,O
vivo,O
chelation,O
of,O
Pu,O
(,O
IV,O
),O
resembled,O
that,O
of,O
structurally,O
hexadentate,B-IUPAC
tris,I-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxypyridinonate,I-IUPAC
),I-IUPAC
and,O
tris,B-IUPAC
(,I-IUPAC
sulfocatecholate,I-IUPAC
),I-IUPAC
ligands,O
and,O
functionally,O
hexadentate,O
tetrakis,B-IUPAC
-,I-IUPAC
(,I-IUPAC
sulfocatecholate,I-IUPAC
),I-IUPAC
and,O
tetrakis,B-IUPAC
(,I-IUPAC
carboxycatecholate,I-IUPAC
),I-IUPAC
ligands,O
.,O
These,O
results,O
make,O
meta,B-MODIFIER
-,I-MODIFIER
substituted,I-MODIFIER
2,B-IUPAC
-,I-IUPAC
phenylhistamines,I-IUPAC
",",O
especially,O
2,B-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
3,I-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
trifluoromethyl,I-PARTIUPAC
),I-PARTIUPAC
phenyl,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
and,O
2,B-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
bromophenyl,I-IUPAC
),I-IUPAC
histamine,I-IUPAC
(,O
39,O
and,O
35,O
",",O
respectively,O
),O
valuable,O
experimental,O
tools,O
for,O
the,O
selective,O
stimulation,O
of,O
histamine,O
H1,O
receptors,O
and,O
the,O
study,O
of,O
H1,O
receptor,O
-,O
mediated,O
functions,O
.,O
rhodesiense,O
(,O
T,O
.,O
All,O
the,O
bromomethylpyrazole,O
nucleosides,O
described,O
showed,O
significant,O
cytostatic,O
activity,O
against,O
HeLa,O
cell,O
cultures,O
.,O
Substitution,O
on,O
the,O
aromatic,O
ring,O
of,O
4b,O
with,O
halogen,O
or,O
increasing,O
the,O
size,O
of,O
the,O
N,B-IUPAC
-,I-IUPAC
alkyl,I-IUPAC
substituent,B-MODIFIER
of,O
4b,O
gave,O
alpha,O
2,O
-,O
adrenergic,O
antagonists,O
without,O
agonist,O
activity,O
.,O
N4,B-IUPAC
-,I-IUPAC
Alkylaminopyrazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidines,I-IUPAC
were,O
generally,O
prepared,O
by,O
displacement,O
of,O
the,O
chlorine,O
from,O
4,B-IUPAC
-,I-IUPAC
chloropyrazolo,I-IUPAC
[,I-IUPAC
"3,4",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
with,O
various,O
amines,O
.,O
The,O
7,B-MODIFIER
-,I-MODIFIER
mono,I-MODIFIER
-,I-MODIFIER
and,O
"5,7",B-MODIFIER
-,I-MODIFIER
disubstituted,I-MODIFIER
-,O
5,B-IUPAC
-,I-IUPAC
deazaaminopterins,I-IUPAC
(,O
1b,O
",",O
d,O
-,O
g,O
),O
were,O
prepared,O
from,O
the,O
respective,O
pyrido,B-IUPAC
[,I-IUPAC
"2,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidines,I-IUPAC
12b,O
",",O
d,O
-,O
g,O
.,O
of,O
less,O
than,O
10,O
nM,O
.,O
None,O
of,O
the,O
new,O
nucleosides,O
or,O
heterocycles,O
displayed,O
selective,O
activity,O
against,O
human,O
cytomegalovirus,O
(,O
HCMV,O
),O
or,O
herpes,O
simplex,O
virus,O
type,O
1,O
(,O
HSV,O
-,O
1,O
),O
.,O
Among,O
them,O
",",O
the,O
highest,O
activity,O
was,O
observed,O
for,O
the,O
3,B-IUPAC
-,I-IUPAC
fluoro,I-IUPAC
-,I-IUPAC
9,I-IUPAC
-,I-IUPAC
methyl,I-IUPAC
derivative,B-MODIFIER
rac,O
-,O
28,O
[,O
about,O
15,O
-,O
fold,O
more,O
active,O
than,O
THA,O
and,O
about,O
9,O
-,O
fold,O
more,O
active,O
than,O
(,O
-,O
),O
-,O
huperzine,O
A,O
],O
.,O
Tissue,O
distribution,O
studies,O
revealed,O
that,O
a,O
number,O
of,O
radioiodinated,O
guanidines,O
showed,O
pronounced,O
localization,O
in,O
the,O
adrenal,O
medullae,O
following,O
intravenous,O
injection,O
",",O
in,O
certain,O
cases,O
exceeding,O
that,O
of,O
either,O
(,B-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
[,I-IUPAC
3H,I-IUPAC
],I-IUPAC
norepinephrine,I-IUPAC
or,O
[,B-IUPAC
14C,I-IUPAC
],I-IUPAC
guanethidine,I-IUPAC
.,O
in,O
electrophysiological,O
experiments,O
using,O
rat,O
alpha,O
(,O
1,O
),O
beta,O
(,O
2,O
),O
gamma,O
(,O
2L,O
),O
GABA,O
(,O
A,O
),O
receptors,O
expressed,O
in,O
Xenopus,O
laevis,O
oocytes,O
",",O
and,O
(,O
3,O
),O
.,O
Analogue,O
3,O
was,O
a,O
good,O
substrate,O
for,O
human,O
folylpolyglutamate,O
synthetase,O
(,O
FPGS,O
),O
derived,O
from,O
CCRF,O
-,O
CEM,O
cells,O
(,O
Km,O
8.5,O
microM,O
),O
.,O
Likewise,O
",",O
for,O
the,O
enones,O
",",O
the,O
order,O
is,O
delta,O
(,O
22,O
),O
-,O
24,O
-,O
one,O
&,O
gt,O
;,O
delta,O
(,O
20,O
(,O
22,O
),O
),O
-,O
23,O
-,O
one,O
&,O
gt,O
;,O
delta,O
(,O
22,O
),O
-,O
20,O
-,O
one,O
&,O
gt,O
;,O
delta,O
(,O
23,O
),O
-,O
22,O
-,O
one,O
.,O
Alkylation,O
with,O
(,B-IUPAC
N,I-IUPAC
",",I-IUPAC
N,I-IUPAC
-,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
chloride,I-IUPAC
yielded,O
basic,O
cyclopropanes,O
.,O
Kinetic,O
comparison,O
of,O
the,O
iodomethylene,O
lactone,O
3,O
with,O
the,O
corresponding,O
protio,O
lactone,O
25,O
indicates,O
that,O
the,O
iodine,O
accelerates,O
the,O
rate,O
of,O
chymotrypsin,O
acylation,O
but,O
produces,O
an,O
acyl,O
enzyme,O
that,O
is,O
more,O
hydrolytically,O
labile,O
than,O
that,O
formed,O
from,O
lactone,O
25,O
.,O
Affinities,O
ranged,O
from,O
582,O
nM,O
[,O
(,O
+,O
/,O
-,O
),O
-,O
9,O
],O
to,O
"29,000",O
nM,O
[,O
(,O
+,O
),O
-,O
8,O
],O
at,O
PCP,O
binding,O
sites,O
and,O
from,O
1130,O
nM,O
[,O
(,O
-,O
),O
-,O
8,O
],O
to,O
"16,300",O
nM,O
(,O
7,O
),O
at,O
sigma,O
sites,O
.,O
Overall,O
",",O
the,O
combination,O
of,O
modified,O
rings,O
A,O
and,O
C,O
increases,O
the,O
potency,O
by,O
about,O
10,O
000,O
times,O
compared,O
with,O
the,O
lead,O
compound,O
",",O
3,B-IUPAC
-,I-IUPAC
oxooleana,I-IUPAC
-,I-IUPAC
"1,12",I-IUPAC
-,I-IUPAC
dien,I-IUPAC
-,I-IUPAC
28,I-IUPAC
-,I-IUPAC
oic,I-IUPAC
acid,I-IUPAC
(,O
8,O
),O
(,O
IC,O
(,O
50,O
),O
=,O
1,O
microM,O
level,O
),O
.,O
Compounds,O
19b,O
",",O
20b,O
",",O
and,O
the,O
3',B-IUPAC
",",I-IUPAC
5',I-IUPAC
-,I-IUPAC
(,I-IUPAC
cyclic,I-IUPAC
),I-IUPAC
phosphate,I-IUPAC
21b,O
are,O
less,O
active,O
than,O
1,O
.,O
For,O
the,O
enantiomers,O
(,O
+,O
),O
-,O
4,O
and,O
(,O
-,O
),O
-,O
4,O
also,O
a,O
remarkable,O
selectivity,O
was,O
achieved,O
.,O
Condensation,O
of,O
diethyl,B-IUPAC
L,I-IUPAC
-,I-IUPAC
glutamate,I-IUPAC
with,O
methyl,B-IUPAC
2,I-IUPAC
-,I-IUPAC
bromomethyl,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
nitrobenzoate,I-IUPAC
followed,O
by,O
catalytic,O
reduction,O
of,O
the,O
nitro,O
group,O
",",O
reductive,O
coupling,O
with,O
2,B-IUPAC
-,I-IUPAC
acetamido,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
formylpyrido,I-IUPAC
[,I-IUPAC
2,I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidin,I-IUPAC
-,I-IUPAC
4,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
-,I-IUPAC
one,I-IUPAC
in,O
the,O
presence,O
of,O
dimethylaminoborane,O
",",O
and,O
acidolysis,O
with,O
HBr,O
/,O
AcOH,O
yielded,O
2,B-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
[,I-IUPAC
5,I-IUPAC
-,I-IUPAC
[,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
acetamido,I-IUPAC
-,I-IUPAC
4,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
-,I-IUPAC
oxopyrido,I-IUPAC
[,I-IUPAC
2,I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidin,I-IUPAC
-,I-IUPAC
6,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
methylamino,I-IUPAC
],I-IUPAC
-,I-IUPAC
2,I-IUPAC
",",I-IUPAC
3,I-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
oxo,I-IUPAC
-,I-IUPAC
2,I-IUPAC
(,I-IUPAC
1H,I-IUPAC
),I-IUPAC
-,I-IUPAC
isoindolyl,I-IUPAC
],I-IUPAC
glutaric,I-IUPAC
acid,I-IUPAC
(,O
1,O
),O
.,O
These,O
analogues,O
of,O
vasotocin,O
are,O
the,O
most,O
potent,O
that,O
have,O
been,O
synthesized,O
to,O
date,O
",",O
and,O
they,O
should,O
serve,O
as,O
useful,O
probes,O
in,O
the,O
isolation,O
and,O
characterization,O
of,O
vasotocin,O
receptors,O
in,O
toad,O
bladders,O
and,O
tissues,O
from,O
other,O
species,O
that,O
use,O
vasotocin,O
as,O
an,O
antidiuretic,O
/,O
pressor,O
principle,O
.,O
Binding,O
to,O
alpha,O
1,O
-,O
ARs,O
was,O
relatively,O
sensitive,O
to,O
size,O
and,O
electronic,O
features,O
of,O
the,O
arylpiperazine,B-IUPAC
portion,O
of,O
the,O
antagonists,O
and,O
permissive,O
to,O
these,O
features,O
on,O
the,O
heteroaryl,O
carboxamide,O
side,O
.,O
Replacement,O
of,O
the,O
ureido,O
moiety,O
of,O
the,O
lead,O
compound,O
with,O
hydroxyguanidine,O
provided,O
a,O
stable,O
cytotoxic,O
agent,O
.,O
Against,O
HL60,O
cells,O
",",O
4,O
was,O
about,O
7,O
-,O
fold,O
more,O
cytotoxic,O
than,O
PDDF,O
(,O
IC50,O
values,O
0.72,O
and,O
5.29,O
microM,O
),O
.,O
Methods,O
employed,O
for,O
the,O
preparation,O
of,O
tetramethoxydiphenylethane,B-IUPAC
intermediates,O
involved,O
(,O
1,O
),O
arylmethyl,O
bromide,O
coupling,O
and,O
(,O
2,O
),O
catalytic,O
hydrogenation,O
of,O
stilbene,O
intermediates,O
derived,O
via,O
Wittig,O
reaction,O
of,O
(,O
arylmethyl,O
),O
phosphonium,O
salts,O
with,O
aryl,O
aldehydes,O
.,O
Single,O
doses,O
(,O
200-400,O
mg,O
/,O
kg,O
),O
of,O
8a,O
and,O
8b,O
produced,O
significant,O
increase,O
in,O
life,O
span,O
(,O
257-371%,O
),O
in,O
mice,O
bearing,O
ip,O
implanted,O
L1210/0,O
leukemia,O
.,O
Finally,O
",",O
we,O
have,O
employed,O
conventional,O
MD,O
simulations,O
to,O
investigate,O
the,O
structural,O
perturbations,O
caused,O
by,O
each,O
mutation,O
to,O
further,O
examine,O
the,O
role,O
played,O
by,O
each,O
individual,O
residue,O
in,O
PKC,O
-,O
ligand,O
binding,O
.,O
Next,O
",",O
cyclo,O
[,O
"21,29",O
],O
[,O
D,O
-,O
Cys,O
(,O
21,O
),O
Cys,O
(,O
29,O
),O
],O
-,O
uPA,O
(,O
21,O
),O
(,O
-,O
),O
(,O
30,O
),O
was,O
yielded,O
by,O
changing,O
the,O
chirality,O
of,O
Cys,O
(,O
21,O
),O
to,O
D,O
-,O
Cys,O
(,O
21,O
),O
.,O
The,O
greatest,O
improvement,O
in,O
FT,O
inhibitory,O
potency,O
was,O
observed,O
for,O
the,O
Tic,O
derivative,O
(,O
IC50,O
=,O
1,O
nM,O
),O
;,O
however,O
",",O
this,O
compound,O
was,O
ineffective,O
in,O
blocking,O
oncogenic,O
Ras,O
-,O
induced,O
transformation,O
of,O
NIH,O
-,O
3T3,O
fibroblast,O
cells,O
.,O
Structure,O
-,O
-,O
activity,O
relationships,O
are,O
discussed,O
in,O
terms,O
of,O
cholesterol,O
-,O
lowering,O
activity,O
together,O
with,O
effects,O
on,O
weight,O
gain,O
and,O
liver,O
lipids,O
.,O
Ring,O
closure,O
of,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
(,I-IUPAC
5,I-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
imidazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
ethanone,I-IUPAC
dihydrochloride,I-IUPAC
(,O
3,O
),O
with,O
triethyl,B-IUPAC
orthoacetate,I-IUPAC
or,O
triethyl,B-IUPAC
orthopropionate,I-IUPAC
gave,O
the,O
C,B-MODIFIER
-,I-MODIFIER
5,I-MODIFIER
methyl,B-IUPAC
and,O
ethyl,B-IUPAC
ketoaglycons,I-IUPAC
",",O
"6,7",B-IUPAC
-,I-IUPAC
dihydro,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
methylimidazo,I-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,3",I-IUPAC
],I-IUPAC
diazepin,I-IUPAC
-,I-IUPAC
8,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
4b,O
),O
and,O
5,B-IUPAC
-,I-IUPAC
ethyl,I-IUPAC
-,I-IUPAC
"6,7",I-IUPAC
-,I-IUPAC
dihydroimidazo,I-IUPAC
[,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
[,I-IUPAC
"1,3",I-IUPAC
],I-IUPAC
diazepin,I-IUPAC
-,I-IUPAC
8,I-IUPAC
(,I-IUPAC
3H,I-IUPAC
),I-IUPAC
-,I-IUPAC
one,I-IUPAC
(,O
4c,O
),O
",",O
respectively,O
.,O
All,O
the,O
double,O
-,O
armed,O
aporphine,O
amide,O
nitrogen,O
mustards,O
(,O
ab,O
-,O
d,O
),O
were,O
found,O
to,O
have,O
antitumor,O
activity,O
.,O
carinii,O
DHFR,O
was,O
20,O
000,O
times,O
greater,O
than,O
that,O
of,O
TMP,O
",",O
with,O
an,O
SI,O
of,O
96,O
",",O
whereas,O
that,O
of,O
TMP,O
was,O
only,O
14,O
.,O
The,O
AE,O
activity,O
score,O
of,O
2,B-IUPAC
-,I-IUPAC
amino,I-IUPAC
-,I-IUPAC
"4,5",I-IUPAC
-,I-IUPAC
dimethyl,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
trifluoromethylbenzoyl,I-IUPAC
),I-IUPAC
thiophene,I-IUPAC
(,O
PD,O
"81,723",O
),O
",",O
which,O
was,O
19%,O
",",O
served,O
as,O
a,O
standard,O
for,O
comparison,O
.,O
These,O
compounds,O
were,O
found,O
to,O
be,O
active,O
in,O
vitro,O
for,O
LTC4,O
/,O
D4,O
inhibition,O
with,O
the,O
potencies,O
(,O
IC50,O
's,O
),O
ranging,O
from,O
0.2,O
to,O
85,O
microM,O
.,O
A,O
number,O
of,O
17,B-PARTIUPAC
beta,I-PARTIUPAC
-,I-PARTIUPAC
(,I-PARTIUPAC
N,I-PARTIUPAC
-,I-PARTIUPAC
alkyl,I-PARTIUPAC
/,I-PARTIUPAC
arylformamido,I-PARTIUPAC
),I-PARTIUPAC
-,I-PARTIUPAC
and,O
17,B-PARTIUPAC
beta,I-PARTIUPAC
-,I-PARTIUPAC
[,I-PARTIUPAC
(,I-PARTIUPAC
N,I-PARTIUPAC
-,I-PARTIUPAC
alkyl,I-PARTIUPAC
/,I-PARTIUPAC
aryl,I-PARTIUPAC
),I-PARTIUPAC
alkyl,I-PARTIUPAC
/,I-PARTIUPAC
arylamido,I-PARTIUPAC
],I-PARTIUPAC
-,I-PARTIUPAC
3,I-PARTIUPAC
-,I-PARTIUPAC
oxo,I-PARTIUPAC
-,I-PARTIUPAC
4,I-PARTIUPAC
-,I-PARTIUPAC
aza,I-PARTIUPAC
-,I-PARTIUPAC
5,I-PARTIUPAC
alpha,I-PARTIUPAC
-,O
steroids,B-MODIFIER
were,O
prepared,O
from,O
17,B-IUPAC
beta,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
azasteroids,I-IUPAC
and,O
evaluated,O
as,O
inhibitors,O
of,O
human,O
5,O
alpha,O
-,O
reductase,O
and,O
antagonists,O
of,O
the,O
androgen,O
receptor,O
.,O
The,O
homoanalog,O
",",O
methyl,B-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
2,I-IUPAC
-,I-IUPAC
isothiocyanatoethyl,I-IUPAC
),I-IUPAC
thiazole,I-IUPAC
-,I-IUPAC
2,I-IUPAC
-,I-IUPAC
carbamate,I-IUPAC
",",O
was,O
prepared,O
from,O
(,B-IUPAC
2,I-IUPAC
-,I-IUPAC
aminothiazol,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
yl,I-IUPAC
),I-IUPAC
acetic,I-IUPAC
acid,I-IUPAC
.,O
The,O
dibenzo,B-IUPAC
[,I-IUPAC
"1,4",I-IUPAC
],I-IUPAC
dioxin,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
carboxamides,I-IUPAC
are,O
active,O
against,O
wild,O
-,O
type,O
P388,O
leukemia,O
in,O
vitro,O
and,O
in,O
vivo,O
",",O
with,O
structure,O
-,O
activity,O
relationships,O
resembling,O
those,O
for,O
both,O
the,O
acridine,B-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
and,O
phenazine,B-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
carboxamide,I-IUPAC
series,B-MODIFIER
of,O
DNA,O
-,O
intercalating,O
antitumor,O
agents,O
.,O
When,O
tested,O
for,O
their,O
antagonistic,O
activity,O
in,O
the,O
above,O
tissues,O
",",O
only,O
VII,O
and,O
VIII,O
were,O
found,O
to,O
inhibit,O
responses,O
to,O
angiotensin,O
II,O
.,O
These,O
compounds,O
have,O
also,O
been,O
screened,O
against,O
Litomosoides,O
carinii,O
",",O
and,O
of,O
these,O
only,O
3f,O
and,O
5a,O
have,O
also,O
been,O
found,O
to,O
be,O
active,O
.,O
The,O
most,O
active,O
anti,O
-,O
DHBV,O
agent,O
(,O
9c,O
),O
",",O
possessing,O
a,O
[,B-IUPAC
4,I-IUPAC
-,I-IUPAC
hydroxy,I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
(,I-IUPAC
hydroxymethyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
butyl,I-IUPAC
],I-IUPAC
substituent,B-MODIFIER
at,O
N,O
-,O
1,O
",",O
exhibited,O
an,O
activity,O
(,O
EC,O
(,O
50,O
),O
of,O
0.01-0.05,O
microg,O
/,O
mL,O
),O
comparable,O
to,O
that,O
of,O
reference,O
compound,O
(,B-IUPAC
-,I-IUPAC
),I-IUPAC
-,I-IUPAC
beta,I-IUPAC
-,I-IUPAC
L,I-IUPAC
-,I-IUPAC
2',I-IUPAC
",",I-IUPAC
3',I-IUPAC
-,I-IUPAC
dideoxy,I-IUPAC
-,I-IUPAC
3',I-IUPAC
-,I-IUPAC
thiacytidine,I-IUPAC
(,O
3,O
-,O
TC,O
),O
(,O
EC,O
(,O
50,O
),O
=,O
0.01-0.05,O
microg,O
/,O
mL,O
),O
.,O
A,O
complete,O
[,O
i,O
-,O
(,O
i,O
+,O
3,O
),O
],O
scan,O
of,O
cyclo,O
(,O
i,O
",",O
i,O
+,O
3,O
),O
[,O
MeTyr1,O
",",O
Ala15,O
",",O
Glui,O
",",O
Lys,O
(,O
i,O
+,O
3,O
),O
",",O
Nle27,O
],O
-,O
hGHRH,O
(,O
1-29,O
),O
-,O
NH2,O
was,O
then,O
produced,O
in,O
order,O
to,O
test,O
the,O
effects,O
of,O
a,O
Glu,O
-,O
to,O
-,O
Lys,O
lactam,O
bridge,O
at,O
all,O
points,O
in,O
the,O
peptide,O
.,O
With,O
use,O
of,O
the,O
correlation,O
as,O
a,O
guide,O
",",O
one,O
additional,O
5,B-IUPAC
-,I-IUPAC
phenylpyrazolo,I-IUPAC
[,I-IUPAC
"4,3",I-IUPAC
-,I-IUPAC
d,I-IUPAC
],I-IUPAC
pyrimidine,I-IUPAC
containing,O
a,O
4,B-IUPAC
-,I-IUPAC
[,I-IUPAC
[,I-IUPAC
(,I-IUPAC
dimethylamino,I-IUPAC
),I-IUPAC
ethyl,I-IUPAC
],I-IUPAC
amino,I-IUPAC
],I-IUPAC
sulfonyl,I-IUPAC
substituent,B-MODIFIER
to,O
improve,O
aqueous,O
solubility,O
was,O
prepared,O
.,O
The,O
EC50s,O
of,O
coronary,O
vasoactivity,O
of,O
several,O
para,O
-,O
substituted,O
analogues,O
are,O
in,O
the,O
subnanomolar,O
range,O
.,O
In,O
vivo,O
",",O
they,O
are,O
comparable,O
to,O
the,O
"6,8",B-IUPAC
-,I-IUPAC
difluoro,I-IUPAC
series,B-MODIFIER
and,O
show,O
up,O
to,O
10,O
-,O
fold,O
improvement,O
in,O
efficacy,O
when,O
compared,O
to,O
their,O
ciprofloxacin,O
counterparts,O
vs,O
Streptococcus,O
pyogenes,O
and,O
Streptococcus,O
pneumonia,O
.,O
The,O
prototype,O
of,O
such,O
a,O
compound,O
was,O
1,B-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
fluorophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
3,I-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
[,I-IUPAC
4,I-IUPAC
-,I-IUPAC
(,I-IUPAC
4,I-IUPAC
-,I-IUPAC
fluorophenyl,I-IUPAC
),I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
piperidinyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
butyl,I-IUPAC
],I-IUPAC
-,I-IUPAC
1H,I-IUPAC
-,I-IUPAC
indole,I-IUPAC
",",O
11a,O
(,O
code,O
no,O
.,O
No,O
"5,6",O
-,O
olefinic,O
bond,O
regeneration,O
was,O
observed,O
for,O
the,O
5,B-IUPAC
-,I-IUPAC
chloro,I-IUPAC
analogs,B-MODIFIER
.,O
The,O
presence,O
of,O
a,O
methyl,B-IUPAC
group,B-MODIFIER
on,O
N,O
(,O
6,O
),O
of,O
the,O
2,B-IUPAC
-,I-IUPAC
alkynyladenosines,I-IUPAC
",",O
inducing,O
an,O
increase,O
in,O
affinity,O
at,O
the,O
human,O
A,O
(,O
3,O
),O
receptor,O
and,O
a,O
decrease,O
at,O
the,O
other,O
subtypes,O
",",O
resulted,O
in,O
an,O
increase,O
in,O
A,O
(,O
3,O
),O
selectivity,O
.,O
The,O
5,B-IUPAC
-,I-IUPAC
iodo,I-IUPAC
-,I-IUPAC
4,I-IUPAC
-,I-IUPAC
nitroimidazole,I-IUPAC
-,I-IUPAC
1,I-IUPAC
-,I-IUPAC
N,I-IUPAC
-,I-IUPAC
(,I-IUPAC
3,I-IUPAC
-,I-IUPAC
picolyl,I-IUPAC
),I-IUPAC
acetamide,I-IUPAC
on,O
further,O
reaction,O
with,O
m,B-IUPAC
-,I-IUPAC
chloroperbenzoic,I-IUPAC
acid,I-IUPAC
produced,O
the,O
corresponding,O
N,O
-,O
oxide,O
.,O
All,O
DTACs,O
and,O
indenes,O
were,O
competitive,O
inhibitors,O
of,O
[,O
3H,O
],O
estradiol,O
binding,O
in,O
the,O
immature,O
rat,O
uterine,O
cytosol,O
receptor,O
assay,O
",",O
with,O
relative,O
binding,O
affinities,O
of,O
0.1-3.6%,O
of,O
estradiol,O
.,O
This,O
paper,O
presents,O
the,O
structure,O
-,O
activity,O
relationships,O
leading,O
to,O
novel,O
tri,B-MODIFIER
-,I-MODIFIER
and,O
tetrasubstituted,B-MODIFIER
guanidines,B-IUPAC
",",O
which,O
exhibit,O
high,O
selectivity,O
for,O
NMDA,O
receptor,O
ion,O
channel,O
sites,O
and,O
weak,O
or,O
negligible,O
affinity,O
for,O
sigma,O
receptors,O
.,O
Under,O
similar,O
conditions,O
analogues,O
(,O
[,B-IUPAC
N,I-IUPAC
(,I-IUPAC
gamma,I-IUPAC
),I-IUPAC
-,I-IUPAC
(,I-IUPAC
IGly,I-IUPAC
),I-IUPAC
Dab,I-IUPAC
(,I-IUPAC
8,I-IUPAC
),I-IUPAC
],I-IUPAC
degarelix,I-IUPAC
",",O
IC,O
(,O
50,O
),O
=,O
1.56,O
nM,O
),O
(,O
21,O
),O
and,O
(,O
[,O
IOrn,O
(,O
8,O
),O
],O
degarelix,O
",",O
IC,O
(,O
50,O
),O
=,O
1.72,O
nM,O
),O
(,O
18,O
),O
had,O
a,O
longer,O
duration,O
of,O
action,O
{,O
inhibited,O
LH,O
(,O
&,O
gt,O
;,O
96,O
h,O
),O
release,O
},O
than,O
azaline,O
B,O
;,O
however,O
they,O
were,O
shorter,O
acting,O
than,O
degarelix,O
.,O
In,O
contrast,O
with,O
cisplatin,O
and,O
carboplatin,O
",",O
five,O
complexes,O
selected,O
significantly,O
increased,O
in,O
life,O
span,O
in,O
mice,O
transplanted,O
with,O
cisplatin,O
-,O
resistant,O
L1210,O
cells,O
.,O
(,O
all,O
-,O
E,O
),O
-,O
1,O
and,O
(,O
13Z,O
),O
-,O
1,O
were,O
both,O
shown,O
to,O
be,O
equally,O
effective,O
as,O
(,B-IUPAC
13Z,I-IUPAC
),I-IUPAC
-,I-IUPAC
retinoic,I-IUPAC
acid,I-IUPAC
in,O
suppressing,O
the,O
proliferation,O
of,O
human,O
sebaceous,O
cells,O
in,O
vitro,O
.,O
Structural,O
alterations,O
in,O
both,O
series,O
did,O
little,O
to,O
enhance,O
the,O
inhibitory,O
activity,O
of,O
the,O
parent,O
compounds,O
"2,6",B-IUPAC
-,I-IUPAC
dihydroxyacetophenone,I-IUPAC
(,O
3,O
),O
and,O
"2,4",B-IUPAC
-,I-IUPAC
dihydroxyacetophenone,I-IUPAC
(,O
27,O
),O
.,O
These,O
agents,O
were,O
evaluated,O
in,O
vitro,O
and,O
in,O
vivo,O
for,O
their,O
ability,O
to,O
suppress,O
HMG,O
CoA,O
reductase,O
",",O
the,O
rate,O
-,O
limiting,O
enzyme,O
of,O
cholesterol,O
biosynthesis,O
.,O
Formylation,O
of,O
amines,O
10-27,O
gave,O
17,B-IUPAC
beta,I-IUPAC
-,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
alkylformamides,I-IUPAC
),I-IUPAC
28-41,O
;,O
however,O
",",O
acylation,O
afforded,O
17,B-IUPAC
beta,I-IUPAC
-,I-IUPAC
[,I-IUPAC
(,I-IUPAC
N,I-IUPAC
-,I-IUPAC
alkyl,I-IUPAC
/,I-IUPAC
aryl,I-IUPAC
),I-IUPAC
alkyl,I-IUPAC
/,I-IUPAC
arylamides,I-IUPAC
],I-IUPAC
42-53,O
.,O
In,O
this,O
report,O
",",O
we,O
describe,O
structure,O
-,O
activity,O
studies,O
of,O
the,O
bicyclic,O
oxytocin,O
antagonist,O
[,O
Mpa1,O
",",O
cyclo,O
(,O
Glu4,O
",",O
Lys8,O
),O
],O
oxytocin,O
.,O
The,O
effect,O
of,O
N,O
-,O
and,O
5,O
-,O
substitution,O
on,O
affinity,O
for,O
the,O
5,O
-,O
HT1A,O
receptor,O
was,O
evaluated,O
in,O
competition,O
experiments,O
using,O
rat,O
hippocampal,O
membranes,O
and,O
[,O
3H,O
],O
8,O
-,O
OH,O
-,O
DPAT,O
as,O
radioligand,O
.,O
The,O
corresponding,O
beta,O
-,O
aryl,O
-,O
substituted,O
lactones,O
",",O
by,O
contrast,O
",",O
are,O
potent,O
acylating,O
agents,O
that,O
lead,O
to,O
acyl,O
enzymes,O
of,O
high,O
stability,O
.,O
Both,O
alkyl,O
and,O
aryl,O
substituents,O
were,O
examined,O
.,O
Pyrazofurin,O
derivatives,O
modified,O
at,O
the,O
1,O
-,O
",",O
4,O
-,O
",",O
or,O
5,O
-,O
position,O
showed,O
neither,O
antiviral,O
nor,O
cytostatic,O
activity,O
in,O
cell,O
culture,O
.,O
The,O
anticonvulsant,O
activity,O
of,O
these,O
compounds,O
against,O
audiogenic,O
seizures,O
was,O
evaluated,O
in,O
DBA,O
/,O
2,O
mice,O
after,O
intraperitoneal,O
(,O
ip,O
),O
injection,O
.,O
In,O
the,O
delayed,O
-,O
type,O
hypersensitivity,O
(,O
DTH,O
),O
mouse,O
model,O
",",O
a,O
model,O
of,O
skin,O
inflammation,O
",",O
a,O
5%,O
solution,O
of,O
7d,O
reduced,O
edema,O
by,O
69%,O
compared,O
to,O
control,O
animals,O
.,O
X,O
-,O
ray,O
analyses,O
of,O
1,O
and,O
2,O
are,O
reported,O
",",O
and,O
compound,O
1,O
is,O
the,O
first,O
example,O
in,O
which,O
the,O
cbdca,O
ligand,O
is,O
coordinated,O
to,O
a,O
ruthenium,O
center,O
.,O
The,O
chloromethyl,O
compounds,O
",",O
5,O
and,O
10,O
",",O
yielded,O
7,B-IUPAC
-,I-IUPAC
acetoxymethyl,I-IUPAC
-,I-IUPAC
12,I-IUPAC
-,I-IUPAC
methylbenz,I-IUPAC
[,I-IUPAC
a,I-IUPAC
],I-IUPAC
anthracene,I-IUPAC
(,O
6,O
),O
and,O
7,B-IUPAC
-,I-IUPAC
acetoxymethyl,I-IUPAC
-,I-IUPAC
5,I-IUPAC
-,I-IUPAC
fluoro,I-IUPAC
-,I-IUPAC
12,I-IUPAC
-,I-IUPAC
methylbenz,I-IUPAC
[,I-IUPAC
a,I-IUPAC
],I-IUPAC
anthracene,I-IUPAC
(,O
11,O
),O
on,O
treatment,O
with,O
acetate,O
ion,O
.,O
